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SUMMARY 
 
Effects of subclinical hypothyroidism on bone mineral density and cardiometabolic-risk: 
genetic and immune influences 
Subclinical hypothyroidism (SH) affects 3-8% of the population and is associated with 
hypertension, dyslipidaemia and altered bone mineral density (BMD). Metabolic anomalies in 
thyroid disease have been attributed to thyroid hormone variation but mice deficient in 
thyrotropin (TSH) receptor (TSHR) have low BMD, despite normal thyroid hormones, 
suggesting that TSH/TSHR function in bone is important. SH has several aetiologies including 
thyroid autoimmunity characterised by thyroid peroxidase autoantibodies (TPO-Ab), 
inactivating TSHR mutations (TSHR-M) and FOXE1 polyalanine tract length (FOXE1-PTL) 
polymorphisms. I hypothesise differential bone effects in SH relating to these causes. Similarly 
the effects of SH on metabolic outcomes is unclear and may also depend on SH aetiology. 
Principle aims - 
1. To determine the prevalence of heterozygous TSHR-Ms in SH.  
2. To evaluate body composition and metabolic parameters according to i) TSH, T4 and 
T3; ii) TPO-Ab; iii) TSHR-M or polymorphism; iv) FOXE1-PTL polymorphism. 
 
156 women and 52 men, mean age 51 with primary untreated SH were recruited. Blood 
samples were obtained for biochemistry (thyroid & lipid profiles, TPO-Ab, HOMA-IR) and 
blood pressure (BP) and anthropometric data collected. TSHR and FOXE1 were genotyped. 
Dual-energy X-ray absorptiometry generated Z-scores. Stepwise multivariate regression 
analyses were performed. 
Half of the cohort had TPO-Ab; 6% had TSHR-Ms (essentially TPO-Ab negative) and 60% 
expressed FOXE114/14-PTL. TSH and TPO-Ab associated negatively with BMD-Z at lumbar spine 
but not hip whereas free-T3 and male gender associated negatively at both sites. TSHR-M 
status did not influence BMD-Z despite lower free-T3 relative to TSH.  
Free-T3 associated positively with BP and HOMA-IR. FOXE1-PTL14/14 associated positively with 
free-T3 and negatively with BP. TSH, TSHR-M and TPO-Ab status showed no metabolic 
associations but unexpectedly TSH showed a positive association with T3. 
SH is considered homogenous but my results illustrate its heterogeneity and highlight the 
need for studies accounting for aetiology in order to optimise clinical management. 
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1 
 
CHAPTER 1:  INTRODUCTION 
 
Subclinical Hypothyroidism (SH) was first described as a specific entity by Hall and Evered 
(1973).  SH describes a biochemical condition consisting of an elevated thyrotrophin hormone 
(TSH) with normal free thyroid hormones (FTH) levels.  As its name suggests this may be 
“subclinical” and not associated with specific symptoms.  SH may be considered a 
compensatory state where a raised TSH overcomes a degree of resistance in the system 
enabling maintenance of normal FTH levels.  This is best explained by understanding the 
Hypothalamic-Pituitary-Thyroid (HPT) axis. 
 
1.1 Hypothalamic-Pituitary-Thyroid axis 
 
The HPT axis describes the endocrine system which maintains and regulates FTH homeostasis 
(Reichlin 1967). Thyrotrophin releasing hormone (TRH) is a peptide hormone synthesised in 
the paraventricular nucleus in the hypothalamus (located just above the brain stem and 
below the thalamus (Rasmussen 1938).  TRH passes down the hypophyseal portal tract 
(vasculature) to the anterior pituitary gland (located below the hypothalamus) where it 
stimulates the release of TSH from the pituitary thyrotrophs (Sonenberg 1958). TSH circulates 
to the thyroid gland (TG) where it interacts with the TSH receptor (TSHR) on thyroid follicular 
cells to stimulate the release of thyroid hormones: Tetraiodothyronine (T4 or Thyroxine) and 
Triiodothyronine (T3).  The thyroid hormones negatively feedback on the hypothalamus and 
pituitary gland (Scanlon et al 1978) to regulate FTH levels (see figures 1.1 & 1.2). 
 
Free thyroid hormone refers to the bioavailable (un-protein bound) and active hormone in 
serum. It makes up <1% of the total circulating pool (Winter & Signorino 2001; Boelaert & 
Franklyn 2005) and feeds back on the HPT axis.  For example, if T4 levels fall, negative 
feedback on the hypothalamus and pituitary falls, enabling TRH and TSH levels to rise to 
increase thyroid hormone synthesis.  Whereas high FTHs have the opposite effect, serving to 
reduce thyroid hormone production.  Thus in health, the HPT axis tightly regulates FTH levels. 
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Figure 1.1:  Schematic illustration of the anatomical location of the Hypothalamus, 
Pituitary and Thyroid Gland relative to a photograph of the author 
 
 
   
 
 
 
 
 
 
 
Figure 1.2: Negative feedback regulation of the Hypothalamic-Pituitary-Thyroid axis 
                                
 
Figures 1.1 & 1.2 depict the hypothalamus in yellow, the pituitary in red and the thyroid in green. Arrow 
heads have adjacent symbols indicating stimulation (+) or suppression (-) within the axis 
 
 
1.2 Thyroid Gland  
 
The TG is present in all vertebrates and is responsible for the synthesis of thyroid hormones 
(Lynn & Wachowski 1951, Dickhoff & Darling 1983).  The development of a specialised gland 
with the ability to concentrate iodide and synthesise thyroid hormone may have been an 
important evolutionary step enabling higher life forms to evolve from the iodine rich ocean 
to the iodine deplete waters and lands (Venturi et al 2000).  The endostyle, a ciliated groove 
Cerebral Hemisphere 
Pons 
Brain Stem 
Cerebellum 
Hypothalamus 
Pituitary Gland 
Thyroid Gland 
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in the ventral pharynx of simpler life forms may represent the primitive origins of the TG (Lynn 
& Wachowski 1951).  
 
The TG was named, and its anatomy described in detail by Thomas Wharton (1656).  The gland 
is located anteriorly in the lower neck just below the cricoid cartilage. It has two lobes 
(connected by an isthmus) that drape around the larynx to the oesophagus posteriorly.  
Embryologically it develops from an outpouching of the immature pharynx (the foramen 
caecum at the base of the tongue marks this point) and descends via the thyroglossal duct to 
this location (Zapanta & Shokri 2014).  A human foetus aged 18-20 weeks has an immature 
but functional HPT axis and is able to synthesis thyroxine (Morreale de Escobar et al 2000).  
Up until 12 weeks gestation a human foetus is completely dependent on the transfer of 
maternal thyroxine across the placenta for normal development.  
 
The TG is composed of a mass of follicles (Hertzler 1939), roughly spherical in shape containing 
a colloid known as thyroglobulin. The follicles alter in size in response to metabolic demand 
(reflecting a change in follicular cell number, and size). The follicles are encased by a layer of 
cells known as follicular cells which lie in proximity to surrounding fenestrated capillaries. 
Scattered between the follicles are parafollicular C-cells responsible for the production of 
calcitonin (Pearce 1966). C-cells are functionally and embryologically distinct from the tissues 
that synthesise thyroid hormone. The C-cells originate from neural crest (Pearce & Polak 
1971) and calcitonin has been considered a neuro-peptide (Zaidi et al 1987). Although 
calcitonin is considered functionally redundant in humans, it lowers serum calcium and 
contributes to calcium homeostasis in lower mammals.   
 
Thyroid follicular cells synthesise and secrete thyroid hormones in response to TSH-TSHR 
engagement. This precipitates a series of physiological events simplified and summarised 
below: - 
 
1. Iodide is trapped; actively transported from blood to thyroid follicular cells via the 
sodium iodide (Na/I) symporter on the plasma membrane.  Pendrin (a protein 
transporter) may enable the efflux of iodide from the follicular cells to the thyroid 
follicle for organification (Bizhanova & Kopp 2009).  
2. Thyroid follicles contain thyroglobulin, a tyrosine rich glycoprotein.  
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3. Thyroperoxidase (TPO) is an enzyme on the apical surface of follicular cells that 
oxidises iodide to iodine (in the presence of hydrogen peroxide; generated by the 
enzyme DUOX2).  TPO covalently binds iodine to tyrosine in thyroglobulin.  
4. TPO generates T4 and T3 by combining diiodothyronines or monoiodothyronines 
(diiodothyronine + diiodothyronine = T4, monoiodothyronine + diiodothyronine (in 
appropriate combination) = T3). Thyroid hormones remain complexed in 
thyroglobulin.  
5. Follicular cells endocytose mature thyroglobulin which undergoes lysosome digestion 
to liberate thyroid hormones. 
6. Thyroid hormones diffuse into surrounding capillaries and on to the general 
circulation.                 (adapted from Boron 2003) 
 
1.3 Thyroid Status 
 
Thyroid status is a term used to describe the relative amounts of FTHs in an individual termed; 
‘hyperthyroid’, ‘subclinical hyperthyroid’ (Shyper), ‘euthyroid’, ‘subclinical hypothyroid’ (SH) 
and ‘hypothyroid’. Hyperthyroidism describes an excess of FTHs; Shyper describes a 
suppressed TSH with normal FTHs; euthyroidism describes normal TSH and FTHs; SH describes 
a raised TSH with normal FTHs, and hypothyroidism describes subnormal FTH levels. 
 
Thyroid Function Tests (TFTs) detail an individual’s TSH and T4 values +/- T3 (at the time the 
sample was taken) and enable the cause of abnormal TFTs to be determined in most cases. 
As such, thyroid disorders are further categorised according to the gland within the HPT axis 
that is failing to function normally. In this context primary refers to the abnormality occurring 
in the TG, secondary to the abnormality occurring in the pituitary, and tertiary to the 
abnormality occurring in the hypothalamus. However, given that TFTs do not differentiate 
secondary from tertiary causes (as TRH is not included in TFTs) these are collectively referred 
to as central hypo or hyperthyroidism (Freeman et al 2009).  These TFT classification 
categories are summarised in table 1.1 below.  
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Table 1.1: Thyroid status and determinants of primary, secondary and tertiary thyroid 
dysfunction 
 
 
Thyroid Status 
(below) 
Free T4 TSH TRH 
 
HPT axis category 
 
Hypothyroidism ↓ 
↑ 
↓/ normal 
↓ 
↑ 
↑ 
↓ 
primary 
secondary 
tertiary 
 
Subclinical 
hypothyroidism 
Normal ↑ ↑ primary 
Euthyroid Normal normal normal 
 
no abnormalities 
 
 
Subclinical 
hyperthyroidism 
Normal ↓ ↓ primary 
Hyperthyroidism ↑ 
↓ 
↑/normal 
↑ 
↓ 
↓ 
↑ 
primary 
secondary 
tertiary 
 
The arrows indicate: subnormal (↓) or supra-normal (↑) hormone levels. HPT represents the 
Hypothalamic-pituitary-thyroid axis 
 
 
1.4 Thyroid hormones, receptors and the deiodinase enzymes 
 
Thyroid hormones are ubiquitous and act on almost all cells in vertebrates (Eales 1997, 
Hulbert 2000).  They are key determinants of the metabolic rate (carbohydrate, protein, lipid 
metabolism and temperature regulation) (Magnus-Levy 1895, Thomas 1957, Tata et al 1962).  
They are necessary for healthy reproductive function (Dittrich et al 2011), and growth and 
development (Khamsi & Eayrs 1966, Tarim 2011).  Their influence on the growth hormone 
(GH) - insulin-like growth factor-1 (IGF-1) axis is recognised (hypothyroidism is associated with 
diminished GH/ IGF-1 secretion (Hervás et al 1976, Chernausek et al 1983, Iglesias et al 2001)).  
 
T3 (rather than T4) is the active cellular hormone, being markedly more potent than T4 (Gross 
& Pitt-Rivers 1953).  The binding affinity of T3 for thyroid hormone receptors (TR) is 
approximately (~) 15 times greater than T4 (Lin et al 1990). In health, ~80% of the hormone 
released from the TG is T4, and ~20% T3 (Kansagra et al 2010). T4 is often considered a 
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‘prehormone’ as it can be converted to T3 by the iodothyronine deiodinase enzymes (DI).  
Indeed ~80% of T3 utilised by cells is generated by tissue specific DI (Irizarry et al 2014).  
 
The DI are selenoenzymes that provide additional defence against abnormal thyroid hormone 
levels at the tissue, cellular and intracellular level (Köhrle 1996).  For example; when FTH 
levels fall D2 DI is upregulated (to increase T3) and D3 DI downregulated (to reduce 
inactivation of T3) (see table 1.2).  The reverse occurs with excess FTH, in an attempt to 
normalise T3 (Salvatore 2011).  The expression of tissue Dis, during development, varies in an 
age- and stage-dependent manner (St Germain et al 2009) thus enabling control of T3-
mediated cellular differentiation, growth and metabolism.  A variety of non-thyroidal 
endogenous signalling molecules also affect the function of DIs (Gereben et al 2008).  
 
 
Table 1.2: The D1, D2 and D3 iodothyronine deiodinase enzymes 
 
 
Iodothyronine deiodinase 
enzyme and gene name 
Location Function 
 
 
D1 (Type 1) 
DI01 
Plasma membrane; 
        Thyroid 
        Liver 
        Kidney 
        Brown fat 
        Skeletal muscle 
 
Converts T4 to T3 
 
(major source of circulating T3) 
 
 
D2 (Type 2) 
DI02 
Endoplasmic Reticulum; 
       Thyroid 
       Pituitary 
       Hypothalamus  
       Brain 
       Brown fat 
       Skeletal muscle 
 
Converts T4 to T3 
 
(local T3 production) 
 
 
D3 (Type 3) 
DI03 
Plasma membrane ; 
       CNS 
       Placenta 
       Pregnant uterus 
       Embryonic tissues 
       Rarely malignancies 
 
Inactivates T4 & T3 :- 
   
    -T4 to reverse T3 
    -T3 to 3,3’-T2 
       (adapted from Wassen 2005) 
 
 
Thyroid hormone receptors (TR) are nuclear receptors that modify gene expression. Although 
the uptake of lipophilic thyroid hormones was thought to be a passive process, we now know 
that this is not the case.  Thyroid hormone transporters include the monocarboxylate 
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transporters; MCT-8 and MCT-10, OATP (Organic Anion Transporting Polypeptide) and the 
amino acid transporters LAT-1 and LAT-2 (Kinne et al 2011). MCT-8 is the most specific and 
well-studied of these transporters and its functional absence in the Allan-Herndon-Dudley 
syndrome demonstrates its importance.  This is an X-linked recessive disorder resulting from 
mutations in MCT8 located on Xq13.2 (Schwartz et al 2005).  The syndrome is characterised 
by global muscle weakness, severe learning difficulties, and an elevated serum T3.  
 
The TRs, TRα or TRβ, are encoded by two distinct genes (THRA and THRB respectively).  Both 
receptors have at least two splice variants:  TRα1, TRα2 and TRβ1, TRβ2, although the TRα2 
variant is functionally redundant (Yen 2001).  Truncated variants of TRα (TR∆a1 & TR∆a2) 
(Chassande et al 1997), and sequence variants of TRβ (TRβ3 & TRβ∆β) are identified in rodents 
(Williams 2000), but their functional relevance is uncertain.   
 
TRα1 and TRβ1 are widely expressed in thyroid hormone-sensitive cells.  TRβ2 was originally 
thought to be expressed specifically in the hypothalamus and pituitary (where it has an 
inhibitory and negative feedback effect (Abel et al 1999)).  However, it has since been 
recognised that TRβ2 plays an important role in sensorineural development of the cochlea 
and retinal cells (Jones et al 2007; Ng et al 2001 respectively).  
 
1.5 TSH and its receptor  
 
The TSH-TSHR interaction is a key event in thyroid biology as it precipitates the synthesis and 
release of thyroid hormones from the TG (Davies et al 2005).  It also enables growth and 
development of the TG, particularly in postnatal life (Van Vliet 2003).  The TSHR is present in 
many extra-thyroidal tissues including brain, testes, heart, kidney, lymphocytes, thymus, 
adipose tissue, bone and fibroblasts (reviewed in Davies et al 2002).  However, its role in these 
tissues is uncertain and remains an area of research and debate.   
 
The TSHR is the antigen against which thyroid autoantibodies develop.  Inactivating 
antibodies block the TSHR and can cause SH or primary hypothyroidism (PH) whilst activating 
antibodies stimulate the TSHR (thyroid stimulating immunoglobulins; TSI) and can cause 
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Shyper or primary hyperthyroidism (i.e. Graves’ Disease (GD)). The ratio of stimulating to 
blocking antibodies influences the clinical presentation (Ando et al 2005).  The TSI-TSHR 
interaction may contribute to the pathogenesis of the non-thyroidal tissue manifestations of 
GD (Fatourechi 2005), these are discussed in section 1.7.1. 
 
The TSHR is a G protein-coupled glycoprotein transmembrane receptor.  The G-protein 
coupled receptor (GPCR) family consist of several thousand receptor types (Ji et al 1998, 
Fredrikssen & Schiöth 2005) ~850 are identified in humans (Fredriksson et al 2003, 
Bjarnadottir et al 2006).  These receptors collectively respond to an array  of chemical and 
biological signals which in humans include sensory perception (light, odours, taste), organic 
compounds (including neurotransmitters, hormones and chemokines), cations, toxins and 
drugs to name but a few.  GPCRs are present in eukaryotes and fungi and also identified in 
some plants (Josefsson 1999).  
 
The GPCRs have a common structural theme with an extracellular, a transmembrane and an 
intracellular portion (Hille 2009).  The ectodomain begins with the amino terminal and may 
be glycosylated (the size and composition of the ectodomain can vary greatly between GPCRs 
(Tuteja 2009).  The transmembrane portion (or serpentine portion) comprises a characteristic 
7 transmembrane loop structure (with 3 extracellular and 3 intracellular portions) followed 
by an intracellular cytoplasmic section ending in the carboxyl terminus.  The extracellular 
portion (+/- the ectodomain of the transmembrane loops) determine binding specificity 
(Barwell et al 2011).  Whereas the serpentine section couples to the G proteins or Guanine 
nucleotide binding proteins. 
 
 G-proteins in GPCRs are heterotrimeric and composed of α, β and γ subunits. The α subunit 
is attached to a guanine residue which is activated when GDP (guanosine diphosphate) is 
exchanged for GTP (guanosine triphosphate) causing the α unit to dissociate from the βγ 
complex.  The dissociated α subunit and (less commonly) the βγ complex initiate 2nd 
messenger signalling cascades (Hurowitz et al 2000), or directly stimulate physiological 
effectors (Kristiansen 2004).  More than 20 Gα subunits are identified in mammals (Baltoumas 
et al 2013), all with diverse cellular effects.  The β and γ subunits have several isoforms 
enabling hundreds of different heterotrimeric G protein combinations to be generated.  The 
G-proteins are commonly described as molecular switches that switch on (stimulating 
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intracellular signalling pathways) when activated, and switch off when GTP is hydrolysed back 
to GDP.  Ligand binding alters the GPCR structure, activating G-proteins and triggering 
intracellular signalling (Hamm 1998); thereby transducing signals from the extracellular to the 
intracellular environment.  
 
TSHR is a GPCR whose genetic code is spread across 10 exons, positioned on the long arm of 
chromosome 14 (genetic locus 14q31.1).  It spans >190, 000 base pairs (Iosco & Rhoden 2009).  
The mature protein’s molecular mass is 84.5kDa and consists of 764 amino acids (including a 
21 amino acid signalling peptide).  Of these amino acids 394 are extracellular, 83 intracellular, 
and those remaining occupy the transmembrane region (Nagayama et al 1989, Misrahi et al 
1990).  The first 9 exons code the extracellular domain (the main determinant of binding 
specificity (Braun et al 1991), whilst Exon 10 (that is more than twice the size of the other 9 
exons combined (Iosco & Rhoden 2009) codes for the transmembrane and intracellular 
regions (Szkudlinski et al 2002).  
 
The TSHR has a large ectodomain (relative to other GPCRs) with substantial sequence 
homology (35-45%) to the ectodomain of the gonadotrophin hormone receptors; follicle 
stimulating hormone (FSH), luteinising hormone (LH) and human chorionic gonadotrophin 
(hCG) receptors (Rapoport et al 1998).  The gonadotrophin hormones and TSH are 
glycoprotein dimers with identical α subunits and distinct β subunits (Pierce & Parsons 1981).  
Therefore structural similarity in their receptors would be expected.  The TSHR and the 
gonadotrophin receptor ectodomains are similar in that they are glycosylated and have 9 
repeat leucine-rich regions that arrange themselves in β-pleated sheets (important to the 
quaternary structure of the receptor).  Thus it might be anticipated that the gonadotrophin 
hormones, when produced to excess, might activate the TSHR.  This is well described with 
hCG (particularly in the 1st trimester of twin and molar pregnancies when hCG precipitates a 
clinical and biochemical picture consistent with hyperthyroidism (Glinoer 1997, Hershman 
1999)).  However, this does not occur with FSH or LH.  
 
Thyrostimulin is a relatively recently described glycoprotein heterodimer with specificity for 
TSHR (Nakabayashi et al 2002).  It induces a response from TSHR that is similar in magnitude 
to TSH. Thyrostimulin is composed of α2 and β5 subunits.  Localisation studies reveal its 
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presence in the anterior pituitary (Nakabayashi et al 2002) and ovary (Sun et al 2010) and a 
role as a paracrine activator, or modulator of TSH and/or TSHR function is suggested. 
 
Figure 1.3:  Illustration of the TSHR 
The TSHR is depicted by a continuous black line extending from the N to the C-terminus. TSHR regions 
are labelled (in blue) and annotated as shown. 
 
 
The TSHR is unique among GPCRs in that it is divided by post translational proteolysis into α 
(A) and β (B) subunits (Loosfelt et al 1992) with loss of a short C-peptide (Hamidi et al 2011).  
In situ they connect at the hinge region via disulphide bonds.  The α-subunit consists of 
ectodomain (encoded by exons 1-8), whilst the β-subunit (encoded by exons 9 and 10) has a 
short extracellular component extending to the C-terminus (Van Durme et al 2006).  Following 
TSHR cleavage, an excess of α-unit shedding leaves surplus β-subunits on the plasma 
membrane (Graves et al 1999) that can form dimers and oligomers (Latif et al 2001). β-subunit 
dimers are more prevalent on thyrocytes than extrathyroidal TSHR-expressing cells reflecting 
TSHR activity (Latif et al 2001).  TSHR cleavage is associated with signal transduction although 
β-subunit dimers appear not to transduce signal (Ciullo et al 2003).  Thus their functional 
significance is unknown. 
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The TSHR ectodomain and hinge region are described as a ‘tethered inverse agonist’ to TSHR 
for the reason that the β-unit (in the absence of the α-unit) has constitutive activity (Vu et al 
2009).  Mutations in the hinge region can have similar effects (Zhang et al 2000, Vlaeminck-
Guillem et al 2002).  It therefore appears that the hinge and extracellular domains have a role 
in maintaining the receptor in a basal, unstimulated state.  The TSHR is unusual amongst 
GPCRs in regard to its constitutive activation in the absence of ligand binding (Van Sande et 
al 1996).   
 
TSHR is considered a ‘promiscuous receptor’ as it can activate several distinct 2nd messenger 
signalling cascades (Allgeier et al 1994, Kleinau et al 2010).  The best known is the Gαs-
adenylyl cyclase-cAMP pathway (responsible for the upregulation of enzymes and proteins 
involved in thyroid hormone biosynthesis (Gilman & Rall 1968, Vassart & Dumont 1992)).  
Others include the Gαq/Gα11 pathway that stimulates the phospholipase C-inositol 
triphosphate (IP3) /Ca2+ signalling cascades (Allgeier et al 1994); the Gαi (which has an 
inhibitory effect on adenylyl cyclase (Taussig et al 1993)) and the Gα12 (which influences the 
cytoskeleton amongst other effects (Majumdar et al 1999)).  TSHR activates members of all 4 
Gα protein subgroups (Laugwitz et al 1996), currently amounting to 11 different G-proteins 
(Holzapfel et al 2002). 
 
Mice genetically engineered to lack Gαq/Gα11 develop hypothyroidism in infancy. Further 
investigation revealed that this pathway enabled upregulation of thyroglobulin pinocytosis 
and TPO-mediated iodide organification in response to rising TSH, and facilitated TG 
hypertrophy in response to a prolonged rise in TSH (Kero et al 2007).  A subsequent case 
report confirmed an iodide organification defect in siblings homozygous for the L653V TSHR 
mutation, all with non-autoimmune SH.  In vitro mutagenesis confirmed that the mutation 
caused a selective defect in IP3 generation (Grasberger et al 2007).  Thus demonstrating the 
importance of IP3 signalling in TG biology. A ~100 fold higher TSH concentration is required to 
activate the IP3 pathway, versus the cAMP pathway (Van Sande et al 1995).  In recent years 
the importance of Gβγ signalling in TSHR cell biology has been recognised.  This pathway 
modifies the P13K-PKB/ Akt pathway that is important in cell survival (Bell et al 2002) and 
adipogeneisis (Kumar et al 2011).  
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The methods used to decipher these intracellular sequencing cascades include observing the 
effects of: toxins (that selectively modify Gα-protein function (Hara et al 1999)), TSHR 
autoantibodies (agonists/ antagonists/ partial agonists/ neutrals) (Morshed et al 2009, 
Morshed et al 2010), and TSHR/ G-protein mutations (innate or induced) (Paschke & Ludgate 
1997, Holzapfel et al 2002, Neumann et al 2005).   
 
TSHR cell biology is more complex than I have suggested as the aforementioned cell signalling 
pathways cross-communicate with each other, as well as with other pathways  (including  
STAT/JAK, NFkB/PKC and Akt/p13) (Morshed et al 2009).  Therefore deciphering TSHR 
signalling cascades and unravelling their complex interactions and effects is challenging. 
 
Figure 1.4: Principal TSHR intracellular signalling cascades  
 
 
 
The dashed lines represent the signalling pathways, blue arrows and arrow heads indicate the target. 
Intermediary enzymes integral to the cascade are shown in blue and subsequent effectors/ enzymes 
are pentagons in brown. The diagram is labelled and annotated as shown.  
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Table 1.3: TSHR cAMP and phosphoinositide signalling pathways 
 
Cell signalling component 
TSHR signalling pathway 
cAMP Phosphoinositide 
Activating G protein Αs αq/α11 
Enzyme activated  Adenylate cyclase Phospholipase C 
2nd Messenger cAMP IP3, (Ca2+), DAG 
Stimulated Protein Kinase A C 
Target/ effectors CREB (primarily)/ ERK Akt/RAF/MEK/ERK 
 
The abbreviations regarding 2nd messengers are as follows; Inositol 1,4,5-trisphosphate (IP3), 
Diacylglycerol (DAG), Calcium (ca2+). 
 
 
1.6 Aetiology of Primary Hypothyroidism and Subclinical 
Hypothyroidism  
 
Primary Hypothyroidism (PH) accounts for ~95% of hypothyroid cases (Baskin et al 2001) and 
is the most common endocrine disorder affecting ~2% of the population (1.9% female (♀) and 
0.1 % male (♂) according to the UK Whickham survey (Tunbridge et al 1977)).  It is ~10 times 
more common in women than men, and less common in African Americans than White 
Americans (NHANES study (Hollowell et al 2002)).  Its incidence increases with advancing age 
(Vanderpump et al 1995).   
 
SH has a prevalence of ~4-9% (Canaris et al 2000, Hollowell et al 2002) and is more prevalent 
in women than men (although sex ratios are more modest than PH affecting ~7.5% ♀ versus 
~3% ♂ (Whickham Study (Tunbridge et al 1977)).  Like PH, SH is more common with advancing 
age. Indeed the NHANES study reported a prevalence of 70% amongst subjects >80 years of 
age (defining SH as a TSH> 4.5mU/L). 
 
Progression from SH to PH is variably quoted at ~3-18% per year (McDermont & Ridgeway 
2001).  A 20 year follow up of the Whickham study (included 1877 of the original 2779 subjects 
(defining SH as TSH>6 mU/L) reported that ~2.6% of antibody negative SH females progressed 
to PH annually, compared with ~4.3% per year if seropositive.  In total, a third of the original 
SH group progressed to PH over a 20 year evaluation period. Interestingly, the risk of 
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progression for a man with SH and +ve antibodies was ~4x that of a woman (Vanderpump et 
al 2005).  However, most subjects with SH remain in this category long-term suggesting that 
many have a reset thyrostat explaining their absence of progression to PH (Kabadi 1993).   
 
The causes of SH are generally the same as PH. Worldwide iodine deficiency is the commonest 
cause (Patrick 2008).  In iodine replete areas, traditionally thought to include the UK (although 
this notion has recently been questioned (Vanderpump et al 2011)) autoimmune thyroid 
disease (ATD) is the most common cause (Vanderpump 2011).  Thereafter, iatrogenic causes 
predominate (eg. following thyroid surgery, radiotherapy, drug induced causes (including 
antithyroid medication)).  Less common causes include thyroiditis (often recoverable) whose 
common aetiologies include postpartum-related, viral and drug-related.  Infiltrative causes 
for SH and PH are rare but include Sarcoidosis, Amyloidosis, lymphoma and 
haemochromotosis-related causes (Bharaktiya et al 2012).  Genetic causes for PH, although 
seemingly rare are an important group and one of the major causes for congenital 
hypothyroidism (CH). Genetic causes for SH are rarely explored.  
 
ATD is believed to relate to genetic susceptibility (~70-80%) and environmental triggers (~20-
30%), (Hansen et al 2006).  Risk factors for developing autoimmune hypothyroidism include a 
family history (FH) of ATD (particularly >1 member), having positive TPO antibodies (risk 
increaing with the antibody titre (Strieder et al 2008, Brent 2010)) and possibly low birth 
weight (Phillips et al 2002). Environmental triggers include drugs (i.e; Amiodarone (Rabinowe 
et al 1986), Interferon-α (Carella et al 2004), antiretrovirals (Chen et al 2005), Campath-1H 
(Cossburn et al 2011) and radiation exposure (Eheman et al 2003).  Other acquired causes 
include pregnancy (post-partum presentation typical (Muller et al 2001), iodine exposure 
(Foley 1992) and infections are implicated (Desailloud 2009, Tomer & Davies 1993).   
Smoking is negatively associated with Hashimoto’s thyroiditis and positively associated with 
GD (Krassas & Wiersinga 2006).  
 
ATD is characterised by lymphocytic infiltration of the TG.  In practice the diagnosis is based 
on clinical presentation and evidence for ATD (i.e. supportive biochemistry, immunology, 
histology or radiology (Weetman 2004)).  Although most patients with ATD are TPO antibody 
+ve, a proportion are seronegative (Dayan & Daniels 1996).  ATD evolves to subclinical disease 
that may progress to hypo- or hyperthyroidism.  Autoimmunity occurs as a consequence of 
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loss of immune tolerance resulting in antigens from thyroid tissue being presented on antigen 
presenting cells. The antibody-antigen interaction stimulates an immune response (Chistiakov 
2005) causing lymphocytic infiltration and inflammation of the TG (Devendra & Eisenbarth 
2003).  Thyroid antigens (with complementary autoantibodies) exist singly or multiply in 
affected individuals and include TSHR, TPO, Na/I symporter and thyroglobulin.  TSHR 
antibodies in Hashimoto’s hypothyroidism have a blocking effect, whilst in GD TSI are 
stimulatory.   
 
CH describes hypothyroidism existing at birth, and typically diagnosed in the neonatal period. 
Primary CH is categorised as dyshormonogenesis, where the TG appears normal but its ability 
to produce thyroid hormone is compromised (due to thyroid biosynthetic defects). Whereas 
in thyroid dysgenesis thyroid hormone deficiency corresponds to an abnormally developed 
TG (hypoplasia, ectopy or athyreosis) (Park & Chaterjee 2005).  Thyroid dyshormonogenesis 
and dysgenesis are distinguished radiologically and biochemically (with thyroglobulin 
assessment (Rastogi & LaFranchi 2010)).  A significant delay in the diagnosis and treatment of 
severe CH (where thyroxine replacement therapy (TRT) is indicated) will result in irreversible 
learning difficulties.  Routine screening for CH was introduced in the UK in 1981 (Department 
of Health and Social Security 1981) and CH is diagnosed in 1/3000 - 1/4000 infants (Gruters 
1996).  A CH female preponderance is recognised (LaFranchi et al 1979). 
 
Dyshormonogenesis accounts for ~10-15% of cases of permanent primary CH and is believed 
to occur as a consequence of epigenetic and genetically determined defects in thyroid 
biosynthetic enzymes (Rastogi & LaFranchi 2010).  This includes defects in TPO, Na/I 
symporter, thyroglobulin, Pendrin, DUOX2 and faults in the hydrogen peroxidase-generating 
system (Jordan et al 2003).  Dyshormonogenesis tends to be autosomal recessive (AR), (Al Taji 
et al 2007).  
 
Thyroid dysgenesis explains ~85% of cases of permanent primary CH (Rastogi and LaFranchi 
2010). It is typically sporadic in presentation with ~2% of cases being familial (Castanet et al 
2000).  The cause remains elusive in most cases, reflecting limitations in knowledge of the 
developmental origins of the TG (Rastogi & LaFranchi 2010).  Genetic causes include defects 
in the TSHR, Gsα, thyroid transcription factors (TTF) (including TTF-1, Pax-8, and FOXE1).  
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When the cause relates to Gsα or TTF defects a syndrome of abnormalities results. This 
reflects the non-organ specific developmental expression of these factors (Trueba et al 2005).   
 
TSHR inactivating mutations can be carried in the homozygous or heterozygous state. 
Homozygous (or compound heterozygous) mutations are typically associated with CH (or SH 
with a markedly raised TSH; Alberti et al 2002) whereas heterozygous mutations (one affected 
and one unaffected allele) are typically associated with SH (and a mild to moderate TSH rise).  
The mode of inheritance is generally described as AR (de Roux et al 1996, Jordan et al 2003, 
Park et al 2004) and genotype/ phenotype correlations described as poor (even amongst 
subjects with the same mutation (Camilot et al 2005)).   
 
The prevalence of heterozygous TSHR mutations (and variant alleles) in non-autoimmune SH 
has been explored infrequently.  This was evaluated independently in two Italian paediatric 
cohorts where its prevalence varied from 11% (n=13/116; Camilot et al 2005) to 30% 
(n=11/38; Nicoletti et al 2009).  This was evaluated in one adult cohort where sporadic cases 
and their SH relatives were screened.  They reported a prevalence of 12% (n=5/42), and all 
cases were familial not sporadic (Tonacchera et al 2004).  Jordan et al (2003) suggested that 
the prevalence of the TSHR nonsense mutation W546X (in its heterozygous state) affected 
~1/180 in a Welsh population (without known thyroid dysfunction (affected 2/368).  
 
It is likely that many cases of non-immune SH are genetically determined but rarely explored.  
These could relate to mutations (or possibly polymorphisms) affecting the thyroid 
biosynthetic and/or developmental enzymes; steps within the cell sequencing cascades, or 
relate to other factors influencing thyroid function.  Studies suggest that TFTs in health are 
tightly regulated, and that inheritance plays a large part in determining these values. 
Estimates suggest that TSH values are ~65% hereditary and FTHs are ~40-50% hereditary 
(Panicker et al 2011).  
 
Genome Wide Association Studies (GWAS) have identified gene polymorphisms that associate 
with TSH values. However their individual contributions to TSH on a population scale are small 
(<4%).  Those receiving particular attention include FOXE1, the mineralocorticoid receptor 
(NR3C2), TSHR, and phosphodiesterase 8B (PDE8B). PDE8B catalyses the hydrolysis and 
inactivation of cAMP, thus increased PDE8B activity would be expected to precipitate a rise 
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in TSH.  This was supported by association studies (Arnaud-Lopez et al 2008, Taylor et al 2011).  
In these studies the FOXE1 polymorphism was negatively associated with TSH (Medici et al 
2011, Taylor et al 2015) as was D727E (the best studied of the TSHR polymorphisms (Panicker 
et al 2011)); whilst the NR3C2 polymorphism was positively associated with TSH (Rawal et al 
2012, Taylor et al 2015).  
 
1.7 Physical effects of thyroid dysfunction 
 
The association between thyroid dysfunction and changes in body composition are well 
recognised.  The English physician Sir William Gull in 1873 appears to have been the first to 
associate atrophy of the thyroid gland with the hypothyroid phenotype (Pearce 2006).  The 
Swiss Surgeon Theodor Kocher was the first in 1888 to introduce TRT (by recommending 
consumption of sheep thyroid to thyroidectomised patients).  Kocher attributed their 
hypothyroid symptoms to thyroidectomy (Kazi 2003).  The Welshman Dr Caleb Parry in 1825, 
and the Irishman Dr Robert Graves in 1835 are recognised for their early descriptions of the 
hyperthyroid phenotype and for linking this to a thyroid goitre (hence the eponym Graves’ 
Disease (GD), (Graves 1835)).  
1.7.1 Hyperthyroidism 
Hyperthyroidism (or thyrotoxicosis) results in a range of physical changes (reflecting this 
enhanced metabolic state) including weight loss (despite hyperphagia), muscle wasting +/- 
myopathies (Kim et al 2013) including cardiomyopathies; heat intolerance, loose stools (from 
enhanced gut transit), bone loss with increased fracture risk (Lee & Ananthakrishnan 2011), 
catecholamine hypersensitisation (Ginsberg et al 1981) with associated resting tachycardia 
and tendency to tachyarrhythmias, systolic hypertension (with risk of heart failure, atrial 
fibrillation (AF) and stroke (Osman et al 2002)), tremor, agitation and anxiety (Schraga 2012).  
Serological abnormalities may include hypercalcaemia, hyperglycaemia, deranged liver 
function tests (LFTs) particularly transaminases (Thompson et al 1978) and elevated alkaline 
phosphatase (ALP) (of bony or hepatic origin (Tibi et al 1989, Schraga 2012).  Untreated 
hyperthyroidism curtails lifespan due to complications of the disease (particularly vascular 
events (Osman et al 2002)) or from systemic decompensation in the context of intercurrent 
illness (i.e. thyroid storm with a ~10-20% mortality despite treatment (Karger & Fuhrer 2008)).  
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Hyperthyroid effects in children include enhanced linear growth and bone maturity (Segni & 
Gorman 2001), which in neonates can cause craniosynostosis (Johnsonbaugh et al 1978).  
Hyperthyroidism in pregnancy increases complication risks, including pre-eclampsia, heart 
failure (Sheffield & Cunningham 2004), placental abruption, intra-uterine growth restriction, 
prematurity, stillbirth and neonatal mortality rates (Krude et al 1997).  
 
Additional effects specific to GD include Graves’ orbitoathy (GO) (affecting up to ~70% 
radiologically (Kahaly 2001), ~30% clinically (Tanda et al 2013) ~3-5% have severe disease 
(Wiersinga & Bartalena 2002)).  GO signs and symptoms include dry, gritty eyes, periorbital 
oedema, exophthalmos +/- optic neuropathies and myopathies (with risk to vision and eye 
movement (Bahn 2010)).  GD may be associated with thyroid dermopathy (localised 
myxoedema most commonly affecting pretibial skin (Lee & Ananthakrishnan 2011), affecting 
~13% with severe GO (Fatourechi 2005).  Thyroid arcropachy (disease of the extremities which 
become swollen, bulbous and severely clubbed) affects ~20% of those with thyroid 
dermopathy (Bahn 2010).  
 
1.7.2 Hypothyroidism 
The signs and symptoms generally depend on the degree of TG failure and age at onset.  
Symptoms may include weight gain, cold intolerance, brittle hair and nails, dependent 
oedema with thick, dry mottled, myxoedematous  skin and tissues (including macroglossia), 
a gruff deepened voice, generalised muscle weakness, slowing of mental and physical 
processes (somnolence, cognition, mood, peristalsis) with slowly relaxing reflexes being a 
classic feature on neurological examination (Bharaktiya et al 2012).  Menorrhagia and 
menstrual irregularities, erectile dysfunction in men, and sub-fertility in both sexes occur 
(Bharaktiya et al 2012).  Physical signs may include goitre, myxoedematous tissue and facies, 
hypertension (particularly diastolic with narrowed pulse pressure (Danzi & Klein 2003)), 
bradycardia and bradyarrhythmias, heart failure (Fazio et al 2004) and obstructive sleep 
apnoea.  In recent years an increased risk of bone fracture (which may not correct with 
treatment of hypothyroidism) is reported (Vestergaard & Mosekilde 2002, Vestergaard et al 
2005).  
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Hypothyroid abnormalities revealed from blood tests include hyponatraemia, 
hyperprolactinaemia, elevated creatine kinase, susceptibility to hypoglycaemia, normocytic 
anaemia (Bharaktiya et al 2012), hyperlipidaemia (Walton et al 1965) and deranged LFTs 
(Huang and Liaw 1995).  Profound untreated hypothyroidism leads to premature death either 
from complications of the disease (i.e. vascular events relating to accelerated 
atherosclerosis), or through a compromised ability to deal with the demands of often minor 
stresses, as seen in myxoedema coma (Mathew et al 2011).  
 
Hypothyroidism in children has additional effects reflecting its impact on growth and 
development.  This includes compromised growth, immature teeth and bones and delayed 
epiphyseal closure (with risk of slipped epiphysis (Foley 2004)), muscle pseudohypertrophy 
(Klein et al 1981, Shaw & Shaw 2012) (rare in adults) and sexual immaturity (although 
reversible precocious puberty is described (Foley 2004)).  Intellectual development is 
compromised with risk of permanent deficits when treatment is not initiated in a timely 
manner (particularly <3 years of age (Foley 2004)).  Adverse effects on mental functioning 
(thought processing, concentration and memory) will compromise a child’s ability to learn, 
although this is usually reversible with TRT.  
 
Hypothyroid infants can display the following additional signs: open cranial fontanelles, 
feeding and breathing difficulties, jaundice, hypotonia and umbilical hernia (Rastogi & 
LaFranchi 2010).  Historically individuals living with the consequences of untreated infant 
hypothyroidism were referred to as “Cretins”, in reference to their physical and mental 
disabilities (Bulugahapitiya 1972). 
 
Hypothyroidism in pregnancy carries additional risks for the mother and foetus (relating to 
gestational stage at onset) including an increased risk of miscarriage, stillbirth, pre-eclampsia, 
placental abruption (Mooney et al 1998), perinatal mortality (Van den Boogaard et al 2011) 
and compromised IQ in offspring (Haddow et al 1999, Smallridge & Ladenson 2001). 
 
Hyperthyroidism and hypothyroidism are therefore associated with significant harm 
untreated and correction is always recommended.  In contrast, the benefit of correcting 
subclinical thyroid diseases (ScTD) is less clear, accounting for considerable heterogeneity in 
their clinical management (McDermott et al 2003).  
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1.7.3 Subclinical Hyperthyroidism 
The recommendations are generally to treat persistent Shyper in older adults (>65 years; 
Cooper 2007, Bahn et al 2011), subjects with suboptimal bone mineral density (BMD), 
particularly postmenopausal women (Faber et al 1998, Mudde et al 1994, Bahn et al 2011); 
subjects experiencing tachyarrhythmias (Forfar et al 1981) or those with co-morbidities who 
would be compromised by hyperthyroidism or tachyarrhythmias (Haentjens et al 2008).  The 
risk of progression to hyperthyroidism may also influence this decision (a higher risk with an 
unmeasurable TSH (versus a sub-normal TSH (Diez & Iglesias 2009)) and with GD versus 
nodular thyroid diseases (NTD) (Rosario 2008).  
 
These recommendations are based on supportive data and expert opinion (Bahn et al 2011, 
Yang et al 2012).  However, evidence to show that these risks abate with treatment are 
generally lacking (Surks et al 2004, Blum et al 2015).  
 
1.7.4 Subclinical Hypothyroidism 
The international guidelines are generally unified in their recommendation to treat persistent 
SH when the TSH remains >10mmol/L (i.e. British Thyroid Association, American Association 
of Endocrinologists, and The Endocrine Society (Surks et al 2004, Garber et al 2012)), 
particularly in subjects <65 years of age (Pearce et al 2013).  At this threshold the evidence 
for a benefit from treating SH in regard to improvements in non-HDL cholesterol (Meier et al 
2001, Pearce et al 2013), cardiovascular risk parameters (Rodondi et al 2010) and avoidance 
of future hypothyroidism (~10% progress to hypothyroidism within 4 years (Somwaru et al 
2012)) are considered satisfactory. However, below this threshold much uncertainty remains.  
 
In the case of mild SH (TSH <10mU/L) it is generally recommended that subjects should be 
considered for treatment on an individual basis (Gharib et al 2005).  This group emphasise 
that a lack of good quality studies to support a treatment benefit (i.e. mood/ cognition (Jorde 
et al 2006), hypertension (Surks et al 2004, Fatourechi 2009), dyslipidaemiaa (Pearce 2012)) 
are not a reason to refute it (villar et al 2007).  They particularly advocate treating subjects 
with comorbidities that are known to improve with treatment of hypothyroidism (including 
hypertension, dyslipidaemia and vascular diseases), and those describing hypothyroid 
symptoms that improve following a trial of TRT (Pearce et al 2013). 
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Pregnant women with SH are considered separately and correction of mild SH (to pregnancy-
specific targets) are recommended (Beastall et al 2006, Abalovich et al 2007).  The data to 
support this practice, although adequate, are by no means consistent across studies (Cleary-
Goldman et al 2008, Reid et al 2010).  There is currently insufficient evidence to advocate 
screening women seeking pregnancy (or in early pregnancy) for thyroid dysfunction (Lazarus 
et al 2012).  However studies that may challenge this practice are in progress (including the 
Cardiff Antenatal Thyroid screening study (CATS) which is re-testing childhood cognitive 
function at age 9).   
 
The extreme elderly (>85 years) should also be considered separately in regard to TRT 
decisions in mild SH.  It is suggested that these subjects are less likely to progress to 
hypothyroidism, are usually asymptomatic, and a higher TSH and lower T4 show favourable 
mortality associations (Meneilly 2005).  Therefore routine treatment is not recommended 
(Pearce et al 2013).  A study by Razvi et al (2008) evaluated cardiovascular outcomes in a 
meta-analysis of SH subjects and reported adverse associations for those <65 years of age but 
not above 65 years.  These observations may reflect the rise in TSH with advancing age 
(Bremner et al 2012), indicating that it may be physiological in many aging subjects. 
 
1.8 Hypothesis building 
 
SH is a heterogeneous and prevalent condition where its natural history and optimum 
management may be aetiology specific.  The controversies and uncertainties surrounding this 
subject area highlight the need for greater research.  In the relatively recent past there have 
been an influx of studies (predominantly in vitro and animal studies) indicating that TSHR 
expression in extra-thyroidal locations might influence cellular processes locally.  
 
This new perspective questions traditional thoughts that attribute all of the physical changes 
occurring in thyroid disorders to aberrant FTHs. Instead, in primary thyroid diseases the more 
substantially and reciprocally altered TSH may be playing a part. 
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Extra-thyroidal TSHR may have a functional or developmental role in these locations. To 
explore this possibility further research has been conducted that aims to modulate TSHR 
activation (in cells, tissues or organisms) whilst seeking to minimise change in FTHs. 
 
My personal interest relates to potential TSHR related effects that may be relevant to body 
composition components (namely bone, fat (or adipose tissue) and muscle). Research that 
relates to these subject areas will now be discussed.  
 
1.9 Bone  
Hyperthyroidism (Lee & Ananthakrishnan 2011) and to a lesser extent Shyper (Faber et al 
1998, Mudde et al 1994)  are associated with accelerated bone turnover (BT) and bone loss; 
whereas hypothyroidism is associated with delayed bone maturity, increased fracture risk, 
and compromised bone healing (Murray 1900, Vestergaard P and Mosekilde 2002).  It is likely 
that SH also has effects on bone although this is less clear. 
 
An important bone disease from a socioeconomic perspective, in developed countries is 
osteoporosis.  Osteoporosis describes thin fragile bones with a propensity to fracture, 
however their mineral content is normal (Glaser & Kaplan 1997).  Osteoporotic fractures are 
common in older people affecting ~50% of women and ~20% of men over fifty (Kanis & Johnell 
2005).  Osteoporotic fractures impose significant morbidity with ~50% losing independence 
(Eddy et al 1998) and ~25% dying within a year of hip fracture (Cooper 1999).  In the UK the 
cost of osteoporotic hip fracture was estimated above ~2 billion pounds per year in 2007 
(British Orthopaedic Association 2007).  Thus associations between thyroid disorders and 
bone health, particularly those that may relate to SH (the most common thyroid condition) 
would be important from a public health and economic perspective. 
 
1.9.1 Background on bone cell biology  
Bone and bone cells function in a coordinated manner and adapt to mechanical and metabolic 
demands.  Bone is resorbed and renewed in a regulated fashion, coupling being the term to 
describe this process (Parfitt 1982).  Bone remodelling is considered in phases; “activation” 
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 when osteoclasts (and precursors) are drawn to the site, “resorption” mediated by 
osteoclasts, “reversal” accumulation of osteoblasts and precursors, “formation” mediated by 
osteoblasts, and ‘quiescence’ the time lag before the next cycle starts (Parfitt 1984).  In adults 
a remodelling cycle lasts ~150-200 days (Wojcicka et al 2013) and is accelerated ~30% in 
thyrotoxicosis (Eriksen et al 1985).  Thyrotoxicosis uncouples BT with greater effect on 
resorption than restoration resulting in a ~10% reduction in bone volume per cycle (Mosekilde 
et al 1990).  If remodelling remains uncoupled, metabolic bone diseases ensue.  The cells that 
mediate bone remodelling and restoration are the chondrocytes, osteoblasts, osteoclasts and 
osteocytes.  
 
Chondrocytes are cartilage forming cells that enable longitudinal growth (Hinchliffe & 
Johnson 1983) until the cartilaginous growth plates (epiphysis) close on attainment of final 
height (Haas 1917).  The mammalian skeleton is ossified from a cartilaginous framework 
(Robinson & Cameron 1956). Many factors control this process including the transforming 
growth factor (TGF-β) superfamily (including bone morphogenic proteins (BMPs)) and the 
vascular endothelial growth factors (VEGF), (Yang et al 2012).  Epiphyseal chondrocytes go 
through phases of maturation; proliferation, differentiation (to mature hypertrophic 
chondrocytes that synthesis cartilage) and apoptosis.  Apoptosis is followed by cell infiltration 
enabling ossification to occur (Rabier et al 2006).  Cartilage persists at the ends of adjoining 
bones with a role in dissipating force and protecting the joint and bone surface (Eckstein et al 
2006).  
 
Osteoblasts are responsible for bone formation (Millett et al 1995) and are derived from 
mesenchymal stem cells (MSCs) originating in bone marrow.  MSCs can differentiate into 
distinct terminal cells (Friedenstein et al 1974; Millett et al 1995) including myocytes, 
chondrocytes, adipocytes and osteoblasts (Y Zhang et al 2012).  Osteoblasts synthesise 
organic bone matrix (osteoid) and mineralise osteoid to mature bone (Millet et al 1995). 
Osteoblasts express the TNF-related protein RANKL (receptor activator of nuclear factor κβ 
ligand (Anderson et al 1997)) on their surface (Yasuda et al 1998).  RANKL interacts with 
osteoclast RANK receptors (with stimulatory effect) whilst its soluble variant encourages 
osteoclast differentiation.  M-CSF (Macrophage Colony-Stimulating Factor) is another 
osteoblast synthesised cytokine encouraging osteoclast differentiation (Tanaka et al 1993).  
Osteoprotegerin is a tumour necrosis factor (TNF) related protein (Simonet et al 1997, Yasuda 
24 
 
et al 1998) secreted by osteoblasts that interacts with RANKL (on its own surface), sterically 
hindering association with RANK (on osteoclasts) thereby controlling bone resorption.  The 
transcription factors Runx2 and osterix have a vital role in osteoblast differentiation (Sinha & 
Zhou 2013).  
 
Osteoclasts are multi-nucleated cells derived from the macrophage-monocyte lineage of 
heamopoetic stem cells (HSCs) in bone marrow (Boyle et al 2003).  Osteoclasts are responsible 
for dissolving and resorbing bone (Chambers & Hall 1991) with release of calcium and 
phosphate to the extracellular compartment (Silver et al 1998).  
 
Osteocytes are osteoblasts trapped in bone, ~10-20% of osteoblasts become osteocytes 
(Noble 2008).  Osteocytes produce proteins that influence bone behaviour locally including 
BT and biomineralisation (Bonewald 2011).  This is accomplished via a network of appendages 
radiating from the osteocyte.  Osteocytes produce many cytokines including TGF-β that 
suppresses bone resorption and encourages osteocyte formation (Mundy 1991), and 
sclerostin that suppresses osteoblast activity (Atkins et al 2011).  Sclerostin mediates its 
effects by interacting with the osteoblast’s Wnt co-receptors (LRP5 and LRP6), thereby 
moderating Wnt signalling (Silverman 2010).   
 
Wnt describes a family of secreted signalling proteins, highly conserved through evolution.  
They mediate effects in an autocrine or paracrine fashion and bind Wnt cell surface receptors 
(Krishnan et al 2006).  Wnt signalling occurs via the non-canonical and canonical pathways to 
moderate transcription of Wnt responsive genes (MacDonald et al 2009).  Wnt signalling is 
important in the growth, differentiation and maintenance of tissues, including bone (Krishnan 
et al 2006).  
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Figure 1.5: Flow diagram illustrating the differentiation pathways and terminal cell 
types originating in bone marrow 
 
 
In figure 1.5 the terminal cells are indicated by arrow heads,  dashed lines indicate the differentiation 
pathways followed (which commonly involve several differentiation steps) originating  from bone 
marrow. 
 
Wnt signalling has osteogenic effects.  This includes encouraging differentiation of MSCs to 
preosteoblasts (versus preadipocytes; Song et al 2012, Hamidouche et al 2008), encouraging 
osteoblastogenesis (Krishnan et al 2006), hindering osteocyte and osteoblast apoptosis 
(Bodine et al 2004) and suppressing osteoclast activity (Spencer et al 2006).  Inhibitors of the 
canonical pathway include secreted frizzled related proteins (Frz) that interfere with frizzled 
receptors i.e. dickkopf (Kawano & Kypta 2003) and sclerostin (Silverman 2010).  The 
importance of Wnt signalling is evident when these pathways are disrupted.  Loss of the LRP5 
co-receptor causes profound early onset osteoporosis in the osteoporosis-pseudoglioma 
syndrome (Gong et al 2001), whereas mutations in LRP5 that reduce dickkopf binding cause 
a high bone mass phenotype (Ai et al 2005, Boyden et al 2002).  Abnormal signalling in the 
non-canonical pathway (i.e. Wnt 5b) are a cause of Robinow syndrome (features include 
craniofacial dysostosis, shortened long limbs and genital defects (Person et al 2010).  Thus the 
canonical and non-canonical Wnt pathways are important in bone biology.  
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1.9.2 Thyroid hormones and bone biology 
FTHs have profound effects on bone. T3 has a stimulatory effect on osteoblasts primarily 
mediated by TRα1 (Bassett & Williams 2009).  TRα1 is the most prevalent of the osteoblast 
TRs, being ≥10 times as prevalent as TRβ (Xing et al 2012, O’Shea et al 2003) although other 
TRα and β splice variants are expressed (Milne et al 1999).  It is suggested that TRβ may 
mediate the immediate osteoblast response to a change in FTHs whilst TRα1 mediates the 
longer term response (Monfoulet et al 2011).   
 
Osteoclasts are stimulated by T3.  This appears to be through moderating the osteoblast 
RANKL/ osteoprotegerin ratio (as T3-osteoclast experiments in the absence of osteoblasts 
generally fail to show an effect).  TRs are probably expressed on osteoclasts (based on the 
extraction of TR mRNA from osteoclastoma cells (Allain et al 1996) and osteoclasts (Abu et al 
2000)).  
 
Chondrocytes are influenced directly and indirectly by FTHs (FTHs moderate the expression 
of Indian Hedgehog protein/PTH-related hormone and receptor expression for GH, IGF-1, and 
fibroblast growth factor (Bassett & Williams 2009)).  Hypothyroid epiphyses display 
disorganised chondrocyte columns and altered cartilaginous matrix, whilst this is essentially 
normal in hyperthyroidism (Stevens et al 2000, Freitas et al 2005).  FTHs accelerate 
hypertrophic chondrocyte differentiation but suppress chondrocyte proliferation (Robson et 
al 2000). TRα1, TRα2, and TRβ1 are expressed on chondrocytes (Ballock et al 1999); with the 
exception of terminal hypertrophic chondrocytes (Robson et al 2000).  The effect on 
epiphyses of knocking out TRs in mice (Bassett & Williams 2009) suggests TRα as the 
predominant receptor (particularly in long limbs).  However, TRβ predominates in neonatal 
mouse rib (Rabier et al 2006) and the TRβ agonist GC-1 ameliorates the skeletal effects of 
hypothyroidism (Freitas et al 2005). 
 
Deiodinase activities alter in bone cells in response to altered FTH levels.  In vitro studies 
confirm the presence of functional D3 in osteoblasts, osteoclasts and chondrocytes (Williams 
et al 2008).  D2 is the only activating deiodinase detected in bone, with expression restricted 
to mature osteoblasts (Williams et al 2008, Morimura et al 2005).  DI02 knockout mice have 
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increased bone fragility attributed to prolonged bone remodelling precipitating pathological 
mineralisation (Bassett et al 2010).  
 
DI02 expression is reported to increase in osteoblasts and human osteoblast-like 
osteosarcoma in vitro in response to TSH (forskolin or dibutyryl cAMP (Morimura et al 2005)).  
Upregulated DIO2 expression in response to TSH is also reported in other tissues including 
skeletal muscle (Hosoi et al 1999), rat brown fat (BAT) (Murakami et al 2001a) and thyroid 
tissue (Murakami et al 2001b).   
 
1.10 TSHR and bone 
The presence of TSHR on osteoblasts was first suggested by Inoue et al (1998).  Experiments 
on a rat osteosarcoma cell line (UMR106 cells) confirmed; TSHR mRNA expression (by 
Northern blotting); a cAMP response to synthetic TSH (or TSI), and radio labelled TSH binding.  
They also demonstrated a TSH-induced cAMP response from human osteosarcoma cells and 
mouse osteoblasts.  This group proposed a link between TSHR expression in bone and 
accelerated bone loss in GD.  
 
Tsai et al (2004) compared TSHR expression in osteoblast-like cells versus TSHR transfected 
CHO (Chinese Hamster Ovary) cells.  An osteoblast response required a 10-fold higher TSH 
concentration than transfected cells (correlating with TSH binding). TSHR mRNA was 
demonstrated in human bone samples using reverse transcription polymerase chain reaction 
(RT-PCR), but not with the more specific RNase protection technique.  This group suggested 
that osteoblast TSHR expression was probably insufficient to contribute to thyroid bone 
disease.  
 
Abe et al (2003) were the first to provide in vivo data indicating that TSHR has a functional 
role in bone.  This group examined BMD, bone histology and bone cell behaviour in TSHR null 
mice (-/-), heterozygotes (-/+) and wild types (WT), (+/+).  Null mice had CH with several 
thousand fold excess of TSH.  They were small, osteoporotic and died at 10 weeks. 
Heterozygotes were macroscopically normal with TFTs in the euthyroid range (T3s similar, 
mean T4s ~↑70%, mean TSHs ~↑30% although differences were not statistically significant).  
Heterozygotes were macroscopically normal but had low BMD.  The null mice were re-
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examined following TRT at weaning.  Although their growth, weight and TFTs at 6 weeks were 
similar to WT (T4s and TSHs were similar, T3 ~↑15% although not statistically dissimilar) BMD 
remained low. Histological assessment of the null mice on TRT revealed woven rather than 
lamellar bone (indicative of high BT), focal osteosclerosis and a 50% increase in mineralisation 
sites.  
Evaluation of bone marrow cultures in the null and heterozygous mice revealed a doubling of 
osteoclastogenesis (believed to be mediated by macrophage TNFα) and increased osteoblast 
differentiation (probably Wnt and VEGF mediated).  Experiments assessing WT cell responses 
to TSH indicated reduced osteoclast activity and osteoblast activity (reflected by protein 
expression profiles), whereas a response was absent in the TSHR null cells.  This group 
concluded that TSHR was functional in bone and described TSHR as a “negative regulator of 
skeletal remodelling” (Abe et al 2003).  The observations of this group has since been 
supported by a similar study (Zhang et al 2014). 
 
Interestingly, a CH child in our unit (homozygous for the inactivating W546X TSHR mutation 
(TSHR-M)) was diagnosed with a benign osteoblastoma (unpublished observation JW Gregory 
& M Ludgate in de Lloyd et al 2010).  The pathogenesis of this condition would fit with the 
suggestion that diminished TSHR function in bone upregulates osteoblast activity (Abe et al 
2003).   
 
Sampath et al’s work supports the notion that enhanced TSHR signalling in bone has 
osteogenic effects.  This group evaluated aged, ovariectomised rats who were administered 
intermittent intraperitoneal TSH for 8 weeks (versus non-ovariectomised controls).  This was 
initiated early post ovariectomy (n=80), or 7 months later (n=152).  Exogenous TSH was found 
to lessen ovariectomy-induced bone loss, and enhance bone accrual and strength in the 
ovariectomised groups. Interestingly this treatment did not affect FTHs (Sampath et al 2007).  
 
Analysis of the ovarectomised rodent’s bone marrow indicated a suppressive effect on 
osteoclast differentiation, and an enhanced effect on osteoblast activity (not seen in non-
ovariectomised controls).  The group concluded that exogenous TSH has anabolic and anti-
resorptive effects on hypogonadal rodent bone (Sampath et al 2007).  A subsequent paper by 
this group advocated exogenous intermittent TSH as a potential future therapy for post-
menopausal osteoporosis (Sun et al 2008). 
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The mechanism by which TSH infusions exert anabolic effects on rodent skeleton have been 
explored.  A favourable osteprotogerin-RANKL ratio probably explains enhanced 
differentiation of MSCs to osteoblasts; a dose-dependent increase in non-canonical Wnt 
components during osteoblast differentiation was observed (Frz and Wnt5a), and is expected 
to increase osteoprotegerin locally.  The effect on MSC differentiation is believed to be PKC 
pathway mediated (given that upregulated PKC phosphorylation was observed (on Western 
blots versus no change in PKA); abrogated by the PKC inhibitor rotterlin (Baliram et al 2011)).   
 
Mazziotti et al (2005) evaluated the effect of exogenous recombinant TSH (rhTSH) on 
thyroidectomised subjects with Shyper (on TRT) with history of thyroid cancer (n=66; 38 pre-
menopausal, 28 post-menopausal).  Bone parameters were compared against age-matched, 
healthy controls (with no thyroid disorders) with comparable FTHs.  Baseline assessments 
showed elevated osteoprotegerin and BTMs, and lower BMDs (assessed at finger phalange) 
in Shyper subjects relative to controls.  The postmenopausal Shyper subjects had lower BMD 
and elevated bone-specific ALP. RhTSH caused TSH >100mU/L at day 2 post administration, 
without a change in FTHs.  At day 2 an acute inhibition of bone resorption markers in the 
postmenopausal but not the pre-menopausal group was seen, associated with a rise in ALP. 
BTMs normalised at day 7 but ALP remained raised.  Osteoprotegerin was unaffected.  This 
group concluded that TSH influences bone physiology in humans and its effects are more 
apparent in post-menopausal women who are susceptible to Shyper induced bone loss. 
 
1.10.1 Human studies exploring TSH-bone relationships 
These data are less robust than the animal data and in the main relate to observational 
association studies. It is clear that there is much discrepancy between studies and the effect 
of TSH on bone (as distinct from the FTHs) remains uncertain.  I have summarised several 
bone-related studies that assessed TSH-bone associations:- 
 
 Table 1.4 reports adverse associations between Shyper and bone parameters.  
 Table 1.5 reports adverse associations between low-normal TSHs (in euthyroid 
subjects or those without known thyroid dysfunction) and bone parameters.  
 Table 1.6 reports positive associations between TSH and bone parameters. 
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Table 1.4:  Studies reporting TSH-bone associations in subclinical hyperthyroidism 
 
Paper Summary of study Key observation 
Lehmke 
et al 
1992 
Evaluated BMD in Shyper subjects related to TRT 
and a past history of thyroid cancer (n=55; 9♂, 25 
pre-menopausal♀, 21 post-menopausal♀). BMDs 
were compared with a healthy reference 
population. 
BMD deficits were reported in the 
appendicular skeleton of post-
menopausal♀ only. 
Mudde  
et al 
1994 
Evaluated 20 postmenopausal♀ with Shyper 
related to NTD, 8 were treated with Carbimazole 
(to normalise TSH). Forearm BMD and BTMs were 
assessed at baseline and over 2 years. 
BMD was higher in the distal 
forearms of the treated subjects. 
There were no differences in BTMs. 
Guo        
et al 
1997 
Evaluated BMD and BTMs in postmenopausal♀ 
on TRT (n=64) over a 2 period (23 euthyroid, 41 
Shyper). Those with Shyper had their TRT doses 
amended to normalise TSH.  
Beneficial changes in BMD and BTM 
were seen in those in whom 
suppressed TSHs were normalised. 
Bauer     
et al 
2001 
Evaluated fracture incidence in postmenopausal♀ 
>65 years (n=686). TSH was assessed in subjects 
with new fractures (148 hip, 149 spine) versus 
398 randomly selected controls. FTHs were not 
evaluated. 
TSH <0.01mU/L was associated with 
a 3 fold increase in hip fracture and 4 
fold increase in lumbar fractures.  
Kisakol   
et al 
2003 
Evaluated BTMs and calcium excretion in patients 
with SH (n=20), Shyper (n=13, all related to GD) 
and euthyroid controls (n=10). 
BTMs and calcium excretion were 
elevated in subjects with Shyper 
only. 
Svare     
et al 
2009 
HUNT2 data on 5778♀ >40 years of age. All had 
TFTs and BMD assessed at the distal forearm. 
A low TSH (<0.5mU/L) associated 
with lower BMD. A history of 
hyperthyroidism associated with a 
higher incidence of osteoporosis. 
Blum      
et al 
2015 
Meta-analysis evaluating fracture risk and 
subclinical thyroid conditions. Collective n= 
70,298 (Prevalence: Shyper ~3%, SH~6%). 
Associations between Shyper and 
fractures reported (HR 1.28, C.I; 
1.06-1.5), but not for SH. 
 
In tables 1.4-1.6 the abbreviations and symbols are as follows: ♀; Female, ♂; Male. BTMs; bone 
turnover markers, BMD; bone mineral density, TRT; thyroxine replacement therapy. Shyper; subclinical 
hyperthyroidism. SH; subclinical hypothyroidism. HR; hazard ratio. C.I; confidence interval, FTHs; free 
thyroid hormones. TFTs; thyroid function tests.  
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Table 1.5:  Studies reporting adverse associations between low-normal TSH and bone 
parameters (in subjects euthyroid, or without known thyroid dysfunction) 
 
 
Paper Summary of study Key observation 
Bertoli    
et al 2002 
Bone mineral content and BMD 
assessed in 32 pre-menopausal♀ 
alongside anthropometric data 
and TFTs. 
A positive association between femoral BMD and 
TSH reported (but no independent associations 
at the spine). 
Kim         
et al 2006 
Evaluated BMD and TFTs in 959 
healthy, post-menopausal 
Korean♀. They compared those 
with low-normal (0.5-1.1) versus 
high-normal TSHs (2.8-5mU/L).  
Association between low-normal TSHs and; 
incidence of osteoporosis (95% C.I; 1.2-4) and 
lower BMD (at lumbar spine and femoral neck).  
Grimnes 
et al 2008 
Evaluated BMD (hip and 
forearm) and TFTs in healthy 
older adults (993♀ and 968♂). 
Reported a negative association between BMD 
at distal forearm and sub-normal TSH (n=46); a 
positive association between BMD at femoral 
neck and TSH >97.5th % in ♀s (n=25).  No 
associations between normal range TSHs and 
BMD seen.  
Morris 
2007 
American NHANES data (included 
BMD and TFTs) on 581 
postmenopausal♀. 
A higher rate of osteoporosis (x 5) and 
osteopenia (x 3) was apparent amongst those 
with low-normal TSHs (0.39-1.8) versus higher-
normal TSHs (1.8-4.5mIU/L). TSH correlated 
positively with BMD.  
Murphy  
et al 2010 
Evaluated BMD and TFTs in 1278 
healthy post-menopausal♀.  
Non-vertebral fracture incidence correlated 
negatively with TSH (minus 35%; P-value 0.028) 
and positively with T4. Hip BMD correlated 
negatively with T4. However, the independent 
influence of TSH could not be determined. 
Mazziotti 
et al 2010   
Evaluated 80 postmenopausal ♀s 
newly referred to an 
osteoporosis clinic. 
Association between low-normal TSH (0.66-1.07 
mU/L) and vertebral fracture seen (versus TSH 
1.13-3.2mU/L (p-value 0.004)). This association 
persisted despite correction for T4.  
Chin        
et al 2013 
Chinese/ Malaysian cross-
sectional study evaluating TFTs 
and calcaneal BMD in adult men 
with no known thyroid disorders. 
Positive correlations between indicators of heel 
BMD and TSH were identified (R +0.08, p-value 
0.04, n=681). 
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Table 1.6:  Studies reporting an adverse association between subclinical 
hypothyroidism and bone parameters. 
 
Paper Summary of study Key observation 
Lee          
et al 2006 
BMD and TFTs were evaluated in 
♀subjects (n=413) without hyper or 
hypothyroidism. 
BMD was significantly lower (at femoral neck 
not lumbar spine) in those with Shyper or SH 
versus euthyroid subjects.  
Nagata    
et al 2007 
TFTs and calcaneal BMD evaluated 
in SH postmenopausal♀ (n=22) 
versus euthyroid controls. 
A negative association between calcaneal 
BMD indicators and TSH was reported and a 
lower bone score observed in SH subjects 
than controls. 
Lee          
et al 2010 
Evaluated 3567 US subjects >65 
years prospectively (over 13 years) 
excluding those with hyper and 
hypothyroidism. 
Fracture incidence was higher for males with 
endogenous Shyper (HR 5; 95% C.I; 1.1-21) 
and endogenous SH (HR 2.5 (95% C.I; 1.3-4.7) 
than euthyroid controls. This association was 
not seen in females. 
Polovina 
et al 2013 
FRAX score (fracture risk predictor) 
and BTMs were compared in post-
menopausal♀ with SH (n=82) versus 
euthyroid controls. 
FRAX score was higher in subjects with SH 
and particularly those with thyroid 
autoimmunity. BTMs were no different. 
Liang       
et al 2014 
Evaluated BMD, TFTs and bone 
profile in SH subjects (n=122) and 
controls.  
SH was associated with lower BMD. 
 
The Abe et al paper (2003) that linked TSHR activation in bone to bone health led researchers 
to evaluate bone parameters in subjects bearing the TSHR D727E polymorphism.  This 
polymorphism is associated with lower TSH values (Peeters et al 2003) suggesting increased 
TSHR sensitivity.  Consistent with this hypothesis Gabriel et al (1999) reported an exaggerated 
cAMP response to TSH versus WT, however this finding was not reproduced by other groups 
(Nogueira et al 1999).   
 
Van Der Deure et al (2008) evaluated associations between BMD (at lumbar spine and hip) 
with the D727E polymorphism in a prospective cohort of 4801 subjects >55years of age 
without known thyroid diseases.  TFTs were assessed in 1089 subjects.  The D727E allele  
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frequency was ~6% (~11% heterozygous and 0.2% homozygous).  Femoral neck BMD was 
reported to be ~2% higher in D727E carriers (0.88 ± 0.01 versus 0·86 ± 0·01, p-value 0.03), an 
association that strengthened with correction for TSH.  In this study TSH showed a weak 
positive association with BMD, and T4 a negative BMD association (Van der Deure et al 2008).  
 
A Chinese study by Liu et al (2012) evaluated the prevalence of D727E in a cohort of 
osteoporotic male subjects (n=150) versus healthy non-osteoporotic controls.  Its prevalence 
was ~9% in osteoporotics and ~5% in controls (p-value <0.05).  They reported lower BMD 
indicators at the calcaneum in the D727E carriers.  Their conclusion opposed that of the 
previous group associating this polymorphism with lower BMD values.   
 
1.10.2 TSHR-bone data not indicating an independent association with TSH  
A number of academics remain sceptical or opposed to the notion that TSH-TSHR activation 
in bone has physiological effects that are independent of FTHs.  One of the principal counter 
arguments relates to the reciprocal relationship between TSH and T4 (in subjects with an 
intact HPT axis) making it difficult to delineate the independent influence, in vivo, of the 
respective hormones.  Therefore, when interpreting subclinical thyroid data, although the 
FTHs are considered to be normal relative to the population range, in Shyper they are 
relatively high (relative to the individuals preferred set point) and the inverse true of SH. Thus 
the assumption that FTHs do not contribute to the phenotype in these conditions may be 
misleading (Bassett & Williams 2008).  
 
Bassett and Williams have published prolifically on thyroid-bone biology and have led on the 
counter debate regarding TSHR signalling in bone.  Their work has explored the skeletal 
effects in mice of knocking out TRα, then TRβ, then both simultaneously to disrupt the HPT 
axis.  This indicated T3 via TRα as the primary TFT parameter mediating bone effects.  They 
observed that despite an excess of TSH(x400), T4(x15) in mice homozygous for a dominant 
negative TRβ mutation; the skeletal effects of thyrotoxicosis were not ameliorated by an 
extremely high TSH. Similarly the skeletal effects of hypothyroidism in TRα knockout mice was 
not ameliorated by normal TSH values (Kaneshige et al 2000, Bassett & Williams 2008).   
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Bassett et al (2008) compared skeletal phenotypes in genetically engineered CH mice (3 per 
group) with functional TSHRs but no thyroid (Pax8-/-), versus no functional TSHRs (Hyt-/-; T4 
~5% of normal); both had grossly elevated TSH.  The skeletons of these mice were reported 
to be similar, and consistent with the expected effect of profound hypothyroidism. The 
skeletal abnormalities in Hyt-/- mice appeared to resolve completely when TRT was given 
(despite barely functional TSHRs), and the skeletons of heterozygous Hyt-/+ mice (with 
relatively normal TFTs) appeared to be normal.  The investigators went on to evaluate the 
effects of TSH ex-vivo on primary osteoblasts and osteoclasts and a cAMP response to TSH or 
TSI was not detected (in contrast to the aforementioned studies).  Thus, this study suggests 
against TSHR having significant effects on bone physiology (Bassett et al 2008).   
 
However, when critically appraising this paper I make the following observations: despite 
fairly marked differences in thyroid hormone levels between the groups (none in Pax8-/- 
versus low levels in Hyt-/-) this did not appear to influence the skeletal phenotype despite 
there being no question over the influence of FTHs on bone. Similarly the Hyt-/+ mice had less 
thyroid hormone than WT (4.8mg/dL +/- 0.7 versus 5.7mg/dL +/-0.8) albeit an insignificant 
difference for the low numbers evaluated, which again appears inconsequential.  I propose 
that a higher TSH in these mice might counter balance an effect from lower T4 on bone.  
Clearly very low subject numbers limits the power of this study to identify differences.  The 
authors focus on the similarities between the mouse skeletons, whereas differences such as 
the femoral bone densities (~18% less than WT in Hyt-/-  versus  ~6% less than WT in Pax8-/-) 
are not considered to be important.  Finally it is possible that the influence of TSHR activation 
in bone may be lost in the context of profoundly abnormal FTHs which does not exclude an 
effect in other circumstances. Nonetheless this work provides evidence against the notion 
that TSHR has direct effects on bone.  
 
In reference to the Abe paper of 2003, Bassett and Williams offer a different interpretation.  
They suggest that the cause of low neonatal BMD in TSHR-/- mice is likely to relate to profound 
hypothyroidism at this crucial stage of development (rather than reduced TSHR signalling). 
The fact that the bone parameters did not normalise completely (in TSHR-/- mice) despite TRT 
at weaning (age 3 weeks) probably reflects the effects of neonatal hypothyroidism, and 
hypersensitivity to TRT thereafter.  The reduced BMD in the heterozygous animals they feel  
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is overstated, being only ~6% below WT.  However, this interpretation has been challenged; 
although neonatal hypothyroidism adversely affects bone quality (epiphyses and bone 
morphogenesis), a remodelling defect is not expected (Gothe et al 1999).  Nonetheless their 
points are valid and correcting for these factors is very difficult. 
 
Bassett and Williams’ review article (2008) raises additional counter concerns regarding the 
TSHR - BMD notion.  These include inconsistent data relaying TSH’s effect on osteoblast 
differentiation (enhanced differentiation reported by Sampath et al (2007), suppressed 
differentiation described by Abe et al (2003) and absent effects observed in their studies 
(Bassett et al 2008)) and the fact that TSI in GD does not appear to protect against 
thyrotoxicosis-related bone loss. However, the clinical studies required to determine the 
influence (if any) from TSI on bone requires adequate subject numbers (with GD versus NTD), 
appropriate matching (age, health, thyroid function (grade & duration), treatment modalities 
and subsequent TFTs) and a sufficient period of observation to confidently determine or 
exclude BMD differences.  Unfortunately such studies are nearly impossible to perform.  
 
Table 1.7 summarises several studies that have attempted to differentiate bone effects in 
subjects with and without GD. It can be seen that In general differences are not seen.  
 
There are many human studies that do not suggest independent TSH - bone associations.  
Several of these studies are summarised in table 1.8.  
 
In regard to making sense of these discrepant reports it is important to remember that 
hormones can have different effects in different environments.  Therefore discrepant effects 
in different environments (i.e. thyroid status related, gender or age-related, duration 
dependent etc) is not a reason to disregard an association.  However, the information 
displayed in tables 1.4-1.8 demonstrate the ongoing uncertainties relating to the TSH - bone 
relationship.  
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Table 1.7:  Studies comparing bone parameters in subjects with Graves’ disease versus 
nodular thyroid disease.  
 
Paper Summary of study Key observation 
Jódar et 
al 1997 
Evaluated BMD in a heterogeneous 
group (regards age, sex, severity & 
duration) with current (n=78) or 
previous (n=49) hyperthyroidism and 
healthy controls (n=43). Aetiology of 
hyperthyroidism was NTD in 25 and 
GD in 102 subjects. 
A generalised decrease in BMD was evident 
in the spine of hyperthyroid subjects that 
improved (not normalised) with treatment. 
No BMD differences related to aetiology of 
hyperthyroidism.  
Senturk 
et al 
(2003) 
Evaluated osteotrophic cytokines; 
Interleukin 1, 6 & 8 and TNFα in 
patients with hyperthyroidism; 14 GD, 
and 36 NTD (versus 30 euthyroid 
controls). 
Cytokines were elevated in hyperthyroidism 
with no differences relating to aetiology.  
Amato et 
al 2004 
Evaluated osteoprotegerin levels in 
hyperthyroid subjects (GD; 93, NTD; 
21) pre and post correction with 
methimazole versus 68 age and sex 
matched controls. 
Osteoprotegerin levels associated with FTHs 
and normalised more slowly with treatment 
in GD than NTD. At 1 year (study end) BTMs 
were similar in treated subjects and 
controls.  No differences related to the 
aetiology of hyperthyroidism. 
Antonelli 
et al 
2006 
Evaluated CXCL10 (an interferon-
inducible chemokine associated with 
osteoclast differentiation (Grassi et al 
2003, Lee et al 2012)) in subjects with 
hyperthyroidism (33 GD, versus 11 
NTD), pre and post methimazole 
treatment. Also evaluated in 11 
thyroidectomised subjects (relating to 
thyroid cancer), on TRT. 
CXCL10 levels were higher in GD (than NTD 
despite similar TFTs) and dropped in GD on 
methimazole. Administration of rhTSH to 
the thyroidectomised subjects did not affect 
levels. They concluded that CXCL10 was 
associated with autoimmunity and did not 
relate to TSHR activation.  
El Hadidy 
et al 
2011 
Evaluated BT and BMD in 52 men with 
treated hyperthyroidism; 31 had GD 
and 21 had NTD. They were compared 
against healthy, euthyroid, age-
matched controls (n=25). 
Hyperthyroid-treated subjects had similar 
BT and BMD, irrespective of cause. Their 
BMD was lower than controls. BT correlated 
negatively with TSH and positively with 
FTHs.   
 
Abbreviations for tables 1.7 and 1.8 are as follows: GD; Graves’ disease, NTD; Nodular thyroid 
disease, BTMs; Bone turnover markers. rhTSH; recombinant TSH, ♂; Male, ♀; Female, TRT; thyroxine 
replacement therapy.  
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Table 1.8:  Studies that do not identify independent TSH-bone associations.  
 
Paper Summary of study Key observation 
Gürlek & 
Gedik 1999 
Evaluated BT and BMD (at lumbar spine) in 15 
premenopausal ♀ with Shyper (TSH<0.1) against 
age- and build-matched euthyroid controls. 
No differences in BMD or 
BT parameters apparent 
between the groups. 
Heijckmann   
et al 2005 
Evaluated BMD (spine and hip) in subjects 
thyroidectomised (relating to thyroid cancer), on 
TRT with TSH <0.05 (n=59). Their DXA Z-scores 
were compared against the NHANES reference 
group.   
BMD was not significantly 
different in the Shyper 
group versus the reference 
cohort. 
Reverter        
et al 2005 
Evaluated BMD in thyroidectomised subjects 
(relating to thyroid cancer) on TRT with Shyper 
(n=88) versus healthy euthyroid age-matched 
controls (n=88). 
BMD was not lower in the 
Shyper group versus 
controls. 
Giusti             
et al 2007 
Evaluated BTMs in response to rhTSH in 
thyroidectomised subjects with a history of thyroid 
cancer (n=24; 7♂, 7 pre-menopausal ♀, and 10 
post-menopausal ♀).  
BTMs (osteoprotegerin 
and RANKL) did not alter in 
response to rhTSH 
administration. 
Papadimitriou 
et al 2007 
Evaluated BMD and BTM on ♂child siblings with CH 
(on TRT) due to a TSH-β mutation causing low TSH.  
BMDs and BTMs were 
within the normal 
reference range for age.  
Roef                
et al 2011 
Evaluated BMD and TFTs in healthy ♂s aged 25-45 
years (n=677). 
An inverse association 
between FTHs (within the 
normal range) and BMD 
was seen but no BMD-TSH 
associations. 
Di mase           
et al 2012 
Evaluated BMD in 36 SH children and adolescents 
with untreated SH versus 25 age- and sex-matched 
healthy euthyroid controls. 
BMD was not significantly 
different between the 
groups.  
Marawaha     
et al 2012 
Examined BMD and TFTs in 1290 Indian subjects 
<50 years old (1115 euthyroid, 175 with SH). The 
participants had no history of overt thyroid 
dysfunction. 
No associations between 
TSH and BMD was 
revealed. 
Van Rijin        
et al 2014 
Evaluated peri-menopausal Dutch ♀s with no 
history of thyroid or bone disorders (n=1477). 
Subjects with SH, TPO antibodies or aberrant T4 
were excluded. 
An inverse independent 
association between T4 
and BMD was seen but no 
TSH-BMD associations. 
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1.11 TSHR and Fat 
 
When considering fat cell biology it is important to be aware of the differences between 
white, brown (BAT) and orbital fat.  Whilst brown and white fat are derived from MSCs, orbital 
fat is derived from neuroectoderm (Billon et al 2008).  In addition ‘beige’ adipocytes are 
recognised (that behave like BAT given appropriate stressors (prevalent in the inguinal regions 
of rodents (Harms & Seale 2013)). Orbital fat resembles BAT in appearance and certain 
behaviours (Joel 1965).  Combs et al (2004) report that mice rendered hyperadiponectinaemic 
developed expanded interscapular BAT and exophthalmos indicating a common response 
from both depots.  The fact that hyper- and hypothyroidism have effects on fat mass (and 
temperature regulation) and GO (relating to TSI) precipitates pathological orbital 
adipogenesis suggests that TSHR activation affects adipose tissue.  
 
Rodbell (1964) reported TSH responsiveness from non-thyroid tissue after investigating the 
effect of TSH on rat adipocytes (testicular fat pad); concluding that it triggered lipolysis. 
Winand & Kohn (1972) postulated the presence of a “response element” in the retro-orbit (of 
guinea pigs) responsive to TSH and an “exophthalmogenic factor” (from the sera of GO 
subjects; likely to represent TSI).  Both enhanced ATPase activity which they surmised would 
be relevant to GO pathogenesis (indicating lipolysis occurring via the TSHR-cAMP-PKA 
pathway (de Lloyd et al 2010)).  Roselli-Rehfuss et al suggested the presence of TSHR in white 
and BAT based on the extraction of TSHR mRNA (messenger RNA) from these sources.  They 
proceeded to propose a role for adipocyte TSHR in thermogenesis (Roselli-Rehfuss et al 1992). 
 
Crisp et al (1997) from our unit demonstrated TSHR mRNA in human fat using Northern 
blotting analysis (and RT-PCR).  It was described to be at the limit of Northern blot detection 
in omental and subcutaneous fat, but readily detectable in GO orbit (as with TG).  They 
surmised that increased preadipocyte numbers in GO orbit may explain this observation.  
TSHR expression is recognised to be upregulated in fat depots undergoing adipogenesis (Crisp 
et al 2000, Haraguchi et al 1996), reflected by increased TSHR transcript numbers (Valyasevi 
et al 1999, Starkey et al 2003); a phenomenon exaggerated in GO. Starkey et al 2003 from our 
unit evaluated TSHR transcription rates in hyperthyroid and hypothyroid mouse fat depots.  
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Hyper- and hypothyroidism did not affect TSHR transcription rates despite being aggravating 
factors for GO (Walsh et al 1999). 
 
A study evaluating TSH effects on adipocytes from preterm human infants (or fetuses) 
revealed a lipolytic effect (not evident in older subjects in whom catecholamines are the 
primary mediator of lipolysis) (Marcus et al 1988, Janson et al 1995).  This observation might 
explain the physiological TSH surge, in neonates, in the first days of life (Oddie et al 1978). At 
this stage a lipolytic TSH effect to generate energy substrate, would be beneficial.  Indeed, 
neonatal adipocytes respond poorly to catecholamines (potentially reflected by a high α2: α1 
adrenoceptor ratio; α2 inhibits lipolysis (Marcus et al 1993, Elgadia et al 2010).  
 
Elgadia et al (2010) generated and investigated adipocytes from TSHR knockout mouse pups 
(in reality knockdowns).  Their adipocytes were 10 times less responsive to TSH-induced 
lipolysis (at physiological concentrations) than controls (although catecholamine-induced 
lipolysis remained normal).  Their adipocytes were larger and basal lipolysis rates higher, 
though similar if corrected for surface area.  They concluded that TSHR expression affects 
adipocyte function although its role was unclear.  
 
Endo and Kobayashi (2012) compared mouse fat stores in PH (through thyroidectomy) versus 
Hyt-/- mice (with non-functional TSHRs).  They noted proportionally reduced epididymal fat 
mass and adipocyte size in the thyroidectomised mice.  They then introduced functional TSHR 
into the Hyt-/- mouse’s unilateral fat pad (via plasmid injection and electroporation) and 
observed a 60% fall in fat mass compared with the control side (method performed using 
empty plasmid).  Lipase mRNA expression doubled in the TSHR-transfected fat pad.  They 
concluded that TSHR has a lipolytic role in the white fat of hypothyroid mice (Endo & 
Kobayashi 2012).   
 
By contrast Jiang et al (2015) report suppression of triglyceride lipase (TL) by TSH.  They 
evaluated adipocyte behaviour in TSHR knockouts (on TRT) versus WT mice, and investigated, 
in vitro, using the 3T3L1 cell line.  TSHR knockout adipocytes had substantially reduced TL 
relative to controls, and TL expression increased in the 3T3L1 cells during differentiation, but 
fell in mature cells in response to TSH.   
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Several groups suggest a role for TSHR in BAT thermogenesis.  Endo and Kobayashi (2008) 
reported that Hyt-/- mice were profoundly hypothermic in cold conditions, despite TRT.  
However, when functional TSHRs were introduced into their BAT, their cold intolerance 
improved.  It is unclear if this observation is relevant to humans where neonatal BAT 
represents ~5% of their birth weight (Lean et al 1986) and declines with age.  However, 
positron emission tomography reveals small amounts of BAT in most adults in mediastinal, 
interscapular and cervical regions (Virtanen et al 2009 & Ouellet et al 2012).  In rodents, BAT 
has a role in non-shivering thermogenesis (BAT contains mitochondria expressing uncoupling 
protein (UCP1); enabling metabolic energy to dissipate as heat (Nicholls 1983)).  If this effect 
could be reproduced in human BAT, then an anti-obesity effect would be anticipated.  
 
Zhang et al (2006) from our unit manipulated GO pre-adipocytes to express a constitutively 
active TSHR (TSHR*).  These cells demonstrated increased early adipocyte differentiation 
markers and UCP1 expression, but reduced late differentiation markers and the cells were 
refractory to PPARγ induced adipogenesis.  A role for TSHR in the differentiation of pre-
adipocytes into BAT was suggested. 
 
TSHR expression is known to increase during adipogenesis. Zhang et al (2009a) from our unit 
evaluated the effect of TSHR* on the mouse 3T3L1 cell line against cells expressing GSP 
(activated Gsα) or transfected WT TSHR. GSP cells showed a reduction in PPARγ1 (non-tissue 
specific), undetectable PPARγ2 (fat-specific isoform required for adipogenesis) and 
unmeasurable phosphorylated FOXO1 (phosphorylated FOXO1 is ubiquinated and degraded, 
whilst FOX01 is a transcription factor that represses adipogenesis from PPARγ promotors 
(Armoni et al 2006).  The effect of TSHR* was intermediate between GSP and WT cells 
suggesting that Gsβγ signalling (via P13K) may be ameliorating these effects.  They concluded 
that Gsα signalling appeared to be suppressing adipogenesis in TSHR-expressing 
preadipocytes (Zhang et al 2009a).   
This observation could suggest that up-regulated TSHR expression during adipogenesis might 
serve to moderate adipogenesis.  In which case up-regulated TSHR expression in GO might be 
a protective response to pathological adipogenesis.  However, this hypothesis does not fit in 
with the observation that raised TSH in PH/SH aggravates GO.  
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Chen et al (2015) reported a reduction of fatty acid synthase (FAS) in mature adipocytes in 
response to TSHR signalling (PKA and ERK mediated).  Whilst TSHR expression and FAS were 
upregulated in obese mouse adipocytes. They suggested that TSHR effects may alter in 
obesity.  
 
Lu and Lin (2008) explored the effect of (supraphysiological) TSH concentrations on mouse 
embryonic stem cell differentiation.  TSH appeared to accelerate the terminal stages of 
adipogenesis, even in the absence of adipogenic factors.  It also enhanced TSHR expression 
on differentiation day 12. This effect appeared to be PKA pathway mediated.  They concluded 
that TSH was an adipogenic factor (Lu & Lin 2008).   
 
Kumar et al (2011) support this conclusion and report that TSI enhanced GO preadipocyte to 
adipocyte differentiation (in adipogenic medium).  They found that the P13K inhibitor 
hindered adipogenesis suggesting the effect was via the TSH-Gβγ-P13K pathway.  This group 
suggest that the contrasting observations from Zhang et al 2009 may relate to the transfection 
process itself. 
 
Lu et al (2012) evaluated TSHR expression in obese mice and humans (versus lean).  They 
observed increased TSHR expression (not corrected for fat mass) in obese mice, and an 
increased TSHR/actin ratio in obese humans relative to lean.  They also reported hindered 
adipogenesis in TSHR knockout 3T3L1 cells (versus controls) and concluded that TSHR 
expression was altered in obesity, and it may contribute to this process.   
 
In conclusion, there is ample data indicating that TSHR signalling influences adipocyte 
function.  It appears that its effects depend on the cell or organism, its differentiation 
potential or stage of development, its source (depot and origin), as well as its ambient 
environment.  However, at present the functional significance of TSHR signalling in adipocyte 
biology remains uncertain. 
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1.12 TSHR and Muscle 
 
Hyper- and hypothyroidism can precipitate pathological changes in muscle tissue.  This can 
range from subtle muscular symptoms to florid signs associated with histological 
abnormalities (i.e. myopathies, pseudohypertrophy).  Although skeletal muscle is most 
commonly affected, cardiac and extra-ocular muscle injury (in GO) occur.  
 
In GO the extra-ocular muscles are typically oedematous, inflamed and the surrounding 
connective tissues expanded (by glycosaminoglycans such as hyaluronan and chondroitin 
sulfate (Hansen et al 1999).  However, the myocytes generally remain intact (Hufnagel et al 
1984) until fibrotic transformation occurs late in the disease (Campbell 1989).  
 
Crisp et al (1997) from our unit investigated the presence of TSHR in human skeletal muscle; 
firstly via mRNA extraction and RT-PCR, and secondly via Northern blotting.  In neither 
method was TSHR demonstrated.  These results were consistent with subsequent reports 
evaluating abdominal skeletal muscle (Busuttil & Frauman 2001, Paschke et al 1993).  
 
Drvota et al (1995) published data supporting the presence of TSHR in human heart.  This was 
revealed through mRNA extraction and RT-PCR and confirmaed by Northern blotting.  In 
addition, a TSH-induced cAMP response from mouse AT-1 cardiomyocyte cells was reported.  
However, subsequent work from Busuttil and Frauman (2001) did not support these findings 
(evaluating 5 human heart samples).  They suggested that previous reports (Koshiyama et al 
1996 and Sellitti et al 1997) were ‘erroneous’, and a likely consequence of contamination 
(from fat/connective tissue) and/or “illegitimate transcription” (i.e ubiquitous and minimal 
genomic transcription in all cells, not of functional significance (Chelly et al 1981)).  Huang et 
al (2014) challenge this opinion by reporting the presence of functional TSHR in rodent 
ventricular myocytes (revealed by RT-PCR and various immunochemistry techniques).  They 
report upregulation of myocyte-associated mRNA transcripts (HMGCR and β-MHC) ex-vivo, in 
H9c2 cells in response to TSH.  In addition, rodent TSHR knockout ventricular cells expressed 
less HMGCR and β-MHC mRNA than WT.  
 
TSHR is reported to be expressed on vascular smooth muscle cells (VSMC) (Sellitti et al 2000). 
Tian et al (2014) stated that TSHR stimulation induced VSMC proliferation and enhanced 
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progression through the cell cycle (determined by flow cytometry). They suggest that this 
observation may be relevant to reports of increased vascular dysfunction and atherosclerosis 
in SH. 
 
Kloprogge et al (2005) evaluated extra-ocular muscle immunohistochemically and reported 
the presence of TSHR within and between myocytes.  However, subsequent investigations 
using in situ hybridisation techniques restricted this to the perimysial fibroblasts within 
muscles (Spitzweg et al 1997). TSHR-expressing fibroblasts were also identified in non-GO 
orbit but to a lesser extent.  
 
Boschi et al (2005) evaluated TSHR expression immunohistochemically in extra-ocular muscle 
comparing GO (n=30) and non-GO samples (n=20).  They reported TSHR expression on 
fibroblast-like cells between myocytes in GO samples only.  The TSHR expressing fibroblasts 
were more prevalent in early disease, and their levels correlated with serum TSI (around 
diagnosis).  They concluded that TSHR-expressing fibroblasts may contribute to the 
pathogenesis of GO myocyte injury.  
 
Subsequent investigation by our group revealed that preadipocyte fibroblasts manipulated to 
express TSHR* respond by increasing hyaluronan synthase expression.  They suggested that 
this observation might explain the increase in subcutaneous hyaluronan observed in thyroid 
diseases (diffuse in PH, and more focal in GD (i.e. pretibial myxoedema and GO (Zhang et al 
2009b)). 
 
Smith (2015) suggest that TSHR-expressing orbital fibroblasts may seed to the orbit 
haematogenously and derive from the HSC-monocyte lineage.  This theory relates to their 
CD34 expression, and their ability to synthesise inflammatory cytokines (given appropriate 
stimulation (i.e. TSHR and IGF-1)).   
 
In conclusion; it is likely that the muscular dysfunction commonly accompanying thyroid 
disorders is caused by altered FTH levels predominantly.  However, it is likely that perimyseal 
TSHR-expressing fibroblasts contribute to inflammatory injury in their vicinity, particularly in 
GO.  Although the majority of studies do not demonstrate TSHR expression on myocytes 
themselves, the data is inconsistent and thus uncertainty remains.  
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1.13 Hypothesis generation and aims 
 
The TSHR is expressed in a range of tissue types that includes those relevant to build (namely 
in bone, fat and muscle).  Its functional significance in these locations is uncertain although 
there is mounting evidence to suggest an independent effect from TSHR activation, 
particularly in bone.  TFT-component and TSH associations are frequently assessed in SH 
cohorts (in relation to parameters of interest) enabling cause-effect relationships to be 
proposed.  
 
I have outlined a range of aetiologies encompassing SH that include genetic causes.  The 
prevalence of inactivating TSHR-M carriers within adult cohorts are rarely determined.  As 
these subjects have inherently reduced TSHR signalling capacity they are a useful group to 
study to explore for potential TSHR signalling-related effects. Subjects with TSHR-Ms and 
other genetic causes for SH are expected to reside in non-autoimmune cohorts. Thus subjects 
with and without thyroid autoimmunity are compared in this study to explore potential 
aetiology-specific effects. 
 
My hypothesis was that the clinical implications of SH are aetiology dependent, and that TSHR 
signalling affects bone physiology.  
 
The primary objectives of this SH study were as follows: 
 
 To determine the prevalence of TSHR-Ms in an adult cohort. 
 To examine whether TSHR-M status correlates with bone parameters (BMD or BT).  
 To examine bone parameters in TPO antibody positive versus negative subjects. 
 To evaluate bone parameters alongside individual TFT components, with a particular 
interest in TSH associations.  
 
The secondary objectives of this study were to explore metabolic-risk parameters (adiposity, 
blood pressure, lipids, insulin resistance) in relation to TFT components, TSHR-M status and 
gene polymorphisms (TSHR and FOXE1 polyalanine tract length (PTL)), and TPO antibody 
status.  These study objectives are discussed in their dedicated results chapters, and all 
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objectives, with their associated observations are provided in the concluding and closing 
chapter.  
 
This study is the largest of its type to assess the prevalence of TSHR-Ms in an adult SH cohort 
and the 1st to compare bone parameters in this subgroup (relating this to TSHR signalling) 
versus the cohort.  It is also the 1st study to determine FOXE1 PTL polymorphism status in a 
dedicated SH cohort.  As such this project is unique in design and is expected to bring helpful 
clinical data to the SH literature and to provide direction for future research.  
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CHAPTER 2:  METHODS 
 
2.1 Recruitment and Participation  
 
Patients with treatment naïve de novo SH (an elevated TSH and a T4 in the normal reference 
range) and aged between 18 and 70 years (at the time of the screening TFT) were recruited 
to the study as follows. Colleagues in the department of biochemistry flagged up and 
reviewed the clinical information provided on the biochemistry request forms of all 
potentially suitable subects. In those whose information did not meet our exclusion criteria 
(section 2.1.2), General Practitioner (GP) letters were prepared (Appendix 2; Letter of 
Approach to GP). This letter summarised the SH studies aims and objectives, provided their 
patient’s identification details and TFT results, and included a GP reply slip.  A patient 
information sheet was also enclosed, to be passed from the GP to subjects suitable for the 
study (Appendix 3). The GP reply slip advised; the subject’s suitability for the study, their 
willingness to participate, and whether the GP had granted us permission to approach their 
patient about the study.  
I collected and processed all reply slips and proceeded to contact all seemingly suitable and 
willing subjects (for which permission to approach the patient was granted). After confirming 
suitability for the study, I offered and arranged study participation to all eligible subjects.  
Participation involved two visits to the hospital. The first was an 8am fasting appointment to 
the Clinical Research Facility (CRF), UHW. The 2nd was to the Medical Physics department, 
UHW for a DXA scan.  
At the CRF appointment after I’d obtained the subjects official consent to study participation 
(section 2.2), I recorded their medical history, anthropometric data and collected and 
processed their blood and urine samples. 
Subsequently I fed back the clinical results from the study to the participant and their GP, with 
clinical recommendations where indicated. 
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2.1.1 Study inclusion criteria 
 Male or female subjects aged between 18 and 70 years (on the screening bloods).  
 Subjects with treatment naieve de novo SH (as demonstrated by a normal free T4 and 
elevated TSH (of any degree)). 
 Subjects for whom written informed consent to participate in the study had been 
obtained, prior to any study related activity. 
 
2.1.2 Study exclusion criteria 
 Subjects aged <18 or >70 years (on screening bloods) 
 Pregnancy and breastfeeding 
 Pre-existing thyroid disease treated with surgery, radioiodine therapy or drugs 
(carbimazole, propylthiouracil, thyroxine or tri-iodothyronine) 
 Metabolic bone disease: hypo/hyperparathyroidism, vitamin D deficiency, Paget’s 
disease 
 Osteoporosis 
 Endocrine disease affecting BMD: Hyperprolactinaemia, Cushing’s syndrome, 
Acromegaly, hypopituitarism (of any degree), hypogonadism 
 Coeliac disease 
 Malabsorption 
 Anorexia nervosa 
 Chronic renal failure 
 Chronic liver disease 
 Cystic Fibrosis 
 Inflammatory bowel disease 
 Currently or recent (within 6 months of study entry) exposure to: glucocorticoids, 
androgens, antiandrogens, glitazones, cyclosporin, chemotherapy, anticonvulsants, 
vitamin D or depot contraceptive preparations. Women taking oral contraceptives or 
oestrogen replacement therapy were eligible to participate but this information was 
recorded (for potential adjustment in the final multivariate analyses). 
 Previous treatment with bisphosphonates, raloxifene, strontium or recombinant PTH  
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2.1.3 Predetermined power calculation 
The study protocol (Appendix 1; Original Study Protocol) describes the original study design 
(section 4) with its associated power calculation (section 5). The original primary objectives 
for the study were to compare bone parameters in the TSHR mutation subjects against the 
TPO positive subjects. At that time it was believed that those with genetic causes of SH would 
reside exclusively within the TPO negative cohort, whereas the TPO positive subject’s 
aetiology would be thyroid autoimmunity.  
The data management assumptions used in the power calculation were as follows; 
 A local audit suggested that ~250 de novo SH subjects would be identified per annum 
by the department of biochemistry 
 A 70% participation rate was anticipated and for recruitment to run over a 2 year 
period 
 2/3rds of the cohort were anticipated to be TPO antibody positive 
 TSHR mutations were expected to affect up to 40% of TPO negative subjects (Alberti 
et al 2002). 
 
The statistical predictions enabling 80% power with significance (α) set at 5% were as follows; 
 A cohort of ~350 subjects would be recruited 
 TSHR mutations would be identified in ~50 subjects 
 The TPO positive group would comprise ~250 subjects 
 A Z-score standard deviation of ~0.44 was predicted 
 
However, the actual study differed from this design in several respects. All study participants 
were screened for TSHR sequence variance irrespective of their TPO status (to test the theory 
that they would reside exclusively in the seronegative cohort). In contrast to the original study 
design; the TSHR sequence variants were compared with their normal TSHR sequence 
counterparts (see chapter 4 section 4.5 and 4.5.1) and the TPO positive subjects were 
compared against their TPO negative counterparts (see chapter 4 section 4.4.4 to 4.4.6). This 
change in the study design limits the utility of the predetermined power calculation. 
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2.2 Consent 
All study participants were provided with written documentation summarising the studies 
objectives and explaining what participation would involve (also explaining that their clinical, 
biochemical and genetic data would be used anonymously for this study (and related research 
in this academic unit (Appendix 3)).  This information was re-affirmed verbally prior to written 
consent being obtained (Appendix 4). 
 
2.3 Participant History  
This included a past medical history, medication list, family history (including osteoporosis 
and thyroid diseases), a social history that included occupation and lifestyle (smoking and 
alcohol history and usage, and usual activity levels).  For women a menstrual and pregnancy 
history were recorded (see Appendix 5). 
 
2.4 Blood Pressure 
Blood pressure (BP) was measured using an automated and appropriately calibrated OMRON 
HEM-CR19 sphygmomanometer (OMRON Healthcare UK Ltd, Milton Keynes, MK15 0DG).  
Subjects were positioned in a seated position with their back and arm supported (Pickering 
et al 2005).  The cuff was positioned at ~mid-sternal level directly over skin, and inflated after 
≥5 minutes at rest (Pickering et al 2005). BP was taken 3 times (as recommended by the British 
Hypertension Society (O’Brien et al 2002), with the average value used in subsequent 
analyses. If one of the readings was discrepant, this was discarded and a further reading 
taken. 
 
2.5 Height 
Subjects were measured without shoes, with head, heel and buttocks touching the Seca 217 
mechanical stadiometer (Supplier Seca UK, Birmingham, B5 5QB).  Subjects stood with feet 
together, and head positioned so that their ear canal was level with their check bone.  The 
stadiometer gauge was lowered on to their head (ensuring hair was flat) and a deep breath 
taken (protocol consistent with the PhenX Tool Kit (2014)).  The gauge indicated their 
height, which was recorded to the nearest 0.5cms 
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2.6 Waist and hip circumference  
This was measured at minimal respiration in an upright position using a flexible 
anthropometric tape measure (recorded to the nearest 0.5cms).  For waist circumference this 
was positioned parallel to the floor between the iliac crest and the 12th rib posteriorly.  The 
tape measure was taut, but not indenting the skin. 
 
Hip circumference was measured at the point of maximal girth across the hips and buttocks 
(over thin, well fitted underpants) with the tape measure parallel to the floor.  
 
Waist to Hip ratio was a simple calculation of waist circumference divided by hip 
circumference, recorded to 2 decimal points.  
 
2.7 Weight and BMI 
Subjects were weighed in light clothes (removing shoes, jackets, belts and emptying pockets) 
on a standard sit-on weighing scale (Seca 955) calibrated daily.  Weight was recorded to the 
nearest 0.1 kilograms.  
 
Body mass index (BMI) was recorded using the standard calculation of weight (in kg) divided 
by height (in metres) squared. 
 
2.8 Percentage body fat  
A Tanita TBF-538 fat monitor/scale (Tanita Corporation, Itabashi-Ku, Tokyo, Japan T174) was 
the bioimpedance meter used to measure ‘Percentage body fat (%BF)’.  The device was pre-
programmed to ‘adult’ and the subject’s sex and height (in metres) entered.  The subject then 
stood barefoot and still on the device’s metal foot plates.  After ~30 seconds a %BF score was 
displayed and recorded to the nearest 0.5 units. 
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2.9 Blood sampling  
A tourniquet was placed on the upper arm and the venepuncture site cleaned with an alcohol 
wipe, prior to venepuncture.  Vacutainer bottles were filled directly, including 2 EDTA 
(ethylenediaminetetraacetic acid) bottles, four SST (serum separating tubes) bottles and one 
Fluoride Oxalate bottle (~25ml of blood in total).  Thereafter the tourniquet was removed, 
needle withdrawn, and a sterile cotton wool ball placed over the puncture site with firm 
pressure applied for 2 minutes prior to a plaster being placed. 
 
2.10 Urine collection 
Participants were provided with a plastic container for midstream urine collection.  
Approximately 20ml of fresh urine was aliquoted from this pot to a universal container for 
storage at minus 20oC. 
 
2.11 Storing blood samples  
The SST vacutainer bottles were placed in the Thermo Fisher Scientific Inc centrifuge in the 
CRF (Heraeus Megafuge 16R) soon after blood was taken.  They were spun at 4000rpm for 15 
minutes at minus 20oC.  Thereafter 0.4ml aliquots of serum were pipetted into appropriately 
labelled Eppendorf tubes; 3 were sent to the University Hospital of Wales (UHW) biochemistry 
laboratory for immediate analysis and those remaining placed in storage at minus 20oC for 
subsequent analysis. Whole blood in EDTA vacutainers was placed directly into storage at 4oC. 
 
2.12 Extraction of DNA from whole blood 
This method was in accordance with the manufacturer’s instructions for QIAamp QIAGEN 
midikit (manufacturer Qiagen, Manchester, UK). 
 
One hundred µl of Qiagen protease was added to 1ml of blood in a 15ml centrifuge tube and 
mixed. 1.2ml of buffer AL was added and mixed thoroughly before leaving to stand at 70oC 
for ≥10minutes. 1ml of 100% alcohol was added and mixed thoroughly before the lysate was 
transferred to the midi-column and placed in the centrifuge tube provided.  This was spun at 
3000rpm for 3 minutes and the filtrate discarded.  The midi-column was replaced in the dried 
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centrifuge tube and 2ml of buffer AW1 added to the column before spinning at 5000rpm for 
a minute.  2ml of buffer AW2 was added to the midi-column and centrifuged at 5000rpm for 
15 minutes before the tube and filtrate were discarded.  The midi-column was replaced in a 
clean centrifuge tube and 200µl of buffer AE pipetted onto the membrane of the midi-column, 
left to stand for 5 minutes, then centrifuged at 5000rpm for 2 minutes.  This step was 
repeated.  The filtrate of extracted DNA was tested for purity and concentration with a 
spectrophotometer (Amersham Pharmacia Biotech) prior to being placing in storage at minus 
20oC.  On the spectrophotometer an absorbance 260:280nm ratio of 1.8 indicates pure DNA, 
and absorbance (at 260nm) of 1.0 equates to DNA concentration of 50 µg/ml. 
 
 
2.13 TSHR departmental DNA primers for PCR amplification  
 
The dHPLC screening tool (section 2.20.7 for details) was the initial test used to look for DNA 
sequence variation in a subject’s TSHR exon.  When this was suggested the exon concerned was PCR 
amplified (2.14), purified (2.15 & 2.17) and sequenced (2.16) for validation (2.18). 
To genotype the TSHR I used previously optimised primer pairs covering all 10 TSHR exons 
and intron/exon boundaries.  Their sequences, annealing temperatures and respective PCR 
amplicon sizes are detailed in table 2.1. 
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Table 2.1: TSHR exon-specific primer sequences, their annealing temperatures and 
respective amplicon sizes.  
 
 
F; forward primer, R; reverse primer. 10a and 10b represent 2 overlapping primer pairs for the larger 
10th exon, all others are represented by single primer pairs.  
 
2.14 Polymerase Chain Reaction (PCR) and Agarose Gel Electrophoresis 
 
PCR was performed using Promega reagents (Manufacturer Wisconsin, USA).  Nuclease-free 
PCR tubes were prepared on ice, each contained 1µl (at 10pM/µl) of forward and reverse 
primer, 1µl of dNTP (10mM), 5µl of 5X buffer, 2µl of Taq polymerase (5U/ul) and ~100ng of 
subject DNA template (~2-4µl depending on concentration).  This was made up to a 25µl final 
volume with nuclease-free water, vortexed and spun briefly prior to transfer to the 
thermocycler. 
 
Exon 5’-3’ sequence 
Annealing 
Temperature (oC) 
Fragment size 
(base pairs) 
1F 
1R 
GAG GAT GGA GAA ATA GCC CCG AG 
CAC TAC TTC GGG CTG TTA TTG AG 
54 302 
2F 
2R 
TAA GGT GAA TTA TTA GAA AAG C 
CTT GAT AGA ACA CGT TTA GAG A 
48 205 
3F 
3R 
GCA GAA TCC ATC AGG GTT GT 
AGA AAC CAG GCC TCC CAT TG 
54 304 
4F 
4R 
ACC CTG TGG CGT AAA TGC ATA T 
CCC GAC CCA GGC TAT ACA CCA TT 
52 329 
5F 
5R 
GCT TTA CTT ATC TTC AAC CTA CC 
AGT TTG ACT ACA GGT TGT CTT C 
52 291 
6F 
6R 
TAT TGT GTC CTG TTA TTT AAG TGC ATA 
GTA CTC TTA GAG TAT ATA TGA TAA GG 
56 293 
7F 
7R 
TGG GAT ACA TAT GTG GGA CCT G 
TGT TGG GTC ACA CTA ACT CTG G 
54 324 
8F 
8R 
TGG TCA CAT TTT ATT CTG ATA TTT GT 
CTC CCC TTA ATG TCT CCA TTT ATT CC 
54 272 
9F 
9R 
TCA TCT CCC AAT TAA CCT CAG G 
GCT TCC AAT TTC CTC TCC AC 
54 408 
10aF 
10aR 
TGG CAC TGA CTC TTT TCT GT 
GTC CAT GGG CAG GCA GAT AC 
56 868 
10bF 
10bR 
ACT GTC TTT GCA AGC GAG TT 
GTG TCA TGG GAT TGG AAT GC 
56 875 
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The PCR program was as follows: Initial denaturation at 95oC x 3 minutes, then 30 
thermocycles of [95oC x 30 seconds, 30 seconds at primer pair-specific annealing temperature 
(Table M.1), 72oC x 1 minute], then 72oC x 10 minutes for the final extension, returning to a 
4oC hold on completion. In negative controls, water replaced genomic DNA. 
A 2% agarose gel was prepared (1.5g Agarose powder boiled with 75ml of TAE buffer* (details 
below), then mixed with 3.75µl of ethidium bromide (EB; 0.5µg/ml).  When solidified, this was 
placed in an electrophoresis tank with TAE buffer and EB at equivalent concentration.  
Samples were prepared for agarose gel wells as follows: 8µl of PCR product (~125ng) mixed 
with 2µl of EB, whilst the ladder comprised 2µl of ladder (0.13µg/µl), 2µl of EB and 8 µl of 
sterile water.  Samples were pipetted into their respective wells and the electrophoresis 
current run for 30 minutes at 120 volts. TSHR amplicons were separated by agarose gel 
electrophoresis and their respective sizes estimated relative to a 100bp ladder (Promega; Cat 
no. G210A).  The gel was inspected under UV light to confirm the presence of DNA bands of 
appropriate size.  [*Tris-acetate-EDTA (TAE) electrophoresis buffer, prepared as a 50X stock solution 
and diluted to 1X (40mM Tris pH 7.6, 20mM Acetic acid, 1mM EDTA) with deionised water]. 
 
2.15 Polethylene glycol (PEG) precipitation  
 
The PCR product was purified using PEG precipitation.  An equal volume of PEG solution (26% 
(w/v) PEG 8000/70mM MgCl2) to PCR product (i.e. 20µl to 20µl) was mixed in Eppendorf tubes 
and left to stand for 10 minutes.  Samples were spun at 13000rpm for 30 minutes and the 
supernatant removed. Five hundred µl of 70% alcohol was added, mixed thoroughly for a 
minute then centrifuged at 13,000rpm for 10 minutes.  The supernatant was removed and 
the tube left to dry (~10 minutes).  The pellet was then re-suspended in 20-40µl of nuclease-
free water.  After confirmation of DNA product the sample was stored at minus 20oC.  
 
2.16 DNA sequencing preparation 
 
The BigDye Terminator sequencing Kit v3.1 (manufacturer Applied Biosystems Thermo Fisher 
Scientific) was used to generate single stranded DNA sequences in preparation for automated 
DNA sequencing (see 2.20.6).  
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Reagents were prepared on ice using nuclease-free PCR tubes.  Into each tube I aliquoted 5µl 
of PEG precipitated DNA sample (~100ng), 1 µl of primer (forward or reverse at 10pM/µl), 2 
µl of nuclease-free water and 2 µl of BigDye Mix. 
The Sequencing PCR thermocycling programme was as follows: 1 cycle at 96oC for 3 minutes, 
then 30 cycles [96oC for 30 seconds and then 60oC for 4 minutes], returning to a 4oC hold upon 
completion. 
 
2.17 Sodium Acetate 
The PCR sequencing product was precipitated with Sodium Acetate as follows, prior to 
automated sequencing.  
One µl of 3M Sodium Acetate was added to 10µl of post-PCR sequencing reaction and 
vortexed thoroughly; 30µl of 100% alcohol was added to the mix and left to stand for 10 
minutes.  This was centrifuged at 13,000rpm for 30minutes, the supernatant removed, and 
the tube left to dry.  Five hundred µl of 70% alcohol was added to the tube, vortexed for a 
minute then centrifuged at 13,000rpm for 10 minutes.  The supernatant was removed and 
the tube left to dry ~10 minutes before being stored at minus 20oC or transferred directly to 
the sequencing laboratory (see 2.20.6). 
 
2.18 DNA sequence interpretation 
The National Centre for Biotechnology Information (NCBI) software was used to compare 
study subject TSHR exon sequence against standard TSHR sequence (from GENE ATLAS).  This 
was performed using their Basic Local Alignment search Tool (BLAST) (see 2.20.6 for an 
example).  
When BLAST identified a sequence nucleotide discrepancy the electropherogram was 
inspected at the equivalent codon position for verification.  In addition the electropherogram 
was inspected along its length as a heterozygous nucleotide change (with duplicate 
nucleotide peak) can be missed by BLAST.  Possible variants (that would change the translated 
amino acid) were confirmed by repeating the sequencing process using the reverse primer 
(to confirm the nucleotide sequence change at that location), thus enabling identification of 
TSHR polymorphisms or mutations.  
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2.19 Statistical Analyses 
I used Microsoft Excel software to prepare data for subsequent analysis in Minitab 16 
statistical programme (also used to create graphs).  
The tests used to compare one data set against another were the unpaired student t-test (for 
continuous data) or ‘proportion’ tests (for categorical data).  The relationship between two 
continuous parameters was assessed using basic regression analysis.  However, the majority 
of my analyses were more complex and for this I used general linear multivariate regression 
analyses and stepwise multivariate regression analysis (see section 4.4).  In keeping with the 
condition of these tests, outlier results were removed and when the data did not follow a 
normal distribution in raw form, it was appropriately converted (log transformed or square 
rooted) to ensure this condition was met prior to its application.  
In my analysis a p-value below 0.05 (a <1/20 probability of getting this result through chance 
alone) defined the threshold at which I rejected the null hypothesis and accepted the 
alternative hypothesis.  The null hypothesis states that there is no difference revealed by the 
analysis other than that expected as a consequence of normal variation alone.  
The 95% confidence interval (C.I) I provide alongside my analyses describe the range of values 
(lower to upper limit) that correlate with this level of confidence.  The true value for the 
population mean (as opposed to the cohort) is expected to lie within the C.I in 95% of samples 
evaluated (with a 95% C.I).  The C.I is calculated as the regression coefficient +/- 1.96 x the 
Standard Error (SE), with SE representing the sampling distribution’s standard deviation (SD).  
The regression coefficient (R) provided in my regression analyses (beside the predictor 
variable assessed) indicates (for significant results) the mean change in the response variable 
(y) for a one unit change in the predictor variable (in a positive (+) or negative (-) direction).  
The R2 value (range 0-100%) provided alongside each regression analysis indicates the 
percentage of the response variable’s variation (R2 = explained variation / total variation) 
explained by a linear model.  
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2.20 Methods in collaboration with others 
 
2.20.1 DXA bone Scan 
BMD was evaluated by dual energy X-ray absorptiometry (DXA) using a Hologic Discovery 
Bone Densitometer (QDR series) and Apex Software (version 3.3.0.1).  The lumbar spine (LS) 
(L1, L2, L3 and L4 and a total value) and left hip (femoral neck, greater trochanter, inter-
trochanter and a total value) were assessed.  The machine was checked daily against a Hologic 
spine phantom, and accommodates weights up to 159kg.  Participants whose torso depth was 
>30cm were scanned on ‘array’ mode; all others were on ‘fast’ mode.  
Participants were positioned supine on the scanner table. To evaluate the LS the patient’s 
calves were supported on a box to position their femur at ~90o to the spine, thereby flattening 
the lumbar lordosis.  With optimum positioning the spine was straight, perpendicular to the 
scanning field, and the laser positioned over mid-L5. The region of interest was then scanned 
in to the software system for evaluation.  
To evaluate the hip, the Hologic Hip positioning fixture was positioned between the patient’s 
feet in the midline.  The left leg was abducted and externally rotated before being internally 
rotated and adducted, securing the foot, via a sling, to the positioning fixture (internally 
rotating the leg at ~25o).  Optimum positioning held the shaft of the femur perpendicular to 
the scanning field revealing very little of the lesser trochanter.  
Participant data was compared against normal population reference data of Caucasian, 
Oriental or Afro-Caribbean ethnic origins to generate T- and Z-scores.  These data were 
provided by the NHANES study (Kelly et al 2009) for hip, and Hologic-specific datasets for LS.  
The total radiation dose for the DXA scan was estimated at 11μSv (~2 days of UK background 
radiation exposure).   
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2.20.2 Automated biochemistry laboratory analyses 
These analyses were performed in the Department of Biochemistry and Immunology, UHW.  
All analyses were performed in accordance with the manufacturer’s recommendations 
(detailed in the operator’s manual) and the Laboratory’s Standard Operating Instructions. 
These methods are briefly summarised in tables 2.2 and 2.3 (providing thyroid-related, and 
non-thyroid related analyses (bone profile, lipids and glucose) respectively).  However, the 
detailed methods can be retrieved locally (laboratory reference file numbers are provided).  
LDL-Cholesterol (LDL-C) was the only biochemistry parameter estimated and not measured 
(using the Friedewald formula applicable to fasting samples (Friedewald et al 1972) and 
shown below).  This equation was applied to all suitable specimens, and the LDL-C results 
were automatically uploaded onto the laboratory software system (in mmol/L).  
 
LDL-cholesterol = Total cholesterol - HDL-cholesterol - Triglyceride/2.2 
 
The equation is not applicable with triglycerides >4.5 mmol/L, or with chylomicrons present.  
Its accuracy is reduced with an estimated LDL <1.8mmol/L and with high triglycerides (Martin 
et al 2013). 
 
2.20.3  Managing the change to the thyrotrophin analyser 
The TFT analyser changed mid- recruitment from the Siemens ADVIA Centeur immunoassay 
to the Abbott Architect i2000SR system. This occurred after the 139th subject had been 
recruited. 
Comparative results from both thyrotrophin immunoassays indicated that the Siemens 
Centeur’s assay results minus 10% provided an acceptable prediction of the Abbott 
Architect’s assay results (see Appendix 8). These data, together with the conversion 
recommendation were provided by colleagues in the department of Biochemistry, UHW.  
Equivalent evaluations on the T4, T3 and TPO antibody results indicated that they were not 
inter-convertible. Therefore these analyses were all run on the Abbott Architect assay; subject 
numbers <140 from stored serum, and numbers >139 on the day of their study participation. 
This limitation to the study is discussed in section 6.2.  
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2.20.4 Urine Iodine 
  
An Inductively Coupled Plasma Mass Spectrometer (ICP-MS) for urine iodine quantification 
was developed in the department of Biochemistry, Immunology and Toxicology, UHW 
supporting an MSc project.  The optimum diluent and concentrations for the procedure were 
determined, and the method validated prior to its use on the SH study participants (Jones et 
al 2013).  
It was performed on an Agilent 7700x ICP-MS with ASX 500 Auto-sampler and integrated 
sample introduction system (Agilent Technologies, Wokingham, UK) in the Trace Element 
laboratory.  Argon gas for ICP-MS plasma and helium gas for ICP-MS collision cell were 
supplied by BOC (Cardiff, UK).   
Iodine standards were prepared by diluting iodine standard 1000 µg/ml (Inorganic Ventures, 
Esslab, Hadleigh, UK) in ultrapure water (Standards 0, 10, 100, 500, 1000 µg/L).  
The assay was validated on three in house urine pools, and monitored through commercial 
quality control and external quality assurance (EQA) via the Centres for Disease Control and 
Prevention EQUIP (Ensuring the Quality of Urinary Iodine Procedures) Programme (Atlanta, 
US). 
Urine creatinine was measured on the Abbott Architect c16000 clinical chemistry analyser 
(Abbott Laboratories Ltd, Maidenhead, UK) and results expressed as urine iodine: creatinine 
ratio.  The reference range was taken from Sieniawska et al 2012, and the cohort’s Iodine 
status categorised according to the World Health Organisation’s recommendations (World 
Health Organisation 2007a).  
 
2.20.5 Analyses outsourced to specialist laboratories 
 
This related to the Insulin and Bone Turnover Marker assays.  Basic details relating to these 
assays are provided in table 2.5. 
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Table 2.2:  Thyroid-related biochemistry analyses performed at UHW 
 
Parameter evaluated,   
Manufacturer (Units)  
 
Brief Method  
(Laboratory reference file) 
Specifications 
Normal 
Reference 
range 
Analytical 
range 
Precision and 
Accuracy 
TSH 
Siemens 
(mu/L) 
Sandwich immunoassay involving acridinium labelled anti-
TSH mouse antibody and anti-TSH sheep antibody bound to 
paramagnetic particles. 
(LP-BIO-ETSH rev1 (2007)) 
0.35-5.0 <0.02; >150 
5.87% at 0.75, 
4.22% at 5.65 & 
3.17% at 19mU/L 
TSH 
Abbott 
(mIU/L) 
CMIA involving antiβ-TSH antibody-coated microparticles 
and acridinium labelled antiα-TSH antibodies. Solutions are 
added to precipitate a chemiluminescent reaction. 
(LP-BIO-ETSH rev1 (2011)) 
0.35-4.5 
<0.05; 100 
(up to 1000 
with dilution) 
<10%  
TPO antibodies 
Abbott 
(IU/ml) 
CMIA involving TPO coated paramagnetic microparticles, 
acridinium labelled anti-human IgG and solutions to trigger a 
chemiluminescent reaction. 
(LP-BIO-AATPO rev1 (2011)). 
<6 0-1000 
<10% 
 if >5.6IU/ml 
T4 
Abbott 
(pmol/L) 
Competitive CMIA involving anti-T4 labelled paramagnetic 
microparticles, T3-acridinium labelled conjugate and 
solutions to trigger a chemiluminescence reaction. 
(LP-BIO-AFT4 rev1 (2011)) 
9-19.1 <5.15; >77.22 
<10% between  
~8.4 and 36 pmol/L 
T3 
Abbott 
(pmol/L) 
Competitive CMIA; equivalent to the T4 assay above but 
substituting anti-T3 for anti-T4 labelled paramagnetic 
microparticles. 
(LP-BIO-AFT3 rev1 (2011)) 
2.6-5.7 <2; >46.08 <10% 
 
The automated analysers were Abbott Architect i2000SR for Abbott (supplier Berkshire SL6 4XF) and the ADVIA Centaur Immunoassay Analyser for Siemens 
(supplier Camberley, Surrey, UK GU16 8QD). Abbreviations; Chemiluminescent Microparticle Immunoassay (CMIA). 
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Table 2.3:  Non-thyroid biochemistry analyses performed at UHW. 
Parameter 
assessed,   
(Units)  
Brief Method  
(Laboratory reference file) 
Specifications 
Normal 
Reference range 
Analytical 
range 
Precision and  
Accuracy 
Calcium 
 (mmol/L)  
Calcium reacts with a chemical (Arsenazo-III), in acid, producing an indigo 
complex measured at 660nm. 
(LP-BIO-ALCa rev1 (2007)) 
2.20-2.60 0.03-6.52 
1.7% at 2.3 & 1.1% 
at 3.48mmol/L 
Phosphate 
 (mmol/L)  
Ammonium Molybdate reacts with Phosphate 
To produce a coloured complex measured at 340nm. 
(LP-BIO-ALPO4 rev1 (2007)) 
0.8-1.45 0.2-817 
1.1% at 1.03 & 0.5% 
at 2.5mmol/L  
ALP 
 (IU/L) 
ALP catalyses hydrolysis of colourless p-nitrophenyl phosphate to yellow 
phosphate and n-nitrophenyl (at alkaline pH) measured at 404nm. 
(LP-BIO-ALAlkP rev2 (2007)) 
30-115 
measurable 
to 22,775  
3.2% at 94 & 2.5% at 
417IU/L 
Total Cholesterol 
(mmol/L) 
Cholesterol oxidation produces H2O2 as a by-product. Peroxide combines 
with reagents (Hydroxybenzoic acid (HBA) and 4-aminoantipyrene) to form 
a chromophore measured at 500nm. (LP-BIO-ALChol rev1 (2007)) 
Not provided 0.26-18.26 
1.6% at 3.36 & 0.8% 
at 6.95mmol/L 
HDL 
Cholesterol 
(mmol/L) 
Phase 1 removes non-HDL cholesterol (using DSBmT (N-bis-(4-sulphobutyl)-
m-toluidine-disodium) producing colourless product.   Phase 2 dissolves 
HDL-C in detergent that reacts with a chromogenic coupler and enzyme, 
producing a blue product measured at 604nm.   
(LP-BIO-ALHDLUlt rev1 (2007)) 
0.7-1.7 
0.13-4.66 
(without 
dilution) 
5.5% at 0.54 & 1.4% 
at 2.04mmol/L 
Triglyceride 
(mmol/L) 
Tg is hydrolysed releasing glycerol. Glycerol is phosphorylated to glycerol-
3-phosphate which is oxidised with H2O2 as a by-product.  Peroxide reacts 
with a chemical (4-aminoantipyrene and 4-chlorophenol) producing red 
product, measured at 500nm.  (LP-BIO-ALTrig rev1 (2007)) 
0.6 - 2 
0.07 - 16.05 
(without 
dilution) 
1.1% at 1.2 & 0.8% 
at 2.13mmol/L 
Glucose 
Abbott 
(mmol/L) 
Glucose is phosphorylated to G6P. Oxidation of G6P reduces NADP to 
NADPH whose absorbance is measured at 340nm. 
(LP-BIO-ALGluc rev2 (2007)) 
3-6 
to 44.4 
(without 
dilution) 
2.2% at 4 & 1.5% at 
15.6mmol/L 
  
All analyses were performed on the Abbot Aeroset analyser that measures absorbance spectrophotometrically (Abbott Diagnostics; supplier Berkshire SL6 
4XF). Abbreviations; Glucose-6-phosphate (G6P), Nicotinamide Adenine Dinucleotide Phosphate (NADP), Alkaline Phosphatase (ALP), High Density Lipoprotein 
(HDL), Cholesterol (-C), Triglyceride (Tg). 
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Table 2.4:  Urine Iodine assay specifications 
 
Specification Value 
Intra-assay and Inter-assay precision 1.7-3.6%; 1.1-3.0% 
Limit of quantification (CV <20%) 1.0 µg/L (8 nmol/L) 
Reporting limit 5 µg/L (39 nmol/L) 
Details provided by Miss Katie Jones, MSc Biochemist, UHW 
 
Table 2.5: Insulin and Bone Turnover Marker assays 
Parameter 
assessed,   
(Units)  
Brief Method  
Specifications 
Normal 
Reference 
range 
Analytical 
Range 
Precision, 
Sensitivity 
Insulin 
(pmol/L) 
Two site immunometric sandwich assay 
involving insulin monoclonal antibody 
bound to a microtitre plate and acridinium 
labelled liquid phase. Luminescence 
relates to insulin concentration. 
Fasting; 
<174 
20-800 
<7.5%, 
0.12pmol/L
. 
P1NP 
(µg/L) 
Electrochemiluminescent sandwich 
immunoassay: Involves biotinylated 
analyte-specific antibody, Streptavidin-
coated microparticles, and analyte-specific 
antibody labelled with ruthenium 
complex. The microparticles are 
magnetically captured on an electrode 
and current precipitates 
chemiluminescence that is translated into 
an analyte concentration. 
♂: 20-76 
PM♀: 19-69 
20-600 
<3%,   
8µg/L 
CTX 
(µg/L) 
 
0.1- 0.5 
 
0.2-1.5 
<3%, 
  0.01µg/L 
 
The insulin analysis was performed by Professor Luzio’s Diabetes Research Group in Swansea 
University. The P1NP and CTX assays were performed by Professor Fraser’s group in Norwich 
University, East Anglia. Abbreviations; Procollagen type 1 N-terminal propeptide (P1NP), C-terminal 
telopeptide of type 1 collagen (CTX). Pre-menopausal Females (PM♀), Males (♂). 
 
 
2.20.6 Automated DNA sequencing 
This was performed within the Biotechnology Services Department at UHW. 
 
Samples were dried of residual ethanol and treated with highly deionised formamide prior to 
being run on the Applied Biosystems Genetic Analyzer (ABGA) 3130xl following its standard 
protocol. 
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The ABGA 3130xl used v3.0 Biosystems software for data collection, and v5.3.1 Biosystems 
software to convert raw sequence data into standard electropherograms. A PDF and printed 
electropherogram of the data were provided. 
 
An example of a BLAST nucleotide alignment image (Figure 2.1) with its associated forward 
and reverse electropherograms (Figure 2.2) are shown below. This example reveals the 
heterozygous TSHR R531W mutation. 
 
Figure 2.1:  Nucleotide alignment image  
 
O46 Sequence:       CTGGACTGGAA 
                                           Standard Sequence:       CTGGACCGGAA 
 
Figure 2.2:  Electropherograms of the forward and reverse sequences for subject 046 
  
Forward Sequence           Reverse Sequence         Magnification 
         
O46 Sequence: CTGGACTGGAA  TTCCAGTCCAG    CAG 
Standard Sequence: CTGGACCGGAA  TTCCGGTCCAG    CGG 
 
The duplicate peak on the forward sequence clearly reveals where T (Thymine) rather than C 
(Cytosine) is reported by the sequence scanner.  The equivalent region on the reverse 
sequence is at the end of the sequence printout where quality is poor.  Although the scanner 
reports a G (Guanine) in this position (consistent with standard sequence) careful inspection 
of the electropherogram reveals an A (Adenine) correlating with this heterozygous base 
change (circled in the reverse trace).   
64 
 
2.20.7 Denaturating High Performance Liquid Chromatography (dHPLC) 
 
This work was commenced in the department of Immunology and Biochemistry (supporting 
PhD higher degrees) and completed by the thyroid research group, Cardiff University. 
 
Thirteen TSHR dHPLC control fragments were designed (1 fragment for exons 1-9, and 4 
overlapping fragments for the 10th exon) and the optimum melting temperature and buffer 
ratio (Buffer A (0.1M Triethylammonium Acetate [TEAA]) to Buffer B (0.1M TEAA and 25% 
acetonitrile)) determined for each dHPLC fragment’s analysis.  This information, along with 
the optimum melting temperature predicted by the dHPLC software system, was 
programmed into the Wave DNA Fragment Analyser System (Transgenomic Inc. Santa Clara 
USA).  The dHPLC protocol was followed in accordance with the manufacturer’s 
recommendations. 
 
Study subject DNA was amplified using dHPLC fragment-specific primers (Tables 2.6 and 2.7).  
Thereafter, 20 µl of subject-specific PCR-amplified DNA was loaded into each well of the 
dHPLC machine (minimum of 5µl required per temperature specific programme).  The 
machine has 196 wells reflecting the maximum number of simultaneous analyses that can be 
performed.  A control sample per fragment assessed was run alongside all batched samples.   
 
 
Table 2.6: Primer-specific annealing temperatures of dHPLC fragments 
 dHPLC Fragment 1 2 3, 5, 7, 10.1 & 10.4 4, 8, 10.2 & 10.3 6 9 
Primer- specific  annealing 
temperatures (oC) 
65.4 55 61.4 57.8 55.1 61.4 
dHPLC fragment numbers correlate with TSHR exon numbers with four fragments (10.1-10.4) for exon 10. 
 
 
Elution profiles (chromatogram waveforms) were determined by the ‘Wave Maker’ 
(Transgenomic Inc software) and generated through a fluorescence (535nm) and ultraviolet 
detector (260nm).  When subject-specific waveforms revealed heteroduplexes or waveforms 
substantially different from control (potentially suggesting heterozygous or homozygous 
mutations respectively), direct DNA sequencing of the subject’s TSHR exon was undertaken.   
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Table 2.7:  PCR programmes used per dHPLC fragment amplified. 
 
Exon PCR preparation 
Initial phase of PCR 
programme 
Later phase of PCR 
programme 
1,2,3,4,7,9 
& 10 
2.5µl human DNA, 10.75µl H2O, 1.5µl 
25mM MgCl2, 2.5µl 10x buffer, 2.5µl 
2mM dNTP, 2.5µl forward primer 
5µM, 2.5µl reverse primer 5µM and 
0.25µl enzyme "Ampli Taq Gold DNA 
Polymerase" in a 25µl reaction. 
95oC for 5mins 
35 cycles [95oC for 30 
seconds, primer-specific 
annealing temperature for 
1 minute, 72oC 1 minute] 
72oC for 5 minutes. 
 
95oC for 5 minutes 
70 cycles [95oC for 
10 seconds, 60oC 
for 10 seconds]. 
70cycles [55oC for 
10 seconds, 25oC 
for 10 seconds]  
Final hold 10oC. 
5,6 & 8 
2µl human DNA, 9.8µl H2O, 2µl 10X 
buffer, 2 µl dNTP 2mM, 2µl forward 
primer 5µM, 2µl reverse primer 5µM 
and 0.2µl enzyme "HotStarTaq DNA 
Polymerase" in a 20µl reaction.  
95oC for 15minutes 
35 cycles [95oC 40 seconds, 
primer-specific annealing 
temperature for 1 minute, 
73oC 1 minute & 50 
seconds]                      
72oC for 10 minutes. 
 
"Ampli Taq Gold DNA Polymerase" was provided by Applied Biosystems, Life Technologies, Paisley, UK. 
"HotStarTaq DNA Polymerase" was provided by Qiagen, Manchester, UK. 
 
 
2.20.8 FOXE1 polyalanine tract length (PTL) determination 
This work was carried out by the thyroid research group, Cardiff University. 
 
PCR FOXE1 primers were designed to cover a portion of the FOXE1 coding sequence and its 
polyalanine tract.  The 5’-3’ nucleotide sequences of these primers are shown below: 
 
FOXE1 Forward: GCG GAG GAC ATG TTC GAG A 
FOXE1 Reverse: CGC GGG GTA GTA GAC TGG AG 
 
FOXE1 PCR was performed in nuclease-free PCR tubes; 2.5µl of 10X PCR buffer was added to 
a solution containing 5µl of Q-solution, 0.5µl (10mM) dNTP mix, 5µM forward primer (2 µl of 
10pmole/µl), 5µM reverse primer (2µl of 10pmol/µL), 0.5 µl of TaKaRa Taq polymerase and 
0.1-1.0 µg of DNA template.  This was made up to a 25µl volume (with nuclease-free water), 
vortexed and spun briefly before transfer to the thermocycler.  
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The FOXE1 PCR program was as follows: initial denaturation at 95oC X 1 minute, followed by 
35 cycles [94oC X 1 minute, 60oC X 1 minute, 72oC X 1 minute] then 72oC X 10 minutes for the 
final extension before returning to a 4oC hold.  
 
The samples were run on a 4% agarose gel alongside a 100bp Qiagen ladder to determine 
their PTL status.  This was confirmed by direct sequencing if required.  
 
An image of a FOXE1 PTL polymorphism gel is shown below. This reveals heterozygosity 
(14/16) for samples in the 4th, 9th and 11th column from the ladder.  All other samples are 
homozygous for the more prevalent FOXE1 14/14 PTL polymorphism. 
 
 
Figure 2.3:  FOXE1 PTL agarose gel image 
 
Courtesy of Dr Ameen Bakhsh, thyroid research group, Cardiff University  
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CHAPTER 3: RECRUITMENT EXPERIENCE AND OBSERVATIONAL 
DATA INCLUDING THYROID FUNCTION TEST DATA  
 AND GENETIC EVALUATIONS IN A SUBCLINICAL 
HYPOTHYROID COHORT  
 
 
3.1 Introduction 
 
Subclinical Hypothyroidism (SH) was first described as a clinical entity in 1973 (Hall & Evered 
1973).  The arbitrary values to define SH vary according to the regional normal range and the 
analytical assay used (Hollowell et al 2002, Casey et al 2005).  However, they are generally 
based on the 95% percentiles of normal thus a TSH >97.5th percentile (raised) with a T4 >2.5th 
and <97.5th percentile (normal) define SH.  
 
Highly sensitive TSH assays were introduced in the late 1980s and early 1990s and 
transformed the diagnostic utility of thyroid function testing (Toft 1988; Hay et al 1991).  
Thyroid function tests (TFTs) are now widely and routinely requested and there is a wealth of 
data correlating the TSH and T4 parameters to each other.  This relationship was originally 
described as inverse log linear, but subsequently recognised to be more complex (Hoermann 
et al 2010).  Hadlow et al (2013) recently described the relationship as a non-linear inverse 
log with sigmoid shaped inflexion points at the extremes of T4 (in that case; 7 and 21pmol/L).  
Variations in the relationship according to sex and age are described (Clarke et al 2012, 
Hadlow et al 2013).  
 
Free-T4 (T4) appears to be the main determinant of TSH levels through its negative feedback 
on the hypothalamus and pituitary (Fonseca et al 2013, Sawin et al 1977, Abend et al 1991, 
Introduction; figure 1.2).  However its purpose appears to be the maintenance of normal free-
T3 (T3) levels (Fonseca et al 2013). T3 is the active hormone with ~15x the affinity of T4 for 
the thyroid hormone receptors (Lin et al 1990). It is recognised that T3 drops acutely in severe 
illness (Economidou et al 2011) whereas T3 and/or T4 are elevated and TSH suppressed in 
primary hyperthyroidism (Dayan 2001).  Outside these contexts the relationship between T3 
versus TSH or free-T4 are rarely explored.  
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The majority of human SH studies are observational studies intent on revealing any adverse 
consequence from SH.  Such studies reflect the epidemiology of SH particularly its female 
preponderance and increased prevalence amongst older subjects (Tunbridge et al 1977; 
Canaris et al 2000, Hollowell et al 2002).  Other observations in SH include the following:  
 SH is often transient, normalising on re-testing in between 25% (Parle et al 1991) and 
50% of subjects (Diez & Iglesias 2009).  For this reason it is recommended that TFTs 
are repeated 12 weeks after an initial SH result is obtained, to confirm the biochemical 
picture (Surks et al 2004).   
 The prevalence of thyroid autoimmunity in SH in iodine replete regions ranges from 
~40% (Surks & Hollowell 2007) to 80% (Allan et al 2000).  However recently iodine 
insufficiency has been demonstrated in these regions (Vanderpump et al 2011).  The 
prevalence in communities traditionally considered as Iodine insufficient is much less 
(Teng et al 2011) although exact figures are scant due to the limited health resources 
in these predominantly underdeveloped regions (Vanderpump 2011). 
 SH is more likely to progress to hypothyroidism in subjects with higher TSH values and 
thyroid autoimmunity (annual progression rates in females (♀) of 4.3% (TPO +ve) 
versus 2.6% (TPO -ve), and higher again in TPO positive men (♂) (x4) according to the 
20 year Whickham study data (Vanderpump et al 1995, Tunbridge et al 1977). 
 SH is less common amongst people of African and Caribbean origins versus Caucasians, 
this is attributed to these races having an inherently lower TSH set-point (Hollowell et 
al 2002) 
 SH is less common in smokers than non-smokers (Knudsen et al 2002).  
 
A challenge for any clinical study is recruiting the target number of participants to enable the 
study objectives to be robustly evaluated. In studies such as mine that depend on General 
Practitioner (GP) participation; participation rates of ~80% may be expected (Roland et al 
2001).  Thereafter participation rates of ~35-50% initially (Cornelia et al 2005) with drop-out 
rates of ~≥20% (Bell et al 2013) are described.  Insufficient recruitment reduces the power of 
a study to determine its objectives and increases the probability of misleading observations 
being made (Patel et al 2003).  It is also difficult to recruit a representative sample i.e. women 
can be under-represented (Harris & Douglas 2000), language difficulties discourage ethnic 
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minorities, homeless subjects lack access to research, and selection bias is present when 
subject and/or GP choice determines participation (Patel et al 2003).  Thus although the data 
obtained from such studies are assumed to reflect the characteristics of the population 
recruited, this may not be the case.  
 
SH has many causes although autoimmune thyroid disease (ATD) is the most widely studied 
and most common in the UK (Vanderpump 2011).  Relatively few studies have explored the 
genetic causes of SH, and where this has been done it has focused on paediatric cohorts.  The 
prevalence of heterozygous TSHR mutations (TSHR-M) (and gene variants) has been explored 
in several Italian paediatric non-autoimmune SH cohorts.  Camilot et al (2005) reported a 
prevalence of 11% (13/116) in their child and adolescent subjects; Calebiro et al (2012) 
reported 12% (18/153) in their group, whilst Nicoletti et al (2009) reported 30% (11/38) in 
their smaller group (aged 1 to 11 years).  Alberti identified TSHR-Ms in 4 of 10 subjects with 
neonatal or juvenile non-autoimmune SH (TSHs 6.6-46mU/L), 8 of whom had familial SH 
(Alberti et al 2002).  Adults were evaluated in a study where SH subjects and their SH relatives 
were screened for TSHR-Ms. TSHR gene aberrance was revealed in 5/42 (12%) samples, and 
all affected subjects had familial not sporadic SH (Tonacchera et al 2004).  In our unit, two 
siblings with congenital hypothyroidism (CH) were diagnosed with homozygous inactivating 
TSHR-Ms secondary to the nonsense mutation W546X.  Thereafter, blood from 368 
individuals in the local South Wales area (184 healthy blood donors and 184 schizophrenic 
patients [thyroid function unknown]) were screened for the W546X mutation; two displayed 
W546X heterozygosity. This indicated a background prevalence of ~1/180 (Jordan et al 2003) 
suggesting that this TSHR-M may be relatively common in the South Wales population. 
 
TSHR-Ms are believed to reside in subjects who lack thyroid autoimmunity (though exceptions 
are reported (Tonacchera et al 2001).  However, the case finding process has generally 
evaluated seronegative subjects.  Interestingly, it is suggested that 70-80% of the 
predisposition to ATD is genetically determined (Hansen et al 2006) and the TSHR has been 
implicated in genetic association studies examining the prevalence of ATDs, including 
hypothyroidism (Akamizu et al 2000).  However, subsequent studies restricted the association 
to Graves’ disease (GD) (Tomer 2010). TSHR polymorphisms (in coding and noncoding regions, 
and in close proximity to TSHR) appear to predispose to GD (Brand et al 2009, Stefan et al 
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2014) and Graves Orbitopathy (Jurecka-Lubieniecka et al 2014). Thus the assumption that 
TSHR gene variance will affect only the seronegative cohort may not be correct. 
 
Common TSHR polymorphisms include the D727E, P52T and the D36H.  The prevalence of 
D727E heterozygosity amongst control groups is variably reported at 10% (Matakidou et al 
2004) to 16% (Mühlberg et al 2000), P52T heterozygosity is estimated at ~7% (Simanainen et 
al 1999) and the D36H at 0.5% to 5% (Peeters et al 2003, Simanainen et al 1999).  The D727E 
polymorphism has been associated with marginally lower TSH levels in twin studies (Hansen 
et al 2006) and previously associated with increased TSHR sensitivity (Gabriel et al 1999).  
However, functional studies to support this statement were not reproduced (Nogueira et al 
1999).  The prevalence of this polymorphism has been explored in a range of thyroid 
conditions including neonatal SH (Teofoli et al 2007), GD (Ho et al 2003) and toxic nodular 
thyroid disease (NTD) (Mühlberg et al 2000).  However, a consistent association with any of 
these conditions is lacking. Interestingly, subjects homozygous for this polymorphism have 
been identified incidentally in studies (rather than consequent to a disease process (Van der 
Deure et al 2008)), suggesting its functional significance, if any, may be small.  The P52T and 
D36H are less widely studied but appear not to be associated with a disease entity (Ho et al 
2003, Sunthornthepvarakul et al 1999) or altered TSHR sensitivity (Cuddify et al 1995, 
Gustavsson et al 1995). 
 
As explained throughout this thesis, one of my primary objectives was to explore bone 
mineral density (BMD) and bone turnover (BT) in relation to the aetiology of SH including 
TSHR-M status (see chapter 4).  This was also explored in TSHR D727E polymorphism carriers.  
This objective relates to the observation that TSHR resides in extra-thyroidal environments 
including bone (reviewed in Davies et al 2002) and that TSHR knockdown status (Abe et al 
2003, Baliram et al 2012) and even TSHR D727E polymorphism status (Van der Deure et al 
2008, liu et al 2012) are reported to influence bone physiology and BMD.  Thus identifying 
TSHR gene aberrations and exploring their associations with thyroid function parameters was 
the first step towards this objective. 
 
One of my secondary objectives was to explore whether body composition parameters vary 
in relation to TSHR gene variance.  This relates to the observation that TSHR is expressed on 
mesenchymal stem cells (Bagriacik et al 2012) with their ability to differentiate into distinct 
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terminal tissue types (including bone, fat and muscle; see figure 1.5).  Thus TSHR activation 
might influence lineage specific differentiation and body composition (de Lloyd et al 2010).  
Given the association between adiposity and metabolic-risk parameters (Eckel et al 2014), 
(results chapter 5) this was something I wished to explore. 
 
The FOXE1 gene (otherwise known as Thyroid Transcription Factor 2) is a member of the 
forkhead family of transcription factors that plays a vital role in thyroid gland morphogenesis.  
The gene is located on the long arm of chromosome 9 (9q22) (Chadwick et al 1997), has 1 
exon and ~1/3rd of the gene is coding sequence (Venza et al 2011).  The FOXE1 gene is 
expressed in a range of cells and tissues with mRNA extracted from liver, muscle, heart, brain 
and fat tissue, and the protein demonstrated in hair follicle outer root sheath (Brancaccio et 
al 2004, Bullock 2007) and testis (Genecards human gene database; FOXE1 
(www.genecards.org)). FOXE1 influences the transcription of thyroglobulin and thyroid 
peroxidase (Francis-Lang et al 1992) and polymorphisms in the FOXE1 gene have been 
associated with altered thyroid hormone and TSH levels (Gudmundsson et al 2009, Taylor et 
al 2015).  A schematic illustration of the protein product is shown below. 
 
Figure 3.1:  Illustration of the FOXE1 protein 
 
The amino acid number from amino to carboxyl terminal is provided. The red box represents the DNA 
binding domain, and the green triangle indicates the location of the variable length of polyalanine tract 
(adapted from the atlas of genetics and cytogenetics in oncology and haematology 
(http:atlasgeneticsoncology.org/genes/FOXE1). 
 
 
Homozygous mutations in FOXE1 cause Bamforth-Lazarus syndrome in humans, and an 
equivalent phenotype in mice (Baris et al 2006, De Felice et al 1998). This syndrome’s features 
include CH (consequent to thyroid dysgenesis), cleft palate and spiky hair (Bamforth et al 
1989).  
The FOXE1 gene has in its makeup a polyalanine tract, with various length polymorphisms 
(PTL) in the tract (12, 14, 16, 17, 19 and 22) identified (Kallel et al 2010, Bullock et al 2012). 
The most prevalent genotype is the homozygous 14 PTL polymorphism affecting 50% of a 
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Slovenian control cohort (Watkins et al 2006) and 97% of a Japanese control cohort 
(Hishinuma et al 2001). Whilst the next most prevalent genotype is the heterozygous 14/16 
carried in ~3% (Hishinuma et al 2001) to ~25% (Watkins et al 2006), according to the 
population studied. All other PTLs are uncommon. It has been shown that the 14 PTL 
polymorphism (or wild type) has higher transcriptional activity than the 16 PTL (Bullock et al 
2012).  
FOXE1 PTL polymorphisms have been explored in association with a range of thyroid 
disorders. The short PTLs (<14) have been implicated (on an infrequent basis) with thyroid 
dysgenesis (TD) (Hishinuma et al 2001). Carré et al (2007) genotyped 115 TD cases versus 129 
controls and reported an association between the 14/14 genotype and TD, with the 14/16 (or 
16/16) being protective. Thyroid cancer association studies have associated the 16/16 PTL 
with an increased risk of papillary thyroid cancer (x~2.5) versus the 14/14 (Kallel et al 2010, 
Bullock et al 2012). To date no association between FOXE1 PTL and ATDs have been made 
(Kallel et al 2010). However, in all studies evidence to support causation between the 
implicated FOXE1 PTL polymorphism and the thyroid disorder are lacking.   
My study is unique in that the total SH cohort will be screened for TSHR gene variance, 
irrespective of TPO antibody status. This will help to determine whether mutations reside 
exclusively in the TPO seronegative patients or not.  This is the largest study to date to screen 
SH subjects for TSHR-Ms, and the first to evaluate FOXE1 PTL polymorphisms in a dedicated 
SH cohort.  
I will now proceed to describe my study recruitment experience and the observational data 
obtained from this cohort including subject characteristics, TFTs and genetic analyses.  
 
3.1.1 Recruitment Experience 
Recruitment ran over a 23 month period from January 2009 to December 2010, during which 
time 1537 GP letters were sent out to 85 GP practices feeding in to our biochemistry 
department, and to 8 outside our catchment area.  93% of feeder practices (79/85) responded 
to at least 1 letter of approach, versus 2 (20%) of GPs outside our catchment area.  Three of 
85 feeder practices expressed a wish to receive no further correspondence on the study. 
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In total, a response from GPs was received on 45% of occasions (692/1537) and their 
responses were as follows: granting permission to approach their patient in 67% (463/693); 
advising not suitable in 17% (116/693), advising that the patient was unwilling to participate 
in 13% (91/693), and in 3% (23/693) advising that the patient was no longer resident at their 
practice (see figure 3.2, and figure 3.3 that summarises my recruitment experience). 
 
Of the 463 patients I was allowed to invite to the study; 220/463 (48%) were confirmed as 
willing and suitable, and appointments to participate were arranged.  Of the others; in 13% 
(61/463) participation was declined, in 21% (98/463) they failed to respond to my letters or 
phone calls, in 15% (70/463) they were willing but unsuitable (included 7 with consent 
difficulties; 4 with minimal English language, and 3 with learning difficulties) and a further 3% 
(14/463) contacted the study after recruitment had closed. 
 
Of the 220 subjects booked in to the study, 12 (5%) repeatedly failed to attend appointments, 
2 were found to be unsuitable at study attendance, and one chose not to be included in the 
study after attending the initial session. 
 
Three subjects were recruited to the study through different avenues; 1 referred by a GP out 
of area (who we had not approached), and 2 (eligible hospital staff) referred themselves to 
the study.  
 
The final study cohort consisted of 208 subjects representing ~14% of those originally 
identified by the department of biochemistry (208/1537).  
 
Of the 208 study participants; 7 (3%) did not have DXA scans (6 due to repeated failures to 
attend appointments, and 1 exceeded the machine’s weight limit) and DXA scans were 
incomplete in a further 6 patients (one due to bilateral hip replacements, 4 due to spinal 
metalwork, and 1 due to a naval piercing).  
 
 
 
 
 
74 
 
 
Figure 3.2:  Pie chart detailing GP responses to our letter of approach 
 
 
The categories are as labelled with subject numbers and their percentage amongst the group provided 
 
 
Figure 3.3:  Flow diagram summarising my subject recruitment experience 
 
The number of subjects (n) and the percentage (%) at each step are provided  
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3.1.2: Study participation in relation to gender and age 
 
In this study gender did not influence study participation (Table 3.1).  
 
 
Table 3.1:  Study participation observations in relation to gender and age 
 Seemingly suitable 
for study 
Not choosing to 
participate 
Study Participants 
Female ratio and %  (349/475), 73% (189/254), 74% 
 
(156/208), 75% 
 
Mean, Median and 
Modal ages (Years) 
51, 53, 65 50, 52, 57 51, 55, 61 
 
The group ‘Seemingly suitable for study’ excluded those not registered with the GP, unsuitable for the 
study, and those with responses too late to participate. The group ‘Not choosing to participate’ 
included those unwilling to participate (from GP response, or my direct communication including those 
failing to respond). 
 
 
Figure 3.4: Histograms illustrating the age distributions amongst subject groups  
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The number of subjects per age group are shown on the y axis and age in years is shown on the x axis. 
The relative distribution of subject ages across each group (a-c) is depicted in the individual graphs.  
 
It is evident that the age distributions are broadly similar across each of the subgroups 
depicted in figure 3.4 (subjects to be approached about the study, those declining 
participation, and those participating in the study). 
These data indicate that the recruited cohort provide a good representation of the greater 
cohort in terms of age and gender ratios.  
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3.2 Demographic and observational data on the SH cohort 
 
 
3.2.1 Demographics 
The study cohort was 75% female (156/208) and 90% Caucasian (9% Asian and 1% Afro-
Caribbean/ Black).  The mean age of participants was 51 years (median age 55) and age at 
study attendance ranged from 20 to 71 years (see figure 3.5 below).  
 
Figure 3.5:   Histogram of age distribution across the cohort 
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        The histogram shows age on the x-axis and subject numbers on the y-axis. 
 
3.2.2  Cohort comorbidities 
 Hypertension; 30% (63/208) had this diagnosis. 
 Diabetes affected 10% (20/208); One with type I and nineteen with type II diabetes (3 
diet controlled, 5 on insulin therapy, and the others were on oral anti-hyperglycaemic 
agents).  One subject was identified with probable undiagnosed diabetes on his study 
participation bloods. 
 Vascular diseases; 5% (10/ 208) had a diagnosis of Ischaemic Heart Disease and 1% 
(3/208) a diagnosis of Cerebrovascular Disease. 
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3.2.3 Lifestyle characteristics and indicators 
 Smoking history;   
30% (64/208) had a significant smoking history (which I define as a >10 pack year 
smoking history (equivalent to 20 cigarettes per day for more than 10 years) or a 10 
pack year history and a current smoker). 
Of the total cohort; 13% (27/208) were current smokers, 33% (68/208) were ex-
smokers, and 54% (113/208) had never smoked. 
 
 Self-reported average alcohol intake;  
22% (46/208) were teetotal, 71% (147/208) drank within recommended limits and 7% 
(15/208) drank in excess of the 1995 Joint societies recommended limits; >21 units 
per week for men and >14 units per week for women (A working group of the Royal 
College of Physicians, Psychiatrists and General Practitioners (Marmot et al 1995)).  
 
 Self-reported activity levels; ~50% (101/208) described their lifestyle as sedentary 
(which I defined as no exercise outside of basic activities of daily living) whilst 6% 
(13/208) described themselves as very fit (>150minutes of vigorous aerobic activity 
per week (Moore et al 2012).  
 
 BMI; 72% (150/208) were overweight or obese (according to the WHO classification 
sytem), (see figure 3.7).   
 
 The cohort’s iodine status was categorised as mildly iodine deficient (at 93 μg/l (range 
8–3340 μg/l)  
 
Urine iodine excretion (as a marker of Iodine sufficiency) was evaluated and 
categorised according to median urine iodine excretion values in accordance with The 
World Health Organisations classification system (WHO 2007a); severe insufficiency 
<20 μg/l, moderate insufficiency 20-49 μg/l, mild insufficiency 50-99 μg/l, adequacy 
100-199 μg/l, surplus 200-299 μg/l and excessive >300 μg/l. 
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I have described the Iodine sufficiency status of individuals within the cohort according to the 
WHO Iodine excretion thresholds (described) However their intended application is to cohort 
and population data only. The data is provided in figure 3.6. 
 
Figure 3.6:       Iodine sufficiency status of individuals within the SH cohort 
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Iodine sufficiency status was categorised according to each subjects urine iodine excretion as; severely 
insufficient <20 μg/l, moderately insufficient 20-49 μg/l, mildly insufficient 50-99 μg/l, adequate 100-
199 μg/l, surplus 200-299 μg/l and excessive >300 μg/l. This information was evailable in 202 subjects. 
 
 
These data suggest that aberrant iodine sufficiency status, particularly in the more extreme 
groups may explain or contribute to these subjects SH (Prete et al 2015). 
 
However, an association between iodine status and TPO antibodies or TSH values was not 
revealed in this study. 
 
  
Iodine sufficiency 
status 
 
Percentage 
of cohort  
-3 
Severely 
Insufficient  
5% 
-2 
Moderately 
Insufficient 
21% 
-1 
Mildly 
Insufficient 
27% 
0 Adequate 32% 
1 Surplus 10% 
2 Excessive 5% 
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Figure 3.7: Pie chart of BMI weight categories across the cohort 
 
 
 
The categories are as labelled with their subject numbers and percentage amongst the group provided 
 
BMI categories are in accordance with the WHO classification system; 
 
 <18.5kg/m2    Underweight 
 18.5-24.9kg/m2  Normal weight for Caucasians (18.5-22.9 for Asians) 
 25-29.9kg/m2   Overweight for Caucasians (23-27.4 for Asians)  
 30-39.9kg/m2  Obese for Caucasians (≥ 27.5 for Asians) 
 ≥40kg/m2  Morbidly Obese 
 
 
3.3 TPO antibody status 
 
Thyroid peroxidase (TPO) autoantibody status was classified as positive (+ve) or negative (-
ve) according to the antibody titre (reference range <6 to >1000 IU/ml (Abbot2000i analyser). 
A titre <6 was considered -ve and above this threshold +ve (see Table 2.2 for assay details). 
 
Half the study cohort were TPO antibody +ve and half -ve. In table 3.2 the cohort have been 
compared for a range of parameters, according to their TPO antibody status.  
  
Underweight, 3, 1%
Normal, 55, 27%
Overweight, 76, 37%
Obese, 65, 31%
Morbidly Obese, 9, 4%
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Table 3.2:  Compares the TPO positive versus negative groups for the parameters listed 
 
Variable 
 
TPO +ve 
 
TPO -ve 
 
difference  
 
 
95% C.I. 
 
 
p-value 
Sex  
(% Male) 
17% 35% 
 
-18% 
 
-6% to -29% 0.003 
 Age  
(years) 
49.2 54.4 
 
-5.15 
 
-1.65 to -8.65 0.004 
Thyroid Family 
History  
53% 31% 
 
+20% 
 
+7% to +33% 0.004 
TSH at study 
attendance 
5.81 4.79 
 
+1.02 
 
+0.34 to +1.7 0.002 
T4 at study 
attendance 
12.71 13.6 
 
-0.9 
 
-1.29 to -0.5 <0.001 
T3 at study 
attendance 
4.05 4.12 
 
0.07 
 
-0.08 to +0.21 0.35 
log10 urine 
Iodine/ 
creatinine  
0.18 0.12 
 
+0.07 
 
-0.03 to +0.17 0.18 
In table 3.2  symbolises mean value, the difference between the TPO +ve and -ve groups are provided 
alongside the 95% confidence interval (C.I.) and p-value. The plus (+) and minus (-) signs indicate the 
direction of the difference. Units are as follows; T4 and T3; pmol/L, TSH; mU/L and Iodine /creatinine 
ratio; µg/L. 
 
 
The differences between the TPO +ve versus -ve groups were as follows: 
 A higher proportion of women (83% versus 65%) 
 A lower mean age (49 versus 54 years) 
 More frequently reported thyroid family history (FH) (53% versus 31%) 
 Lower mean T4 (12.7 versus 13.6pmol/L) and higher mean TSH (5.8 versus 4.8mU/L) 
 
T3 and Urine Iodine excretion were not significantly different between the groups. 
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3.4 Thyroid Function Tests in the SH cohort 
 
3.4.1 Interval change in TSH across the cohort 
The average time between the original TFTs being taken (that enabled study participation) 
and repeat TFTs being performed at study attendance was 11 weeks (range; 3-14). 
The TSH fell during this time period in 77% (160/208), back into the reference range (<5mU/L) 
in 47% (96/208).  However it remained ≥3mU/L in 90% (184/208) and above 2.5mU/L in 93% 
(193/208) (many experts consider TSH <2.5mU/L as a true normal value (Wartofsky & Dickey 
2005).  See figures 3.8-3.10. 
 
Figure 3.8: Histogram illustrating the distribution of the original TSHs that enabled 
study participation 
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Figure 3.9:  Histogram illustrating the distribution of subsequent TSHs taken at study 
participation 
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Figure 3.10: Superimposed histogram of original and subsequent TSHs  
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      In figures 3.8-3.10 these data relate to those subjects who participated in the study (n=208). 
 
I evaluated the “percentage (%) change in TSH” on interval testing across the cohort (figure 
3.11).  This identified a rise >40% from baseline in 5% of the cohort. Of these subjects half had 
a TSH <10mU/L and could represent a group at higher risk of hypothyroidism (see table 3.3). 
 
Figure 3.11: Histogram depicting percentage change in TSH on interval testing  
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Subjects with a >40% rise in TSH are represented by red bars, all others are grey. 
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Table 3.3:  Characteristics and thyroid parameters of five subjects with a ≥40% increase 
in TSH but a subsequent TSH <10mU/L. 
 
Study 
Number 
Sex 
Age 
(years) 
 
TPO 
Status 
 
Subsequent 
TSH 
(mU/L) 
 
% 
change 
in TSH 
 
Subsequent 
T4 
(pmol/L) 
% 
change 
in T4 
180 F 45 +ve 7.6 +40 14.3 -6 
181 F 61 +ve 9.3 +40 11.9 0 
137 F 65 -ve 7.3 +41 13.0 +20 
210 F 68 +ve 8.9 +66 12.2 -3 
87 F 46 +ve 9.1 +70 12.1 -15 
 
In this table F is for female, +ve and -ve indicates their TPO antibody status.  Percentage (%) change in 
T4 and TSH are described as a rise (+) or fall (-) in value relative to original values. T3 was normal in all 
cases.  
 
TSH changed appreciably (which I define as a >5% change) rising in 18% (38/208) ~70% of 
whom were TPO +ve.  This TSH rise was associated with an appreciable fall in free-T4 (>5% 
drop) in ten subjects (25%). 
 
When I compare those with an appreciable change in TSH on interval testing (rise versus a 
fall (figure 3.12); a greater proportion with TPO positivity were in the TSH rise group (71% 
versus 45%; 95% C.I. for the difference +10 to +42%, p-value 0.002).  Ethnicities, sex ratios 
and % change in T4 were similar across both groups.  
 
Figure 3.12: Comparing the TPO positive to negative ratio in subjects with a >5% rise in 
TSH values (3.12a) versus those with a >5% drop in TSH values (3.12b)  
  
      
The subject numbers per group were 38/208 in the >5% rise in TSH group (3.12a) and 151/208 in the 
>5% fall in TSH group (3.12b). The legend is as shown. 
71.1%
28.9%
Figure 1.9a
Negative
Positive
45.0%
55.0%
Figure 1.9bFigure  3.12a Figure  3. 2b 
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When I evaluated the TPO antibody titre (categorised as negative (<6mU/L), positive (6-
999mU/L) or strongly positive (>1000mU/L) according to SH natural history; remitting SH (TSH: 
<5mU/L), persisting SH (TSH: 5 to <10mU/L) or progressive SH (TSH: ≥10mU/L or TSH rise of 
>40%).  It was evident that TPO antibody titre associated with progression of SH (figure 3.13).  
 
I fund that there was a substantially smaller proportion with negative antibodies in the remitting 
(57%) versus the progressive SH group (18%) (p-value for the difference; <0.001), and a higher 
proportion with strongly positive antibodies in the progressive (60%) versus remitting (21%) or 
persisting groups (24%) (p-value for the difference; 0.002 and 0.006 respectively).  
 
Figure 3.13: Displays the natural history of SH on repeat TFTs in relation to TPO antibody titre. 
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The numbers of subjects in each subcategory are provided. Study participation TSHs were <5mU/L in 
the remitting category; 5 to 9.9mU/L in the persisting category and ≥10 or a >40% rise from baseline 
TSH in the progressive SH category.  
 
3.4.2 Evaluating the subgroup with a TSH ≥10 mU/L 
This group were evaluated separately as a TSH ≥10mU/L represents the threshold at which 
thyroxine initiation is generally recommended (ATA/AACE guidelines Garber et al 2012). Of 
these 12 subjects (representing 6% of the cohort); 10 (83%) were TPO +ve, half described a 
FH of thyroid dysfunction, and their ages ranged from 20 to 64 years (see table 3.4).  Other 
observations were as follows:-  
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 A TSH ≥10mU/L was identified on original TFTs in 5 subjects, 2.5%, and on participation 
TFTs in 10 subjects, 5% of the total cohort. 
 
 Only 2 subjects amongst this group demonstrated a fall in TSH on re-testing; both male, 
1 was TPO +ve (TSH; 10-7.3mU/L), and one TPO -ve (TSH; 11.46-5.53mU/L). Therefore a 
TSH ≥10 does not preclude a fall in TSH.  
 
 T4 fell significantly (>5%) in 3 of the 12 subjects and below the normal reference range 
(<9pmol/L) in one subject (Number 093; T4 8.7pmol/L). T3 was normal in all cases. 
 
 This group was similar to the total cohort in regard to:- 
- mean % change in T4 (figure 3.14 versus figures 3.15 and 3.16)   
-The proportion with a FH of thyroid dysfunction 
-Sex ratio (despite a greater proportion of males in this group (42% (5/12) versus 
25% in the total cohort; the difference was not statistically significant (p-value 0.25)). 
 
 This group was dissimilar to the total cohort in regard to:- 
- mean % change in TSH (+35 (≥10mU/L) versus -22 (Difference; +57%, p-value 0.003) 
- TPO positivity (75% (≥10mU/L) versus 50% (Difference; 25%, p-value 0.04) 
 
Figure 3.14:  Percentage change in T4 and TSH on interval testing in subjects with a TSH 
≥10mU/L 
      Figure 3.14a:  Scattergraph data                Figure 3.14b:  Boxplot data 
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In Figure 3.14a the red dots represent subject values and the blue line is the best linear relationship 
between these parameters. In Figure 3.14b the boxplots display the median values and the 25th and 
75th quartile points. The whiskers indicate the range of values. 
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Table 3.4:  TFTs and basic characteristics of subjects with a TSH ≥10mU/L 
Study No Sex Age (Years) 
Original TSH 
(mU/L) 
Study TSH  
(mU/L) 
 % ∆ TSH 
Initial T4  
(pmol/L) 
StudyT4  
(pmol/L) 
% ∆ T4 
TPO 
Status 
TPO titre 
<6; >1000 
FH 
103 F 20 6.29 10.19 +62% 12.91 14.1 +9% +ve >1000 No 
164 M 62 6.56 14.15 +116% 10.7 10.7 0 +ve 625 Yes 
132 M 43 6.85 10.4 +52% 10.32 9 -13% +ve >1000 
Yes; 
cancer 
93 F 45 7.08 14.06 +100% 9.87 8.7 -12% -ve 1.9 No 
90 F 32 8.19 13.63 +66% 12.59 12.3 -2% +ve >1000 Yes 
198 F 32 9.21 10.1 +10% 11 11 0 +ve 689 Yes 
200 M 51 9.73 18.68 +92% 9.2 9.2 0 +ve 682 No 
4 M 31 10 7.31 -27% 12.87 14.7 +14% +ve >1000 No 
174 F 63 10.02 10.54 +5% 13.4 13.4 0 -ve 6 No 
51 F 67 10.3 11.83 +15% 13.03 13 0 +ve >1000 No 
18 M 68 11.46 5.53 -52% 13.93 13 -7% -ve 1.1 Yes 
108 F 44 11.76 12.39 +5% 10.82 11.3 +5% +ve 886 Yes 
 
The abbreviations in this table are No (for Number), F for Female and M for Male, ∆ is the symbol for ‘change’, + and - indicate positive and negative directions of 
change respectively, +ve and -ve indicate TPO positivity and negativity respectively. FH for Thyroid Family history. Highlighted in red are; Females, TSH readings ≥10 
mU/l, a fall in T4, positive TPO antibodies and a positive family history (FH) of thyroid disorders.  
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3.4.3 Exploring the interval change in TSH versus T4 across the cohort 
This was evaluated on the expectation that an inverse correlation between percentage 
change in T4 and TSH would be revealed (Hoermann et al 2010).  A small, negative relationship 
between these parameters was seen (correlation coefficient (R) -0.07, p-value 0.02).  In 
general a small change in T4 was associated with a much larger change in TSH consistent with 
the inverse log linear relationship described between these parameters (Hoermann et al 
2010), (See figures 3.15 and 3.16 below).  
Figure 3.15: Percentage change in TSH versus T4 on interval testing 
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The percentage (%) change in individual’s free-T4 and TSH values are shown by red spots. The 
blue line represents the best linear relatonship between these parameters. 
 
Figure 3.16:  Boxplot illustrating the percentage change in T4 and TSH on interval testing 
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The percentage (%) change in value is shown on the y-axis. The box plots display the median value 
together with the 25th and 75th percentiles. Whiskers represent the upper and lower 25% distribution 
(excluding outliers). Outliers are represented by diamond shaped dots. 
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3.4.4 Evaluating TFT-component associations across the cohort 
In this section the TFT components taken at study participation are evaluated across the 
cohort.  This revealed a negative relationship between TSH and T4 (figure 3.17), an 
unexpected positive association between TSH and T3 (figure 3.18), and a positive association 
between T4 and T3 (figure 3.19).  The regression equations are provided below each figure.  
 
Figure 3.17:      Relationship between TSH and T4 across the cohort  
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Regression equation;   T4 = 14.2 - 0.21 x TSH,  p-value <0.001,  R2 11% 
 
 
 
Figure 3.18:      Relationship between TSH and T3 across the cohort  
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Regression equation;  T3= 3.9 + 0.04 x TSH,  p-value 0.01,   R2 3.3% 
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Figure 3.19:      Relationship between T4 and T3 across the cohort  
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Regression equation;  T3 = 2.7 + 0.1 T4, p-value <0.001,   R2 10%  
 
In figures 3.17-3.19 the red spots represent individual subject values and the blue line 
represents the best linear relationship between these parameters. 
 
3.5  Genetic analyses on the thyrotrophin receptor 
 
This was determined by dHPLC screening all 10 exons of the TSHR, on all study participants.  
When sequence aberration was suggested, direct DNA sequencing was undertaken to 
determine and confirm the sequence variant. The methods are all described in chapter 2. 
 
3.5.1  TSHR mutations  
Twelve TSHR-Ms (or suspected mutations) in twelve study subjects were identified.  Table 3.5 
details the basic thyroid biochemistry and characteristics of these subjects.  
 
The salient observations on this group were as follows:-  
 
 All but one subject had unmeasurable TPO antibodies. The exception (subject 022) 
had low-positive antibodies (titre 61 KU/L; reference range <6 to >1000).  This 
observation is substantially different from the total cohort data where half were TPO 
antibody positive (difference of ~-42%, p-value <0.001) 
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 The TSH on testing ranged from ~2.9 to 9.1mU/L with a mean of 5.7 and a median of 
5.9mU/L (the TFTS obtained on the screening and study participation samples were 
included in generating these figures).  
 5 of 12 were male (42%) representing a higher male proportion than in the total cohort 
(25%). However the difference did not meet statistical significance (p-value 0.3) 
 1 in 12 (~8%) were Asian; similar to the total cohort data (~9% Asian). 
 5 of 12 (42%) described a FH of thyroid disorders (a similar proportion to total cohort). 
 Age was more evenly distributed across the recruitment ages whereas total cohort 
data was skewed towards older ages. The mean ages were similar.   
 The W546X mutation was identified in 7 of 12 subjects (3% of the total cohort) 
indicating a prevalence 6x higher than the assumed background rate of ~1/180(Jordan 
et al 2003). 
 10 of the 12 mutations resided in exon 10.  The two exceptions were the P162A in 
exon 6, and the Y195C in exon 7. 
 The R531W (Exon 10) and the P162A (Exon 6) identified are both known mutations 
(Cangul et al 2010 & Sunthornthepvarakul et al 1995). 
 
 
Two novel sequence variants were identified:-  
 
 The W488X (identified in subjects 022 and 111); where a sequence terminating amino 
acid (X) replaces tryptophan (W) at codon 488 (Exon 10).  The identically positioned 
W488R is a recognised inactivating TSHR-M (De Marco et al 2009).  
 The Y195C (subject 032) is a sequence variant where Cysteine (C) replaces tyrosine (Y) 
at codon 195 (exon 7). Both amino acids are polar and therefore the functional 
significance of this substitution needs to be determined.   
 
 
Although the functional impact of the Y195C on TSHR signalling needs to be determined; for 
the purpose of my analyses this group of 12 subjects are considered ‘The mutation group’. 
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Table 3.5:  Basic characteristics and thyroid biochemistry in the TSHR mutation group.  
 
Study Number Sex, Age & Race 
Sequence variance  & 
exon 
Original 
TSH (mU/L) 
Study TSH 
(mU/L) 
Study T4 
(pmol/L) 
Study T3 
(pmol/L) 
TPO titre (<6; 
>1000) (KU/L) 
Thyroid Family 
History 
003 F, 34, C 
W546X 
10 
7.88 3.4 12.9 3.09 <6 Yes 
022 F, 40, C 
W488X 
10 
6.11 4.88 13.65 3.82 61 No 
 
032 
M, 43, A 
Y195C 
7 
6.45 3.42 13.72 4.5 <6 No 
046 F, 61, C 
R531W 
10 
5.8 7.66 14.07 4.53 <6 No 
078 M, 38, C 
P162A 
6 
5.69 6.16 15.37 3.74 <6 No 
084 F, 44, C 
W546X 
10 
5.28 4.65 11.72 3.76 <6 No 
099 M, 63, C 
W546X 
10 
9.1 5.95 13.62 4.39 <6 No 
111 F, 66, C 
W488X 
10 
6.45 5.66 13.04 3.95 <6 Yes 
119 F, 52, C 
W546X 
10 
6.17 4.03 12.74 3.83 <6 Yes 
148 M, 38, C 
W546X 
10 
6.98 7.01 11.7 3.44 <6 Yes 
172 M, 61, C 
W546X 
10 
6.6 4.18 15.5 2.87 <6 No 
177 F, 58, C 
W546X 
10 
5.46 2.88 15.1 4.32 <6 Yes 
Sex is categorised as female (F) or male (M). Age is recorded in years, race is categorised as Asian (A) or Caucasian (C). The family history was considered positive when 
hyperthyroidism, hypothyroidism or SH affected a first or second degree relative. 
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3.5.2 D727E polymorphism group 
Nine subjects (4% of the cohort) were identified as being heterozygous carriers of the D727E 
polymorphism.  This is substantially less than the 10% prevalence reported in a British and 
Canadian control cohort (Matakidou et al 2004).  Table 3.6 details their thyroid biochemistry 
and basic characteristics.   
 
 
Table 3.6:  Basic characteristics and thyroid biochemistry in the D727E polymorphism 
group 
 
Study 
Number 
Sex, Age & 
Race 
Original 
TSH 
(mU/L) 
Study TSH 
(mU/L) 
Study T4 
(pmol/L) 
Study T3 
(pmol/L) 
TPO  
(KU/L) 
Family 
History 
012 F, 38, C 6.14 6.68 11.8 3.65 <6 Yes 
081 F, 63, C 6.31 4.75 11.88 3.87 <6 Yes 
096 M, 39, A 9.03 7.16 11.58 3.91 <6 No 
124 F, 56, C 6.06 4.6 11.57 4.28 6 No 
132 M, 43, C 6.85 10.4 10.32 3.69 >1000 Yes 
158 F, 31, C 5.28 3.26 14.8 4.8 <6 Yes 
184 F, 47, C 5.6 3.54 12.6 4.7 <6 Yes 
190 F, 46, C 8.36 4.58 15 4.22 <6 Yes 
193 F, 59, C 5.54 6.38 14.7 5.27 <6 No 
 
Sex is categorised as female (F) or male (M). Age is recorded in years, and race categorised as Asian (A) or 
Caucasian (C). The family history was positive if hyper or hypothyroidism/SH was reported in a first or 
second degree relative.  
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The salient observations on the D727E group were as follows:- 
 Eight of nine had negative TPO autoantibodies; substantially different from the total 
cohort data (difference minus ~40%, p-value <0.001). 
 The male to female ratio (2: 7) was similar to the total cohort, as was the proportion 
reporting a thyroid FH (66% versus ~40% of in total cohort data, p-value 0.1 )  
 
3.5.3  The P52T polymorphism group 
Thirteen subjects carrying the P52T polymorphism were identified giving a prevalence of ~6%, 
similar to that reported amongst control populations (Simanainen et al 1999).  Table 3.7 
details their thyroid biochemistry and basic characteristics.  The salient observations on this 
group were as follows:- 
 There was a higher proportion of Asian subjects (6/13) in this group than in the total 
cohort (difference ~ +40%, p-value 0.008). This potentially reflects different gene 
pools in subjects of different ethnic origins.   
 Five of thirteen had positive thyroid autoantibodies, a ratio similar to the total 
cohort (difference minus ~10%, p-value 0.4). 
 The female to male ratio (11:2), was similar to the total cohort (difference ~+10%, p-
value 0.4).  
 Four of thirteen reported a FH of thyroid disease, similar to the total cohort (difference 
minus 10%, p-value 0.5).  
 
3.5.4 The D36H polymorphism 
This polymorphism was identified in one subject suggesting a prevalence similar to the 0.5% 
prevalence described in control cohorts (Peeters et al 2003).  This subject was a 69 year old 
Caucasian female who was TPO antibody negative and her TSH normalised at study 
attendance (5.8 to 1.8mU/L). 
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Table 3.7:  Characteristics of the P52T polymorphism group.  
 
Study 
Number 
Sex and 
Race 
Screening 
TSH 
(mU/L) 
Study 
TSH 
(mU/L) 
Study   
T4 
(pmol/L) 
Study    
T3  
(pmol/L) 
TPO 
antibodies 
(KU/L) 
Thyroid 
Family 
History 
25 F, 59, C 5.92 4.27 14.29 4.7 >1300 No 
26 F, 37, A 6.5 3.51 14.2 4.45 >1300 No 
42 F,59, C 9.48 8.47 10.4 3.36 >1300 Yes 
92 F, 51, A 3.79 5.39 11.75 3.79 <6 No 
97 M, 64, A 3.92 6.12 13.63 3.92 <6 No 
104 F, 54, C 3.43 7.52 11.83 3.43 <6 No 
110 M, 67, A 4.32 5.64 12.9 4.32 <6 No 
130 F, 56, A 4.26 6.29 13.3 4.26 30 Yes 
154 F, 47, A 3.72 5.71 14.1 3.72 <6 No 
184 F, 47, C 4.7 5.6 12.6 4.7 <6 Yes 
195 F, 64, C 5 5.26 14.7 5 30 Yes 
196 F, 58, C 3.1 5.66 16.8 3.1 <6 No 
201 F, 49, C 3.64 6.3 14.1 4.53 <6 No 
 
Sex is categorised as female (F) or male (M). Age is recorded in years, and race is categorised as Asian 
(A) or Caucasian (C). The family history was positive if hyper or hypothyroidism/SH was reported in a 
first or second degree relative.  
 
 
3.6 TFT evaluations in the TSHR mutation & polymorphism groups 
versus the total cohort 
 
The TFTs in the TSHR-M and D727E groups were compared (except for D727E subject 132, 
with ATD).  All analyses here on relate to the TFTs taken at the time of study participation. 
 
Although the likelihood of revealing true differences is limited by low subjects numbers; a 
lower T3 in the TSHR-M subjects (of borderline significance) is revealed (see table 3.8).  
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 Table 3.8:  Compares TFT values between the TSHR mutation and D727E carriers 
TFT 
Parameter 
 
Mutation  
(n = 12) 
         
D727E       
(n = 8) 
Difference 95% C.I  p-value 
T4 (pmol/L) 13.59 13 +0.6  -0.84 to 2.05 0.38 
TSH (mU/L) 5.04 5.07 -0.03 -1.4 to 1.4 0.97 
T3 (pmol/L) 3.8 4.34 -0.5 0.01 to -1 0.055 
In this table; represents the mean value, C.I represents the confidence interval and the plus (+) and 
minus (-) signs indicate the direction of the difference. 
 
I subsequently evaluated the TFTs in the TSHR-Ms versus the rest of the TPO negative subjects 
(with study TSHs in a similar range; 2.8 to 9.1mU/L (excluding the D727E subjects)). This 
analysis revealed a lower mean T3 value in the TSHR-M group (Table 3.9).  
 
Table 3.9: Compares TFT parameters between the mutation group and the TPO 
negative cohort across a similar TSH range. 
 
TFT 
Parameter 
Mutation 
              
(n = 12) 
TPO -ve 
cohort  
(n=75) 
Difference 95% C.I p-value 
T4 (pmol/L) 13.59 13.67 -0.07 -0.95 to +0.8          0.86 
TSH (mU/L) 5.04 4.8 +0.25 -0.72 to +1.2  0.59 
T3 (pmol/L) 3.8 4.2 -0.35 -0.65 to -0.05  0.026 
In this table: represents the mean, C.I represents the confidence interval and the plus (+) and minus 
(-) signs indicate the direction of the difference. 
 
I subsequently evaluated a range of parameters from the total cohort data that might 
influence T3 (including TSHR-M status).  This was evaluated in a multiple regression analysis 
(MRA) as shown overleaf. 
Please see sections 2.19, and 4.4.1 for an explanation of the use and interpretation of MRAs.  
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The parameters assessed against T3 in this MRA were TSHR-M, Male Sex, TSH, T4 and TPO 
antibody positivity.  Table 3.10 details the results of this analysis.  
 
 
T3 = 1.9 - 0.36 TSHR-M + 0.14 Male(1) + 0.76 (Log10TSH) + 0.13 T4 - 0.04 (TPO+ve) 
N=207,  R2= 21% 
 
 
Table 3.10:  MRA evaluating T3 against the predictors listed including TSHR-M status 
 
Predictor 
 
R 
 
SE  
 
95% C.I. 
 
p-value 
Constant +1.9 0.36 +1.2 to +2.6 <0.001 
TSHR-M -0.36 0.14 -0.6 to -0.1 0.01 
Male(1) +0.14 0.08 -0.02 to +0.3 0.06 
Log10TSH (mU/L) +0.76 0.19 +0.4 to +1.1 <0.001 
T4 (pmol/L) +0.13 0.023 +0.08 to +0.2 <0.001 
TPO+ve(1) -0.04 0.07 -0.18 to +0.1 0.6 
 
In Table 3.10: The regression coefficient (R), standard error (SE) and confidence intervals (C.I) are 
provided. The plus (+) and minus (-) signs indicate the direction of the association. 
 
 
The T3 MRA supports the observation that TSHR-M status correlates negatively with T3.  
This association was subsequently explored in a stepwise MRA (Model 3.1) which reveals 
strengthening of the relationship between T3 and mutation status as confounders are 
added in to the analysis; supporting an independent negative association between T3 and 
TSHR-M status.  
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Model 3.1:  Stepwise regression model exploring the association between mutation-carrier 
status and T3; assessed singularly and subsequently adjusted for confounders. 
 
N   R   95% C.I.  p-value  
Step 1; crude (mutation carrier status against T3 only) 
207   -0.26   (-0.6, +0.03)  0.08   
Step 2; Step 1 also adjusted for T4  
207   -0.31   (-0.6, -0.04)  0.03   
Step 3; Step 2 also adjusted for log10TSH 
207   -0.33   (-0.6, -0.06)  0.02   
Step 4; Step 3 also adjusted for TPO antibody status  
207   -0.35    (-0.6, -0.08)  0.01   
Step 5; Step 4 also adjusted for Male Sex 
207   -0.36   (-0.6, -0.09)  0.01  
Model 3.1 details the number of subjects in the analysis (N), the regression coefficient (R), the 95% 
confidence interval (C.I) for each analysis step and its p-value. The minus (-) or plus signs (+) indicate 
the direction of the association.    
 
I subsequently repeated the T3 MRA of table 3.10, but substited D727E status (excluding 
the subject with ATD) for TSHR-M status.  This analysis did not reveal a clear association 
between T3 and D727E status (see table 3.11 where this MRA is summarised).  
 
 
Table 3.11:  MRA evaluating T3 against the predictors listed that include D727E status  
 
Predictor R SE Coefficient 95% C.I. p-value 
Constant +1.87 0.35 1.2 to 2.6  <0.001 
D727E +0.3 0.17 -0.03 to +0.6  0.08 
Male Sex +0.16 0.08 +0.02 to +0.34 0.05 
Log10TSH (mU/L) +0.74 0.19 +0.1 to +0.37 <0.001 
T4 (pmol/L) +0.13 0.02 +0.1 to +0.17 <0.001 
In Table 3.11: The Regression Coefficient (R), Standard Error (SE) and Confidence Intervals (C.I) are 
provided. The plus (+) and minus (-) signs indicate the direction of the association. 
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An equivalent MRA was performed for the P52T polymorphism group (n=13).  This did not 
reveal an association between the P52T polymorphism and T3 values (R minus 0.06, p-value 
0.55 (MRA not shown)).  
 
3.7 FOXE1 polyalanine tract length polymorphism evaluations 
  
 
FOXE1 polyalanine tract length (PTL) polymorphism status was determined in 203 study 
subjects (5 had insufficient quantity or quality of DNA for analysis).    
 
This work revealed the homozygous FOXE1 14 PTL as the prevalent genotype (identified in 
62% (126 subjects)), followed by the heterozygous 14/16 combination in 35% (71 subjects).  
Other combinations occurred in 3% (figure 3.20). 
 
       Figure 3.20: Pie chart depicting FOXE1 PTL genotype frequencies across the cohort 
14/14
14/16
Other
3.0%
35.0%
62.1%
 
The FOXE1 PTL polymorphism genotype categories are indicated by the legend 
(homozygous14/14 in green, heterozygous14/16 in red, and all other combinations in blue).  
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3.7.1 Characteristics of the cohort according to FOXE1 PTL polymorphism 
 status 
 
 
The FOXE1 PTL polymorphism status across the cohort was evaluated as the 14/14 
combination versus all others (see table 3.12).  This revealed no differences between the 
groups in regard to; 
 TPO antibody status 
 Sex ratios  
 Ethnicity 
 T4 values 
 TSH values 
However a higher T3 amongst the FOXE1 PTL14/14 group was revealed.  This relationship was 
subsequently explored in a parsimonious stepwise MRA (Model 3.2) that supports this 
observation. 
 
Table 3.12:  Comparison between the FOXE114/14 PTL versus all other PTL combinations 
for the parameters listed.  
Parameter 14/14 (n=126) Other (n=77) Difference p-value 
% TPO +ve 50 53 -3 0.61 
% Male 24 26 -2 0.75 
% Asian 9% 9% <0.02 0.7 
TSH (mU/L) 5.43 5.22 +0.21 0.52 
T4 (pmol/L) 13.08 13.16 -0.08 0.72 
T3 (pmol/L) 4.16 4.0 +0.16 0.02 
In table 3.12: represents the mean value in each group. The differences in the % between groups 
for each parameter listed, with respective p-values are provided.  
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Model 3.2:  Stepwise regression model exploring the association between the FOXE114/14 
PTL status and T3 values; assessed singularly and subsequently adjusted for 
confounders. 
 
N   R   95% C.I.  p-value  
Step 1; crude (14/14 status against T3 only) 
202   +0.17   (+0.03, +0.3)  0.02  
  
Step 2; Step 1 also adjusted for T4  
202   +0.18   (+0.04, +0.32)  0.009  
  
Step 3; Step 2 also adjusted for log10TSH 
202   +0.18   (+0.05, +0.3)  0.008  
  
Step 4; Step 3 also adjusted for TSHR mutation status 
202   +0.2   (+0.06, +0.32)  0.005  
 
Model 3.2 details the number of subjects in the analysis (N), the regression coefficient (R), the 95% 
confidence interval (C.I) at each step and its respective p-value. The minus (-) or plus signs (+) 
indicate the direction of the association.    
 
3.7.2 FOXE1 PTL status in association with TSHR gene sequence variance 
FOXE1 PTL polymorphism status could be assessed in 11 of 12 TSHR-M subjects and 8 of 9 
D727E subjects. Basic analysis revealed a lower than expected prevalence of the FOXE114/14 
PTL polymorphism genotype amongst the D727E subjects, but no differences from total 
cohort data amongst the TSHR-M group (see table 3.13).  
 
Table 3.13:  Comparison of FOXE114/14 genotype frequencies between the TSHR-M or 
D727E groups versus total cohort data 
 
FOXE114/14 genotype 
frequency in TSHR group 
FOXE114/14 genotype 
frequency in TC (n=203) Difference 
95% C.I p-value 
Mutation (n=11); 0.73  0.62 +0.11 -0.16, +0.4 0.4 
D727E (n=8);        0.25 0.62 -0.4 -0.12, -0.7 0.005 
In this table; stands for mean, TC for Total Cohort and C.I for Confidence Interval.   
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3.8 Discussion 
 
3.8.1 Recruitment 
Study recruitment fell short of anticipated numbers with 208 recruited rather than the target 
number of 350.  The study protocol accurately predicted the number of subjects to be offered 
study participation (463 versus 500 expected).  However, a recruitment rate of 45% fell short 
of the 70% anticipated.  The expectation that 30% would not be recruited was similar to the 
34% of subjects ‘unwilling’ or uncontactable.  However, the fact that ~20% of GP approved 
subjects were unsuitable for the study and that only 45% of GPs would respond to our letter 
of approach was not expected (figures 3.2 and 3.3 respectively).  
 
The recruitment rates achieved were similar to those reported by Cornelia et al (2005) who 
quoted 30-50%. Of the patients I approached directly, 65% wished to participate although 
15% were unsuitable.  Thereafter dropout rates were low, with ~5% (12/220) failing to attend 
study appointments, and 3% (6/208) failing to attend DXA appointments.  Dropout rates were 
considerably less than the >20% rate reported by Bell et al 2013.  High attendance rates may 
reflect my practice of re-contacting and rearranging appointments for subjects who failed to 
attend.  In this study a subject’s sex did not influence their tendency to participate (Table 3.1).  
 
GP participation rates of 45% were considerably less than those reported in other studies 
(~80% Roland et al 2001).  The reason for this is unclear but presumably reflects GP’s 
disinclination locally to take on this additional workload.  
 
3.8.2 Demographics 
A female preponderance (75%) and an age distribution favouring older subjects (modal age 
65 years (see Figure 3.5) was revealed.  This reflects the fact that SH (like primary 
hypothyroidism) is more prevalent in women and with advancing age (Canaris et al 2000, 
Hollowell et al 2002).  The Whickham Study reported SH in 7.5% of women and 2.8% of men 
(Tunbridge et al 1977); a similar sex ratio was observed in this study.  The antibody status of 
the cohort was 50% positive and 50% negative, an observation falling within the reported 
range for areas traditionally considerd to be iodine sufficient (~40% (Surks & Hollowell 2007) 
to 80% (Allan et al 2000) but a lower prevalence of TPO positivity than anticipated in the study 
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protocol (Appendix 1 & section 2.1.3; 2/3rds TPO +ve were anticipated).  The ethnicity of 
participants (90% Caucasian, 9% Asian and 1% of Afro-Caribbean) suggested that Asian 
subjects may be slightly over represented in this study (2011 census data reported; 90% 
Caucasian, 5% Asian, 1% Black and 3% ‘other ethnicities’ (census data from the Cardiff and 
Vale Health Board, table LC2101EW; Ethnic group by Sex and Age) reflecting my observation 
that GPs working in areas where ethnic minorities are prevalent in Cardiff (ie; Grangetown, 
Cardiff Bay and Riverside) were active referrers to the study.   
 
The comorbidity rates amongst study participants appeared to be higher than that described 
for the local population (Director of public health’s report for Cardiff and Vale Health Board 
2012); Hypertension affected 30% versus 10% of the local population; Ischaemic Heart 
Disease affected 5% versus 2.5% of the local population and 68% of participants were 
overweight (BMI >25) versus 53% of the local population.  However, the fact that these figures 
are not age group and sex ratio equivalent limits their utility in drawing inferences about the 
recruited cohort.  Nevertheless it is possible that the SH cohort may have poorer health status 
than the local population although individuals with poorer health status might be more likely 
to be recruited to the study.  
 
The self-reported lifestyle behaviour amongst participants was similar to that described for 
the local population (Director of public health’s report for Cardiff and Vale Health Board 
2012); 30% had a significant smoking history and 13% were current smokers (versus 21% of 
the local population), 50% described their lifestyle as sedentary (whereas 75% of the local 
population are known not to meet recommended activity levels).  Only 7% confessed to 
drinking above weekly recommended alcohol limits (versus 45% of the local population) 
suggesting that self-reported alcohol intake may have been underestimated. 
 
3.8.3 Thyroid function tests 
The TFTs at study participation revealed TSH to have fallen in ~80% of the cohort (160/208), 
falling back into the reference range in ~half (figure 3.9).  This scenario is recognised with SH 
remittance rates of 25% (Parle et al 1991) to 50% (Diez and Iglesias 2009) described.   
The TSH rose in ~20% (43/208) of the cohort with ~6% (12/208) meeting standard criteria for 
TRT (TSH ≥10mU/L; Surks et al 2004). A rise ≥40% from baseline was apparent in ~5% of the 
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cohort (figure 3.11) and I postulate that this group might represent subjects with more rapidly 
progressive thyroid dysfunction who may also benefit from TRT (if so increasing numbers 
requiring TRT to 17 subjects (~8%)).  However, this is not described. 
 
The Whickham Study reported progression from SH to PH to affect ~ 4.3% per year amongst 
TPO +ve females, versus ~2.6% per year amongst TPO -ve females (Tunbridge et al 1977).  In 
my cohort progression of SH (to a ≥10mU/L) within the ~3 month TFT re-evaluation period 
occurred in ~10% of the TPO +ve group (10/104) and 2% (2/104) of the TPO -ve group.  Thus 
supporting the notion that progression of SH is more common amongst TPO +ve subjects. 
 
Twenty year follow-up of The Whickham Study reported progression of SH as ~4x higher 
amongst TPO antibody +ve men with SH than women (Vanderpump et al 1995).  I too observe 
greater progression (to TSH ~≥10) amongst TPO +ve men (4/17; 23%) versus women (6/87; 
7%) although this difference did not meet statistical significance (p-value 0.12).  
 
Progression of SH correlated with TPO antibody titre in this cohort (Figure 3.13) as also 
reported by Zhang et al 2010.  However half of the subjects with progressive SH (to a TSH 
~≥10mU/L had a TPO titre <1000 (TPO titres; 163, 170, 689, 625, 689 mU/L).  
 
Exploration of the relative change in T4 and TSH values across cohort (Figures 3.15 & 3.16); 
and in progressive SH (Figure 3.14) revealed a small negative association between these 
parameters.  However, on an individual subject level change in T4 was a poor indicator of 
change in TSH. I found that free-T4 tended to remain relatively constant in both groups 
despite marked fluxes in TSH.  This observation would potentially support the use of TSH-only 
assays to monitor well patients with diagnosed SH in the community setting.  
 
The TFT associations across the cohort revealed an expected negative relationship between 
TSH and free-T4 (figure 3.17); a positive relationship between free-T4 and free-T3 (figure 3.19) 
and an unexpected positive association between TSH and free-T3 (figure 3.20).  This suggests 
that there may be over compensation of the mechanism to maintain normal free-T3 levels in 
compensated SH (T3 is the active cellular hormone and is markedly more potent than T4 
(Gross & Pitt-Rivers 1953)).  The suggestion that progressive SH may be associated with 
increased thyroid hormone efficacy at the tissue level (rather than the inverse of this) would 
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be a new concept. However, the possibility that this small rise in T3 compensates for the more 
substantial fall in T4 remains.   
 
A rising T3 in SH might be driven by peripheral effects (i.e. deiodinase enzyme mediated), 
central effects (i.e. modulating the T3:T4 synthetic ratio from the thyroid gland) and/ or 
modulation of T3 degradation and excretion.  A falling T4 upregulates DIO2 to increase 
peripheral T3 synthesis however this might predict a negative relationship between T4 and 
T3 which is not seen.  TSH might be driving deiodinase effects as reported in osteoblasts 
(Morimura et al 2005), skeletal muscle (Hosoi et al 1999) and thyroid tissue (Murakami et al 
2001b).  However, further investigation is required firstly to explore intra-subject TFT 
variability with progression of SH (for verification purposes), and secondly to elucidate its 
physiological mechanism.   
 
3.8.4  TSHR mutations 
Twelve TSHR sequence variants (SVs) in 12 subjects were identified. Eleven of whom were 
TPO antibody negative, and one had low-positive antibody titres.  This supports the notion 
that TSHR-Ms lie overwhelmingly in seronegative SH cohorts (Alberti et al 2002).  Their 
prevalence was 6% across the cohort and ~11% amongst seronegative subjects which is 
equivalent to the prevalence reported in other seronegative SH cohorts (Camilot et al 2005, 
Nicoletti et al 2009 and Tonacchera et al 2004). 
 
Exon 10 is the largest of the TSHR exons being more than twice the size of the other 9 exons 
combined (Iosco & Rhoden 2009). The majority of TSHR-Ms reside here (~123 of 147 
mutations and 32 of 51 inactivating mutations (Paschke 2013; TSH receptor database)).  
Eleven of the twelve SVs identified in this study reside in Exon 10. However, this was not the 
observation of the aforementioned Italian studies; Nicoletti et al (2009) identified 5 of their 
11 mutations in Exon 10 (2 x Exon 1; 1 x Exon 2; 1 x Exon 4; 1 x Exon 5 and 1 x Exon 6),  Camilot 
et al identified 4 of 13 mutations in Exon 10 (1 x Exon 9, 1 x Exon 6, 2 x Exon 4, and 5 x Exon 
1), and Tonacchera’s group did not report any of  their 5 familial mutations to be in Exon 10 
(3 x (P162A) Exon 6, and 2 x (L252P) Exon 9).  
 
A predominance of SVs in exon 10 in my cohort is likely to reflect the local South Wales gene 
pool.  Indeed the W546X mutation that renders the TSHR non-functional (Clifton-Bligh et al 
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1997) was 6x more prevalent in this cohort than a local control cohort in whom TFTs were 
unknown (Jordan et al 2003).  The novel W488X mutation was identified in two study subjects.  
Observations on the SV group (table 3.5) suggested a modest female prevalence (7 Female: 5 
Male) compared to the total cohort ratio (3:1).  Exploring this further I found other studies 
where a male predominance for inactivating TSHR-Ms were described. Nicoletti et al (2005) 
described mutations in 7 SH males versus 3 SH females.  A study from Taiwan evaluating the 
R450H TSHR mutation in Congenital Hypothyroidism (CH) reported 4 of 5 subjects to be male 
(despite a female excess within this population (Chang et al 2012)).  In our unit male siblings 
homozygous for the TSHR mutation W546X were reported (Jordan et al 2003), and Cerbone 
et al (2013) report male siblings heterozygous for TSHR inactivating mutations.  Given that a 
higher prevalence of TSHR-Ms would not be expected in males, it might be that their clinical 
effects are more pronounced. However, further study to verify and explore this suggestion 
are required.  
 
The TSH ranged between 2.9 and 9.3 mU/L in the SV group. Given that subjects were recruited 
because their original TSH was ≥5 mU/L and subjects with TSH ≥10 mU/L were generally 
unsuitable for the study (as TRT commenced) this may not accurately reflect the TSH range in 
this subgroup.  Previous studies suggest that the natural history of subjects with partial TSH 
resistance is not one of progressive thyroid dysfunction (Tenenbaum-Rakover et al 2009).  
Genotype-phenotype correlations in this group are poor, reflected by the fact that 
heterozygous mutations have been identified at neonatal screening (reflecting more extreme 
TSH levels (Tenenbaum-Rakover et al 2009, Camilot et al 2005) and also rarely  identified with 
a normal TSH (<2mU/L) (Clifton-Bligh et al 1997). 
 
TSHR inactivating mutations are generally considered to be transmitted in an autosomal 
recessive (AR) manner (de Roux et al 1996, Jordan et al 2003, Park et al 2004), presumably 
reflecting the fact that homozygous or compound heterozygous inactivating mutations are 
typically associated with CH. As such, we may have expected this group to infrequently report 
a family history (FH) of thyroid disease, however ~half did.  However, it is recognised that 
heterozygous inactivating TSHR-Ms commonly run in families (Tonacchera et al 2004, 
Tenenbaum-Rakover et al 2009) suggesting an AR inheritance pattern may be misleading and 
a partial dominant inheritance pattern for SH may be more accurate. Indeed several studies 
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support this notion (Cerbone et al 2013, Calibiro et al 200, Alberti et al 2002).  Interestingly, 
a thyroid FH was less frequently reported in the TPO negative group (~30%) with TSHR-Ms 
removed.  
 
Of the SVs identified in the cohort; The R531W and the P162A are known mutations.  Both 
have been reported in their homozygous state in neonates (identified at neonatal screening), 
each with normally positioned thyroid glands and normal T4s. TSHR modelling analysis 
suggested a mild destabilising effect from each mutation (Cangul et al 2010).   
 
The W488X and the Y195C identified are novel SVs.  W488X is a nonsense mutation that will 
truncate the receptor and is expected to impact on TSHR function.  In the Y195C (exon 7) 
cysteine replaces tyrosine in the hinge region of the TSHR.  Although both of these amino 
acids are polar, disulphide bonds between cysteine residues can be important to 3D modelling 
(Betz SF, 1993) and therefore this might impact on TSHR structure and function.  However 
needs to be determined.  
 
I evaluated TFT parameters in the SVs against the D727E subjects and the rest of the cohort 
(section 3.6).  Interestingly this revealed lower T3 values (relative to other TFT parameters) in 
the TSHR-M group.  This observation potentially fits in with thyroid hormone physiology given 
that TSHR activation on thyroid follicular cells triggers a cascade of events resulting in thyroid 
hormone synthesis (Vassart & Dumont 1992).  As such partial TSHR resistance related to 
heterozygous inactivating mutations might be expected to impact on this process.   
It is also possible that TSH (acting via the TSHR) moderates deiodinase enzyme activities 
peripherally (as suggested in brown fat and osteoblasts (Morimura et al 2005)) accounting for 
lower T3 values (relative to T4 and TSH) in these subjects.   
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3.8.5 D727E polymorphism 
The D727E polymorphism was identified in ~4% of the cohort, a lower prevalence than 
described amongst control groups (10% (Matakidou et al 2004) to 16% (Mühlberg et al 2000).  
This may reflect its association with increased TSHR sensitivity (Gabriel et al 1999) and lower 
TSH values (Hansen et al 2007).  It was therefore surprising to identify this in a group of 
predominantly TPO negative (8/9) subjects.  
 
When I compared TFT associations in this group, a positive association with T3 was identified 
(Table 3.11) albeit not statistically significant.  It is possible that this effect is being abrogated 
by a prevalence of the FOXE114/16 polymorphism in this group (negatively associated with T3).  
If the D727E polymorphism is positively associated with T3 then this would potentially 
support reports of enhanced TSHR sensitivity and lower TSH levels in this group. However, 
small subject numbers limits the reliability of my observations and postulations, as does the 
absence of euthyroid controls. 
 
3.8.6  FOXE1 PTL polymorphisms 
The FOXE1 PTL 14/14 polymorphism was the prevalent genotype in this cohort (62%), 
followed by the 14/16 (35%) (Figure 3.20). This is broadly similar to a Slovenian and New 
Zealand study that identified the 14/14 in 46% and the 14/16 in 36% of their controls (Watkins 
et al 2006), but differs from a Chinese study where 96% of controls (n = 106)  had the 14/14 
genotype and 4% had the 14/16 genotype. 
 
A positive association between the 14/14 polymorphism and T3 levels (versus other PTL 
combinations) was revealed.  Higher transcriptional activity in the 14 versus the 16 PTL 
polymorphism is described (Bullock et al 2012) which may be relevant to this observation.  
This observation is interesting and would suggest that common FOXE1 PTL polymorphisms 
are likely to influence TFTs. 
 
The limitations to the study that are of relevance to this chapter are discussed in the 
concluding and closing chapter. 
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CHAPTER 4: BONE AND THRYOID FUNCTION PARAMETERS IN 
SUBCLINICAL HYPOTHYROIDISM 
  
4.1 Introduction 
Frank thyroid diseases are associated with changes in body composition. Changes in 
hypothyroidism include weight gain, myxoedematous tissues and organs (including muscle 
pseudohypertrophy (Foley 2004) and myopathies (Torres & Moxley 1990), and delayed linear 
growth and physical maturation in children.  Changes of hyperthyroidism include weight loss, 
muscle wasting and weakness (Kim et al 2013) and accelerated linear growth in children 
(Schlesinger et al 1973).  In hyperthyroidism there are additional non organ-specific effects 
related to this hypermetabolic and catecholamine-sensitised state (Ginsberg 1981).   
 
The association between abnormal thyroid function and changes in bone are well established. 
Hypothyroidism in children curtails bone growth and maturation leading to short stature, 
growth arrest (in severe cases) and susceptibility to slipped epiphysis (Foley et al 2004).  Bone 
healing is severely compromised in hypothyroidism (Murrray 1900).  More recently there has 
been recognition of increased susceptibility to bone fracture in adults (even in subjects with 
corrected hypothyroidism (Vestergaard & Mosekilde 2002).  Examination of hypothyroid 
epiphyses reveals disorganised chondrocyte columns and suboptimal quality of the 
cartilaginous matrix (Stevens et al 2000).  In contrast, these parameters appear essentially 
normal (though temporally advanced) in hyperthyroidism (Stevens et al 2000, Freitas et al 
2005).  Hyperthyroidism accelerates bone growth and maturation (Segni & Gorman 20001, 
Buckler et al 1986) which in cases of severe congenital hyperthyroidism can cause 
craniosynostosis (Johnsonbaugh et al 1978).  In children, hyperthyroidism can cause earlier 
epiphyseal closure, which may compromise final height (Rivkees et al 1988, Segni et al 2001).  
In adults, hyperthyroidism uncouples the bone remodelling process resulting in net bone loss 
(Fraser et al 1971).  Bone loss reduces bone volume, strength, and increases susceptibility to 
fracture (Lee & Ananthakrishnan 2011).  However, it appears that this increased fracture risk 
returns to near normal, with time, following correction of hyperthyroidism (Vestergaard & 
Mosekilde 2002).  
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Free thyroid hormones (FTHs) influence bone cell biology to a large extent.  T3 has the 
following effects: it accelerates chondrocyte differentiation (Robson et al 2000), stimulates 
osteoblast activity and osteoblastogenesis (Bassett & Williams 2009), and stimulates 
osteoclast activity and osteoclastogenesis (although this effect is probably mediated 
indirectly via the osteoblast (Britto et al 1994)).  Thyroid receptors (TR) are expressed on 
osteoblasts (TRα and TRβ (Xing et al 2012, O’Shea et al 2003) and differentiating chondrocytes 
(Ballock et al 1999, Williams et al 2009).  It is less clear whether they are expressed on 
osteoclasts although TR mRNA has been extracted from osteoclastoma cells (Allain et al 1996) 
and multinucleated osteoclasts (Abu et al 2000). T4 and T3 have similar effects on cell biology 
although T3 is more potent (Gross & Pitt-Rivers 1953) and has ~15 times the affinity of T4 for 
TRβ1 (Lin et al 1990).  
 
Historically the metabolic impact of thyroid diseases have been attributed to the effects of 
the FTHs.  However, data to suggest an independent effect from the reciprocally and more 
significantly altered TSH value (occurring in common primary thyroid disorders) is mounting 
(Abe et al 2003, Fatourechi et al 2009, de Lloyd et al 2010). 
 
The TSH receptor (TSHR) has been detected in a number of extra-thyroidal sites (including 
adipose tissue, bone and fibroblasts; reviewed in Davies et al 2002), suggesting it may have a 
functional or developmental role in these sites.  Mesenchymal stem cells (MSC) express TSHR 
(Bagriacik et al 2012) with the potential to differentiate into different terminal cells and 
tissues that influence body composition, including fat, muscle, cartilage and bone.  It has been 
hypothesised that TSHR activation may influence lineage-specific differentiation (de Lloyd et 
al 2010).  This theory is supported by the observation that MSC TSHR activation encourages 
chondrocyte and possibly osteoblast differentiation (Baliram et al 2011, Bagriacik et al 2012).  
Interestingly, an inverse relationship between bone and fat differentiation has been observed 
(Ng & Duque 2010) that could be influenced by this pathway.  
 
The presence of TSHR in bone has raised academic interest, particularly given the 
socioeconomic impact of osteoporotic fractures (estimated at ~2 billion pounds per year in 
the UK in 2007; British Orthopaedic Association, 2007).  Many studies intent upon delineating 
the role of TSHR in bone have been performed.  Abe et al (2003) genetically engineered mice 
to be heterozygous or homozygous TSHR knockouts.  It was observed that TSHR knockout 
110 
 
animals had low bone mass (and areas of focal osteosclerosis) despite normal (heterozygous) 
or normalised (homozygous animals) FTH values.  Cell culture analysis of the TSHR-deficient 
and haploinsufficient bone cells revealed accelerated osteoclastogenesis and a greater 
number of colony forming unit-osteoblasts than wild type (WT).  This group hypothesised that 
these changes were a likely direct consequence of diminished TSHR expression in bone.  
Sampath et al (2007) subsequently reported that exogenously administered TSH 
(administered to ovariectomised, euthyroid rodents) improved bone architecture and 
strength.  Experiments evaluating osteoclastogenesis in vitro suggested an inhibitory effect 
from TSH or TSH-stimulating antibodies (occurring in Graves’ disease) (Ma et al 2011) 
supporting the notion of a direct TSHR-mediated effect.  More recent TSHR knockout 
experiments revealed exaggerated  bone loss in TSHR deficient mice in the context of 
hyperthyroidism, relative to WT (both groups were rendered hypothyroid prior to 
precipitating hyperthyroidism) (Baliram et al 2012).  It was suggested that TSHR signalling in 
the context of an unmeasurable TSH may relate to a bone marrow derived functional TSHβ 
splice variant (Vincent et al 2009) upregulated by T4 (Baliram et al 2012).  However the 
Bassett & Williams group have challenged the conclusions relating to genetically modified 
animal models and suggest that their physiological observations can be largely explained by 
altered FTH values and sensitivities (Bassett et al 2008). 
 
In subclinical thyroid diseases (ScTD) FTH values are in the normal range whilst TSH is outside 
it.  These cohorts may therefore lend themselves to the identification of TSH-specific effects 
(independent of FTHs).  Subclinical hyperthyroidism (Shyper) has been associated with 
accelerated bone loss, particularly in post-menopausal women (Faber et al 1998, Mudde et 
al 1994, Kim et al 2015).  Indeed, the Joint American Endocrine Societies support this 
observation by advocating consideration to treating Shyper in all postmenopausal women 
and subjects ≥65 years of age not on bone protective medication (Bahn et al 2011).  By 
contrast, the effect of SH on bone is less clear.  Consequently, at present the Joint Endocrine 
Societies make no recommendations regarding bone health management in SH.   
 
Several observational studies exploring the TSH-bone mineral density (BMD) relationship 
describe this as positive (athough this is predominantly described across euthyroid cohorts; 
see Table 1.5).  This was the observation of a Chinese/ Malaysian cross-sectional study on 
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men (Chin et al 2013) that described a positive correlation between heel quantitative 
ultrasound readings and TSH (R +0.08, p-value 0.04, n=753).  The Rotterdam study evaluated 
older adults (>55 years of age) with no history of thyroid disease and described this 
relationship at the femoral neck (Van der Deure et al 2008).  Kim et al (2006) evaluated 
postmenopausal euthyroid Korean women and reported lower BMD and higher rates of 
osteoporosis amongst women with low-normal TSH (versus high normal TSH). Mazziotti et al 
(2005) evaluated thyroidectomised women with iatrogenic Shyper (n=66) and revealed 
suppression of bone resorptive markers (C-telopeptide of type 1 collagen) and a rise in bone-
specific ALP within 2 days of administering recombinant TSH, an effect specific to the 
postmenopausal women (n=28).  Thus supported the notion that TSH may have antiresorptive 
effects on bone.  
 
However, other studies contradict these views and, describe a negative relationship between 
TSH and BMD in SH (Polovina et al 2013, Lee et al 2010, Liang et al 2014, Nagata et al 2007), 
or no relationship at all (in Indian adults <50 years of age (Marwaha et al 2012).  An 
observational study (n=1477) on perimenopausal Dutch women screened for osteoporosis 
(with no history of thyroid disease or osteoporosis) reported a negative association between 
BMD and T4 at the lumbar spine (R -0.02, 95% C.I (-0.04 to -0.004) but no BMD-TSH 
relationship (Van Rijn et al 2014).  Thus, much uncertainty remains.   
 
Polovina et al (2013) evaluated FRAX score (an estimate of 10 year risk of fracture) in 
postmenopausal SH women (n=82) (with no prior history of thyroid disease) versus matched 
euthyroid controls (n=51).  They identified a higher FRAX score in SH women (6.50±4.58 
versus 4.35±1.56; p-value 0.001), particularly those with autoimmune thyroid disease (ATD); 
although bone turnover markers (BTMs) were no different between the TPO +ve and -ve 
groups.  Lee et al (2010) explored incident fracture prevalence in older subjects (≥65 years) 
who were euthyroid or had ScTD.  Their data revealed an increased incidence of hip fracture 
in men, but not women with ScTD (multivariable-adjusted hazard ratio (MVHR) for men with 
SH (n=184/3567) was 2.31 (95% CI; 1.25-4.27), MVHR for men with Shyper (n=29/3567 adults) 
was 3.27 (95% CI, 0.99-11.30)).  However, a recent meta-analysis (n>70,000) did not reveal an 
association between SH and incident fracture but did report this association for Shyper (Blum 
et al 2015). 
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Human studies have explored the BMD-TSHR subject area further by evaluating the influence 
of TSHR polymorphisms on BMD.  The D727E polymorphism was presumably selected for 
study because of its high prevalence and its association with lower TSH values (Hansen et al 
2007).  This was thought to relate to increased TSHR sensitivity (Gabriel et al 1999) although 
this was not demonstrated in other studies (Nogueira et al 1999).  The Peeters group (Van der 
Deure et al 2008) associated this polymorphism with increased femoral neck BMD (~+2%), 
whilst a Chinese study drew the opposite conclusion; reporting a higher prevalence amongst 
osteoporotic men (n=150) versus controls (n=150), (Liu et al 2012). 
 
In summary, thyroid diseases impact on bone metabolism and body composition markedly.  
However, their influence in ScTD, particularly SH, remains unclear.  The ScTD are not uniform 
pathologies but arise from an array of causes.  These include inflammatory, destructive, 
substrate-mediated (i.e iodine deficiency or excess), autoimmune and genetic causes (such as 
TSH receptor mutations (TSHR-Ms).  It might therefore be anticipated that the natural history 
and metabolic consequence of SH will depend on its cause.  Given the high prevalence of SH 
(affecting ~4-9% of the adult population (Canaris et al 2000, Hollowell et al 2002)) and the 
adverse socioeconomic impact of osteoporosis I thought it would be helpful to explore the 
TFT-BMD relationship further in an SH cohort and to relate this to aetiology.   
 
I have recruited and evaluated an adult, treatment naïve, SH cohort and screened all subjects 
for TSHR-Ms.  Metabolic bone data, including a DXA scan (evaluating bone mineral density at 
the lumbar spine (LS) and hip), serum bone profiles (for calcium, phosphate and alkaline 
phosphatase (ALP)) and serum BTMs (CTX as the bone resorption marker and P1NP as the 
bone formation marker), and anthropometric data and medical histories were collected. 
 
One of my primary objectives was to explore whether TSHR-M subjects (anticipated to be 
inactivating mutations in this cohort and genetically similar to Abe et al’s knockdown mice) 
were more prone to altered BMD or bone turnover (BT).  However as I anticipated having too 
few mutation subjects to draw meaningful conclusions; in addition I would compare bone-
related parameters in those with and without thyroid autoimmunity.  This was to see whether 
aetiology of SH; autoimmune versus non-autoimmune causes might influence these 
parameters. The TSHR-M subjects and those with other genetic causes for SH were expected 
to reside predominantly in the TPO negative cohort (Alberti et al 2002).   
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I have also explored the relationship between BMD and TFT components (free-T4 (T4), free-
T3 (T3) and TSH) across the cohort, with my particular interest being TSH.  In addition these 
relationships were assessed according to subject’ TSHR-mutation (primary objective) or 
polymorphism status (secondary objective) and according to their FOXE1 polyalanine tract 
length (PTL) polymorphism status (secondary objective). Given that the FOXE1 gene is 
involved in thyroid gland morphogenesis and polymorphisms in proximity to FOXE1 have been 
associated with altered TFT values (Gudmundsson et al 2009, Medici et al 2011, Taylor et al 
2015) an effect on bone parameters is feasible.    
 
I will now proceed to provide and discuss the metabolic bone observations made in this 
heterogeneous, adult SH cohort. 
 
4.2  DXA BMD scores in the SH cohort 
BMD was evaluated across the cohort using Z-scores rather than T-scores; both are provided 
on standard DXA (Dual-energy X-ray absorptiometry) reports.  A DXA report provides a score 
for each bone parameter assessed, in this case at the 1st to 4th lumbar vertebrae (L1, L2, L3 & 
L4), and an average value for the total lumbar spine (TLS).  At the hip, scores were provided 
for the femoral neck (FN), the trochanter, the inter-trochanteric region and an average total 
hip value (TH). 
 
DXA scores indicate the number of standard deviations (SDs) the patient’s value lies above (+) 
or below (-) the mean value for a sex-matched, healthy, normal reference population.  The T-
score compares the patient’s BMD against a reference population at the stage of peak bone 
mass (~30 years of age), whereas the Z-score compares the patient’s value against an age-
matched, healthy population (World Health Organisation (WHO) 2007b).  Therefore, the Z-
score is a useful way of comparing DXA values across a cohort of various ages (in this case; 20 
- 71 years). 
 
The T-score is the parameter used by the WHO in their definition of low bone mass.  This was 
initially applied to women at or above the age of 50 years, although subsequently applied to 
men (WHO 2007b).  According to this definition a T-score above one SD below the mean is 
normal, whereas a value between 1 to 2.49 SDs below the mean defines osteopenia.  A value 
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2.5 SDs or more below the mean defines osteoporosis (WHO; 1994 and 2007b).  It is estimated 
that the risk of hip fracture increases ~2.6 fold for every SD drop in hip BMD, and ~2.3 fold for 
every SD drop in vertebral BMD (Marshall et al 1996).  Osteoporosis is also diagnosed on 
purely clinical grounds when a low energy fracture is sustained.  Once osteoporosis is 
diagnosed it is generally advisable to treat it (when benefit outweighs risk) to reduce the risk 
of future fractures. 
 
Figure 4.1 illustrates the proportion of the cohort with BMD T-scores in each of the 3 WHO 
SD categories; normal, osteopenia, and osteoporosis.  This reveals that half the cohort have 
low BMD T-scores (~40% with osteopenia (n = 76) and ~12% with osteoporosis (n = 25)).  
However, when these data are evaluated using Z-scores (Figure 4.2); a quarter have low BMD 
for age (which I define as a Z-score less than 1 SD below the reference mean) and 2.5% (n = 
5) have a BMD value greater than 2.5 SDs below the reference mean.  As explained below, 
this represents a higher than expected rate of low BMD.  
 
 
Figure 4.1:  Pie chart illustrating the proportion of subjects in my cohort with DXA  
T-scores falling in to each of the three WHO categories 
 
T-score above -1
T-score -1 to -2.49
T-score below -2.49
25, 12.4%
76, 37.8%
100, 49.8%
 
Figure 4.1 details the number and percentage of subjects falling into each of the three 
WHO categories. T-scores; above -1 (normal), between -1 to -2.49 (osteopenia), and below 
-2.49 (osteoporosis).  The lowest T-score at any site determined the T-score category. 
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Figure 4.2: Pie chart illustrating the proportion of subjects in my cohort with 
DXA Z-scores in each of three BMD categories 
 
Z-score above -1
Z-score -1 to -2.49
Z-score below -2.49
5, 2.5%
48, 23.9%
148, 73.6%
 
Figure 4.2 details the number and percentage of subjects falling into each of three DXA Z-
score categories: above -1, between -1 and -2.49, and below -2.49.  The lowest Z-score at 
any anatomical site determined the Z-score category.   
 
The distribution of DXA BMD scores across this cohort at TLS and TH are represented by 
normal distributions (Figure 4.4).  When I consider that a perfect normal population 
distribution would identify ~16% of the population with Z-scores >1 SD below the mean, and 
~0.6% >2.5 SDs below the mean, it appears that low BMD is over-represented in my cohort; 
see figure 4.3.  This is particularly so given that subjects with diagnosed osteoporosis or 
evident risk factors for osteoporosis were excluded from study participation (exclusions; 
section 2.1.2).  
 
Further evaluation of the cohort’s DXA scores (analysis not shown) revealed that low BMD (T-
score below -1 (n=101 with complete data)) was over represented at the LS. Indeed 50% of 
this group (n = 50) had low BMD specifically affecting the LS (≥1 SD difference between LS and 
hip T-scores) versus 12% with low BMD specifically affecting the hip; an observation replicated 
when using the Z-score data.  Further exploration revealed minor discordance (1 SD difference 
in T- or Z-scores between sites) in 89% of these subjects (55/62) and all those with major 
discordance (≥2 SD difference in T- or Z-scores between LS and hip) had lower BMD at the LS.  
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Figure 4.3:  A perfect normal distribution detailing the percentage of a population 
expected within standard deviations of the mean 
 
 
 
 
 
 
 
 
 
Figure 4.3 illustrates the percentage (%) of a perfect normal population falling into each SD sub-
category. Copyright courtesy of Mathplanet: (http://www.mathplanet.com/education/ algebra -
2/quadratic-functions-and-inequalities /standard-deviation-and-normal-distribution) 
 
 
 
 
Figure 4.4:  Histograms illustrating the DXA Z-score distributions across the cohort at  
(a) Total Lumbar Spine and (b) Total Hip  
(a)          (b) 
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Total Lumbar Spine α= 0.42, SD =1.26  Total Hip α= 0.56, SD =1.0  
 
Figure 4.4 displays the complete data of unadjusted DXA Z-score distributions at Total Lumbar Spine 
(a) and Total Hip (b) across the cohort. The mean Z-score (α) and SD are provided beneath each graph. 
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4.3  DXA Z-score against TSH at Lumbar Spine and Hip  
The TFT values provided in the figures and analyses that follow relate to those taken at study 
attendance.  The TFT associations explored across the cohort so far revealed a negative 
association between TSH and T4 (Figure 3.17), and a small positive association between TSH 
and T3 (Figure 3.18).  These associations should be borne in mind when considering the TSH-
BMD relationships [Please see Section 2.19 for an explanation of the statistical parameters 
that are provided in the analyses that follow; p-values, confidence intervals (C.I), multiple 
regression analyses (MRAs), R2 values, regression coefficients (R) and standard errors (SE)]. 
 
Figures 4.5 and 4.6 illustrate the unadjusted associations between TSH and BMD Z-scores 
(displaying the total cohort data, without removal of outliers) at the TLS (figure 4.5) and 
Femoral Neck (figure 4.6). Their respective regression equations are shown below.  A negative 
relationship between Z-score and TSH at both anatomical sites was revealed.   
 
 
Total Lumbar Spine Z-score  =  1.13 - 0.13 TSH,  p-value <0.001,  R2 6.5% 
 
Femoral Neck Z-Score  =  0.92 - 0.1 TSH,  p-value = 0.001,  R2 5% 
 
 
Table 4.1 details the regression coefficients (R) between TSH and Z-score at all anatomical 
sites evaluated by DXA. In general the negative relationship between TSH and Z-score is more 
pronounced at the LS than the hip. 
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Figure 4.5: Scattergraph illustrating the relationship between TSH and Total Lumbar 
Spine Z-score across the cohort 
 
TSH values are shown on the x-axis and total lumbar spine Z-scores on the y-axis. Red dots represent 
participant’s values and the blue line represents the best linear association between these parameters.  
 
Figure 4.6:  Scattergraph illustrating the relationship between TSH and Femoral Neck   
Z-score across the cohort 
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TSH values are shown on the x-axis and femoral neck Z-scores on the y-axis. Red dots represent study 
participant readings and the blue line represents the best linear relationship between these 
parameters. 
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Table 4.1:  Regression coefficients between TSH and Z-score at each anatomical site 
evaluated by DXA 
 
 
Region Evaluated 
 
R 95% C.I. R2 (%) p-value 
 
Total Lumbar Spine 
 
-0.13 -0.2,  -0.06 7 <0.001 
1st Lumbar Vertebrae -0.125 -0.18, -0.05 6 
 
<0.001 
 
2nd Lumbar Vertebrae -0.14 -0.21, -0.07 7.3 
 
<0.001 
 
3rd Lumbar Vertebrae -0.13 -0.21, -0.05 5.3 
 
0.001 
 
4th Lumbar Vertebrae -0.12 -0.18, -0.03 4.5 
 
0.003 
 
Total Hip -0.07 -0.13, -0.02 3 
 
0.014 
 
Femoral Neck -0.13 -0.13, -0.04 5.8 
 
0.001 
 
Inter-Trochanter -0.06 -0.12, -0.003 2 
 
0.04 
 
Trochanter -0.07 -0.13, -0.01 2.5 
 
0.015 
 
 
The anatomical regions evaluated by DXA are listed together with their corresponding Z-score-
TSH regression coefficients (R), 95% Confidence Intervals (C.I), R2 and p-values.   
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4.4 Multiple Regression Analyses 
Single factor associations (depicted in Figures 4.5 and 4.6) are not the recommended way to 
evaluate complex relationships as other factors (known and unknown) may be influencing or 
explaining this relationship and are not being accounted for.  Instead, relationships are more 
robustly evaluated by analyses that consider multiple parameters simultaneously, as is the 
case with multiple regression analysis (MRA).  
In MRAs the contribution of each parameter within an equation is assessed, and its 
contribution towards that relationship predicted statistically.  Although an MRA might suggest 
an association, this does not confirm a cause-effect relationship.  This is because causation 
needs to be determined through prospective case-controlled studies where one variable at a 
time is altered and its impact determined.  However, an MRA is a helpful tool to identify 
relationships that can be hypothesised to be inter-dependent.  In many cases I have 
proceeded to evaluate relationships through a step wise parsimonious MRA.  This enables the 
relationship between parameters of interest to be evaluated step by step as potential 
confounders are added in to the model.  A consistent relationship between these parameters, 
despite the step-wise addition of confounders, allows greater confidence that this 
relationship is true.  
One of the conditions of MRAs is that continuous data must be normally distributed (with 
appropriate transformation if necessary) and outliers removed, as the data and its 
interpretations thereafter may otherwise be misleading.  These conditions of MRA are applied 
in every case where it is used.  
 
4.4.1 MRAs of DXA Z-scores  
These MRAs assess dichotomous as well as continuous variables. in this context the 
affirmative status of the binary parameter in the MRA is being assessed.  The symbols used 
for the binary parameters are as follows; Smoking(1) for a >10 pack year smoking history; 
Alcohol(1) for not tee-total; Activity(1) for a non-sedentary lifestyle, TSHR-M for TSHR-
mutation status, D727E or P52T for the respective TSHR polymorphism status,  FOXE1(14) for 
homozygous FOXE1 PTL 14 status, TPO (+ve) for TPO seropositivity, and male(1) for male sex. 
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The association coefficient (R) for the opposing binary parameter (i.e. female instead of male) 
is the inverse of the association coefficient given. 
 
Alcohol intake was assessed several different ways in these evaluations (i.e unit intake per 
week; heavy intake (>14 units Female, >21 units Male) versus non-heavy intake; consumer 
versus non-consumer, and in all evaluations an associations with Z-score was not revealed. 
 
In the Z-score MRAs that follow, smoking history, alcohol history and T4 are not included. This 
is because no Z-score associations were shown, and the more variables included in the MRA 
the higher the chance of revealing false associations (Type 1 errors).  
 
4.4.2 Total Lumbar Spine MRA 
The parameters assessed in the TLS Z-score MRA include waist to hip ratio (WHR), activity 
status, male sex, TSH and T3 values.  The MRA with its respective regression table are shown 
below.  
TLS Z-score = -0.26 + 4.1 WHR + 0.32 Activity(1) - 0.8 Male(1) - 1.7log10 TSH - 0.4 T3
    N = 196,  R2 = 18% 
 
Table 4.2:  Summarises the MRA evaluating Total Lumbar Spine Z-score against the 
predictors listed. 
 
 Predictor R SE coefficient 95% C.I p-value 
Constant -0.26 1.18 -2.6, +2.0 0.82 
WHR +4.1 1.14 +1.8, +6.3 <0.001 
Activity (1) +0.32 0.17 -0.01, +0.65 0.07 
Male Sex (1) -0.8 0.23 -1.25, -0.35 0.001 
Log10 TSH mU/L -1.7 0.45 -2.56, -0.8 <0.001 
T3 pmol/L -0.40 0.17 -0.73, -0.07 0.02 
Table 4.2 details the Regression Coefficient (R) for each predictor assessed in the MRA evaluating TLS 
Z-score. The standard errors (SE), 95% confidence intervals (C.I) and p-values are provided. The minus 
(-) or plus signs (+) indicate the direction of the association.   
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This MRA revealed the following TFT associations against TLS Z-score;- 
 A negative correlation against (Log10)TSH (R; -1.7, p-value <0.001) 
 A negative correlation against T3 (R; -0.4, p-value 0.02) 
 
This MRA revealed the following non-TFT associations against TLS Z-score;- 
 A negative correlation against male sex (R; -0.8 , p-value 0.001) 
 A positive correlation against WHR (R; +4.1, p-value <0.001) 
 
4.4.3 Total Hip MRA 
The parameters assessed in this MRA (evaluating TH Z-score) include WHR, activity status, 
male sex, TSH and T3 values. The MRA with its respective regression table are shown below.  
 
TH Z-score = - 1.6 + 4.3 WHR + 0.06 Activity (1) - 0.8 Male(1) - 0.67 Log10TSH - 0.2 T3 
N=198,   R2 = 16%    
 
Table 4.3:  Summarises the MRA evaluating Total Hip Z-score against the predictors 
listed 
Predictor R SE coefficient 95% C.I p-value 
 
Constant -1.6 1.0 -3.6, +0.36 0.1 
WHR +4.3 0.97 +2.4, +6.2 <0.001 
Activity (1) +0.06 0.15 -0.23, +0.35 0.69 
Male(1) -0.80 0.2 -1.2, -0.4 <0.001 
Log10 TSH mU/L -0.67 0.40 -1.5, +0.1 0.09 
T3 pmol/L -0.20 0.14 -0.07, +0.47 0.16 
 
Table 4.3 provides the regression coefficients (R) for each predictor assessed in the MRA evaluating TH 
Z-score. The standard errors (SE), 95% confidence intervals (C.I) and p-values are provided. The minus 
(-) or plus signs (+) indicate the direction of the association.   
 
The TH Z-score MRA did not reveal associations with TFT components but did reveal the 
following associations;- 
• A negative correlation with male sex (R -0.8, p-value 0.001) 
• A positive correlation with WHR (R +4.3, p-value <0.001) 
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The MRAs evaluating TLS and TH Z-scores were subsequently re-evaluated substituting body 
mass index (BMI) for WHR which revealed slightly different associations.  At both sites R2 
improved (18% to 24% at TLS, 16% to 36% at TH) and Activity became positively associated 
with Z-score (LS; R +0.4, p-value 0.01, TH; R +0.3, p-value 0.037).  At TH, a negative association 
against T3 was now revealed (coefficient -0.35, p-value 0.005) (see Appendix 6, Table 1)  
 
I subsequently evaluated how the correlation coefficient (R) between DXA Z-score and TSH 
changed with the addition of confounders using a stepwise parsimonious regression model at 
TLS and TH (Model 4.1).  
 
Stepwise regression Model 4.1 revealed a small attenuation in R at TLS as confounders were 
added in to the model (over steps 1-4).  This supports the hypothesis that TSH correlates 
independently and inversely against Z-score at TLS.  The equivalent analysis at TH showed a 
more substantial fall in R as confounders were added in to the model with a final p-value 
falling short of statistical significance (0.09).  This does not support an independent 
correlation between TSH and Z-score at TH, although alternatively the study may be 
underpowered to reveal this effect.  
 
A further parsimonious stepwise regression analysis was performed comparing correlation 
coefficients for DXA Z-score and TSH, with DXA Z-score and T3.  This was evaluated at TLS 
(Model 4.2) and then TH (Model 4.3).  A Bonferroni corrected p-value of 0.025 was used here 
to define statistical significance given that the TSH and T3 correlations were compared. BMI 
was the build parameter used in these models. 
 
Stepwise regression models 4.2 and 4.3 support the observation that TSH correlates 
negatively with Z-score at TLS (Model 4.2) (despite a diminution in the coefficient for TSH with 
addition of confounders (not seen for T3).  Model 4.3 does not support an independent 
correlation between TSH and DXA Z-score at TH.  Both models revealed a negative association 
between T3 and DXA Z-score at TH and TLS sites. 
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Model 4.1: Stepwise regression model exploring R between TSH and DXA Z-score at 
total lumbar spine & total hip; assessed singularly and subsequently 
adjusted for confounders 
 
Total Lumbar Spine      Total Hip 
 
N R 95% C.I. p-value  N R 95% C.I. p-value 
Step 1; crude (against TSH only) 
198 -1.9 (-1, -2.8) <0.001   200 -0.87 (-0.1, -1.65) 0.03 
Step 2; adjusted for step 1 including T3 
198 -1.7 (-0.8, -2.6) <0.001   200 -0.77 (0.02, -1.56) 0.057 
Step 3; adjusted for step 2 including male sex 
198 -1.65 (-0.75, -2.54) <0.001   198 -0.72 (0.06, -1.5) 0.07 
 Step 4; adjusted for step 3 including waist:hip ratio and non-sedentary lifestyle 
196 -1.68 (-0.8, -2.57) <0.001   198 -0.67  (0.1, -1.42) 0.09 
  
 
 
Model 4.2: Stepwise regression model evaluating R between total lumbar spine Z-score 
and TSH (firstly) then total lumbar spine and T3 (secondly); both are 
subsequently adjusted for confounders 
 
Adjusted for TSH      Adjusted for T3  
N R 95% C.I. p-value  N R 95% C.I. p-value 
Step 1; crude 
198 -1.9 (-2.8, -1) <0.001   198 -0.54 (-0.88, -0.2) 0.002 
Step 2; adjusted for step 2 including activity status 
198 -1.93 (-2.8, -1.0) <0.001   198 -0.54 (-0.9, -0.2) 0.002 
 Step 4; adjusted for step 3 including log10 BMI  
198 -1.73 (-2.6, -0.9) <0.001   196 -0.67  (-1.0, -0.36) <0.001 
 Step 5; adjusted for step 4 including male sex 
198 -1.61 (-2.5, -0.76) <0.001   196 -0.6  (-0.9, -0.3) <0.001 
 Step 6; adjusted for step 4 including T3 or TSH respectively 
198 -1.36 (-2.2, -0.5) 0.002   196 -0.5  (-0.8, -0.2) 0.002 
 
Models 4.1 and 4.2 detail the number of subjects in the analysis (N), the correlation coefficients (R) 
between either TLS Z-score and TSH, and TH Z-score and TSH (Model 4.1); or between TLS Z-score 
and log10TSH, and TLS Z-score and T3 (Model 4.2). The 95% confidence interval (C.I.) and p-valus at 
each step are provided.  The minus (-) or plus (+) signs indicates the direction of the association.  
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Model 4.3:   Stepwise regression model exploring R between total hip Z-score and TSH 
(firstly) and total hip Z-score and T3 (secondly); both are subsequently 
adjusted for confounders  
 
Adjusted for TSH      Adjusted for T3  
N R 95% C.I. p-value  N R 95% C.I. p-value 
Step 1; crude  
200 -0.87 (-1.65, -0.1) 0.03   200 -0.26 (-0.55, +0.02) 0.07 
Step 2; adjusted for step 2 including activity status 
200 -0.8 (-1.6, -0.02) 0.045   200 -0.27 (-0.6, +0.02) 0.063 
 Step 3; adjusted for step 3 including log10 BMI   
198 -0.54  (-1.22, +0.14) 0.12   200 -0.45  (-0.7, -0.2) <0.001 
 Step 4; adjusted for step 4 including male sex 
198 -0.42  (-1.1, +0.23) 0.20   200 -0.37  (-0.6, -0.13) 0.003 
Step 5; adjusted for step 4 including T3 or TSH respectively 
198 -0.25  (-0.9, +0.4)  0.46   198 -0.35  (-0.6, -0.1) 0.005 
 
Model 4.3 details the number of subjects used in the analysis (N), the correlation coefficient (R) 
between TH Z-score and TSH, or TH Z-score and T3. The 95% confidence interval (C.I.) and p-
values are provided.  The minus (-) or plus signs (+) indicate the direction of the association.   
 
 
 
4.4.4  DXA Z-score associations according to aetiology of SH with respect to TPO 
 antibody status and thyroid genetic data  
 
In this section the aetiology of SH was assumed to be autoimmune thyroid disease (ATD) in 
subjects bearing positive (+ve) TPO antibodies, and assumed to be due to TSHR-Ms where 
these were identified.  
Associations between Z-score and TSHR-polymorphism status (D727E and P52T) and FOXE1 
PTL polymorphism status are assessed in this chapter (see introduction; section 4.1).   
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The following figures illustrate the relationship between Z-score and TPO+ antibody status 
(Figure 4.7a-c), TSHR gene sequence (TSHR mutation, TSHR polymorphisms (D727E or P52T) 
and standard TSHR sequence (Figure 4.8a-c) and FOXE1 PTL polymorphism status (Figure 4.9a-
c).  The statistical evaluations that relate to these figures are provided in section 4.4.6. 
 
Figure 4.7 a-c:   DXA Z-score according to TPO antibody status at (a) Total Lumbar Spine,  
  (b) Total Hip and (c) Femoral Neck    
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Figure 4.7 depicts DXA Z-scores according to TPO antibody status (positive or negative) at each of three 
anatomical sites: a) Total Lumbar Spine, b) Total Hip, c) Femoral Neck. The red dots represent 
individual’s values that collectively indicate the distribution within the cohort.  
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Figure 4.8 a-c: DXA Z-score according to TSHR sequence status at (a) Total Lumbar 
Spine, (b) Total Hip and (c) Femoral Neck 
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Figure 4.8 depicts DXA Z-scores according to TSHR gene sequence at each of three anatomical sites:   
a) Total Lumbar Spine, b) Total Hip, c) Femoral Neck. The TSHR sequence categories are those with 
mutations, polymorphisms (D727E or P52T) or standard sequence. The red dots represent individual’s 
values that collectively indicate the distribution within the cohort.  
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Figure 4.9 a-c:  DXA Z-scores according to FOXE1 PTL polymorphism status at    
a) Total Lumbar Spine, b) Total Hip, c) Femoral Neck  
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Figure 4.9 depicts DXA Z-scores according to FOXE1 PTL polymorphism status categorised as 14/14 (14) 
or ‘other’ polyalanine tract length combinations. These data are provided at a) Total Lumbar Spine, b) 
Total Hip and c) Femoral Neck. The red dots indicate individual’s values that collectively indicate the 
distribution within the cohort.  
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4.4.5  Thyroid function, anthropometric and bone data according to TPO antibody status 
 
Half my study cohort were TPO antibody positive (+ve) (104/208) and half TPO negative       
(-ve).  Table 4.4 compares the biochemical and clinical characteristics of participants 
according to their TPO status.  
 
Table 4.4:  Biochemical and clinical characteristics of the cohort according to TPO 
antibody status 
 
 
Variable 
 
TPO +ve 
 
TPO -ve 
 
difference 
 
95% C.I 
 
p-value 
 
% male 16% 34% -16% -0.29, -0.06 0.003 
Age (years) 49.2 54.4 -5.2 -8.7, -1.7 0.004 
BMI 27.5 29.7 -2.2 -4, -0.37 0.02 
WHR 0.84 0.88 -0.04 -0.07, -0.02 0.001 
proportion active 0.6 0.43 +0.16 +0.03, +0.3 0.02 
TSH (mU/L) 5.8 4.8 +1 +0.34, +1.7 0.002 
T4 (pmol/L) 12.7 13.6 -0.9 -1.3, -0.5 0.001 
T3 (pmol/L) 4.05 4.13 -0.08 -0.2, +0.06 0.24 
Ca2+ (mmol/L) 2.34 2.35 -0.02 -0.03, +0.01 0.28 
Phosphate (mmol/L) 1.1 1.09 +0.01 -0.03, +0.04 0.7 
ALP (IU/L) 75 86 -11 -20, -0.7 0.035 
CTX (µg/L) 0.234 0.228 +0.007 -0.02, +0.04 0.7 
P1NP (µg/L) 41 43 -2 -7.1, +3.2 0.46 
 
Table 4.4 lists parameters whose mean ( ) proportion, %, or value was compared between the TPO 
+ve and -ve groups. The difference, 95% confidence intervals (C.I), and p-values are provided. The 
minus (-) or plus signs (+) indicate the direction of the associations.   
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Table 4.4 reveals that the TPO +ve group differed from the -ve group in the following respects: 
• A greater proportion of women (84% versus 66%). 
• Younger mean age (49 years versus 54 years). 
• Lower mean T4s (12.7 versus 13.6pmol/L) and higher mean TSHs (5.8 versus 4.8mU/L).  
 Lower mean BMIs and WHRs. 
 Fewer subjects with a sedentary lifestyle.  
 Lower mean alkaline phosphatase (ALP) values (75 versus 86 IU/L). 
The following factors were not appreciably different: 
• Mean T3s.  
• Mean corrected calcium and phosphate values. 
• Mean BTMs; CTX (bone resorption marker), and P1NP (bone formation marker).  
 
4.4.6 Multiple regression analyses evaluating DXA Z-scores against TPO antibody
 status and the thyroid genetic data 
 
In the MRAs that follow, the parameters assessed against Z-score are as previously reported 
(in section 4.4.2) but now include TPO antibody status and the thyroid genetic data; TSHR-M, 
TSHR polymorphism status (D727E or P52T) and FOXE1 PTL(14) status. 
 
The MRAs evaluating DXA Z-score at TLS and TH are shown below with their respective 
regression tables (tables 4.5 and 4.6 respectively).  
 
Z-Score at Total Lumbar Spine = 0.8 + 3.4 WHR + 0.39 Activity - 0.86 Male(1) - 1.4 Log10 TSH - 
0.5 T3 - 0.65 TPO(+ve) - 0.27 TSHR-M - 0.3 D727E + 0.05 P52T - 0.23 FOXE1 PTL(14)  
N = 191,  R2 = 25% 
 
Z-Score at Total Hip = - 0.7 + 3.5 WHR + 0.08 Activity - 0.8Male - 0.7 Log10TSH - 0.2 T3 - 0.3 
TPO (+ve) - 0.07 TSHR-M - 0.2 D727E + 0.01 P52T -0.1 FOXE1 PTL(14)   
N = 193, R2 = 17% 
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Table 4.5:  Summarises the MRA evaluating Total Lumbar Spine Z-score against the 
predictors listed (including TPO status and the genetic data).  
Predictor R SE coefficient 95% C.I p-value 
Constant +0.8 1.2 -1.6, +3.2 0.5 
WHR +3.4 1.15 +1.15, +5.7 0.004 
Activity (1) +0.39 0.18 +0.04, +0.74 0.03 
Male (1) -0.86 0.23 -1.31, -0.41 <0.001 
Log10 TSH mU/L -1.3 0.46 -2.2, -0.4 0.004 
T3 pmol/L -0.5 0.17 -0.8, -0.17 0.003 
TPO (+ve) -0.65 0.18 -1.0, -0.3 <0.001 
TSHR-M -0.27 0.36 -1.0, +0.4 0.45 
D727E -0.32 0.44 -1.2, +0.5 0.5 
P52T +0.05 0.25 -0.44, +0.5 0.83 
FOXE1 (14) +0.23 0.17 -0.1, +0.6 0.19 
 
 
Table 4.6:  Summarises the MRA evaluating Total Hip Z-score against the predictors 
listed (including TPO status and the genetic data).  
 
Predictor R SE coefficient 95% C.I p-value 
Constant -0.7 1.1 -2.9, 1.5 0.5 
WHR +3.5 1 +1.5, +5.5 0.001 
Activity  (1) +0.08 0.15 -0.2, +0.4 0.6 
Male (1) -0.8 0.20 -1.2, -0.4 <0.001 
Log10TSH (mU/L) -0.65 0.4 -1.4, +0.13 0.1 
T3 (pmol/L) -0.2 0.15 -0.5, +0.09 0.15 
TPO (+ve) -0.3 0.15 -0.6, 0.0 0.05 
TSHR-M -0.07 0.31 -0.7, +0.5 0.81 
D727E -0.22 0.4 -1, +0.6 0.56 
P52T -0.01 0.21 -0.42, +0.4 0.95 
FOXE1 (14)  -0.1 0.14 -0.4, +0.2 0.5 
 
Tables 4.5 and 4.6 provide the regression coefficients (R) for each predictor assessed in the MRA 
evaluating TLS Z-score or TH Z-score respectively. The corresponding standard errors (SE), 95% 
confidence intervals (C.I) and p-values are provided. The minus (-) or plus signs (+) indicate the direction 
of the association.    
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The MRAs displayed in Table 4.5 and 4.6 reveal the following associations: 
 
 TPO positivity is negatively associated with Z-score at TLS (coefficient -3.6, p-value 
<0.001) and has a borderline negative association at TH (coefficient -0.3, p-value 0.05).  
There were no associations with the polymorphisms (TSHR-M, TSHR-D727E or P52T or 
FOXE1 PTL (14) status). 
 
 The TPO-Z-score data is illustrated in Figure 4.7a-c.  This suggests that a greater 
proportion of the TPO +ve cohort have Z-scores in the lower half of the Z-score 
distribution.  By contrast, the equivalent graphs for the TSHR gene sequence data 
(Figure 4.8) and FOXE1 PTL polymorphism data (Figure 4.9) do not depict obvious 
associations (although the numbers in these distributions are less). 
 
 
The relationship between Z-score and TPO antibody status at TH and TLS was subsequently 
evaluated in parsimonious stepwise regression analyses (Model 4.4). 
 
Model 4.4 reveals a consistent negative association between TPO positive status and Z-score 
at TLS. Whereas at TH; no association is revealed until the final step that is of borderline 
significance.  Given the discrepancy between associations at the 5th and final step this is likely 
to represent a chance finding.  The model therefore supports a negative relationship between 
TPO positivity and Z-score at TLS only.  
 
The relationship between Z-score and TPO status was subsequently explored, for further 
verification using a bootstrap analysis (with thanks to Dr Pete Taylor Cardiff University).  This 
statistical method differs from MRAs in that it evaluates an extensive number of random 
samples within the data set (1000) that are combined to provide the final association 
coefficients and significance scores.  The bootstrap analyses are summarised in Table 4.7 (TLS) 
and Table 4.8 (TH).  These analyses support the observation of earlier MRAs indicating a 
negative relationship between TPO positivity and Z-score at TLS but not TH. 
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Model 4.4: Stepwise regression model exploring R between DXA Z-score and TPO 
antibody positivity assessed at total lumbar spine and total hip singularly, 
and subsequently adjusted for confounders. 
 
Total Lumbar Spine      Total Hip 
N R  95% C.I. p-value   N R 95% C.I. p-value 
Step 1; crude (against TPO status only) 
198 -0.56         (-0.9, -0.22) 0.001  198 -0.25 (-0.54, +0.33)   0.09 
Step 2; adjusted for step 1 including waist:hip ratio 
198 -0.54         (-0.9, -0.19) 0.003  198 -0.17 (-0.5, +0.12)   0.26 
Step 3; adjusted for step 2 including male sex 
196 -0.6         (-0.95, -0.26) 0.001  198 -0.23 (-0.5, +0.05)   0.11 
 Step 4; adjusted for step 3 including TSH and T3 
196 -0.52         (-0.85, -0.18) 0.003  198 -0.2 (-0.5, +0.09)   0.18 
 Step 5; adjusting for step 4 including activity status 
196 -0.56         (-0.9, -0.2) 0.001  198 -0.21 (-0.4, +0.1)   0.16 
Step 6; adjusting for step 5 and the genetic data (D727E, TSHR-M, P52T & FOXE1(14)) 
191 -0.65          (-1, -0.3)  <0.001  193 -0.3 (-0.6, +0.0005) 0.05 
 
Model 4.4 details the number of subjects in the analysis (N), the correlation coefficient (R) between 
TLS or TH Z-scores, and TPO positive status. The 95% confidence intervals (C.I.) and p-values at each 
step are provided.  The minus (-) or plus signs (+) indicate the direction of the associations.  
 
 
Table 4.7:  Bootstrap analysis evaluating total lumbar spine Z-score.  
Predictor  R SE coefficient 95% C.I p-value 
Constant +0.34 1.11 -1.8, +2.5 0.76 
TP0 (+ve)  -0.56 0.17 -0.88, -0.23 0.001 
Male (1) -0.88 0.24 -1.35, -0.4 <0.001 
WHR +3.60 1.0 +1.6, +5.6 <0.001 
Log10 TSH mU/L -1.38 0.42 -2.2, -0.56, 0.001 
T3 pmol/L -0.43 0.17 -0.77, -0.9 0.013 
Activity (1) +0.38 0.18 +0.03, +0.7 0.03 
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Table 4.8:  Bootstrap analysis evaluating total hip Z-score.  
Predictor  R SE coefficient 95% C.I p-value 
Constant -1.41 1.01 -0.56, +3.3 0.16 
TP0 (+ve)  -0.21 0.14 -0.5, +0.06 0.13 
Male (1) -0.83 0.2 -0.4, -1.2 <0.001 
WHR +4.09 1.0 +2.1, +6 <0.001 
Log10 TSH (mU/L) -0.56 0.4 -0.2, +0.3 0.16 
T3 (pmol/L) -0.21 0.14 -0.5, +0.06 0.5 
Activity (1) +0.09 0.14 -0.18, +0.36 0.19 
 
Tables 4.7 and 4.8 provide bootstrap analysis for the TLS- and TH Z-score analyses respectively. For 
each predictor variable its regression coefficient (R), standard error (SE), 95% confidence interval (C.I) 
and p-values are given. The minus (-) or plus signs (+) indicate the direction of the association.   
 
 
4.5 In-cohort matching to compare the TSHR mutation and control 
subjects 
 
The number of mutation patients in this study (n = 12) was extremely low and insufficient to 
demonstrate an impact on bone parameters using MRA alone. 
 
Given this limitation I felt it would be worthwhile looking at this subgroup using in-cohort 
matching analysis.  For this analysis I selected three control subjects for every mutation 
subject.  All controls had standard TSHR sequence and were matched in the first instance for 
sex and TPO antibody status.  Thereafter controls were matched as closely as possible for age, 
BMI and TSH values (at study attendance).  
 
The matched data for the mutation and control subjects are provided in Table 4.10, and 
compared in Table 4.9.  This revealed no significant differences.   
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Table 4.9:   Comparison of matched data between mutation and control subjects  
Parameter  Mean value Difference 95% C.I p-value 
Age Mutation 49.8 years  
0.53 years 
 
-7.99,  +9.05 
 
0.9 
Age Control 49.3 years 
BMI Mutation 27.8 kg/m2  
-0.35 kg/m2 
 
-3.88,  +3.18 
 
0.84 
BMI Control 28.1 kg/m2 
TSH Mutation 5.06 mU/L  
0.14 mU/L 
 
-0.880,  +1.15 
 
0.78 
TSH Control 4.92 mU/L 
 
The mean values for each group, their differences, associated confidence intervals (C.I) and p-values 
for the difference are provided. The minus (-) or plus signs (+) indicate the direction of the difference. 
 
 
The bone data comparing the mutation and control groups are provided in Table 4.11. 
Although this revealed a marginal reduction in TLS BMD amongst the mutation subjects (of 
borderline significance; difference -0.07, p-value 0.05) this did not tally with T-score 
differences and is unlikely to represent a true difference.  
 
Another difference of borderline significance (and previously recognised) is that the mutation 
carriers had lower T3s than controls (difference 0.03, p-value 0.046).   
 
The percentage body fat (%BF) and WHRs were not different between the groups (although 
subjects were matched for BMI). 
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Table 4.10:  Matched data on TSHR-mutation and control subjects. 
 
Mutation subjects Controls 
Study 
Number 
Age 
(years) 
BMI 
(kg/m2) 
   TSH 
(mU/L) 
Study 
Number 
Age 
(years) 
BMI 
(kg/m2) 
TSH 
(mU/L) 
3 34 17.3 3.4 
77 22 21.9 6.11 
83 20 21 3.37 
83 20 21 3.37 
22 40 29.2 4.88 
186 39 28.9 5.41 
205 47 25.8 4.12 
208 44 28.2 4.82 
46 61 24.5 7.66 
137 65 32.5 7.31 
160 63 27.2 7.3 
179 64 24.9 4.94 
84 44 32.3 4.65 
14 38 25.4 6.68 
145 47 39.8 5 
153 42 31.4 4.58 
111 66 30.8 5.66 
67 67 39.8 5.72 
80 65 36.6 5.96 
146 69 31.7 4.07 
119 52 25.5 4.83 
29 52 22.5 5.44 
31 53 24.3 3.86 
55 55 22.7 5.03 
177 58 38.1 2.88 
15 59 28.9 3.04 
39 53 34.8 3.21 
53 57 29 2.28 
32 43 26.4 3.42 
58 42 23.5 4.88 
156 37 37 4.02 
159 33 33 5 
78 38 26 6.16 
5 52 29.8 5.03 
9 25 20 6.7 
159 33 27.9 5 
99 63 29.4 5.95 
17 66 31.4 5.37 
18 68 29.2 5.53 
173 62 30.7 6.32 
148 38 27 7.01 
1 47 28.3 4.6 
58 42 23.5 4.88 
96 37 23.1 7.16 
172 61 26.9 4.18 
19 66 27 4.09 
141 58 25.6 4.1 
191 64 26.5 4.23 
 
Table 4.10 displays subject study numbers, ages, BMIs and TSH values for mutation subjects and their 
3 respective controls. Red font represents female subjects and blue represents male subjects. Subject 
‘83’ is used twice as a control for mutation subject 3 due to insufficient matches for this young woman 
(BMI 17; normal 18.5-24.9). 
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Table 4.11: Comparative data on TFTs, bone and build parameters between the 
mutation and control subjects. 
 
Parameter 
 
 
Mutation 
mean 
 
Control 
mean 
 
Mean 
difference 
 
 
95% C.I  
 
p-value  
T4  
(pmol/L) 
13.59 13.43 +0.16 -0.76,  +1.1 0.72 
T3  
(pmol/L) 
3.85 4.17 -0.32 -0.64, -6 x10-3  0.046 
BMD TLS 
 (g/cm2) 
1.02 1.09 -0.07 -0.14, +8x10-4 0.05 
BMD TH 
 (g/cm2) 
0.96 1.0 -0.04 -0.13, +0.05 0.36 
BMD femoral 
neck  (g/cm2)  
0.81 0.87 -0.06 -0.13, +9x10-3 0.08 
T-score TLS -0.32 0.19 -0.5 -1.2, +0.19 0.15 
T-score TH -0.01 0.36 -0.36 -1.04, +0.31 0.27 
T-score 
femoral neck 
-0.48 -0.09 -0.4 -1.05, +0.27 0.23 
Log10 P1NP 1.59 1.59 +0.006 -0.14, +0.13 0.93 
Log10 CTX -0.76 -0.65 -0.1 -0.25, +0.05 0.18 
% body fat 32.8 33.3 -0.5 -7.9,  +6.9 0.89 
WHR 0.88 0.86 +0.02 -0.05, +0.09 0.58 
 
The differences between mean values for the parameters listed are provided with their 95% confidence 
intervals (C.I) and p-values.  The minus (-) or plus signs (+) indicate the direction of the difference. 
 
 
4.5.1  Evaluation of mutation subjects against the rest of the cohort not matching for 
 build 
 
This analysis was performed in case the matching process in section 4.5 concealed true build 
differences (BMI, %BF, WHR & BMD) between the groups.  In this analysis the mutation group 
were matched against standard TSHR sequence controls (as closely as the cohort allowed) for 
the parameters listed below.  This enabled 12 mutation subjects to be compared against 56 
controls.  
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Note that mutation subject 3 was included in this analysis although her BMI was 17 making 
her an outlier in the cohort. 
 
 Age    TSHR-M: 34 - 68 years  Controls: 36 - 68 years  
 
 TSH    TSHR-M: 2.88-7.66mU/L  Controls: 2.8-7.3mU/L 
 
 Sex ratio   TSHR-M: 5/12 Male  Controls: 21/56 Male 
 
 TPO status  All TPO antibody negative 
 
 Comorbidities  No insulin users in either group 
 
 Activity   No self-reported ‘very active’ subjects in either group 
 
 
Table 4.12 displays the comparative data between the mutation and control groups for the 
matched parameters.  Aside from a higher mean age amongst the control group (56 versus 
50 years), which fell short of a statisticaly significant difference (p-value 0.09); TSH values, sex 
ratios and the proportion of ‘non-sedentary’ subjects were similar across the groups. 
 
 
Table 4.12:  Compares matched parameters between the mutation and control groups 
 
Parameter 
Mean value 
Mutations     Controls 
Mean  
Difference 
95% C.I p-value 
Age (years) 50 56 -6 -14.08, +1.14 0.09 
Proportion male 0.4 0.38 +0.02 -0.3, +0.39 0.8 
TSH (mU/L) 5.04 4.68 +0.36 -0.6, +1.3 0.4 
% Active (non-sedentary) 0.58 0.43 +0.16 -0.19, +0.50 0.36 
 
 
Differences between mean values for the matched-parameters are provided with their 95% confidence 
intervals (C.I) and p-values.  The minus (-) or plus signs (+) indicate the direction of the difference. 
 
The mutation and control groups were compared for a range of parameters (as shown in table 
4.13) and no build differences were apparent.  The observation of a lower T3 amongst the 
mutation subjects was upheld.  
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The comparative build data are presented graphically in figures 4.10 (BMI) and 4.11 (DXA Z-
scores).  DXA Z-scores rather than T-scores were used on account of the small age discrepancy 
between the groups.   
 
Figure 4.10:  BMI of mutation and control subjects 
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Figure 4.10; depicts the BMI value plots for the mutation and control subjects. 
The plots collectively indicate the BMI distribution across each group.  
 
 
 
Figure 4.11:  DXA Z-scores of Mutation and Control subjects at (a) Total Lumbar Spine, 
(b) Total Hip, and (c) Femoral Neck  
 
 
(a)  Total Lumbar Spine    (b) Total Hip 
 
ControlsMutations
5
3
1
-1
-3
Z-
sc
o
re
      
ControlsMutations
3
2
1
0
-1
-2
Z-
Sc
or
e
 
 
  
140 
 
 
               (c)  Femoral Neck 
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Figure 4.11. Depicts the DXA Z-score plots for the mutation and control subjects. The plots 
collectively illustrate the Z-score distribution within each group.  
 
 
Table 4.13:     Comparing mutation and control groups for parameters that include build.  
 
Parameter 
Mean values 
Mutations,  Controls 
Difference 95% C.I p-value 
BMI 
(kg/m2) 
27.8 30.2 -2.4 -6, +1.15 0.17 
% Body Fat 32.8 36.3 -3.5 -10.8, +3.8 0.32 
WHR 0.89 0.88 +0.005 -0.07, +0.06 0.9 
T3 (pmol/L) 3.8 4.2 -0.4 -0.67, -0.05 0.024 
T4 (pmol/L) 13.6 13.3 +0.3 -0.56, +1.2 0.45 
TLS Z-score 0.35 0.84 -0.49 -1.2, +0.20 0.16 
TH Z-score 0.47 0.75 -0.28 -1.1, +0.5 0.5 
Femoral Neck  
Z-score 
0.27 0.59 -0.32 -1.0, +0.4 0.36 
 
 
The differences between the mean values for each parameter are provided together with their 95% 
confidence intervals (C.I) and p-values.  The minus (-) or plus signs (+) indicate the direction of the 
difference. 
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4.6  In-cohort matching to compare TSHR-D727E polymorphism subjects 
with their controls 
 
Given the interest in the TSHR D727E polymorphism and its proposed influence on BMD (Van 
der Deure et al 2008, Liu et al 2012), I evaluated the D727E polymorphism subjects (n = 9) in 
an identical manner to the TSHR-M carriers (section 4.5).  
 
I selected three control subjects for each D727E subject (excluding D727E subject 132 due to 
coexisting ATD (TSH; 10.4mU/L, TPO >1300KU/L).   
 
All control subjects had standard TSHR sequence and were matched in the first instance for 
sex and TPO status.  Thereafter controls were matched as closely as possible for age, BMI and 
TSH (at study attendance) to each D727E subject (raw data displayed in Table 4.15).  The 
comparative analyses on the matched data revealed no significant differences between the 
groups (see Table 4.14). 
 
Table 4.14: Compares the matched parameters between D727E subjects and their controls 
Parameter Mean value Difference 95% C.I p-value 
Age D727E 47.4 years 
-2.5 -12.6, +7.6 0.60 
Age Control 49.8 years 
BMI D727E 29.2 kg/m2 
0.06 -5.7, +5.8 0.98 
BMI Control 29.14 kg/m2 
TSH D727E 5.12 mU/L 
0.2 -1.07, +1.45 0.75 
TSH Control 4.93 mU/L 
 
 
 
Differences between matched parameter mean values are provided, together with their 95% 
confidence intervals (C.I) and p-values.  The minus (-) or plus signs (+) indicate the direction of the 
differences. 
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Table 4.15:  Data on the D727E polymorphism subjects and their controls. 
 
D727E Subjects Controls 
Study 
Number 
Age 
(years) 
BMI 
(kg/m2) 
TSH 
(mU/L) 
Study 
Number 
Age 
(years) 
BMI 
(kg/m2) 
TSH 
(mU/L) 
 
012 
 
38 
 
25.6 
 
6.68 
029 52 22.5 5.44 
134 57 30.3 5.88 
185 57 27.2 5.79 
 
081 
 
63 
 
33.2 
 
4.75 
115 57 32.4 6.26 
146 69 31.7 4.07 
185 57 27.2 5.79 
 
124 
 
56 
 
22.3 
 
4.6 
027 55 22.7 5.03 
067 62 22.1 4.01 
207 60 21.3 3.5 
 
158 
 
31 
 
22.6 
 
3.26 
014 38 25.4 6.6 
077 22 21.9 6.11 
201 49 24.7 3.56 
 
184 
 
47 
 
35.3 
 
3.54 
028 53 36.7 4.33 
157 42 35.2 3.04 
192 51 35 4.26 
 
190 
 
46 
 
38.5 
 
4.58 
145 47 39.8 5 
157 42 35.2 3.04 
192 51 35 4.26 
 
193 
 
59 
 
33 
 
6.38 
080 65 36.6 5.96 
105 53 32.6 3.58 
115 57 32.4 6.26 
 
96 
 
39 
 
23.1 
 
7.16 
009 25 20 6.7 
058 42 23.5 4.88 
159 33 27.9 5 
 
Table 4.15. Displays subject; study numbers, ages, BMIs and TSHs for each D727E subjects and their 3 
respective controls. Red font represents female subjects and blue font represents male subjects.  
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The metabolic and bone data on D727E subjects and their controls was compared (Table 
4.16).  This revealed a lower mean TLS BMD in D727E subjects but no other differences. 
However, given the low D727E subject numbers contributing to the bone data (n=7 as one 
subject failed to attend the DXA) the results should be interpreted with caution. 
 
Table 4.16: Comparative data on the D727E subjects and their controls. 
Parameter 
D727E 
mean 
Control 
mean 
Difference 95% C.I p-value 
T4  
(pmol/L) 
13 13.4 -0.4 -1.9, +1.07 0.6 
T3  
(pmol/L) 
4.34 4.26 +0.08 -0.4, +0.56 0.73 
BMD TLS 
(g/cm2) 
0.92 1.04 -0.12 -0.22, -0.02 0.025 
BMD TH 
(g/cm2) 
0.9 1.0 -0.1 -0.25, +0.07 0.22 
BMD Femoral Neck  
(g/cm2) 
0.76 0.84 -0.08 -0.2, +0.04 0.17 
TLS 
T-score  
-1.19 -0.08 -1.11 -2.06, -0.15 0.027 
TLS 
Z-score  
-0.26 0.87 -1.1 -2.1, -0.2 0.024 
TH 
T-score  
-0.46 0.21 -0.67 -2.0, +0.67 0.27 
TH 
Z-score  
0.16 0.86 -0.71 -2.2, +0.75 0.29 
Femoral Neck 
T-score  
-0.9 -0.2 -0.7 -1.7, +0.40 0.19 
Femoral Neck 
Z-score  
0.0 0.68 -0.68 -1.9, +0.5 0.22 
Log10 P1NP 1.62 1.52 +0.1 -0.024, +0.22 0.11 
Log10 CTX -0.64 -0.7 +0.06 -0.11, +0.2 0.5 
 
Differences between the mean values are provided together with their 95% confidence intervals (C.I) 
and p-values.  The minus (-) or plus signs (+) indicate the direction of the difference. 
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4.7 Bone parameters, serum calcium, phosphate and alkaline 
phosphatase evaluated against TFTs 
 
Corrected calcium (calcium), alkaline phosphatase (ALP) and phosphate values are provided 
on a bone profile (a fairly routine blood test on medical inpatients).  This was determined on 
all my study participants.  
 
ALP is an enzyme found in bone and liver primarily. Its levels rise in healing bone (Sharland & 
Overstall 1979) reflecting accelerated bone formation by osteoblasts, and in liver disorders 
(including hepatosteatosis; associated with obesity (Webber et al 2010)).  The ALP provided 
in a standard bone profile does not differentiate organ origin.  
 
Serum calcium and phosphate rise transiently in acute bone resorption (reflecting release 
from hydroxyapatite crystals in bone (Gallacher et al 1990)) prior to a prompt homeostatic 
correction (parathyroid hormone is the major player).  Phosphate and, less commonly calcium 
can be sub-normal in osteomalacia, a complication of profound vitamin D deficiency. 
 
I performed MRAs on each of these parameters to explore for TFT and BMD associations.  
 
4.7.1 Corrected Calcium 
The MRA evaluating calcium identified an extremely small positive association with T3 (R: 
+0.03, p-value 0.009) (see Appendix 6, Table 2).  
 
There were no correlations with: 
 - BTMs; P1NP or CTX or the ratio of these parameters. 
- TSH 
- T4 
- TPO status 
- DXA T or Z- scores (at hip or spine) 
 
The association coefficient (R) between T3 and calcium was explored in a parsimonious 
stepwise regression analysis (Model 4.5).  This showed no diminution in R with the addition 
of confounders supporting the notion of a positive relationship between calcium and T3.  
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Model 4.5: Stepwise regression model exploring R between Calcium and T3; assessed 
singularly and subsequently adjusted for confounders 
 
Step 1; Crude association 
N  R   95%C.I.   p-value 
207  +0.026  +0.005, +0.05  0.015 
Step 2; Step 1 including male sex 
207   +0.03  +0.05, +0.01  0.004 
Step 3; Step 2 including age 
207  +0.03  +0.05, +0.01  0.003 
Step 4; Step 3 includes TSH, Waist: hip ratio, activity status and ALP 
206  +0.028  +0.05, +0.007  0.009 
 
Model 4.5 details the number of subjects in the analysis (N), the correlation coefficient (R) between 
corrected-calcium and T3. The 95% confidence interval (C.I.) and p-values at each step are provided.  
The minus (-) or plus signs (+) indicate the direction of the association.  
 
 
4.7.2 Phosphate 
The MRA evaluating Phosphate did not reveal associations with thyroid related parameters 
(T3, TSH, T4 or TPO antibody status).  There were also no associations with BTMs or DXA Z or 
T scores (see Appendix 6, Table 3). 
 
4.7.3 Alkaline Phosphatase 
The MRA evaluating ALP showed a very small negative association between ALP and BMD Z-
score at TLS and TH (see Appendix 6, Tables 4 and 5). 
 
No associations were revealed between ALP and: 
 Thyroid parameters;  T3,  TSH, T4 or TPO status 
 BTMs 
 
The lifestyle parameter assessments revealed a positive association between ALP and BMI 
(see figure 4.12 with associated regression equation), and a negative association between ALP 
and activity (non-sedentary lifestyle).  
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This relationship between ALP and BMI is recognised (Webber et al 2009).  
 
Figure 4.12:   Scatterplot of log10 ALP versus Log10 BMI 
                            
 
Figure 4.12 displays logged BMI on the x-axis and logged ALP on the y-axis. Red dots represent 
individual’s values and the blue line represents the best linear relationship between these parameters. 
 
A parsimonious stepwise regression analysis was performed exploring the relationship 
between ALP and Z-score at TLS and TH (Model 4.6).  This demonstrated that the relationship 
between ALP and Z-score became apparent when BMI was added to the model (step 2).  Given 
that ALP and BMI are positively correlated (Figure 4.12), and BMI is positively correlated with 
Z-score (section 4.4.3), the negative relationship between ALP and Z-score is independent of 
BMI. 
  
Log10ALP = 1.4 + 0.35 Log10BMI 
P-value < 0.001, R2 7.5% 
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Model 4.6: Stepwise regression model exploring the regression coefficient for alkaline 
phosphatase (Log10 ALP) against DXA Z-score at total hip and total lumbar 
spine; assessed singularly and subsequently adjusted for confounders. 
N    R      95% C.I      p-value  
Step 1; crude (adjusting for the respective Z-score site)  
TH;  200  -0.007   -0.03,  +0.01   0.48 
TLS;  198  -0.01   -0.03,  +0.005   0.19  
 Step 2; Step 1 with adjustment for BMI 
TH;  200  -0.03   -0.05,  -0.01   0.002 
TLS;  198  -0.02   -0.04, -0.005   0.01  
 Step 3; Step 2 with adjustment for activity 
TH;  200  -0.03   -0.05, -0.01   0.003  
TLS;  198  -0.02   -0.03, -0.003   0.021 
 Step 4; Step 3 with adjustment for T3, TSH, TPO 
TH;  200  -0.03   -0.05, -0.01   0.004 
TLS;  198  -0.02   -0.04, -0.004   0.017 
 
Model 4.6 details the number of subjects in the analysis (N), the correlation coefficient (R) between 
log10ALP and total hip (TH) Z-score, or log10ALP and total lumbar spine (TLS) Z-score. The 95% 
confidence interval (C.I.) and p-values are provided.  The minus (-) or plus signs (+) indicate the direction 
of the associations.   
 
4.8 Analysis of the Bone Turnover Markers 
The bone formation marker measured on my study participants was serum P1NP (procollagen 
type 1 N-terminal propeptide). P1NP represents pro-collagen N-terminal extensions released 
with the maturation of procollagen to collagen during bone formation (Risteli et al 1995).  
 
The bone resorption marker measured on my study cohort was serum CTX (C-terminal 
telopeptide of type 1 collagen). CTX is a telopeptide fragment of type 1 collagen released 
during bone resorption (Rosen et al 2000). 
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4.8.1 Bone formation marker; P1NP  
The P1NP MRA did not show associations against the predictor variables assessed including:  
 Thyroid-related parameters (TSH, T4, T3, TPO status or the thyroid genetic 
data)  
 Lifestyle parameters (BMI or %BF or activity status)  
 DXA Z or T-scores (at hip or LS) 
 Bone profile parameters (Calcium, ALP or phosphate) 
 
The P1NP MRA is provided in Appendix 6, Table 6 
 
4.8.2 Bone resorption marker; CTX 
The CTX MRA did not reveal associations against the predictor variables assessed including:  
 Thyroid-related parameters (listed above)  
 Lifestyle related parameters (listed above)  
 DXA Z or T-scores 
 Bone profile parameters (listed above) 
 
The CTX MRA is provided in Appendix 6, Table 7 
 
4.8.3 P1NP CTX product 
Enhanced bone loss is associated with a rise in anabolic and catabolic BTMs (Garnero et al 
2000), whilst a fall in BTMs can signify a response to antiresorptive osteoporotic therapies 
(Bergmann et al 2009).  For this reason I have evaluated the ‘CTX’ ‘P1NP’ product (log10CTX x 
log10P1NP). 
 
This P1NP CTX product MRA did not reveal associations with any of the predictor variables (p-
values >0.2, R2 1%) including: 
• Thyroid-related parameters (as listed).  
• Lifestyle-related parameters (as listed).  
• DXA Z or T-scores (at Hip or Lumbar Spine) 
• Bone profile parameters  
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4.8.4 P1NP CTX ratio 
I evaluated the P1NP to CTX ratio as I assumed that a more positive ratio would indicate bone 
formation as the dominant process, whereas a less positive ratio would indicate bone 
resorption as the prevalent process.  
 
The Log10P1NP/ Log10CTX MRA did not reveal associations with the: 
 Thyroid-related parameters (as listed). 
 Lifestyle parameters (as listed). 
 
Positive associations with ALP (R +0.5, p-value 0.002, R2 5%; see Appendix 6, Model 1) and 
phosphate (R +0.36, p-value 0.02) were seen. 
 
A negative TLS Z-score association of borderline significance was observed but was not 
supported by an associated stepwise parsimonious regression analysis (Appendix 6, Model 2).  
 
 
4.9 Discussion 
 
The key observations in this chapter are: 
 
(1) Identifying a higher than expected rate of low BMD at the lumbar spine.   
(2) Revealing negative DXA Z-score associations with;  
 TSH 
 T3  
 TPO antibody positivity  
 male sex 
 
 
I will now detail, discuss, and reflect upon the observations made in this chapter.  
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4.9.1  BMD - TFT observations 
I reveal a higher than expected rate of low BMD in this cohort (with 12% having T-scores in 
the osteoporotic range) despite osteoporosis and evident risk factors for osteoporosis being 
exclusion criteria (section 2.1.2). Exploring this observation further I revealed over-
representation of low BMD at the lumbar spine (LS), with BMD discordance affecting 40%.  
Although discordance itself is not unusual (Woodson 2000, Moayyeri et al 2005, El Maghraoui 
et al 2007, Mounach et al 2009) the rate of major discordance (normal BMD at one site and 
osteoporosis in another), all with vertebral osteoporosis, appeared to be over-represented in 
this cohort (occurring in 11% of discordant cases versus a ~3-4% prevalence described 
(Moayyeri et al 2005, Mounach et al 2009, Woodson 2000).  
 
When BMD discordance does occur, it is more often in this direction, and is more common in 
obese subjects (Moayyeri et al 2005).  However given that obesity can overestimate DXA 
scores, particularly at the LS (Bansal et al 2011), and obese subjects have higher BMDs in 
general than lean subjects (Albala et al 1996, Douchi et al 2000, Fawzy et al 2011) this does 
not explain the high rates of low LS BMD in this cohort.   
 
I hypothesise that the prevalence of BMD discordance observed (with lower BMD at LS) could 
relate to differing trabecular to cortical bone ratios between these sites; higher in vertebrae 
than hip (Clarke 2008, Dempster et al 2006). Trabecular and cortical bones differ in many 
respects including their development (membranous ossification versus endochondral 
ossification respectively), structure and composition (trabecular bone has a higher surface 
area to blood ratio), and metabolism; higher in trabecular bone (Clarke 2008); possibly 
explaining why inflammatory conditions (Akgöl et al 2014; Spondyloarthritis, Klaus et al 2002; 
Crohn’s disease), chronic diseases (Alcalde Vargas et al 2012; liver cirrhosis, Lin et al 2012; 
chronic hepatitis C infection) and acute oestrogen deficiency of early menopause (Elders et al 
1988, Finkelstein et al 2008) has a greater negative effect on trabecular than cancellous bone.  
As such these bone-types respond differently to stressors, which may include altered thyroid 
function in SH.  
However, given that the ratio of cortical to trabecular bone alters markedly across different 
regions of a DXA scanned hip (Bohr & Schaadt 1985) other potential explanations for this 
observation should be sought. 
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Across the cohort I reveal an inverse relationship between TSH and DXA Z-score at all sites, 
potentially indicating an adverse TSH effect on bone. My analyses support an independent 
association between TSH and Z-score at LS, but not at TH.  This negative BMD-TSH association 
specific to LS, could relate to increased TSHR expression at LS, or enhanced TSHR mediated 
effects at LS; offering alternative theories to the bone-type postulation discussed above.  
 
The negative TSH - BMD relationship observed was not anticipated. In fact, this is contrary to 
the observations of many studies that associate low TSH (Faber et al 1998, Mudde et al 1994, 
Kim et al 2015) and low-normal TSH with lower BMD (Kim et al 2006); and the inverse for 
raised or high-normal TSH (Van der Deure et al 2008, Chin et al 2013)).  However, as discussed 
in the introduction (section 4.1); much uncertainty remains. 
 
The Abe et al paper was a landmark paper as it provided in vivo and in vitro data indicating 
that TSH had direct effects on bone.  The authors found that TSH (via TSHR) had inhibitory 
effects on osteoclasts, and osteoblasts, and uncoupled the bone remodelling process when 
TSHR signalling was compromised.  However, as effects on osteoclasts were predominant (in 
TSHR knockdown animals), low BMD was observed (alongside focal osteosclerosis (Abe et al 
2003)).  When I relate these conclusions to my own observations it would suggest that the 
inhibitory effect of TSHR signalling on osteoblasts outweighs that of osteoclasts, accounting 
for a negative (rather than positive) association observed between TSH and BMD Z-score at 
LS. The fact that Abe et al’s animals were young mice and my subjects are mostly mature 
humans may be important in regard to differences in TSHR-bone physiology.  
 
An alternative hypothesis regarding the TSH-Z-score (LS) observation is that TSH may have a 
negative indirect effect on BMD.  This would fit in with Abe et al’s observation of low BMD in 
TSHR insufficient animals (whose TSH values were raised), mirroring my own observations.  
The fact that Abe et al’s homoinsufficient (TSHR–/–) mice continued to have low BMD despite 
correction of TSH (with thyroxine replacement therapy) cannot be attributed to TSH 
correction alone as hypersensitivity to thyroid hormones will occur in these animals with 
congenital hypothyroidism (Bassett et al 2008). However, a potential problem with this theory 
is that it is inconsistent with the observations of Sun et al (2008) who describe BMD accrual 
in response to intermittent exogenous TSH administration, in euthyroid ovariectomised 
rodents.  However, the fact that these rodents were euthyroid, and excess TSH exposure was 
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intermittent may account for its seemingly paradoxical effects. Sun et al (2008) suggested that 
TSH may have different effects in different conditions rather like parathyroid hormone (PTH). 
Indeed, PTH accelerates bone loss in primary and secondary hyperparathyroidism but 
encourages bone accrual when used therapeutically as an osteoporosis treatment. 
 
A negative relationship between Z-score and T3 was revealed across the cohort (at hip and LS 
with BMI was the build parameter).  This relationship is recognised in hyperthyroidism 
(Bassett & Williams 2009) but not previously described in an SH cohort.  No relationship 
between BMD and T4 was identified.   
 
A small positive relationship between T3 and TSH (Figure 3.18) was observed across the 
cohort suggesting that contrary to traditional thinking, T3 levels may increase (rather than 
decrease) in compensated SH.  A negative relationship between TSH and T4 is recognised 
(Figure 3.17, Hoermann et al 2010, Hadlow et al 2013). A drop in T4 will activate the D2 
deiodinase enzymes to increase T3 production (Gereben et al 2008) and there might be 
overcompensation of this mechanism in SH. If so then altered T3 values (+/- heightened 
sensitivity to T3) may contribute to enhanced bone loss in SH.  
 
4.9.2 BMD, TPO antibody status and thyroid genetic data  
A negative relationship between TPO antibody positivity (+) and DXA Z-score at TLS (R minus 
0.65, p-value <0.001) was revealed.  This was initially suggested at TH but this was not 
supported by subsequent analyses. 
 
Associations between inflammatory autoimmune disorders and bone loss are well described 
(Schett & David 2010), although not in autoimmune hypothyroidism or SH.  A study evaluating 
FRAX scores (fracture risk scores) in postmenopausal SH women (82 cases, 51 controls) 
reported a positive association between TPO+ and FRAX score (Polovina et al 2013), as well 
as between SH and FRAX score (versus euthyroid controls).  This study differed from our own 
in that it reported lower BMD scores affecting the hips of these subjects rather than the spine.  
Another study evaluating the response of mononuclear cells to a TPO antibody rich serum, 
reported that this induced synthesis of inflammatory cytokines, including TNF-alpha (Nielsen 
et al 2009); TNF-alpha being a key player in osteoclast mediated bone loss in chronic 
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inflammation (Azuma et al 2000).  However, other studies differ in their observations.  A 
Nordic prospective study on adults (>40 years of age) without known thyroid dysfunction or 
fractures (♀ n = 16,610, ♂ n = 8,595) reported an increased risk of hip fracture (MVHR; 1.87 
(95% CI 1.11–3.16) in the 12 year observation period in TPO-ve female subjects, but not TPO 
+ve.  However, TPO status was only assessed on subjects with TSH>4mU/L (included 946 
women) (Svare et al 2013).  Whilst Blum et al (2015) did not reval any associations between 
fracture incidence (n>70,000) and SH. 
 
I performed MRAs to examine the effect of heterozygous TSHR-Ms on bone parameters, and 
no associations were revealed.  However, given my expectation that TSHR function might 
influence BMD (Abe et al 2003) and that the mutation (TSHR-M) subject numbers (n=12) were 
insufficient to reliably exclude differences, further evaluation was undertaken. Although the 
selected case-control analyses (used for this purpose) initially suggested that TSHR-M subjects 
may be inclined to lower BMD at TLS, this was not subsequently upheld. Another matching 
analysis was performed to explore potential ‘build’ differences between the groups and none 
were suggested.  This was assessed because the TSHR is expressed on pleuripotent MSCs and 
it was hypothesised that altered TSHR activation during development (in TSHR-M subjects) 
might influence final body composition.  
 
My analyses have consistently revealed lower T3s (for an equivalent TSH) in the TSHR-M 
group.  This alteration in T3 would be anticipated to impart a positive BMD effect (given T3 α 
1/BMD). However, this wasn’t apparent. It is therefore possible that this effect is being offset 
by a negative BMD effect relating to TSHR-M status (indicating a direct TSHR effect).  This 
hypothesis would then support the work of Terry Davies’ group who describe their TSHR-
knockout rodents as having lower BMDs than controls (Abe et al 2003).   
 
It is important to consider potential direct versus indirect effects of TSH on BMD. If TSH 
signalling has a direct negative effect on vertebral BMD then TSHR-M carriers should be 
protected (to some extent) from this effect and would be expected to have higher BMDs than 
normal sequence SH counterparts (assuming other factors are equivalent).  Indeed, the BMD 
of TSHR-M carriers (with SH) and euthyroid normal-sequence controls should be equivalent.  
This is because reduced TSHR signalling in mutation carriers is assumed to be counter 
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balanced exactly by a rise in TSH, negating its effect.  If instead TSH has an indirect negative 
effect on BMD then TSHR-M status would not influence this process and no BMD differences 
between SH subjects with or without TSHR-Ms would be expected.  As my observations did 
not reveal BMD differences between these groups, this potentially supports the concept of 
TSH having an indirect negative effect on vertebral BMD.  However, given the low TSHR-M 
numbers in my cohort, my observations (and postulations) may be unreliable. Clearly much 
larger subject numbers are required to validate these observations. 
 
The analyses performed on the D727E polymorphism subjects versus controls revealed lower 
TLS DXA-scores in the D727E subjects.  If this difference is true, it is at a clinically relevant 
magnitude.  However, given the extremely low D727E subject numbers (n=7) this observation 
could simply be a chance finding. However, this observation supports that of Liu et al (2012) 
who report the polymorphism to be more prevalent in osteoporotic men than their controls 
(although another study makes an opposing postulation (Van der Deure et al 2008)).  
However, if true the mechanism for this observation is obscure given that the D727E 
polymorphism appears not to be consistently associated with altered TFTs, or altered TSHR 
constitutive activity. 
 
4.9.3 Non-thyroid related BMD observations across the cohort 
Analyses were performed that evaluated the non-thyroid factors that could be affecting BMD.  
These revealed a positive association between DXA Z-score and WHR (BMI or %BF); activity-
status (non-sedentary lifestyle), and a negative association with male sex. 
 
The positive relationship between BMD and weight-related parameters or activity are 
recognised.  This relates to the fact that bone is a dynamic organ that adapts to demand; 
increasing BMD in response to increased transmitted force.  A force that may relate to 
increased weight (Felson et al 1993), or to weight-bearing exercise (Todd & Robinson 2003). 
 
Male sex correlated negatively with BMD which was an unexpected finding (Daly et al 2013, 
Rico et al 1992).  Initially I thought this might relate to a bone protective effect of oestrogen 
in the pre-menopausal women (Langeland 1978).  However, this was not the case as the 
results were unchanged with the pre-menopausal women removed from the analysis.  This 
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may therefore suggest that SH has a greater negative effect on the BMD of men than women, 
although the mechanism for this is obscure. Interestingly Lee et al (2010) evaluated incident 
hip fractures in older US adults (≥65 years) and identified a higher rate of fractures in men 
with SH, but not women. 
 
4.9.4 Analysis of bone profile components and bone turnover markers 
Evaluation of bone profile components with the TFT-components and TPO status identified a 
very small positive association between corrected-calcium and T3, but no ALP or phosphate 
associations.  
 
An association between calcium and FTHs is recognised in hyperthyroidism (Baxter & Bondy 
1966).  This is believed to reflect enhanced bone resorption with release of complexed 
calcium from bone through the action of FTHs (Baran & Braverman 1991).  Whether this 
mechanism is similar in SH subjects cannot be determined (particularly given the absence of 
vitamin D and parathyroid hormone assessment on these subjects).  A relationship between 
T3 and serum calcium has not been previously described in an SH cohort.  
 
A very small negative association between ALP and Z-score at the hip and TLS was revealed.  
Given that the ALP-BMI relationship is positive, and the BMI-Z-score relationship is positive, 
this relationship is independent of BMI.  This association has been observed in premenopausal 
(Krahe et al 1997), and postmenopausal women where it is associated with occult spinal 
fractures (Ross et al 2000). Indeed, a fall in bone-specific ALP can indicate a response to 
bisphosphonate therapy in osteoporosis (Dresner-Pollak et al 2000). Given that bone-specific 
ALP is elevated in healing bone, this was not an unexpected observation.  
 
The analyses assessing the bone turnover markers (BTMs); ‘P1NP’, CTX’, their product, and 
their ratio did not reveal associations with the TFT-components, TPO+ or DXA Z-scores. 
Interestingly Polovina et al (2013) reported higher FRAX scores in SH women, particularly 
those with ATD but no differences in their BTMs compared with euthyroid controls. 
 
Although BTMs have been available for some time their use is primarily in research settings 
(rather than practice).  A systematic review (on behalf of the National Institute for Health 
Research) did not advocate their use as a standard of care for osteoporosis patients (Burch et 
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al 2014) although they are considered useful in predicting patient compliance and response 
to osteoporosis treatments (Bergmann et al 2009).  Their use as a single point assessment in 
evaluating cross-cohort trends is limited by wide inter-subject variability (Burch et al 2014) 
possibly explaining the absence of BTM associations in this cohort. Alternatively a change in 
BMD in SH may be too gradual to be sensitive to these tests, or perhaps its mechanism may 
not relate to altered bone turnover.  
 
 
4.9.5 Summary and closing comments 
Important BMD associations have been made on this treatment naive, heterogeneous SH 
cohort in whom I identify a higher than expected rate of low BMD at LS. This suggests that SH 
may have an adverse effect on BMD.  
 
With respect to the TFT components evaluated, I identified a negative association between 
TSH and Z-score at LS, and a negative association between T3 and Z-score at LS and hip.  Thus 
T3 and TSH may have independent negative effects on BMD in the context of SH.  The positive 
association between TSH and T3 revealed across this cohort was unexpected. 
 
Interestingly, a negative association between BMD and male sex was revealed, indicating that 
men may be more susceptible to bone loss in SH than women. 
 
In regard to TPO antibody status, a negative association between TPO+ and DXA Z-score at LS 
was identified, indicating that aetiology of SH is likely to be important in regard to its clinical 
manifestations.  
 
Analyses on the TSHR-M subjects did not reveal associations with either BMD or build 
parameters.  However validation in much larger studies are required.  
 
In conclusion, my observations suggest that bone health should be actively evaluated in SH, 
particularly in men, people with thyroid autoimmunity or those with additional risk factors 
for osteoporosis.  
 
 
The limitations of this study that are of relevance to this chapter are detailed in the closing 
chapter. 
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CHAPTER 5:   CARDIOMETABOLIC-RISK PARAMETERS IN RELATION 
TO THYROID FUNCTION AND FOXE1 POLYMORPHISMS IN A 
SUBCLINICAL HYPOTHYROID COHORT 
 
5.1 Introduction 
Thyroid hormones are ubiquitous hormones that act on almost all cells in vertebrates (Eales 
1997, Hulbert 2000).  They are key regulators of metabolic processes and temperature 
(Magnus-Levy 1895, Thomas 1957, Tata et al 1962).  Hyper- and hypothyroidism are 
associated with an array of changes in metabolic parameters (as well as the bone parameters 
discussed in Chapter 4).  
Hypothyroidism is associated with weight gain (Esmail et al 2013), dyslipidaemias (Walton et 
al 1965) (including a rise in LDL-cholesterol and apolipoprotein B (Staub et al 1992), diastolic 
hypertension (Danzi & Klein 2003) and increased systemic vascular resistance (Diekman et al 
2001).  Untreated hypothyroidism is associated with accelerated atherosclerosis (Kocher 
1883, Kazi 2003, Cappola & Ladenson 2003) and a predisposition to ischaemic heart disease 
(Becker 1985) and cerebrovascular diseases (Qureshi et al 2006).  The physiological and 
systemic changes of hypothyroidism (reduced cardiac contractility, reduced heart rate and 
reduced blood volume) reduce exercise capacity.  However, congestive cardiac failure 
attributable to hypothyroidism alone is unusual (Hussain 1997). 
The metabolic changes that commonly accompany hyperthyroidism include weight loss, a 
reduction in lipids (Walton et al 1965), (Total Cholesterol (TC), LDL-cholesterol (LDL), ApoB, 
Lp(a) and HDL-Cholesterol (HDL) (Kung et al 1995)), systolic hypertension (Danzi & Klein 2003), 
reduced systemic vascular resistance (Diekman et al 2001), a rise in insulin resistance 
(Maratou et al 2009) and changes in coagulation factors that may predispose to thrombosis 
(Erem et al 2002).  The physiological changes of hyperthyroidism (increased myocardial 
contractility, oxygen demand and vascular volume; widened pulse pressure and increased 
heart rate) predispose to heart failure (Fadel et al 2000).  Complications from hyperthyroidism 
include those that relate to tachyarrhythmias, including atrial fibrillation (AF) with its 
predisposition to embolic stroke (Jayaprasad & Francis 2005). 
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It might be assumed, by extrapolation, that adverse cardiometabolic effects would occur but 
to a lesser extent in subclinical thyroid diseases (ScTDs).  In these conditions subjects have 
normal levels of free thyroid hormones (FTHs) but TSH values outside it.  In general, this 
compensatory change in TSH is sufficient to keep FTH values close to each individual’s target 
value (Andersen et al 2003).  Consequently, it might be assumed that any metabolic changes 
observed in the ScTDs may be more attributable to TSH, than to the much smaller relative 
change in FTH values.  
Subclinical hyperthyroidism (Shyper) has been associated with an increased risk of 
tachyarrhythmias, particularly AF (Forfar et al 1981), especially in elderly subjects (Cooper 
2007) or those pre-disposed to arrhythmias (Haentjens et al 2008).  SH with TSH ≥10mU/L is 
associated with adverse metabolic risk parameters (relating to lipids, blood pressure (BP)) 
(Surks et al 2004) and adverse cardiovascular outcomes (Ochs et al 2008, Razvi et al 2010).  
However, below this threshold the merit of correcting SH remains unclear (see Table 5.1). 
The TSH receptor (TSHR) has been detected in a number of extra-thyroidal sites including 
fibroblasts and adipose tissue (reviewed in Davies et al 2002).  Mesenchymal stem cells 
express TSHR (Bagriacik et al 2012) and have the potential to differentiate into different 
terminal cells (see Figure 1.5) and tissues including fat, muscle, cartilage, mesenchyme and 
bone; tissues that collectively influence body composition.  It has been suggested that TSHR 
activation might influence lineage specific differentiation (de Lloyd et al 2010).  Interestingly, 
an inverse relationship between bone and fat differentiation has been observed (Ng & Duque 
2010) which could be influenced by this pathway.  
Graves’ hyperthyroidism is an autoimmune disease where the TSHR is activated by thyroid 
stimulating immunoglobulins (TSI).  TSI activates thyroidal TSHR, driving thyroid hormone 
synthesis independently of TSH. Preadipocytes express TSHR and expression is upregulated in 
fat depots undergoing adipogenesis (Valyasevi et al 1999, Crisp et al 2000).  This observation 
led to the hypothesis that orbital preadipocyte TSHR may be an important antigen in the 
pathogenesis of Graves’ Orbitopathy (GO) (Crisp et al 2000, Ludgate & Baker 2002, Khoo & 
Bahn 2007).  In GO there is pathological accumulation of fat and inflammatory mediators 
within the confines of the bony orbit resulting in proptosis and ocular injury (Ludgate & Baker 
2002).  Cell culture experiments exploring the biological effect of TSHR activation on 
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adipocyte biology indicate that effects are fat-depot source dependent (Zhang L et al 2012).  
These data indicate that TSHR signalling may affect fat cell biology which is itself associated 
with vascular and metabolic risk (Schäfer & Konstantinides 2011).  
The SH subjects recruited to my study all had their BP measured, fasting lipids and glucose 
assessed, insulin resistance scores (HOMA-IR) calculated and full thyroid function tests (TFTs) 
performed. In addition, body composition was recorded (by measurement of BMI, waist to 
hip ratio (WHR), and percentage body fat (%BF).  The data was evaluated alongside the TFTs 
recorded at study attendance. 
Participants were all screened for TSHR mutations (TSHR-M), likely to be inactivating 
mutations in this population.  In addition I determined subjects’ FOXE1 polyalanine tract 
length (PTL) polymorphisms (see section 3.1 for more detail).  Given that I found TSHR-M 
status to be negatively associated with T3 (Table 3.9 and 3.10) and the prevalent FOXE114/14 
PTL polymorphism to be positively associated with T3 (Model 3.2) it is plausible that these 
genetic aberrations may influence metabolic parameters.  The FOXE1 gene is expressed in a 
range of cells and tissues with mRNA extracted from liver, pancreas, muscle, brain and fat 
tissue (Genecards human gene database; FOXE1 (www.genecards.org)).  Thus it is conceivable 
that FOXE1 PTL polymorphisms could influence metabolic parameters. 
I have analysed the associations between TFT components and the metabolic data collected 
on my study participants. These have also been evaluated in association with the genetic data 
and the TPO antibody status of my subjects. However, as these were not pre-defined primary 
outcome measures in this study, they are considered as exploratory analyses only. 
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Table 5.1: Summarises a number of clinical studies to demonstrate the inconsistent metabolic associations reported in Subclinical Hypothyroidism 
Parameter Adverse association with SH No independent association with SH 
Blood 
pressure 
•Cai et al’s (2011) cross sectional meta-analysis compared SH subjects with 
controls. Adverse SH associations on MRA with systolic BP (R; +1.89 mmHg, 
95% CI; 0.98-2.80, p-value <0.05) and diastolic BP (R; +0.75 mmHg, 95% CI; 
0.24-1.27, p-value <0.05) were reported. 
•Liu et al’s (2010) cross-sectional questionnaire survey of 1319 adults 
reported hypertension as more prevalent in SH ♀s than euthyroid ♀s. 
•Ye et al’s (2014) meta-analysis (n=50,147) reported an association 
between SH and BP that was age-dependent.  
•Walsh et al (2006) did not identify an SH-Hypertension association 
in their cross sectional study (SH; n=105, euthyroid; n=1859). 
Subjects were not on anti-hypertensives and had no known thyroid 
disease. 
Insulin 
resistance 
•Vyakaranam et al (2014) associated SH with insulin resistance (HOMA-IR) in 
their matched case control study (n=30 pairs). Although SH subjects 
generally had TSHs >10mU/L (14.2 ±5.23) and non-significantly higher BMIs 
(27.8 ± 2.8 vs 23.4 ± 1.8). 
•Maratou et al (2009) reported greater insulin resistance and impaired 
translocation of Glut4 transporters in monocytes of SH subjects (n=12) vs 
controls (n=21).  
 
•Posadas-Romero et al (2014) evaluated insulin resistance and 
metabolic parameters in a cross sectional study of adult subjects 
(n=753). An SH - insulin resistance association was identified but 
dependent on the co-existance of fatty liver. 
Lipids 
•Bindels et al’s (1999) cross sectional analysis (n=1200) revealed a positive 
association between total cholesterol category (<5, 5-8 or >8mmol/L) and 
prevalence of SH. 
•Canaris et al (2000) reported an adverse association between SH and 
serum lipids (inclusive of the SH subjects with TSH <10mU/L) from their 
cross sectional study (n=25,862).  
•Cheserek et al (2014) associated SH with triglycerides in ♂s specifically (R; 
0.13, p=0.006), independendent of BMI. Their data was taken from a 
voluntary health assessment on 1150 university employees.  
•Hueston and Pearson (2004) evaluated subjects >40years of age 
(SH; n= 205, euthyroid; n= 8,013); an association between SH (TSH; 
6.7-14.9mU/L) and lipids (LDL-cholesterol, HDL-cholesterol, 
triglycerides) was lost when adjusted for confounding factors.  
•Vierhapper et al (2000) did not correlate SH with LDL-cholesterol or 
triglycerides (SH; n=1055, euthyroid; n=4886).  
• Pearce’s (2011) review article describes the SH - dyslipidaemia 
association as inconsistent across studies, and an association with 
HDL-cholesterol as unlikely. 
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Adiposity 
•A positive association between adiposity and TSH is described across 
euthyroid cohorts (de Moura Souza & Sichiere 2011, Nyrnes et al 2006). 
• A fall in TSH (from a mean of 4.5 to 1.9mU/L) in response to bariatric 
surgery induced weight loss (mean drop in BMI; 49 to 32kg/m2) is 
described (n=86). SH affected 10.5% of subjects, all of whom normalised 
post-surgery (Chikunguwo et al 2007)  
•Garin et al (2014) evaluated US subjects ≥65 years of age (SH; 
n=427, euthyroid; n=2864). No association between SH and weight 
gain (assessed over 6 years) or adiposity (assessed in a subset of 
1276 subjects) was revealed.  
• A weight loss benefit from treating mild SH (TSH <10mU/L) with 
TRT over a 6 month observation period was not demonstrated in a 
blinded, placebo-controlled study (n=40; TRT; n=23, placebo; n=17) 
(Kong et al 2002). 
Cardiovascular 
events 
•Ochs et al’s (2008) meta-analysis associated CV events with SH (no 
upper TSH limit). The RR of CV events in SH was 1.02-1.08 overall 
(inclusive of only higher quality papers); 1.5 (CI; 1.09-2.09) if <65 years of 
age, and 1.12 (CI; 1-1.26) if >65 years of age. 
•Razvi et al (2010) evaluated the 20 year follow-up data to the Whickham 
study (SH; n=97, SH TSH; 6-15mU/L; euthyroid n=2279). A greater 
prevalence of CV disease in SH subjects was reported. However CV events 
and CV mortality was not different in those with or without TRT, although 
total mortality was lower in the treated group. 
•Razvi et al (2012) evaluated subjects <70 years of age (n=3093) and >70 
years of age (n=1642) with mild SH (TSH; 5-10mU/L). A lower rate of CV 
events in the younger group with TRT (vs untreated; 4.2% vs 6.6% (CI; 
0.39-0.95) but no treatment benefit revealed in the older group.  
•Rodondi et al (2010) reported an adverse SH-cardiovascular 
outcome association that applied only to SH subjects with TSH 
>10mU/L (metanalysis of prospective cohort studies, n=55,287). 
•Boekholdt et al (2010) report on their prospective study (n=11,554 
ages; 45-79 years, follow up; 10.6 years). An association between 
baseline TFTs in the SH range and future CV events or mortality was 
not seen (a correction for subsequent TRT was not possible). 
•At this time there is no definitive evidence that treating and 
correcting mild SH (TSH <10mU/L) has beneficial effects on CV 
morbidity or mortality (Surks et al 2004, Fatourechi 2009).  
 
In Table 5.1 the abbreviations are as follows; CI; Confidence Interval, R; Regression Coefficient, RR; Relative Risk, ♀;Female, ♂;Male, SH; Subclinical Hypothyroidism 
CV; Cardiovascula, MRA; Multivariate Regression Analysis, vs; versus, n;  subject number, TRT; thyroxine replacement therapy to correct SH. 
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5.2 TPO antibody status and cardiometabolic risk parameters 
 
The metabolic parameters evaluated in this section include BMI (body mass index), WHR 
(waist to hip ratio), BP (blood pressure), fasting glucose (f-glucose), calculated insulin 
resistance scores (HOMA-IR), fasting lipid profiles (Total cholesterol (TC), low density 
lipoprotein cholesterol, high density lipoprotein cholesterol (LDL and HDL respectively), 
triglycerides (Tg) and self-reported lifestyle factors (activity versus inactivity, smoking history 
and alcohol consumption).  It is recognised that adverse metabolic and lifestyle parameters 
serve to increase a subject’s cardiovascular risk score (Eckel et al 2014).  
 
I have evaluated the metabolic data on the cohort according to TPO antibody status (positive 
(+ve) or negative (-ve)) as shown in table 5.2. 
 
Previous analyses revealed that the TPO +ve group (versus TPO -ve group) were younger (49 
versus 54 years), had lower mean BMIs (27.5 versus 29.2 kg/m2), lower WHRs (0.84 versus 
0.88), were less sedentary (40% versus 57%) and the group comprised more women (84% 
versus 67%).  In addition, they had higher TSHs (5.8mmol/L versus 4.8mmol/L), and lower T4s 
(12.7mmol/L vs 13.6mmol/L) (see Table 4.4).  
 
Table 5.2 reveals that, in addition, the TPO +ve group have less smoking history, fewer 
hypertensive subjects, and borderline higher mean HDLs.  Thus it appears that the TPO -ve 
subjects display higher cardiovascular risk scores on account of their lifestyle parameters.  The 
next section will explore for independent TPO antibody - metabolic parameter associations. 
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Table 5.2:  Cardiometabolic data in relation to TPO antibody status 
Parameter 
TPO +ve 
(n=104) 
TPO -ve 
(n=104) 
Difference 95% C.I p-value 
Number with >10 pack 
year smoking history 
24 40 -15% -0.28 to -0.03 0.015 
Number of ‘heavy’ 
alcohol consumers 
7 8 +1% -0.06 to +0.08 0.79 
Number with 
Hypertension 
23 40 -16% -0.29 to -0.04 0.009 
Number with    
Diabetes 
7 13 -6% -0.14 to +0.02 0.16 
Number with 
 IHD or CVD 
4 9 -5% -0.11 to +0.02 0.15 
TC 
(mmol/L) 
5.36 5.22 0.14 -0.2 to +0.45 0.41 
LDL 
(mmol/L) 
3.31 3.21 +0.1 -0.18 to +0.38 0.5 
HDL 
(mmol/L) 
1.42 1.32 +0.1 -0.002, +0.2 0.05 
Tg 
(mmol/L) 
1.48 1.56 -0.08 -0.5 to +0.34 0.71 
 
The mean ( ) % differences between the groups are provided with confidence intervals (C.I) and p-
values. Minus (-) or plus (+) signs indicate the direction of the differences. Heavy alcohol consumption 
was considered as >14 units/week (female) and >21 units/week (male). Abbreviations include IHD; 
Ischaemic Heart Disease and CVD; Cerebrovascular Disease. 
 
 
5.3 Cardiometabolic-risk parameters in relation to TFTs, TPO status and 
thyroid genetic data  
 
A diagnosis of hypertension is made when repeated BP values are elevated.  A systolic BP 
>140mmHg and/or diastolic BP >90mmHg is generally used to define hypertension (Mancia 
et al (2013) on behalf of the European Society of Hypertension, and Cardiology).  Untreated 
hypertension causes vascular damage through a range of mechanisms that include 
endothelial injury, endothelial dysfunction, end arteriolar infarction, oxidative stress and 
acceleration of the atherosclerotic process.  These processes collectively contribute to end 
organ injury (Alexander 1995).  
 
The BP associations across the cohort are provided in section 5.3.1-5.3.3. 
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In my multiple regression analyses (MRAs) the effect of the affirmative binary parameter on 
the dependent variable is being assessed.  These were as follows: 
 Activity(1) predicts the effect of a non-sedentary lifestyle  
 FOXE1(14) predicts the effect of homozygosity for the FOXE1-14 PTL polymorphism  
 TPO(+ve) predicts the effect of TPO antibody positivity  
 Alcohol(1) predicts the effect of consuming  alcohol (as opposed to tee-total). 
 Smoking(1) predicts the effect of having a >10 pack year history  
 TSHR-M predicts the effect of carrying a TSHR mutation 
 Male(1) predicts the effect of male sex  
 
For detail regarding the interpretation of MRAs please see Chapter 2, section 2.19. 
 
The values used in the BP analyses represent the mean of 3 readings taken at study 
attendance (see section 2.4). All participants were fasted and were advised to take their 
antihypertensive medication after their clinical assessment. 
 
The first BP MRA I performed evaluated against a range of parameters that included T4, 
smoking history, alcohol history, TSHR-M and TSHR polymorphism (D727E and P52T) status.  
However, as these parameters did not associate with BP (and are not known or expected to 
influence BP), for simplicity (and to reduce the likelihood of type 1 errors) they are not 
included in the BP MRAs that follow.  
 
5.3.1  Systolic Blood Pressure 
 
This MRA explored the relationship between systolic BP and WHR, activity status, male sex, 
TSH, T3, TPO+, subject age, and FOXE1 PTL status; see MRA below and its corresponding table 
(table 5.3). 
 
Systolic BP = 49 + 18WHR - 1.4Activity(1) + 2.5Male(1) - 1.5 Log10TSH + 11.7T3 + 0.6 - 
0.9TPO+ve(1) + 0.4Age - 7.4FOXE1(14)       
N=201  R2 = 31% 
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Table 5.3:  MRA evaluating systolic BP against the predictors listed  
Predictor R SE coefficient 95% C.I p-value 
Constant +49 14.6 +21, +78 0.01 
WHR +19 15 -10, +48 0.2 
Activity(1) -1.4 2.2 -5.7, +3 0.53 
Male(1) +2.6 3 -3, +8.4 0.39 
Log10 TSH (mU/L) -1.5 5.8 -12, +10 0.8 
T3 (pmol/L) +11.7 2.1 +7.5, +16 <0.001 
TPO+ve(1) -0.9 2.2 -12, +10 0.7 
Age (years) +0.4 0.09 +0.3, +0.6 <0.001 
FOXE1(14) -7.4 2.2 -11.6, -3.2 0.001 
Table 5.3 provides the regression coefficient (R) for each predictor assessed in the MRA evaluating 
Systolic BP. The corresponding standard errors (SE), confidence intervals (C.I) and p-values are 
provided. The minus (-) or plus signs (+) indicate the direction of the association.  
 
The systolic BP MRA reveals the following associations: 
 A positive T3 association (R +11, p-value <0.001) 
 A negative FOXE1(14) association (R -8, p-value <0.001). 
 A positive association with age (R +0.4, p-value <0.001), as expected. 
 
When this analysis was repeated substituting BMI for WHR the associations were similar but 
the significance scores improved (see Appendix 7, Table 1). 
 
5.3.2 Diastolic Blood Pressure 
 
The MRA evaluating diastolic BP (equivalent to the systolic BP above) failed to reveal 
associations against the predictor variables (including T3 [R+0.02, p-value 0.55], and 
FOXE1(14) [R-0.06, p-value 0.17]). 
 
However, when BMI was substituted for WHR the associations changed; the T3 association 
fell just short of statistical significance, and the FOXE1(14) association was restored (R; minus 
3.5, C.I; minus 6.3 to minus 0.7, p-value 0.015).  See Appendix 7, Table 2.   
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5.3.3  Exploring the relationship between blood pressure and T3, and blood pressure 
and FOXE1 PTL polymorphism status 
 
The blood pressure regression analyses thus far indicate that T3 and FOXE1 PTL polymorphism 
status correlate with BP.  To explore these associations further I used stepwise parsimonious 
regression models.  
 
Model 5.1 explores the relationship between BP and T3 whilst Model 5.2 explores the 
relationship between BP and FOXE1(14) PTL polymorphism status. 
 
BMI is the build parameter used in these regression models.  
 
Model 5.1 reveals a positive crude association between systolic BP, and diastolic BP with T3 
(Step 1). The coefficient for both values is notable (~3 for diastolic and ~11 for systolic) 
although ~3 fold higher for systolic than diastolic BP.  
 
 
Model 5.1.  Stepwise regression model exploring the association between blood pressure 
and T3; assessed singularly and subsequently adjusted for confounders. 
 
 
Systolic      Diastolic 
 
N R 95%C.I. p-value  N R 95%C.I. p-value 
Step 1; crude (against T3 only) 
207 +11 (+6.6, +15.4) <0.001   206 +3.8 (+1, +6.5) 0.008 
Step 2; Step 1 also adjusted for BMI (log10BMI) 
206 +9.6 (+5.2, +14) <0.001   206 +3.1 (+0.4, +5.8) 0.037 
Step 3; Step 2 also adjusted for FOXE1 PTL(14) polymorphism status 
201 +11 (+6.7, +15.3) <0.001   201 +3.8 (+1, +6.6) 0.008 
Step 4; Step 3 also adjusted for age and sex  
201 +10.8  (+6.7, +15) <0.001   201 +3 (+0.3, +5.7) 0.035 
Step 5; Step 4 also adjusted for TPO positivity, activity and TSH (log10 TSH)  
201 +10.8 (+6.6, +15) <0.001   201 +2.7 (-0.1, +5.5) 0.058 
 
Model 5.1 details the number of subjects in each analysis (N), the correlation coefficient (R) between 
systolic BP and T3, or diastolic BP and T3. Alongside is the 95% confidence interval (C.I) for each 
analysis step and its p-value. The minus (-) or plus sign (+) indicate the direction of the association.  
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The statistical significance of the association (p-value) falls for diastolic BP as confounders are 
added in to the analysis (particularly at the final step), but remains highly significant for 
systolic BP.  This could indicate that the association with T3 applies only to systolic BP, or 
alternatively that the sample size is underpowered to consistently reveal this relationship 
with diastolic BP.  
 
Model 5.2 explores the relationship between BP and FOXE1 PTL14/14 polymorphism status. 
Although the crude associations fall short of statistical significance for systolic and diastolic 
readings, they become significant when T3 is added into the model at step 2 and R rises with 
the addition of confounding factors. This relationship is more substantial for systolic than 
diastolic BP in regard magnitude of R (-7.2, versus -3.3), and its p-value (<0.001 versus 0.014). 
 
Model 5.2:   Stepwise regression model exploring the association between blood 
pressure and FOXE114/14 polymorphism status; assessed singularly and 
subsequently adjusted for confounders 
 
Systolic BP      Diastolic BP 
N R 95% C.I. p-value  N R 95% C.I. p-value 
Step 1; crude association  
202 -4.7 (0.12, -9.5) 0.058   202 -2.7 (-5.6, +0.2) 0.07  
Step 2; adjusted for Model 1 including T3 
202 -6.8 (-2.2, -11.4) 0.004   202 -3.5 (-6.4, -0.6) 0.02 
Step 3; adjusted for model 2 including BMI (log10BMI) 
201 -7 (-10.9, -2.5) 0.003   201 -3.5 (-6.4, -0.6) 0.016  
Step 4; adjusted for model 3 including age and male sex 
201 -7.6  (-12, -3.7) <0.001   201 -3.5 (-6.2, -0.8) 0.014  
Step 5; adjusted for model 4 including TPO positivity, activity and TSH (log10 TSH) 
201 -7.8 (-12, -3.6) <0.001   201 -3.5 (-6.3, -0.7) 0.014 
 
Model 5.2 details the number of subjects in each analysis (N) and the correlation coefficient (R) 
between either systolic BP or diastolic BP and the FOXE1 PTL14/14 polymorphism. The corresponding 
95% confidence intervals (C.I) and p-values at each step are provided. The minus (-) or plus signs (+) 
indicate the direction of the association. 
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To summarise, Model 5.1 supports the hypothesis of an independent and positive relationship 
between T3 and systolic BP. Model 5.2 reveals a negative association between FOXE114/14 PTL 
polymorphism status and BP.  
 
5.4  Adiposity  
 
Body Mass Index (BMI) is a calculated value used to indicate a subject’s weight category.  For 
example, a BMI <18.5 suggests a subject is underweight, whereas a value >40 indicates 
‘morbid obesity’ (WHO categories applicable to Caucasians).  
However, the reliability of BMI for accurate weight categorisation is limited by the fact that it 
does not consider the subject’s build.  For example, an athlete with high muscle mass may be 
categorised incorrectly as obese, whilst a subject with isolated central obesity and thin limbs 
or low muscle mass (particularly the elderly) will have their obesity category underestimated 
(Rothman 2008).  Similarly, tall people tend to have their adiposity underestimated (versus 
short people) (Bagust & Walley 2000).  However, in the majority of cases BMI is a helpful 
indicator of weight category.  
Percentage body fat (%BF) is another way of measuring adiposity and this was measured in 
all my study participants.  However, this value has been suggested to overestimate obesity in 
normal BMI subjects, particularly those of Asian origin.  The counter view is that BMI is less 
accurate than %BF in these groups (Carpenter et al 2013). 
Another popular tool to categorise adiposity is the waist to hip ratio (WHR) or even waist 
circumference alone.  These measures of central obesity are simple to perform and helpful 
adverse cardiovascular risk predictors (de Koning et al 2007).  They have been suggested by 
some to be more accurate adverse risk predictors than %BF or BMI (Cepeda-Valery et al 2011). 
An MRA to explore the predictors that might influence, or associate with BMI is shown below.  
The TPO antibody and genetic data are not included in this analysis as no associations against 
these predictors were revealed (R +/- 0.02, p-values >0.2). 
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BMI was log transformed prior to MRA to normalise the data. BMI was evaluated against 
smoking, alcohol and activity status, male gender, TSH, T3 and T4 values (as shown below).  
The relationship between these predictors and BMI is summarised in table 5.4. 
 
Log10BMI = 1.35 + 0.03Smoking(1) - 0.01Alcohol(1) - 0.06Activity(1) + 0.02Male(1) - 0.04 
log10TSH + 0.02T3 + 0.004T4        
N=207  R2 = 18% 
Table 5.4:  MRA evaluating BMI against the predictors listed  
Table 5.4 provides the regression coefficient (R) for each predictor assessed in the MRA evaluating BMI. 
The corresponding standard errors (SE), 95% confidence intervals (C.I) and p-values are provided. The 
minus (-) or plus sign (+) indicate the direction of the association.   
 
The BMI MRA did not reveal associations with the TFT components (or TSHR-M or TPO 
antibody status (data not shown)).  
In regard to the lifestyle factors associated with BMI; activity was negatively associated, and 
smoking status was positively associated, although both correlation coefficients were small.  
When I compared the MRA results substituting %BF for BMI, the results were similar although 
male sex showed a negative correlation (see Appendix 7, Table 3). When this was performed 
using WHR (in place of BMI) a positive association with male sex was seen (see Appendix 7, 
Table 4). These associations reflect the recognised build differences between men and 
women (Stevens et al 2010). 
 
Predictor R SE coefficient 95% C.I p-value 
Constant +1.4 0.07 +1.3, +1.5 <0.001 
Smoking(1) +0.03 0.01 +0.01, +0.05 0.02 
Alcohol(1) -0.01 0.02 -0.05, +0.03 0.7 
Activity(1) -0.06 0.01 -0.08, -0.04 <0.001 
Male(1) +0.016 0.014 -0.01, +0.04 0.3 
Log10 TSH (mU/L) -0.04 0.04 -0.12, +0.04 0.2 
T3 (pmol/L) +0.02 0.01 -3 x 10-3, 0.05 0.09 
T4 (pmol/L) +0.004 0.004 -0.04, +0.12 0.4 
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5.5  Fasting Glucose  
The study subjects excluded from this analysis were diabetics treated with insulin (n=5) or on 
oral hypoglycaemic agents (n=3).  In addition I excluded one subject with probable newly 
diagnosed diabetes (fasting glucose (f-glucose) 11mmol/L (Diabetes ≥7mmol/L). 
 
The MRA to evaluate the f-glucose associations (data not shown) did not demonstrate 
correlations with TFT components, TPO status or the thyroid genetic parameters assessed (Rs 
<0.02, p-values >0.16). As expected, f-glucose correlated positively with BMI (or WHR or %BF 
when these parameters were substituted into the equation).   
 
5.6 Insulin resistance: HOMA-IR 
HOMA-IR is a non-invasive method to estimate insulin resistance using fasting insulin and 
glucose values. It is commonly used in clinical research settings.  The calculation for HOMA-IR 
is shown below; 
 
HOMA-IR = glucose (mmol/L) x Insulin (mU/L)/ 22.5 
 
HOMA-IR was log transformed prior to MRA evaluation to normalise the data.  
The HOMA-IR MRA was initially evaluated against TPO positivity, FOXE1(14) status, TSHR-M 
and polymorphism status (D727E & P52T).  However, as these parameters did not associate 
with HOMA-IR to any extent (Rs <0.007, p-values >0.3), for simplicity (and to avoid type 1 
errors) they are not included in the MRA below.  Similarly, alcohol intake and smoking status 
showed no associations and are not included. 
HOMA-IR was evaluated against BMI, activity status, male gender, TSH, T3 and T4 values (as 
shown below).  The relationship between these predictors and HOMA-IR is provided in table 
5.5. 
 
Log10 HOMA-IR = -3.5 + 2.3Log10BMI - 0.2Activity(1) + 0.1Male(1) - 0.02Log10 TSH + 0.1T3 - 
3X10-3T4     
N = 196,  R2 = 38% 
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Table 5.5:  MRA evaluating HOMA-IR against the predictors listed 
 Predictor R SE coefficient 95% C.I p-value 
Constant -3.5 0.5 -2.5, -4.5 <0.001 
Log10BMI +2.3 0.3 +1.7, +2.9 <0.001 
Activity(1) -0.2 0.05 -0.1, -0.3 <0.001 
Male(1) +0.1 0.06 -0.02, +0.2 0.05 
Log10 TSH (mU/L) -0.02 0.15 -0.3, +0.3 0.9 
T3 (pmol/L) +0.1 0.06 -0.02, +0.2 0.05 
T4 (pmol/L) -3x10-3 0.02 -0.04, +0.04 0.9 
Table 5.5 provides the regression coefficients (R), standard errors (SE), 95% confidence interval (C.I) 
and p-values for each predictor evaluated in the HOMA-IR MRA. The minus (-) or plus signs (+) 
indicate the direction of the association.  
 
The HOMA-IR MRA suggests T3 as the only thyroid parameter that may correlate although its 
positive association is small, and p-value of borderline significance (R +0.1, p-value 0.05).  
In regard to the lifestyle and personal characteristics evaluated against HOMA-IR, BMI 
associates positively, and activity associates negatively (both are as expected).  
When WHR was substituted in place of BMI (with T4 removed as it showed no association) 
the correlations were similar although the association with T3 was now significant (R +0.2, p-
value 0.006 (See Appendix 7, Table 5). 
The relationship between T3 and HOMA-IR was explored in a parsimonious stepwise 
regression analysis shown in Model 5.3.  This supports the observation that T3 correlates 
positively with HOMA-IR.   
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Model 5.3:   Stepwise regression model exploring the association between HOMA-IR and 
T3; assessed singularly and subsequently adjusted for confounders. 
 
 
N    R   95%C.I.  p-value 
Step 1; crude (against T3 only) 
199   +0.2   (+0.06, +0.3)  0.003   
Step 2; Step 1 adjusted for WHR 
197   +0.12        (+0.02, +0.2)  0.03   
Step 3; Step 2 adjusted for activity 
197   +0.13   (+0.03, +0.2)  0.016   
Step 4; Step 3 adjusted for male sex 
197   +0.15   (+0.04, +0.2)  0.01  
   
Step 5; Step 4 adjusted for TSH 
197   +0.14   (+0.04, +0.2)  0.007  
Step 6; Step 5 adjusted for TPO, TSHR-M, FOXE1, smoking & alcohol status 
192   +0.17   (+0.05, +0.29)  0.003 
 
Model 5.3 details the number of subjects in the analysis (N), the correlation coefficient (R) between 
Log10HOMA-IR and T3, its associated 95% C.I and p-value for each step. The minus (-) or plus sign (+) 
indicate the direction of the association. 
 
 
5.7 Lipids 
 
In regard to cardiovascular risk parameters (generally applicable to higher risk individuals), an 
elevated LDL cholesterol is considered an adverse risk predictor (reflecting transfer of 
cholesterol to the body), whilst HDL cholesterol is considered protective (reverse transports 
cholesterol back to the liver).  
The Total Cholesterol (TC) to HDL cholesterol ratio (TC/ HDL) is commonly reported in a lipid 
profile.  An adverse ratio (variably considered >4.5) is another adverse risk predictor that is 
considered to be a better risk predictor than individual lipid components (Millán et al 2009). 
Triglycerides (Tg) are associated with obesity, the metabolic syndrome, and are inversely 
associated with HDL. However, their independent influence on cardiovascular outcomes 
remains unclear (Miller et al 2011).  
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5.7.1 LDL Cholesterol 
 
The MRA evaluating LDL did not show associations with TFT components, TPO status or the 
thyroid genetic data (TSHR-M or polymorphism status or FOXE1(14) status).  In addition, 
lifestyle factors (activity status or any of my measure of adiposity) did not show associations.  
The LDL MRA with its corresponding table are provided in Appendix 7, Table 6.  
 
5.7.2  HDL Cholesterol 
 
The MRA evaluating HDL cholesterol did not show associations with; TFT components, TPO 
status or the genetic data.  
 
The associations revealed were as follows: 
• A negative association with BMI (R minus 0.1, p-value 0.008) 
• A positive association with activity (R +0.03, p-value 0.001) 
• A negative association with male sex (R minus 0.05, p-value <0.001). 
 
The MRA for this analysis is provided in Appendix 7, Table 7.  
 
5.7.3 Total Cholesterol to HDL ratio 
 
The MRA evaluating the TC: HDL did not show associations with the TFT components, TPO 
antibody status or the genetic data. 
 
The personal and lifestyle factors that showed a positive association were:  
 BMI (R +0.35, p-value< 0.001) 
 Male sex (R +0.06, p-value 0.005) 
 
The MRA for this analysis is provided in Appendix 7 Table 8.  
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5.7.4 Triglycerides  
 
The triglyceride (Tg) MRA was initially evaluated against TPO antibody status, the genetic 
data, alcohol and smoking status.  However, as these parameters did not associate with Tg to 
any extent they are not included in the MRA below.  
 
The Tg MRA was evaluated against activity status, male gender, BMI, T3, TSH, and T4 as shown 
below.  The relationship between these predictors and Tg is provided in Table 5.6. 
 
Log10Tg = -1 - 0.06Activity(1) + 0.04 Male(1) + 0.6 Log10BMI + 0.08T3 + 0.003 
Log10TSH - 2x10-3 T4           
N=204  R2 = 17%  
 
 
Table 5.6: MRA evaluating triglycerides against the predictors listed  
Predictor R SE coefficient 95% C.I p-value 
Constant -1 0.3 -1.6, -0.4,  <0.001 
Activity(1) -0.06 0.03 -0.12, -1x10-3 0.04 
Male(1)  +0.04 0.03 -0.02, +0.1 0.3 
Log10BMI +0.6 0.2 +0.2, +1 0.001 
T3 (pmol/L)  +0.08 0.03 +0.02, +0.14 0.01 
Log10TSH (mU/L)  -3x10-3 0.09 -0.17, +0.18 1.0 
T4 (pmol/L) -2x10-3 0.01 -0.02, +0.02 0.9 
Table 5.6 provides the regression coefficients (R), standard errors (SE), 95% confidence intervals (C.I) 
and p-values for each predictor variable evaluated in the Tg MRA. The minus (-) or plus sign (+) 
indicate the direction of the association. 
 
 
The Tg MRA revealed the following associations: 
 A small positive association with T3 (R +0.08, p-value 0.01); this was the only thyroid 
parameter to show an association. 
 Of the lifestyle and personal characteristics, BMI correlated positively (R +0.6, p-value 
0.001) and activity correlated negatively (R-0.06, p-value 0.04) as expected.  
 
I subsequently evaluated the relationship between T3 and Tg further using a stepwise 
parsimonious regression model (Model 5.4).  
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Model 5.4:  Stepwise regression model exploring the relationship between triglycerides 
and T3; assessed singularly and subsequently adjusted for confounders 
 
N   R       95% C.I   p-value 
Step 1; crude (against T3 only) 
205   +0.11   (+0.05, +0.17)   <0.001 
Step 2; step 1 adjusted for Log10BMI 
204   +0.09   (+0.03, +0.15)   0.003 
Step 3; step 2 adjusted for male sex 
204   +0.08   (+0.02, +0.14)   0.005 
Step 4; step 3 adjusted for Log10TSH and T4 
204   +0.08   (+0.02, +0.15)   0.01 
Model 5.4 details the number of subjects in the analysis (N), the regression coefficient between 
log10triglyceride and T3, its associated 95% confidence interval (C.I) and p-value for each step. The plus 
sign (+) and minus (-) signs indicates the direction of the association. 
 
 
5.8 Discussion 
 
This chapter explored the association between metabolic parameters (measured in my SH 
cohort) and TFT components, the genetic characteristics of subjects (TSHR-M status, TSHR 
polymorphism status, and FOXE1 PTL polymorphism status) and their TPO antibody status.  
These analyses identified a number of interesting associations. 
The evaluations on blood pressure (BP) as the outcome variable revealed a positive 
association between systolic BP and T3, but no relationships with TSH or T4.  This is consistent 
with the recognised association between hyperthyroidism and systolic hypertension (Prisant 
et al 2006), thought to be T3-mediated.  However, this relationship has not been previously 
described in an SH cohort.  This observation suggests that any tendency to hypertension in 
SH subjects (inconsistently described in some studies (Cai et al 2011)) may be T3-driven.  The 
absence of an association between TSH and BP (even after removing T4 and then T3 from the 
analysis) suggests that this is not related to TSH (despite the weak positive association 
between T3 and TSH revealed across the cohort; Figure 3.18).  
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Given the positive association between TSH and T3 (and an inverse association between T4 
and T3) across this cohort, I hypothesise that thyroxine initiation to correct SH might also 
reduce T3.  Remarkably, the effect of thyroxine initiation (in SH) on T3 levels (though 
described to be within population norms) has not been studied.  In fact, monitoring of T3 in 
these subjects is not advised (American Association of Clinical Endocrinologists and American 
Thyroid Association Taskforce on Hypothyroidism in Adults 2012 (Garber et al 2012)).  It is 
recognised that a falling T4 (in progressive SH) upregulates T4 to T3 conversion peripherally 
(Lum et al 1984) which might explain this observation.  If true, one would anticipate a 
potential decline in BP (dependent on degree of SH, and a subject’s tendency to hypertension) 
as SH is corrected with thyroxine, and a potential adverse BP effect related to treating 
hypothyroidism or SH with T3.  However, where T3 replacement therapy has been used (+/-
T4) and evaluated in healthy hypothyroid subjects (in extremely small numbers and over short 
time periods) an adverse BP effect was not reported (Bunevicius et al 1999).  
My analyses revealed a surprising negative association between BP and the homozygous 
FOXE1 PTL 14 polymorphism (versus other PTL combinations).  I previously identified that this 
genotype was associated with higher T3 values for an equivalent TSH (Model 3.2).  If this was 
simply T3-mediated I would predict a higher and not a lower BP in this group.  When I review 
stepwise regression model 5.2 it is apparent that the negative association with FOXE1(14) and 
BP becomes more apparent when T3 is added into the model.  Given that the homozygous 14 
PTL genotype is the prevalent and normal genotype, it is rather the case that alternative 
genotypes have lower T3s (relative to TSH) and may be less tolerant to the systemic vascular 
effects of T3 (as reflected in BP).  It would therefore be interesting to explore FOXE1 PTL 
polymorphism frequencies according to tolerance (or otherwise) of the systemic effects of 
hyperthyroidism, and also to explore their prevalences in matched hypertensive versus 
normotensive cohorts.  
The FOXE1 gene plays a vital role in thyroid morphogenesis and influences the transcription 
of thyroglobulin and thyroid peroxidase (Francis-Lang et al 1992).  Bullock et al (2012) 
reported higher transcriptional activity of the FOXE1 14 PTL polymorphism versus the 16, 
potentially explaining functional differences between these common polymorphisms.  The 
FOXE1 gene is also expressed in a number of extra-thyroidal tissues that include the central 
nervous system and liver (Genecards human gene database; FOXE1 (www.genecards.org)).  It 
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is therefore feasible that subtly altered FOXE1 function in either or both these sites could also 
be behind this observation.   
Comparative observations evaluating cardiovascular risk parameters according to TPO 
antibody status indicated a higher score amongst TPO negative (versus positive) subjects 
(Table 5.2).  However, subsequent MRAs indicate that this difference was attributable to 
differing characteristics of the groups (comorbidities, lifestyle and personal characteristics 
and) and did not relate to TPO status per se. 
My analyses did not identify associations between TFT parameters and any of the measures 
of adiposity used in this study (BMI, WHR or %BF).  Therefore my observations do not support 
an association between adiposity and TSH that has been suggested in some studies (though 
these associations tend to have been reported across euthyroid cohorts (Mehran et al 2012, 
Nyrnes et al 2006)).   
The fasting glucose MRAs revealed no associations with the thyroid parameters assessed. 
However, the HOMA-IR analysis showed a small positive association with T3 (Model 5.3).  An 
association between insulin resistance and T3 is recognised (Bakker et al 1999) though 
appreciated in the context of hyperthyroidism (Chu et al 2011).  This association between T3 
and HOMA-IR has not been previously observed within an SH cohort.  No association between 
HOMA-IR and TSH was revealed. 
My analyses evaluating the lipid profile (TC, LDL and HDL cholesterol values) did not reveal 
associations with the TFT components or the genetic parameters evaluated in this study.  This 
would support the notion that mild SH (TSH <10mU/L) does not influence cholesterol values 
appreciably (Vierhapper et al 2000, Hueston & Pearson 2004).  However, this remains an area 
of contention (Pearce 2012).  
The triglyceride evaluations revealed a small unexpected positive association with T3, but no 
associations with T4, TSH or the genetic parameters evaluated.  I found this association 
described in one previous study that evaluated elderly subjects with no history of thyroid 
diseases (Maugeri et al 1999).  A rise in triglycerides has been described in hyperthyroid and 
hypothyroid subjects relative to euthyroid controls (Nikkilä & Kekki 1972).  This positive T3-
triglyceride association has not been previously described in an SH cohort.  
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In conclusion, my analyses revealed a positive association between T3 and systolic BP, HOMA-
IR, and triglycerides across this SH cohort.  My genetic analyses identified an unexpected 
negative association between the FOXE114/14 polymorphism and blood pressure which 
warrants further investigation.  TPO antibody status, TSH and T4 values did not associate with 
any of the metabolic parameters assessed in this cohort and are therefore unlikely to have 
clinically significant independent metabolic (non-bone) effects in this context. 
These findings would suggest that alterations in T3 or T3 sensitivity may be behind the 
adverse metabolic parameters reported, albeit inconsistently, in the context of SH.  There 
were no independent metabolic parameter - TSH associations demonstrated in this study. 
 
The limitations of this study that are of relevance to this chapter are detailed in the closing 
chapter. 
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CHAPTER 6:  STUDY OVERVIEW AND CONCLUSIONS 
Subclinical Hypothyroidism (SH) has remained a popular subject for research since its 
definition and description in 1973 (Hall & Evered 1973).  The clinical management 
recommendations for hyper and hypothyroidism advocate its treatment and correction in all 
cases, whereas the recommendations relating to the subclinical thyroid diseases (ScTD) are 
much less specific.  Recent guidelines advice treating and correcting persistent SH routinely 
when the TSH exceeds 10mU/L in subjects less than 65 years of age (Pearce et al 2013; ETA 
Guidelines).  This is primarily to avoid future morbidity related to progression of SH to 
hypothyroidism though there may also be metabolic benefits on lipids (Caraccio et al 2002, 
Razvi et al 2007) and endothelial function (Cabral et al 2011) from correcting SH.  The merit 
of treating SH at lower TSH thresholds remains uncertain.  These guidelines also advocate a 
trial of thyroxine replacement therapy (TRT) in subjects symptomatic of SH (despite TSH 
<10mU/L) with continuation of TRT in those describing symptomatic benefit (Pearce et al 
2013). 
 
There is ample data linking suppressed TSH in subclinical hyperthyroidism (Shyper) to 
accelerated bone loss (Faber et al 1998, Mudde et al 1994), particularly in post-menopausal 
women. Specialty guidelines support this statement by advocating the treatment and 
correction of Shyper in subjects’ ≥65 years of age and those with osteoporosis (American 
Thyroid Association & American Association of Clinical Endocrinologists in Bahn et al 2011). 
 
As reiterated throughout this thesis; the bone health and metabolism data in SH is 
inconsistent and even contradictory across studies.  However, most studies suggest beneficial 
bone mineral density (BMD) associations relating to a rise in TSH (the inverse of Shyper).  The 
specialty guidelines reflect this uncertainty by refraining from making bone related 
recommendations regarding the clinical management of SH.  
 
SH is often considered to be a uniform condition which as explained throughout this thesis is 
not the case. It may be that its clinical implications are in fact cause specific.  It is recognised 
for example that the rate of progression from SH to hypothyroidism (though not inevitable) 
is higher in subjects with thyroid autoimmunity (Vanderpump et al 1995).  However, in 
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general, the clinical guidelines do not differentiate cause of SH when recommending on its 
management. 
 
The landmark paper by Abe et al (2003) was instrumental in my decision to explore bone 
parameters (BMD and bone turnover markers (BTMs)) in treatment naïve SH subjects and to 
relate this to aetiology (heterozygous TSHR mutations (TSH-M) versus normal sequence 
subjects, and thyroid autoimmunity versus other causes).  The Abe et al group linked 
accelerated bone loss and low BMD in general (alongside focal areas of osteosclerosis) with 
TSH receptor (TSHR) insufficiency in their genetically modified mice.  This was in spite of 
normal free thyroid hormone values (FTHs) in animals heterozygous for TSHR insufficiency 
(with SH) or normalisation of FTHs (through TRT) in animals lacking TSHR (who are otherwise 
hypothyroid).  This group described TSH as a negative regulator of bone remodelling with 
inhibitory effects demonstrated on osteoblasts and osteoclasts.  They believed that their 
observations indicated a direct role for TSHR signalling in bone.  
 
I assumed that by evaluating bone-related parameters in human subjects heterozygous for 
inactivating TSHR-Ms (genetically similar to heterozygous TSHR knockdown mice) this might 
add helpful human observational data to this work. 
 
On planning this project I anticipated that subjects heterozygous for inactivated TSHR-Ms 
would reside predominantly in SH cohorts (rather than euthyroid or hypothyroid cohorts 
(Cassio et al 2013).  I also anticipated that subjects bearing TSHR-Ms would be seronegative 
for thyroid autoantibodies (in the main), as the mechanism for their SH is not autoimmunity 
(Alberti et al 2002).  As such I set out to recruit a cohort of treatment naïve SH subjects with 
primary endogenous SH, and to screen all participants for TSHR-Ms (expected to be 
inactivating mutations in this context).  Treatment naive subjects with primary SH were 
recruited to avoid a confounding effect on metabolic and bone parameters relating to 
medication use (including TRT) or another disease process (including a history of 
thyrotoxicosis).  
 
Studies that evaluated the prevalence of heterozygous TSHR-Ms (primarily in paediatric 
cohorts) report a prevalence of ~1:10 amongst TPO negative subjects (Camilot et al 2005, 
Tonacchera et al 2004).  One paper on adults with non-autoimmune SH and variably raised 
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TSH (6.6-46mU/L) identified mutations in 4 of 10 subjects, 8 with familial SH (Alberti et al 
2002).  
 
The SH literature indicated that I might reveal thyroid autoimmunity in between 40% (Surks 
& Hollowell 2007) and 80% (Allan et al 2000) of SH subjects.  Thus, assuming that ~60% would 
be seropositive this would predict identifying ~4 mutation bearing subjects per 100 recruited 
to the study.  It was therefore evident at the planning stage of this project (when anticipated 
recruitment was ~350), that I was unlikely to have enough mutation subjects to enable 
meaningful evaluation of their bone parameters.  However, I expected to have sufficient 
numbers to make evaluations according to their TPO antibody status.  
 
In recent years it has been identified that many subjects residing from areas traditionally 
considered to be iodine sufficient (such as the UK) are not iodine sufficient (Vanderpump et 
al 2011, Bath et al 2014).  Whilst iodine sufficiency is associated with thyroid autoimmunity, 
iodine insufficiency is not (Teng et al 2011).  Consequently I chose to evaluate the iodine 
status of my participants retrospectively.  This was not part of the prespecified study protocol. 
 
The primary objectives of this SH study were as follows; 
 
1. To determine the prevalence of heterozygous TSHR-Ms in an adult cohort residing in 
the Cardiff area. 
 
2. To evaluate bone parameters (DXA Z-scores at hip and lumbar spine (LS) and BTMs) in 
TSHR-M subjects versus normal sequence counterparts (albeit within the limitation of 
low subject numbers).  
 
3. To evaluate bone parameters in TPO antibody positive versus negative subjects.  
 
4. To evaluate bone parameters alongside individual TFT-components, with a particular 
interest in TSH.  
 
Denaturing High Performance Liquid Chromatography (dHPLC) was the genetic screening tool 
used to identify subjects bearing TSHR-Ms.  Participants were screened across all 10 TSHR 
exons and anomalous dHPLC waveforms were followed up with direct DNA sequencing.  This 
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identified TSHR sequence variants including TSHR polymorphisms and TSHR-Ms.  Given the 
academic interest in the TSHR D727E polymorphism (in particular) and its suggested influence 
on TFTs (Gabriel et al 1999) and BMD (Van der Deure et al 2008, Liu et al 2012); I chose to 
evaluate bone parameters in D727E subjects in a similar way to the mutation subjects. 
 
Study participants had their FOXE1 polyalanine tract length (PTL) polymorphism status 
determined.  The FOXE1 gene is involved in thyroid gland (TG) morphogenesis and mutations 
in this gene lead to Bamforth-Lazarus syndrome (thyroid agenesis, and cleft lip amongst other 
syndromic features (Bamforth et al 1989).  Although FOXE1 PTL polymorphisms have not been 
evaluated in a dedicated SH cohort previously, FOXE1 polymorphisms are associated with 
alterations in TSH values (Gudmundsson et al 2009, Taylor et al 2015).  I therefore wished to 
see if FOXE1 PTL polymorphism TFT-component associations would be revealed in this cohort.  
This particular study objective was added in to the study while recruitment was underway 
and was not part of the study protocol. 
 
A range of metabolic measurements were recorded on study participants at the time of their 
study attendance.  This included TFTs, fasting glucose, lipids, blood pressure (BP) and 
morphometric measurements.  Serum BTMs were evaluated on every participant and a DXA 
bone scan arranged.  
 
These data enable anthropometric, bone (BMD-DXA scores and BTMs) and metabolic 
parameters to be evaluated according to subject TFT-components, TSHR-M status, TPO 
antibody status and FOXE1 PTL polymorphism status.  
 
The secondary objectives of the study were as follows: 
 
a) To describe the observational and descriptive characteristics of the cohort (including 
TPO autoantibody status, TFTs and change in TFTs relative to the initial bloods as well 
as determine the iodine sufficiency status). 
 
b) Characterise the cohort according to: 
- TSHR-M or polymorphism status 
- FOXE1 PTL polymorphism status 
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c) Evaluate body composition components (BMD, adiposity) and metabolic parameters 
according to: 
- TPO autoantibody status 
- TSHR-M or polymorphism status 
- FOXE1 PTL polymorphism status 
- TFT-components 
-  
 
Two hundred and eight adults with primary, treatment naïve SH have been recruited and 
evaluated in this study.  The primary objectives of the study were met and reveal the following 
observations:- 
 
1. The prevalence of heterozygous TSHR-Ms was ~1:10 amongst TPO negative subjects, 
and 1:18 within the cohort. 
 
I identified TSHR-Ms in 12 study participants.  The prevalent mutation in this cohort was the 
W546X, identified in 7 subjects.  Previous research from our unit revealed this mutation in 
1:180 healthy blood donors (Jordan et al 2003) revealing a prevalence 6 times higher in this 
cohort.  
 
I identified 3 known mutations (W546X, R531W and P162A) and 2 novel mutations. The novel 
mutations are the Y195C and W488X (in two participants).  
 
The association between TPO seronegativity and TSHR-M status was supported in this study.  
Eleven of the twelve subjects were TPO antibody negative and one had low measureable 
antibodies (W488X; TPO antibody titre 60 [range <6 to >1000IU/ml]).  
 
T3 values were lower (relative to TSH and T4) in the TSHR-M group relative to other subjects.  
A degree of TSHR resistance imposed by the mutation is expected (Tenenbaum-Rakover 
2012).  Potential explanations for this observation are a negative impact on thyroidal T3 
synthesis and/ or reduced peripheral D2 deiodinase activity reducing T4 to T3 conversion.   
Upregulated DI02 in response to TSH activation is described in skeletal muscle (Hosoi et al 
1999), rat brown fat (BAT) (Murakami et al 2001a) and thyroid tissue (Murakami et al 2001b).  
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2. No association between TSHR-M status and bone parameters were revealed. 
However, the study was insufficiently powered to be confident in this observation. 
 
Although I do not reveal associations between TSHR-M status and bone parameters in this 
study this does not rule out an effect (albeit if present it is likely to be small and not of clinical 
relevance).  Indeed there are a few considerations worthy of comment. 
 
Firstly given that I observe a negative association between BMD and T3 (across the cohort) 
and TSH-M subjects appear to have inherently lower T3 (relative to TSH); a positive BMD 
correlation might have been expected.  However, if this is being offset by a direct negative 
BMD effect from TSHR-M status, then this would support Abe et al’s (2003) conclusions 
associating lower BMD values with TSHR insufficiency.    
 
An alternative perspective is that the negative association between TSH and BMD across the 
cohort reflects an indirect TSH - BMD effect that is independent of TSHR-M status (potentially 
explaining the absence of an association between TSHR-M status and BMD DXA scores).  
 
 
3. A negative association between TPO antibody seropositivity and BMD at the lumbar 
spine (LS) was revealed.  
 
This association between BMD and TPO antibody positivity is interesting as it implies that the 
aetiology of SH is important in regard to its clinical implications.  This could be the 
consequence of inflammatory mediators stemming from the TG (the site of autoimmune 
injury in ATD) enhancing bone resorption distally in the spine.  This mechanism is proposed 
to explain enhanced bone loss in inflammatory conditions including the spondylarthritides 
(Akgöl et al 2014) and Crohn’s disease (Klaus et al 2002). Given that the trabecular to cortical 
bone ratio is higher in vertebrae than hip, and trabecular bone has a higher basal metabolic 
rate (Clarke 2008) and surface area to mass ratio (Watts 1999). This offers a potential 
mechanism contributing to the negative relationship observed between DXA Z-score and TPO 
antibody positivity at the LS specifically.  
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4. Independent negative associations between TSH and DXA Z-score at the LS, and 
between T3 and DXA Z-score at the hip and LS were observed. 
 
A negative relationship between T3 and BMD is well recognised however this is in the context 
of hyperthyroidism (Lee & Ananthakrishnan 2011) or Shyper, particularly in postmenopausal 
women (Faber et al 1998, Mudde et al 1994, Bahn et al 2011), but not in SH.  What is equally 
interesting is a positive T3 - TSH relationship revealed across this cohort which is contrary to 
traditional thinking.  
 
My data suggests that a rise in T3 (which could be accompanied by increased sensitivity to T3) 
may be contributing to adverse bone effects in SH.  This may relate to altered deiodinase 
enzyme activities (in the thyroid or peripheries), that might be TSH mediated (Hosoi et al 
1999, Murakami et al 2001a and 2001b).  The negative BMD - T3 association observed across 
the cohort suggests that changes to FTHs, even within normal population reference ranges 
may mediate functional effects. 
 
The inverse association between TSH and BMD at LS supports the notion that TSH has adverse 
effects on BMD in the context of SH (Lee et al 2006, Lee et al 2010, Polovina et al 2013, Liang 
et al 2014).  The fact that that my data reveals adverse independent TSH associations at LS 
but not hip could relate to the differing proportions of trabecular to cortical bone at these 
sites. Though perhaps, more plausibly there may be enhanced TSHR expression +/- sensitivity 
+/- potency of effect in the vertebrae versus the hip; potentially explaining this observation.  
 
It is interesting that the BMD associations revealed across the cohort did not correlate with 
BTM associations.  Possible explanations for this were discussed in section 4.9.4. 
 
A negative association between male sex and BMD at hip and LS was observed (Appendix 6, 
Model 3).  Given that testosterone is expected to have a protective effect on BMD (Baran et 
al 1978) and is not expected to potentiate TSH or T3 mediated effects, the explanation for 
this is obscure.  However testosterone levels were not assessed in this study and therefore a 
confounding effect from altered testosterone levels cannot be ruled out.  However it is 
interesting that Lee et al (2010) reported incident hip fracture rates to be elevated in older 
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(≥65 years) US men with SH (Hazard ratio 2.3 (95% CI 1.25-4.27) but not women.  Nonetheless, 
this observation was unexpected and requires verification and investigation in future studies. 
 
The secondary objectives of the study were met and revealed the following observations:  
 
a) Observational data on the cohort 
Three quarters of the cohort were female, age distribution showed a negative skew, and 50% 
were TPO autoantibody positive.  These observations were consistent with expectations in SH 
(Tunbridge et al 1977, Fatourechi 2009).  The iodine status of the cohort was described as 
mildly deficient (World Health Organisation 2007) supporting recent data identifying iodine 
insufficiency in regions traditionally considered iodine sufficient (Vanderpump et al 2011). My 
assessment of individual’s iodine status (see figure 3.6 and content of pg 78) suggest that 
iodine excess or deficiency may have caused SH in those cases. However, Iodine status did 
not correlate with TSH levels or TPO antibody status in this cohort.  
 
The TSH fell on retesting in three quarters of the cohort, and back into the reference range 
(<5mU/L) in just under half.  This phenomenon is described for newly identified SH (Diez & 
Iglesias 2009).  However, TSH remained above 3mU/L in 90% and many experts consider a 
TSH <2.5mU/L to be a true normal (Wartofsky & Dickey 2005).  T4 fluctuations on re-testing 
were much more modest.  An expected negative association between T4 and TSH was 
revealed (Hoermann et al 2010), along with the unexpected T3 - TSH relationship (discussed).  
 
Progression of SH to a TSH ≥10mU/L (standard criteria for TRT) occurred in 10% of TPO 
positive subjects versus 2% of TPO negative subjects.  Progression of SH was found to 
correlate with TPO antibody titre (Figure 3.13). Both of these associations are recognised 
(Vanderpump et al 2005, Zhang Y et al 2010 consecutively).  
 
b) The TSHR polymorphism D727E was identified in 4% of the cohort and an association 
with TPO seronegativity was revealed.  
 
The FOXE1 14/14 polyalanine tract length (PTL) polymorphism was identified as the 
most prevalent genotype, whilst the 14/16 was revealed in approximately a third. A 
positive association between the 14/14 polymorphism and T3 was revealed.  
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The prevalence of the D727E polymorphism is less than that reported in control cohorts (10-
16% prevalence described; Matakidou et al 2004, Mühlberg et al 2000 respectively).  This 
could possibly reflect its association with lower TSH values (Hansen et al 2007), variably 
described.  The association I observe with seronegatively was unexpected and could indicate 
a linked gene effect.  Interestingly an association with FOXE1 PTL14/16 status was revealed.  
However, low subject numbers (n=9) limits my confidence in any of these observations. 
 
The association between FOXE1 PTL status and TFTs indicates that this polymorphism may 
have functional relevance (presumably exerted in the thyroid gland where it influences the 
transcription of thyroglobulin and TPO (Francis-Lang et al 1992)).  Indeed reduced 
transcriptional activity in the 14/16 relative to the 14/14 genotype is described (Martyn 
Bullock 2007, Bullock et al 2012), and may be relevant to this observation. 
 
 
c) TPO antibody positivity associated negatively with BMD at LS.  No independent 
associations with adiposity or any of the cardiometabolic parameters evaluated in 
the study were revealed. 
 
TSHR-M status did not correlate with alterations in body composition components 
or cardiometabolic parameters (although low subject numbers are a limitation). 
 
TSHR D727E polymorphism status associated negatively with BMD at LS (on selective 
matching analysis).  Although low subject numbers are a limitation. 
 
FOXE1 PTL polymorphism status did not show BMD or adiposity associations.  
However, an unexpected negative association between the 14/14 polymorphism 
and blood pressure (BP) was revealed. 
 
TSH did not show independent associations with adiposity or any of the 
cardiometabolic risk parameters assessed in this study and neither did T4. Positive 
associations between T3 and BP, and T3 and HOMA-IR were revealed. 
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Autoimmunity is associated with inflammation which in turn is associated with endothelial 
dysfunction (a factor in the pathogenesis of atherosclerosis (Steyers & Miller 2014).  However 
my small study did not reveal independent associations between TPO antibody positivity and 
any of the cardiometabolic-risk parameters assessed.  
 
TSHR-Ms have not been associated with altered adiposity or cardiometabolic-risk parameters 
previously.  Given that TSHR-Ms are associated with a degree of functional TSHR resistance, 
presumably overcome by an appropriate rise in TSH; metabolic effects relating to TSHR-M 
status may not have been expected.  
 
The negative association between the D727E polymorphism and LS BMD supports the 
observations of liu et al (2012) who reported a higher prevalence of this polymorphism 
amongst osteoporotic Chinese men versus their non-osteoporotic controls.  However, other 
studies are contradictory (Van der Deure et al 2008).  Clearly this observation requires 
verification with much larger subject numbers.  
 
The negative association between the FOXE1 PTL14/14 polymorphism and BP is interesting and 
independent of its T3 association.  I hypothesis that as this group have higher T3s relative to 
‘other’ genotypes they may be better adapted in the vascular effects of T3, as reflected in this 
BP association.  This effect could relate to FOXE1 expression in the nervous system +/- liver 
(based on mRNA extraction from these sources (Genecards human gene database; FOXE1 
(www.genecards.org)) thereby affecting vascular tone. However, this observation was 
unexpected and warrants further investigation. 
 
TSH did not show independent associations with adiposity or any of the metabolic parameters 
assessed in this study.  Given that the majority of subjects in my cohort had TSH levels 
<10mU/L at study participation (95%); these observations potentially support the notion that 
with a TSH <10mU/L there is unlikely to be a clinically significant effect on metabolic 
parameters for the majority of subjects (Parle et al 1992, Geul et al 1993, Villar et al 2007, 
Garin et al 2014, Ye et al 2014, Walsh et al 2006).  However, the cross sectional nature of this 
study is not designed to adequately address this question. 
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Interestingly a positive association between T3 and; HOMA-IR and BP was revealed.  These 
associations are recognised in hyperthyroidism (insulin resistance; Maratou et al 2009, 
hypertension; Danzi & Klein 2003), and have even been reported in euthyroidism (Bakker et 
al 1999) but are not described in SH.  This again suggests that FTH variance within the normal 
reference range may be important.  
 
These observations might suggest that adverse cardiometabolic associations that are often 
reported in SH (Serter et al 2004, Iqbal et al 2006, Ochs et al 2008, Teixeira et al 2008, Rodondi 
et al 2010) may be the consequence of a relative rise in T3 (+/-altered T3 sensitivity) rather 
than relate to altered TSH or T4 levels.  
 
6.1 Summary and the future direction of the study 
 
This SH project is the largest of its kind to evaluate TSHR-M status in an adult cohort, and to 
evaluate this alongside full thyroid function parameters, TPO antibody status and a range of 
metabolic and bone related parameters.  To my knowledge this is the first study to determine 
FOXE1 PTL polymorphism status in a dedicated SH cohort.  This study has revealed a number 
of interesting observations.  
 
The key observations from this study are as follows: 
 
Triiodothyronine levels are mildly and positively associated with TSH.  This suggests that 
patients with mild SH (TSH <10mU/L) are not in a state of mild hypothyroidism but are 
appropriately compensated, or may even be over compensated from a FTH perspective.  
Interestingly adverse T3 associations were revealed against; BMD, HOMA-IR and BP.  This 
suggests that adverse metabolic associations variably reported in SH may relate to a relative 
rise in free-T3. 
 
Negative BMD associations were revealed against TSH, TPO antibody positivity and male sex.  
These observations suggest that SH may have negative effects on BMD that are more relevant 
to subjects with autoimmune SH, additional risk factors for osteoporosis, and men.  Should 
these observations be verified in future studies then active evaluation of bone health, in these 
groups will be indicated. 
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I suggest that future prospective studies of adequate duration and power are planned to 
evaluate bone parameters in subjects with and without SH, and with and without thyroid 
autoimmunity.  In addition studies to determine whether the natural history of SH (in regard 
to bone health) is altered in the event of its optimum correction (with TRT) are indicated.  
However, the practicality of performing these studies, on the scale required may be difficult.  
 
TSHR-Ms were found to affect 1:10 TPO negative subjects and were found to reside as 
expected, and overwhelmingly in the TPO negative cohort.  A negative association between 
TSHR-M status and T3 was revealed although this did not translate into obvious metabolic or 
BMD associations.  Two novel TSHR-Ms were identified in this study (W488X (in 2 subjects) 
and the Y195C).  
 
The FOXE1 PTL polymorphism data revealed a positive association between the prevalent 
14/14 PTL polymorphism and T3, and an inverse association between this genotype and blood 
pressure.  These observations require verification in future cohort and population studies.   
 
 
6.2 Limitations of the study 
 
 The number of subjects recruited to the study (13% of those identified by the 
department of biochemistry) fell short of those anticipated (208 recruited versus 350 
anticipated) reducing the power of the study to determine its objectives.  
 
 Recruitment was un-randomised creating opportunity for selection bias.  Therefore 
the cohort may be poorly representative of the SH population (i.e. more or less 
diseased, or biasing observations towards or away from the null hypothesis).  
 
The major sources of bias were;-  
- Poor and sporadic GP participation across the region. 
- Subject choice to participate 
 
 The fact that nearly half the subjects recruited to the study had TFTs at study 
attendance within the normal TSH range could be considered a limitation. However 
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this limitation applies to all cross sectional SH studies where correlations are made 
against TFT values taken at a point in time, which indicate SH. 
 
 The heterogeneity of the cohort (i.e. age, comorbidities, lifestyle factors and 
morphometric characteristics) reduces the power of the study to determine 
differences that relate specifically to the parameters of interest. 
 
 As the study design involved a one stop study attendance I am limited in assessing 
trends across the cohort.  Evaluating intra-individual variation with time, or comparing 
observations against a well matched, euthyroid control group would have been a 
more powerful means of exploring these objectives. 
 
 The statistical observations made on this cohort were assessed against TFTs taken at 
the time of study attendance.  The study, by its nature assumes these values are 
representative of the subject’s TFTs over a considerable length of time.  However, a 
substantial change in TSH values (particularly) was commonly seen (Figure 3.15). 
 
 BTMs are known to display wide inter-subject variability thereby limiting their utility 
as a single point assessment tool (Burch et al 2014).  This may explain the absence of 
observed BTM associations in this cohort.  
 
 BP was assessed at a single appointment session and may be poorly representative of 
the subject’s usual BP.  
 
 It is unfortunate that the TFT and TPO assay changed ((from Siemens Centaur to Abbott 
i2000R) after the 139th subject had been recruited to the study.  As the T4, T3 and TPO 
antibody results were not convertible between assays, all former samples were re-
evaluation on the Siemens Centaur assay (from stored and frozen samples).  Instead, 
subject numbers >139 were evaluated fresh on the day of study attendance.  These 
differing conditions surrounding the T4, T3 and TPO antibody assessments may have 
introduced selective error in to the results obtained. 
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 The TSH values on the Siemens Centeur and Abbott Architect i2000R did appear to be 
readily convertible between assays (see Appendix 8). However the fact that only 40 
samples were evaluated to generate the data is a limitation. In addition the conversion 
recommendation between assays is an imprecise estimate. As this conversion was 
only required for subject numbers >139, selective error is introduced in to the TSH 
results obtained. 
 
 The Insulin values (for HOMA-IR evaluation), like the TFTs (in subject numbers <140) 
were assessed from stored and frozen serum that had been in storage for variable 
durations (months to years).  It is likely that degradation of serum may have occurred 
(possibly aggravated by the freeze-thaw process) potentially affecting the reliability of 
these results.  
 
 The lifestyle information recorded at study attendance (I.e. activity levels, alcohol 
intake per week, smoking history) was provided by the subject and may not be exact.  
However, these parameters were categorised into broad groups for evaluation 
(Activity; sedentary versus non-sedentary, Alcohol; abstinent versus non-abstinent, 
Smoking; more than 10 pack year history versus not) reducing subjective error.  
 
 There was a variable delay in the DXA scan being performed post study attendance 
(same day to up to several months later).  However, as BMD is expected to change 
slowly with time (over years) I would not anticipate a detrimental effect relating to 
this arrangement.  DXA values were reported against White, Oriental or Afrocaribbean 
datasets (more ethnic-specific reference data was not available). 
 
 DXA Z-scores were used in this study as a surrogate indicator of bone health and 
fracture risk.  However, BMD is one of many factors affecting fracture risk (i.e. age, 
BMI, balance, strength, co-morbidities, medication and alcohol use etc (Hippisley-Cox 
& Coupland 2009).  The limitation of DXA as a fracture risk tool is exemplified by the 
fact that ~50% of women with vertebral fractures have lumbar BMD in the normal 
range (Kanis et al 2006).  
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 The study was greatly underpowered to determine BMD differences relating to TSHR-
M (n=12) or TSHR D727E polymorphism status (n=7).  This related to their low 
prevalence, wide DXA Z-score standard deviations, and suboptimal cohort 
recruitment.  Thus, to demonstrate a Z-score difference of 0.4 as statistically 
significant on MRA; a cohort of ~580 subjects are required assuming a significance at 
5% and power of 80% (predicts ~30 with the DNA sequence of interest).  
 
 As a consequence of low subject numbers I chose to evaluate the TSHR-M and TSHR 
D727E groups using a case-selected control method.  However, the matching process 
was compromised through having relatively few suitable matches available and was 
un-randomised and vulnerable to selection bias. 
 
 The novel TSHR-Ms that were identified (in 3 of 12 subjects) have not been 
functionally assessed.  The nonsense mutation (W488X x2 subjects) is expected to 
affect function whereas the missense mutation (Y195C) may not.  Thus, although I 
consider these subjects as a unified group for evaluation purposes, functional studies 
on the novel mutations (particularly Y195C) are indicated. 
 
 The original study protocol differed from the actual study performed in several 
respects;-  
a) The original intention was for the TPO +ve subjects to be compared against TSHR 
mutation subjects, as the causes of their SH differed. However, the actual study compared 
the TPO +ve subjects with TPO -ve subjects, and TSHR mutation subjects with normal TSHR 
sequence subjects (as these were considered to be more suitable comparative groups). 
However, this fundamental change to the study design (thereby limiting the application 
of the prespecified study protocol and power calculations) may compromise the study in 
its ability to robustly evaluate its principle objectives.  
b) As there was no pre-specified plan to identify (or evaluate) subjects bearing 
TSHR or FOXE1 PTL polymorphisms; the observations on these sub-groups should be 
considered in hypothesis generation only.  
c) These changes to the study resulted in a greater number of statistical tests being 
performed, thereby increasing the likelihood of type 1 errors occurring.   
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Despite these limitations I feel that this has been a valuable and informative project.  The 
observations I have made will provide a platform for future research; potentially enabling a 
more precise understanding of the physiology, pathophysiology and heterogeneity of SH to 
be made.  
 
I hope that this work might ultimately contribute towards improvements in the clinical care 
of subjects with subclinical hypothyroidism.  
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1. Title: Effects of a single functional TSH receptor on bone metabolism and body composition   
 
2. Introduction 
Subclinical hypothyroidism (SH), defined as an elevated thyroid stimulating hormone (TSH) in 
the presence of normal circulating levels of free thyroxine (T4) and free tri-iodothyronine (T3), 
is a common condition affecting 3-6% of the UK population (1, 2). Most cases have an 
autoimmune basis (chronic lymphocytic thyroiditis) with 50-80% of patients possessing anti-
thyroid peroxidase antibodies (3). In these individuals, SH is frequently a prelude to overt 
hypothyroidism with conversion rates of up to 5% annually, especially in individuals with higher 
levels of TSH (>10mU/l) (4). However, treatment of SH remains controversial, especially for 
individuals with lower degrees of TSH elevation. Although the data are largely consistent for 
modest beneficial effects of thyroxine on the lipid profile, cardiac and vascular function in SH, 
symptomatic benefit is less well established (3) and the effects of SH on bone health have not 
been widely studied. Current recommendations therefore support thyroxine replacement only 
in subjects with higher levels of TSH (>10 mU/l) (5).   
Much recent interest has focused on the effects of TSH on the skeleton and body composition. 
Thyroid hormone excess has long been known to accelerate bone remodelling, leading to 
negative calcium balance and bone loss (6) which, at least in overt thyrotoxicosis, may be 
associated with increased risk of osteoporosis and fractures (7). This has traditionally been 
viewed as a consequence of thyroid hormone action alone, in line with data from some animal 
models which suggest that TSH has little or no bearing on bone turnover (8). However, a 
recent publication has challenged this assertion, indicating that TSH is itself a negative 
regulator of skeletal remodelling (9). The authors produced mice null for the TSH receptor 
(TSHR) and found that even the heterozygotes displayed profound osteoporosis with focal 
osteosclerosis. Subsequent in vitro experiments demonstrated inhibition of osteoclast 
production and survival, combined with inhibition of osteoblast differentiation, by TSH. The 
absence of these mechanisms in the TSHR -/-, and their reduction in TSHR +/- mice, explains 
the phenotype. 
It is not known whether TSH, via its receptor, has a similar action on bone metabolism in 
humans, although recent data from a large population-based study in the Netherlands 
supports an important independent action of TSH on bone mineral density (BMD) (10). In this 
study, BMD at the femoral neck and cortical thickness increased with serum TSH, a response 
only partly driven by increased body mass index (BMI). Furthermore, carriers of a Glu727 
polymorphism in the TSHR, which is associated with higher receptor activity as less TSH is 
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required to maintain normal T4 levels (11), showed a 2.3% increase in femoral neck BMD 
(10). Our own observations in the clinic (unpublished data) of an osteoblastoma on the forearm 
of a child homozygous for the TSHR nonsense mutation W546X (equivalent to TSHR-/- mice), 
is intriguing and adds further weight to the notion that loss of TSHR function may have 
important consequences on bone function in humans.  
We have previously shown that heterozygosity for the W546X variant is common in the local 
general Caucasian population, occurring at an estimated prevalence of 0.5% (12). This 
mutation causes TSH resistance with a biochemical phenotype usually typical of SH, namely 
normal T3 and T4 with elevated TSH (12-14). Screening for germline mutations in the TSHR 
in other populations with SH supports a comparatively high prevalence in the antibody 
negative subgroup, variably estimated at 12-40% (15, 16). These reports indicate that 
possession of a single functional TSHR can cause SH and that an allele producing this 
genotype is common in the UK. This suggests that many SH patients are the equivalent of the 
TSHR +/- mice and are at risk for the development of osteoporosis. If confirmed, this finding 
would not only improve our understanding of the molecular basis for osteoporosis, a disease 
which accounts for over 200,000 fractures and an annual health service cost of £1 billion in 
the UK, but would also have immediate relevance to the management of patients with SH and 
other thyroid disorders. This might include avoidance of thyroxine replacement in antibody-
negative patients with SH found to have a single functioning TSHR, because attempted TSH 
lowering with T4/T3 could further worsen an already lowered BMD.     
 
In light of these observations, we postulate that loss-of-function of a single allele of the TSHR 
is a common cause of SH in the UK but may have important phenotypic differences from 
autoimmune SH in relation to bone physiology. We aim to test this hypothesis in our local 
population.  
 
3. Aims 
1. To determine the proportion of SH due to TSHR heterozygosity by genotyping. 
2. To assess bone metabolism in SH patients expressing one loss-of-function TSHR allele 
and compare it with SH patients who develop autoimmune thyroiditis, using biochemical 
markers of bone turnover and measuring bone mineral density (BMD).  
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4. Investigational Plan 
Study overview 
Patients with de novo SH and no known history of previous thyroid disease or treatment will 
initially be identified via the Department of Medical Biochemistry and invited, via their GP or 
referring physician, to participate in the study. Subjects who indicate a willingness to 
participate and who meet the eligibility criteria will be asked to attend the Clinical Research 
Facility (CRF) at the University Hospital of Wales (UHW) for further review. After obtaining 
consent, pre-menopausal women will be tested for pregnancy (excluded if positive) and all 
patients will undergo simple anthropometric measurements (height, weight, waist 
circumference and standard bioimpedance for assessment of body composition), blood and 
urine testing (stored for later measurement of markers of bone turnover). Blood will also be 
drawn for repeat measurement of thyroid function (free T4, free T3, TSH) and antibody status 
(anti-thyroid peroxidase and thyroid blocking antibodies, TBAB) according to routine clinical 
practice. Subjects will then undergo a standard DEXA scan for measurement of bone mineral 
density (BMD) at the lumbar spine and left hip. The cohort will subsequently be split into two 
groups: those with positive anti-thyroid antibodies (autoimmune thyroiditis; expected to be 
approximately 2/3 of the total) will form the control group while the remaining patient samples 
will undergo TSH receptor (TSHR) genotyping to search for loss-of-function mutations 
(expected to occur at a frequency of ~40% in the antibody negative subjects). Any novel 
mutations will be characterised using established in vitro protocols; allele frequencies will also 
be determined in the antibody positive group. DEXA scores, bone biochemical markers and 
body composition measurements will finally be compared between subjects harbouring one 
mutant TSHR allele (approximately 50 over a two year period) and TPO antibody positive 
controls (~250), with appropriate adjustment for age, gender and BMI. 
 
Study population/inclusion and exclusion criteria 
Patients will be identified via the Biochemistry department at the UHW. A recent audit reported 
that approximately 250 new patients with SH are detected at UHW per annum, once those 
with known thyroid disease or receiving thyroid medication are excluded. Assuming two years 
recruitment and a 70% participation rate we would expect to generate a cohort of ~350 
individuals of whom 2/3 will be TPO antibody positive (control group). The remaining 120 
individuals will undergo TSHR genotyping, of whom we would expect ~40% (50 subjects; 
affected group) to harbour a single functioning TSHR allele (16).  
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Inclusion criteria  
 Male or female patients aged between 18 and 70 years (on screening bloods)  
 Patients with SH as demonstrated by a normal free T4 and elevated TSH (of any 
degree) 
 Patients for whom written informed consent to participate in the study has been 
obtained prior to  any study related activity 
 
Exclusion criteria 
 Subjects aged <18 or >70 years (on screening bloods) 
 Pregnancy and breastfeeding 
 Pre-existing thyroid disease treated with surgery, radioiodine therapy or drugs 
(carbimazole, propylthiouracil, thyroxine or tri-iodothyronine) 
 Metabolic bone disease: hypo/hyperparathyroidism, vitamin D deficiency, Paget’s 
disease 
 Osteoporosis 
 Endocrine disease affecting BMD: Hyperprolactinaemia, Cushing’s syndrome, 
Acromegaly, hypopituitarism (of any degree), hypogonadism 
 Coeliac disease 
 Malabsorption 
 Anorexia nervosa 
 Chronic renal failure 
 Chronic liver disease 
 Cystic Fibrosis 
 Inflammatory bowel disease 
 Currently taking or recent (within 6 months of study entry) exposure to: glucocorticoids, 
androgens, antiandrogens, glitazones, cyclosporin, chemotherapy, anticonvulsants, 
vitamin D or depot contraceptive preparations (e.g. depo-Provera). Women taking oral 
contraceptives or oestrogen replacement therapy will be eligible to participate but 
these variables will be adjusted for in the final analyses 
 Any previous treatment with bisphosphonates, raloxifene, strontium or recombinant 
PTH  
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Investigational measurements 
Subjects will attend the CRF at 0800 hours in a fasted state. Informed consent will initially be 
obtained and all pre-menopausal women will be tested for pregnancy; any found to be 
pregnant will be excluded from further participation. Eligibility criteria will be reviewed and 
patients will be asked about previous medical history (including fractures), medication, 
smoking status, alcohol intake, exercise history and family history of thyroid disease or 
osteoporosis. Three blood pressure measurements will be obtained and averaged using a 
validated OMRON sphygmomanometer. Body height (without shoes) will be measured to the 
nearest 0.5 cm using a stadiometer and body weight (in light clothing without shoes) to the 
nearest 0.5 kg on a balance beam scale. Waist circumference will be measured at minimal 
respiration and reported to the nearest 0.5 cm by positioning a flexible anthropometric tape 
parallel to the floor and immediately above the iliac crest. Hip circumference will be measured 
at the maximum circumference over the buttocks and recorded to the nearest 0.5 cm. Body 
mass index (BMI) will be calculated as weight (kg) divided by height (m) squared. Waist:hip 
ratio (WHR) will be calculated as waist circumference divided by hip circumference. Standard 
bioimpedance will be used to determine lean body mass, fat mass and fat percentage (Tanita 
bioimpedance meter).  
Approximately 20 ml of blood will be drawn from the antecubital vein for the measurement of 
thyroid function (free T4, free T3, TSH), thyroid antibodies (anti-thyroid peroxidase, thyroid 
blocking antibodies (TBAB)), bone profile (calcium, phosphate, alkaline phosphatase), total 
cholesterol, HDL, LDL, triglycerides, glucose, insulin and TSHR genotyping. Serum will also 
be saved (frozen at -30C) for later batched analysis of osteocalcin, bone-specific alkaline 
phosphatase, procollagen type 1 aminoterminal propeptide, C-cross-linking terminal 
telopeptide of type 1 collagen and tartrate specific acid phosphatase (TRAP). A urine sample 
will be obtained for measurement of free deoxypyridinoline and N-telopeptide of collagen 
cross-links.  
For the TSHR genotyping the patients will be screened initially to detect markers of 
autoimmune or atrophic thyroiditis including antibodies to thyroid peroxidase and thyroid 
blocking antibodies (TBAB) both using in-house assays. To our knowledge, we are the only 
academic centre in the UK able to assay for the full spectrum of thyroid autoantibodies, 
including their biological function. 
We would predict that approximately two-thirds of the cohort would be positive for thyroid 
antibodies and will genotype the TSHR in the remaining ~120 patients. Initially, to estimate 
the allele frequency of the W546X mutation in the thyroid antibody negative SH patients, we 
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will genotype individuals, using single nucleotide primer extension and an ABI 3100, as 
previously described (12-14). Subsequently, for those patients who do not express W546X, 
we will use Denaturing High Performance Liquid Chromatography (dHPLC). We will screen 
the entire coding region and about 1000 bp of 5’ flanking sequence, which will include the 
promoter. Since DHPLC uses fragments of 400-500 bp, 13 separate fragments will suffice to 
cover the promoter, all 10 exons and intron/exon boundaries of the gene.  
We have extensive experience in genotyping the entire TSHR in individuals by conventional 
methods and of large-scale genotyping using DHPLC (12-14). 
If we find any novel TSHR mutations their function, in terms of TSH binding, signal 
transduction and surface expression will be compared with the WT TSHR. We have previous 
experience in producing the required expression vectors, their transfection (both stable and 
transient) and functional comparison with WT receptor. In addition, we will genotype the 240 
antibody positive SH patients for any TSHR mutations, to assess their allele frequencies. 
BMD will be evaluated by dual energy x-ray absorptiometry (DXA) using a Hologic Discovery 
A absorptiometer. The following regions will be examined: (a) lumbar spine (L1, L2, L3 and L4 
separately and total), (b) hip (femoral neck, greater trochanter and inter-trochanteric region 
individually and total). Given the phenotype of the TSHR +/- and -/- mice, it is possible that 
changes in bone density will not be uniform. Such heterogeneity can be detected by detailed 
examination of the localised sites.  Quality assurance will be assessed using a Hologic spine 
phantom, measured once prior to all DXA measurements. In addition to absolute BMD 
(expressed in g/cm2) DXA results will also be interpreted according to BMD expressed as a T 
score, giving the standard deviation score relative to mean peak bone mass in young adults, 
and the Z score relative to age- and gender-matched controls. The World Health Organisation 
(WHO) definitions will be used to classify subjects as normal (T-score value for BMD > -1), 
low bone mass/osteopenia (T-score value for BMD <-1 but >-2.5) or osteoporosis (T-score 
value for BMD <-2.5). 
The total radiation dose is estimated as 11μSv (or the equivalent of about 2 days of background 
radiation exposure in the UK).   
Endpoints 
Primary endpoints 
The primary endpoints of the study will be differences in BMD (total or local) at the lumbar spine 
and left hip in the affected (mutation positive) group compared with controls (autoimmune SH). 
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Secondary endpoints 
Secondary endpoints will include percentages of subjects in each group meeting WHO 
definitions of normal, low bone mass and osteoporosis; serum and urine markers of bone 
turnover, lipids, insulin resistance (measured by HOMA-IR) and body composition.  
 
5. Data management 
Sample size calculations and statistical analyses  
Sample size calculations have been performed in conjunction with Professor Robert 
Newcombe (Department of Primary Care and Public Health, Centre for Health Sciences 
Research, Cardiff University). A comparison of 50 ‘affected’ patients with 250 TPO antibody 
positive ‘controls’ detects a shift of 0.44 SDs with power 80% at the conventional 5% alpha 
level. Comparisons of continuous variables between groups will be performed by unpaired t-
test or Mann-Whitney U test for normally or non-normally distributed variables respectively. 
Chi square tests will be used to compare distribution of categorical variables. Since the test 
and control groups will both be derived from individuals with SH, who by definition have 
'normal' circulating T4 and T3, we do not anticipate any confounding effects due to variation 
in thyroid hormone levels, but analyses will be adjusted if necessary for these and other 
potential confounders such as age, gender and BMI.  
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7. Project management 
Dr Anna de Lloyd (Clinical Research Fellow) will be responsible for the day-to-day conduct of 
the study. She will co-ordinate recruitment, obtain consent, undertake the blood and urine 
sampling, perform the bioimpedance analysis and perform the TSHR genotyping in 
conjunction with colleagues in the Centre for Endocrine and Diabetes Sciences (supervised 
by Dr Marian Ludgate, Reader) and Department of Medical Biochemistry (Dr Carol Evans, Dr 
Hilary Durrant). She will also be responsible for data entry and storage and will at a later stage 
conduct statistical analysis on the data obtained, in conjunction with Dr Rees and Professor 
Robert Newcombe from the Department of Primary Care and Public Health, Centre for Health 
Sciences Research, Cardiff University. 
Miss Sarah Darlington, Mrs Rebecca Pettit and Dr Will Evans (Department of Medical Physics, 
University Hospital of Wales) will perform the DEXA measurements.  Dr Aled Rees and Dr 
Marian Ludgate, the Principal Investigators, will act directly as Dr de Lloyd’s supervisors. A 
formal meeting will take place on a weekly basis to discuss all aspects of the study and to plan 
the work for the forthcoming week. Dr Rees and Dr Ludgate will ensure that Dr de Lloyd is 
trained in all the necessary clinical and laboratory procedures, including attendance at a Good 
Clinical Practice training day. Informal discussions regarding any difficulties that arise with the 
project will also take place as required.  
A further monthly meeting involving Dr de Lloyd and Dr Rees/Dr Ludgate will occur to discuss 
overall progress and to focus on manuscript/abstract preparation as the results allow. 
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Study data will be stored for 15 years after completion of the study. Dr Rees will act as 
custodian of these data and only Dr Rees, Dr Ludgate and Dr de Lloyd will have access to the 
data. 
8. Administrative Procedures 
Changes to the protocol 
Any change or addition to this protocol will require a written protocol amendment. 
Amendments significantly affecting the safety of subjects, the scope of the investigation or the 
scientific quality of the study will be submitted for additional approval by the Local Research 
Ethics Committee and the Research and Development departments at Cardiff and Vale NHS 
Trust and Cardiff University.  
 Auditing procedures 
As part of Good Clinical Practice, Dr Rees will ensure that the study protocol and 
documentation are closely monitored. The study will be conducted as outlined in the study 
protocol and in accordance with all applicable government regulation. All study documentation 
will be available for inspection at any time by appropriate regulatory authorities including 
internal audits by the Cardiff and Vale NHS Trust and/or Cardiff University Research and 
Development audit officers. 
Publication of results 
Any formal presentation or publication of data from this study will be considered as a joint 
publication by the investigators and authorship will be determined by mutual agreement. The 
research findings will be disseminated through peer reviewed publications and presentations 
at regional/national/international meetings. Following scientific peer review and publication, 
the results of the study will be communicated directly to all participants and, additionally, to 
local patient support groups where appropriate. 
9. Consent 
Potential participants will initially be identified by members of the patient’s direct healthcare 
team, specifically Dr Carol Evans and Dr Hilary Durrant, Department of Medical Biochemistry, 
UHW.  Drs Evans and Durrant are responsible for the daily validation of patients’ thyroid 
function test results and will screen all patients identified as having SH for evidence of previous 
thyroid disease or prior or current thyroid hormone or anti-thyroid drug treatment, where this 
information is available; these patients will not be considered for this study. The remaining 
patients, estimated to be approximately 5 per week, will be assumed to have de novo disease. 
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The referring GP or hospital physician responsible for their care will then be contacted by Dr 
Evans or Durrant via telephone and letter. This initial letter, which will enclose a patient 
information sheet, will outline the principles of the study and will request that the GP/physician 
contacts the patient to make them aware of the study and to enquire whether they might be 
willing to consider participation. Recognising that many practitioners would prefer referral to 
an Endocrinologist, the letter will also offer rapid review in Dr Rees’ clinic as an alternative. 
The patient information sheet will explain the nature of the study, its purpose, the procedures 
involved, the expected duration, the potential risks and benefits involved and any discomfort 
it may entail. Each subject will be informed that participation in the study is voluntary and 
he/she may withdraw from the study at any time and that withdrawal of consent will not affect 
his/her subsequent medical treatment or relationship with the treating physician. Patients will 
be given 1 week to review the patient information sheet and will be provided with a contact 
number for the study team such that they can ask questions about any aspects of the study. 
Patients who express an interest in participation will subsequently be invited to attend the CRF 
at the UHW where the consent process will take place. The following individuals will be 
permitted to take consent: 
Dr Anna de Lloyd (Clinical Research Fellow) 
Dr Aled Rees (Principal Investigator)    
This informed consent will be given by means of a standard written statement, written in non-
technical language. The subject should read and consider the statement before signing and 
dating it, and will be given a copy of the signed document. If the subject cannot read or sign 
the documents, oral presentation may be made or signature given by the subject’s legally 
appointed representative, if witnessed by a person not involved in the study, mentioning that 
the patient could not read or sign the documents. No patient can enter the study before his/her 
informed consent has been obtained. 
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INITIAL LETTER OF APPROACH   
 
Effects of a single functional TSH receptor on bone metabolism and body composition 
Dear Dr……………………………   Regarding ……………………………........ 
You recently requested a thyroid function test on the above patient which has been analysed 
and shows evidence of subclinical hypothyroidism (SH) 
Result    Free T4……………………..(pmol/l) 
    TSH…………………………(mU/l) 
We are currently conducting a study examining the prevalence of mutations in the TSH 
receptor gene as a cause for SH and how this may influence bone mineral density. We wish 
to recruit subjects with primary, treatment naive Subclinical hypothyroidism (SH). The 
details of the proposal are outlined below:  
SH, defined as an elevated thyroid stimulating hormone (TSH) in the presence of normal 
circulating levels of free thyroxine (T4) and free tri-iodothyronine (T3), is a common condition 
affecting 3-6% of the UK population. Most cases have an autoimmune basis (chronic 
lymphocytic thyroiditis) with 50-80% of patients possessing anti-thyroid peroxidase antibodies. 
In these individuals, SH is frequently a prelude to overt hypothyroidism with conversion rates 
of up to 5% annually, especially in individuals with higher levels of TSH (>10mU/l). However, 
treatment of SH remains controversial, especially for individuals with lower degrees of TSH 
elevation, with current recommendations supporting thyroxine replacement only in subjects 
with higher levels of TSH (>10 mU/l).   
We, and others, have recently shown that mutations in the TSH receptor (TSHR) gene may 
be a relatively common cause of SH in patients who are negative for thyroid antibodies, 
affecting up to 40% of this group. However, this requires confirmation in larger studies. 
Furthermore, recent data from animal studies and a large study of middle-aged volunteers in 
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the Netherlands suggest that the TSHR may have an important role in protecting against 
osteoporosis independently of thyroid hormones.  
Patients with SH whose disease is caused by mutations in the TSHR gene will only have one 
functional TSHR allele, in contrast to patients with autoimmune SH who possess two working 
copies of this gene. We hypothesise that patients with ‘mutation SH’ may have lowered bone 
mineral density and aim to test this by comparing bone metabolism in SH patients whose 
disease is caused by mutations in the TSHR gene with autoimmune SH patients, using 
biochemical markers of bone turnover and measuring bone mineral density (BMD).  
Subjects who choose to participate in our study will undergo the following investigations: 
Anthropometric measurements (height, weight, waist circumference, blood pressure, 
bioimpedance) 
DXA scan  
Blood tests (markers of bone turnover, lipids, insulin, glucose, C-reactive protein, thyroid 
function tests, thyroid autoantibodies and TSH-receptor mutation analysis) 
Urinalysis for markers of bone turnover. 
As we are not directly involved in your patient’s care we would be grateful if you would be 
willing to approach your patient to discuss this study with them, perhaps when they attend 
for review of the above test result. We enclose a patient information sheet which contains 
the details of the measurements proposed and the contact details of the study team should 
your patient wish to participate. Alternatively, we also recognise that many clinicians would 
prefer for their patients with SH to be reviewed by an Endocrinologist. If you would prefer this 
please refer your patient to Dr Aled Rees, Senior Lecturer in Endocrinology (study Principal 
Investigator), UHW, who will arrange prompt review and treatment if indicated.  
We enclose a tear-off slip and stamped addressed envelope.   
Participation in this study will not affect your patient’s routine care and patients will be free to 
withdraw from this study at any time. Should you have any queries regarding this study, please 
do not hesitate to contact ourselves or Dr Aled Rees at the University Hospital of Wales on 
either of the following numbers: 
02920 745002 (Dr Rees) or 02920 748367 (Dr Carol Evans) 
Yours sincerely, 
 
Dr Carol Evans    Dr Hilary Durrant 
 
Department of Medical Biochemistry  
 
………………………………………………………………………………………………Cut here 
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Name and address of patient   Name and address of GP 
………………………………………………… …………………………………………………. 
………………………………………………… …………………………………………………. 
………………………………………………… …………………………………………………. 
Please tick appropriate box 
 I have provided my patient with a copy of the patient information sheet 
 
 
 The patient is not suitable for the study 
 
 I give permission for this patient to be approached regarding this study 
 
 The patient does not wish to participate in the study 
 
 I want an outpatient appointment with Dr Rees to be arranged 
 
Please return in the enclosed envelope to: Dr Carol Evans, Department of Medical 
Biochemistry, University Hospital of Wales, Heath Park, Cardiff 
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Effects of a single functional TSH receptor on bone metabolism and body 
composition 
 
PATIENT INFORMATION SHEET 
(Version 2 December 2008) 
 
PART 1  
 
 
1. Title of study 
 
TSH receptor and bone 
 
2. Introduction 
 
You are being invited to take part in a clinical research study. Before you 
decide whether you wish to become involved it is important that you 
understand why the research is being done and what it will involve. Please 
take time to read the following information carefully and discuss it with others 
if you wish. 
 
Part 1 tells you the purpose of this study and what will happen to you if you 
take part. 
 
Part 2 gives you more detailed information about the conduct of the study. 
 
Please do not hesitate to ask us if there is anything that is not clear or if you 
would like more information. Take time to consider whether or not you would 
wish to take part. 
 
Thank you for reading this. 
 
 
3. What is the purpose of this study? 
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Underactivity of the thyroid gland (‘hypothyroidism’) is a common condition 
affecting 2-5% of the UK population. Sometimes this is very mild and 
identified only on blood testing (a condition called ‘subclinical hypothyroidism’ 
or ‘SH’). Most patients who develop SH (roughly 2/3) do so because of 
antibodies destroying the thyroid tissue which can be measured by a simple 
blood test (‘autoimmune SH’). A decision to treat or simply monitor thyroid 
function tests (TFT) is often difficult but patients with significant symptoms 
and signs of more severe thyroid underactivity may be treated with thyroid 
hormone (‘thyroxine’).  
 
We have recently found that some patients with blood tests showing SH, but 
whose antibody tests are negative, have this condition because of a change 
in the code (‘mutation’) in a thyroid system gene (called the ‘TSH receptor’ 
gene).  
 
We wish to test how common these mutations are as a cause of SH and also 
to determine whether patients with mutations as a cause for SH have any 
reduction in bone thickness (bone mineral density) compared with patients 
with autoimmune SH.  
  
4. Why have I been chosen? 
 
You have been chosen for this study as your recent blood tests have shown 
that you have SH. A total of 350 patients will be studied. 
  
5. Do I have to take part? 
 
It is up to you to decide whether or not to take part. If you decide to take part 
you will be given this information sheet to keep and be asked to sign a 
consent form. If you decide to take part you are still free to withdraw at any 
time and without giving a reason. A decision to withdraw at any time, or a 
decision not to take part, will not affect the standard of care you receive.   
 
6. What will happen to me if I take part? 
 
The study will take place at the Clinical Research Facility (CRF) and the 
Department of Medical Physics at the University Hospital of Wales. You will 
be asked to attend in the morning having only had water to drink (i.e. no 
breakfast, tea or coffee). Each visit will last approximately one and a half 
hours.  
 
If you are a woman of child-bearing age we will firstly require you to have a 
pregnancy test before carrying out any measurements. 
 
We will then measure your weight, height, blood pressure, waist 
circumference, hip circumference, fat percentage (on an instrument called a 
bioimpedance machine) and take a brief clinical history.  
We will take blood samples (approximately four tablespoons) to check levels 
of ‘bone’ proteins, thyroid function tests, thyroid antibodies, cholesterol, 
insulin, glucose and a further sample which we will use to test your TSH 
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receptor gene. We will also measure a urine sample for markers of bone 
metabolism.  
 
Finally we will measure the density of your bones (bone mineral density; 
BMD) using a technique called a DEXA scan. This is a simple, rapid and non-
invasive technique which is used routinely in clinical practice to measure 
BMD at the hip and over the spine. This scan does involve exposure to a 
small amount of radiation but the risk is negligible. 
 
7. Expenses and payments  
 
If you wish we will be able to reimburse any travelling expenses / car parking 
fees incurred while attending for the study visit. 
 
8. What do I have to do? 
 
It is important that you take your regular medication in the normal way on the 
day of study attendance (unless we advise otherwise).  
 
There are no lifestyle or dietary restrictions and you can continue your daily 
activities normally. We request that you report any illnesses to us as they 
may influence the timing of your test visit.  
 
You should inform us if there is any possibility of you being pregnant and this 
will be tested for in all women of a child-bearing age. If you are pregnant you 
will not be able to participate in this study.  
 
For the study visit, we ask that you attend the CRF at 8 o’clock in the morning 
having fasted from midnight the previous night. You can drink water freely up 
to this point.  
 
9.  What are the possible disadvantages and risks of taking part? 
 
Other than possible discomfort (temporary pain, swelling, bruising and rarely 
infection) caused by the collection of blood, no other side effects are 
anticipated from the study procedures, though as outlined above, a DXA scan 
does involve exposure to a small amount of radiation but the risk is negligible. 
It is possible that the blood tests or DXA scan could by chance pick up an 
unsuspected abnormality, in which case you will be given an opportunity to 
discuss these findings further with Dr Aled Rees.  
 
The genetic blood sampling will test for variation in your TSH receptor gene. 
These changes occur commonly in the general population and currently have 
no known effects other than to give a similar thyroid hormone pattern in the 
blood as SH. The samples will be fully anonymised and the results of these 
genetic tests will have no implications for you in terms of insurance status.  
If you are found to have a ‘mutation’ in the TSH receptor gene you will be 
invited to attend a further appointment with Dr Aled Rees to discuss this in 
greater detail. 
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10. Are there any implications for members of my family? 
 
Because mutations in the TSH receptor gene can be inherited, if you are 
discovered to have a mutation it is possible that other members of your family 
might also be affected, leading to mild underactivity of the thyroid gland or 
‘SH’. If you are found to have a mutation we will therefore ask for your 
permission to contact your immediate family members (parents, 
brothers/sisters, children) to see whether they would also wish to be tested. 
There are currently no effects known from TSH receptor mutations other than 
causing underactivity of the thyroid.      
  
11. What are the potential benefits of taking part? 
 
There are unlikely to be any direct benefits for you but the study may provide 
us with important information in determining whether changes in the TSH 
receptor gene are a common cause of SH and whether these are associated 
with a lower BMD and potential risk for development of osteoporosis in the 
future.  
 
12. What if something goes wrong? 
 
Any complaint about the way you have been dealt with during the study or 
any possible harm you might suffer will be addressed. The detailed 
information on this is given in Part 2.  
 
13. Will my taking part in this study be kept confidential? 
 
Yes. We will follow ethical and legal practice and all information about you 
will be handled in confidence. The details are included in Part 2.  
 
This completes Part 1.  
 
If the information in Part 1 has interested you and you are considering 
participation, please read the additional information in Part 2 before making 
any decision.  
 
PART 2 
 
1. What if relevant new information becomes available? 
 
Sometimes we get new information about the treatment being studied. If this 
happens, we will tell you and discuss whether you should continue in the 
study. If you decide not to carry on, we will make arrangements for your care 
to continue. If you decide to continue in the study we may ask you to sign an 
updated consent form.  
 
2. What will happen if I don’t want to carry on with the study? 
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If you withdraw from the study, we will destroy all your identifiable samples, 
but we will need to use the data collected up to your withdrawal. A decision 
to withdraw at any time will not affect the standard of care you receive.   
 
3. What if there is a problem? 
 
If you have a concern about any aspect of this study, you should ask to speak 
to the researchers who will do their best to answer your questions (contact 
number 02920 745002).  
This study is being indemnified by Cardiff University. If you are harmed by 
taking part in this research project, there are no special compensation 
arrangements. If you are harmed due to someone’s negligence, then you 
may have grounds for a legal action but you may have to pay for it. 
Regardless of this, if you wish to complain, or have any concerns about any 
aspect of the way you have been approached or treated during the course of 
this study, the normal National Health Service complaints mechanisms 
should be available to you.  
  
4. Will my taking part in this study be kept confidential? 
 
All information which is collected about you during the course of the research 
will be kept strictly confidential. Any information about you which leaves the 
hospital will have your name and address removed so that you cannot be 
recognised from it. With your permission your GP will be informed of your 
participation in this study. With your permission we may also look at sections 
of your medical notes which are relevant to the research study.  
 
5. What will happen to any samples I give? 
 
The blood samples will be collected and stored securely for later analysis in 
the Centre for Endocrine and Diabetes Sciences at the UHW. Only immediate 
members of Dr Rees’ research team will have access to these samples. All 
identifiable information will be removed from the samples which will be 
destroyed by incineration once the tests are complete.   
 
 
    
6. What will happen to the results of the research study? 
 
The results of the research study will be prepared for publication in 
appropriate medical journals together with presentation at medical 
conferences. Patients participating in the study will be able to obtain a copy 
of the results after they have been published in the relevant journal(s). 
Patients will not be identified in any report/publication.  
 
7. Who is organising and funding the research? 
 
The study is being organised by Dr Aled Rees (the Principal Investigator) and 
Dr Anna de Lloyd (Research Registrar) from the Centre for Endocrine and 
Diabetes Sciences at the University Hospital of Wales. Funding for the study 
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is provided from funds within the Centre for Endocrine and Diabetes Sciences 
at the UHW. The doctors conducting the research are not being paid for 
including and looking after patients in the study. 
 
8. Who has reviewed the study? 
 
The study has been reviewed by the Cardiff and Vale NHS Trust Research 
and Development Office and by the South Wales Research Ethics 
Committee. 
 
9. Further information and contact details 
 
Should you have any further queries regarding this research study, then 
please do not hesitate to contact me on 02920 745002 or 07746 780566. You 
can also contact me via e-mail on reesda@cf.ac.uk. 
 
Thank you for considering taking part in this study. 
 
 
 
 
 
Dr Aled Rees 
Senior Lecturer in Endocrinology 
 
 
You will be given a copy of this Patient Information Sheet and a signed 
consent form to keep. 
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APPENDIX 4 
 
University Hospital of Wales 
Ysbyty Athrofaol Cymru 
Eich cyf/Your Ref: 
Ein cyf/Our Ref:  DAR/JE 
Welsh Health Telephone Network 1872 
Direct line/Llinell uniongyrchol  
 029 20742341 ,  029 2074 4671 
Heath Park 
Cardiff CF14 4XW 
Phone 029 2074 7747 
Minicom 029 2074 
3632 
Parc Y Mynydd Bychan 
Caerdydd CF14 4DW 
Ffôn 029 2074 7747 
Minicom 029 2074 
3632 
 
Effects of a single functional TSH receptor on bone metabolism and body 
composition 
 
Patient Identification Number for this study: 
 
   PATIENT CONSENT FORM 
(Version 2, December 2008)  
 
 
Title of Study:  TSH receptor and bone 
  
Name of Researchers:  Dr Aled Rees, Dr Anna de Lloyd    
         
              
Please initial box 
 
1. I confirm that I have read and understood the information sheet dated 
December 2008 (version 2) for the above study and have had the 
opportunity to ask questions.  
 
2. I understand that my participation is voluntary and that I am free to 
withdraw at any time, without giving any reason, without my medical care 
or legal rights being affected. 
 
3. I understand that sections of my medical notes may be looked at by 
responsible individuals from regulatory authorities where it is relevant to 
my taking part in research. I give permission for these individuals to have 
access to my records. 
 
4. I consent to my GP being informed of my participation in the Study. 
 
 
5. I consent to a pregnancy test (if indicated) .                               
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6. I agree to take part in the above study. 
 
 
__________________________  _____________ 
 ____________________  
Name of patient    Date    Signature 
 
 
__________________________  _____________ 
 ____________________ 
Researcher     Date    Signature 
 
 
__________________________  _____________ 
 ____________________ 
Name of person taking consent  Date    Signature 
(if different from researcher) 
 
 
1 copy for patient; 1 for researcher; 1 to be kept with hospital notes 
 
 
 
 
 
 
 
 
 
 
  
220 
 
APPENDIX 5 
        Thyroid/ Bone Page 1 
Participant data collection Sheet 
Patient study number; 
Date;         
Consent; □ 
Past Medical History 
 
 
 
Drug History 
 
 
 
Family History (FH)   Bone FH;    Thyroid FH;  
 
 
Social History 
Occupation; 
Exercise over and above the basic activities of daily living?    
Example; 
Average weekly alcohol intake; 
Smoking History?   Pack year history; 
Women;-   
Age of Menarche?   Oligomenorrhoea?  Age of Menopause? 
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Patient Study Number;      Thyroid/ Bone Page 2 
 
Number of pregnancies;  Duration of breast feeding; 
       
Blood Pressure; 
1.                                                    2.                                                 3.                   
 
Height (cm); 
 
Weight (kg); 
 
BMI; 
 
Waist circumference (cm);    Hip circumference (cm); 
 
Percentage body fat; 
 
Urine Sample collected; □ 
 
Bloods taken? 
2 x EDTA; □  4-5 x SST; □  1 X Fluoride Oxalate; □ 
 
Bloods stored; □   Urine Stored; □ 
 
DXA scan booked; □  
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APPENDIX 6: Supplementary data to Chapter 4 
 
Total Hip MRA 
This MRA evaluates against BMI as the build parameter.   
N=200,   R2 = 36%    
Appendix 6, Table 1: MRA evaluating total hip Z-score (assessed against BMI) 
Predictor R SE coefficient 95% C.I p-value 
Constant -7.9 1.14 -10, -5.7 <0.001 
Log10BMI +7 0.73 +5.6, +8.4 <0.001 
Activity (1) +0.27 0.13 +0.02, +0.5 0.04 
Male (1) -0.46 0.14 -0.7, -0.2 0.001 
Log10 TSH mU/L -0.25 0.34 -0.9, +0.4 0.46 
T3 pmol/L -0.35 0.12 -0.6, -0.1 0.005 
 
Appendix 6, Table 1 provides the regression coefficients (R) for each predictor assessed in the MRA 
evaluating Z-score at total hip. The standard errors (SE), 95% confidence intervals (C.I) and p-values 
are provided. The minus (-) or plus signs (+) indicate the direction of the association.   
 
Serum corrected calcium MRA 
The following parameters are not included in this MRA as they did not associate with calcium 
values: BTMs, non-sedentary lifestyle, T4 and WHR (or BMI).  The corrected calcium MRA is 
detailed in Table 2.    
N=205,  R2 = 13% 
Appendix 6,Table 2:  MRA evaluating calcium  
Predictor R SE coefficient 95% C.I p-value 
Constant 2 0.09 +1.8, +2.2 <0.001 
T3 (pmol/L) +0.03 0.01 +0.01, +0.05 0.002 
Male (1) -0.03 0.01 -0.05, -0.01 0.006 
Log10 TSH (mU/L) -0.02 0.03 -0.08, +0.04 0.43 
Age (years) +9x10-4 4x10-4 +1x10-4, +2x10-3, 0.02 
Log10 ALP (IU/L) +0.1 0.04 +0.02, +0.2 0.01 
 
Appendix 6, Table 2 details the regression coefficients (R) for each predictor assessed in the MRA 
evaluating Calcium. The standard errors (SE), 95% confidence intervals (C.I) and p-values are provided. 
The minus (-) or plus signs (+) indicate the direction of the associations.  
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Phosphate MRA 
The phosphate MRA is summarised in Appendix 6, table 3 below.  
N = 207,  R2 = 8% 
 
Appendix 6, Table 3: MRA evaluating Phosphate 
Predictor R SE coefficient 95% C.I p-value 
Constant 1.6 0.16 +1.24, +1.88 <0.001 
T3 pmol/L -0.01 0.02 -0.05, +0.02 0.43 
Log10TSH mU/L +0.03 0.05 -0.05, +0.13 0.51 
Activity (1) -0.005 0.02 -0.04, +0.03 0.8 
Male (1) -0.04 0.02 -0.08, -0.03 0.037 
Log10BMI -0.29 0.1 -0.5, -0.08 0.006 
TPO (+ve) -0.01 0.02 -0.05, +0.02 0.4 
 
Appendix 6,Table 3 details the regression coefficients (R) for each predictor assessed in the phosphate 
MRA. The standard errors (SE), 95% confidence intervals (C.I) and p-values are provided. The minus(-) 
or plus signs (+) indicate the direction of the associations.  
 
 
Alkaline phosphatase MRAs 
Appendix 6, table 4 details the alkaline phosphatase (ALP) MRA whose predictors include Z-
score at TLS.  ALP is log transformed to normalise the data. 
    N = 195, R2 = 13% 
 
 
Appendix 6, Table 4: ALP MRA (predictors include TLS Z-score)  
 
Predictor R SE coefficient 95% C.I p-value 
Constant +1.4 0.18 +1.06, +1.77 <0.001 
T3 pmol/L -0.008 0.02 -0.05, +0.03 0.70 
Log10TSH mU/L +0.04 0.05 -0.07, +0.15 0.47 
TPO (+ve) -0.04 0.02 -0.08, -0.003 0.05 
Activity (1) -0.04 0.02 -0.08, -0.03 0.035 
Log10BMI +0.4 0.12 +0.12, +0.6 0.003 
TLS Z-Score -0.02 0.009 -0.04, -0.004 0.017 
 
Appendix 6, Table 4 details the regression coefficients (R) for each predictor assessed in the ALP MRA (that 
includes TLS Z-score). The standard errors (SE), 95% confidence intervals (C.I) and p-values are provided. 
The minus (-) or plus signs (+) indicate the direction of the associations.  
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Appendix 6, table 5 summarises a similar ALP MRA that evaluates against TH rather than TLS 
Z-score.   N = 197,  R2 = 15% 
 
 
Appendix 6, Table 5: ALP MRA (predictors includes TH Z-score)  
 
 
Predictor R SE coefficient 95% C.I p-value 
Constant 1.2 0.2 0.86, 1.6 <0.001 
T3 pmol/L -0.008 0.02 -0.04, +0.03 0.70 
Log10TSH mU/L +0.06 0.05 -0.04, +0.16 0.26 
TPO  (+ve) -0.03 0.02 -0.07, +0.006 0.10 
Activity (1) -0.05 0.02 -0.09, -0.007 0.02 
Log10BMI +0.50 0.13 +0.22, +0.74 <0.001 
Total hip Z-Score -0.03 0.01 -0.05, -0.01 0.04 
 
Appendix 6, Table 5 details the regression coefficients (R) for each predictor assessed in the ALP MRA 
(that includes Total Hip Z-score). The standard errors (SE), 95% confidence intervals (C.I) and p-values 
are provided. The minus (-) or plus signs (+) indicate the direction of the associations.  
 
P1NP MRA 
Appendix 6, table 6 summarises the P1NP MRA.  P1NP was log transformed prior to analysis 
to normalise the data.  When TH Z-score was substituted for TLS Z-score; results were similar 
(R -0.07, P-value 0.68).  N = 185, R2= 2%  
Appendix 6, Table 6: P1NP MRA (predictors include TLS Z-score) 
 
Predictor R SE coefficient 95% C.I p-value 
Constant 2.0 0.53 0.93, 3 0.00 
TPO (+ve) 0.003 0.03 -0.06, +0.06 0.94 
T3 (pmol/L) 0.004 0.03 -0.06, +0.06 0.9 
Log10TSH (mU/L) 0.03 0.09 -0.14, +0.2 0.76 
Activity (1) 0.02 0.03 -0.04, +0.08 0.60 
Male (1) -0.008 0.04 -0.08, +0.06 0.82 
Log10BMI -0.0007 0.2 -0.4, +0.4 1.0 
Total LS Z-Score 0.008 0.02 -0.03, +0.02 0.56 
Corr Ca2+ (mmol/L) -0.06 0.2 -0.45, +0.34 0.8 
Log10ALP (IU/L) -0.16 0.13 -0.4, +0.08 0.2 
Phosphate (mmol/L) 0.002 0.12 -0.23, +0.23 1.0 
 
Appendix 6, Table 6 details the regression coefficients (R) for each predictor variable assessed in the 
MRA evaluating P1NP. The standard errors (SE), 95% confidence intervals (C.I) and p-values are 
provided. The minus (-) or plus signs (+) indicate the direction of the associations.  
225 
 
CTX MRA 
Appendix 6, Table 7 details the CTX MRA. CTX was log transformed prior to analysis to normalise the 
data.  When TH Z-score was substituted for TLS Z-score, results were similar (R; 6 x 10-3, p-value 0.7).
     N = 187, R2= 2% 
Appendix 6, Table 7: CTX MRA (predictors include TLS Z-score) 
Predictor R SE coefficient 95% C.I p-value 
Constant -0.12 0.58 -1.3, +1 0.84 
TPO(+ve) 0.01 0.04 -0.06, +0.08 0.71 
T3 (pmol/L) 0.05 0.04 -0.02, +0.11 0.17 
Log10TSH (mU/L) 0.01 0.1 -0.17, +0.2 0.91 
Activity (1) 0.02 0.03 -0.05, +0.09 0.54 
Male (1) -0.01 0.04 -0.09, +0.07 0.80 
Log10BMI -0.02 0.21 -0.4, +0.4 0.94 
Total LS Z-Score 0.007 0.01 -0.02, +0.04 0.64 
Corr Ca2+ (mmol/L) 0.21 0.21 -0.6, +0.2 0.33 
log10ALP -0.09 0.14 -0.35, +0.2 0.52 
Phosphate (mmol/L) -0.05 0.13 -0.3, +0.2 0.70 
Appendix 6, Table 7 details the regression coefficients (R) for each predictor variable assessed in the 
MRA evaluating CTX. The standard errors (SE), 95% confidence intervals (C.I) and p-values are 
provided. The minus (-) or plus signs (+) indicate the direction of the associations.  
 
P1NP/CTX versus alkaline phosphatase stepwise regression model 
Appendix 6, Model 1: Stepwise regression model exploring R between the P1NP CTX ratio 
(log10P1NP/log10CTX) and ALP; assessed singularly and then adjusted for confounders 
 
Step 1; Crude association 
N  R   95% C.I   p-value 
181  +0.45  +0.16, +0.74  0.004 
Step 2; Step 1 including male sex 
181  +0.45  +0.14, +0.76  0.004 
Step 3; Step 2 including age & BMI 
181  +0.54  +0.23, +0.85  0.001 
Step 4; Step 3 includes TSH, T3, activity, TPO+ and TSHR Mutation status 
181  +0.55  +0.22, +0.88  0.001 
Appendix 6, Model 1 details the number of subjects in the analysis (N), the correlation coefficient (R) 
between log10P1NP/log10CTX and log10ALP. The 95% confidence interval (C.I.) for each analysis is 
provided with respective p-values.  The minus (-) or plus signs (+) indicate the direction of the 
association.  
226 
 
P1NP/CTX versus DXA Z-score stepwise regression model 
Appendix 6 Model 2: Stepwise regression model exploring R between the P1NP: CTX ratio 
(log10P1NP/log10CTX) and DXA Z-score (at hip and lumbar spine); assessed singularly and 
subsequently adjusted for confounders 
N    R      95% C.I      p-value 
Step 1; crude (adjusting for respective Z-score at that site)  
TH  183  -0.04   -1 x10-3, +0.07   0.06 
TLS  181  -0.03   -1 x 10-3, +0.06  0.065  
 Step 2; Step 1 with adjustment for BMI and activity 
TH  183  -0.04   -0.07,  +0.03   0.1 
TLS  198  -0.02   -0.06, +1x10-3   0.12  
 Step 3; Step 2 with adjustment for TSH, T3 and TPO+ 
TH  183  -0.04   -0.08, +5x10-3   0.07 
  
TLS  198  -0.04   -0.08, -4 x10-3   0.046 
 
Appendix 6, Model 2 details the number of subjects in the analysis (N), the correlation coefficient (R) 
between log10P1NP/log10CTX and Z-score at Total Hip (TH) or Total Lumbar Spine (TLS). The 95% 
confidence interval (C.I.) for each step with respective p-values are provided.  The minus (-) or plus signs 
(+) indicate the direction of the association. 
 
DXA Z-score versus male sex stepwise regression model 
Appendix 6, Model 3:   Stepwise regression model exploring R between DXA Z-score and 
male sex assessed at total lumbar spine and total hip singularly, and subsequently adjusted 
for confounders. 
 
Total Lumbar Spine      Total Hip 
N R  95% C.I. p-value   N R 95% C.I. p-value 
Step 1; crude (against male sex only) 
198 -0.4         (-0.8, -0.04) 0.03  200 -0.4 (-0.7, -0.07) 0.02 
Step 2; adjusted for step 2 including Log10BMI and activity status  
197 -0.57         (-0.9, -0.2) 0.03  200 -0.23 (-0.8, -0.3) <0.001 
 Step 3; adjusted for step 3 including T3 
197 -0.44         (-0.8, -0.07) 0.02  200 -0.47 (-0.74, -0.2) 0.001 
 Step 4; adjusted for step 3 including log10TSH 
196 -0.4         (-0.75, -0.05) 0.03  200 -0.46 (-0.73, -0.2) 0.001 
 Step5; adjusting for step 4 including TPO antibody positivity 
196 -0.54         (-0.9, -0.2) 0.004  200 -0.5 (-0.8, -0.2) 0.001 
 
Appendix 6, Model 3 details the number of subjects in the analysis (N), the correlation coefficient (R) 
between Z-score and male at Total Lumbar Spine or Total Hip. The 95% confidence interval (C.I.) for 
each step with respective p-values are provided.  The minus (-) or plus signs (+) indicate the direction 
of the association.  
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APPENDIX 7: Supplementary data to Chapter 5 
MRA to evaluate associations with systolic BP 
 
Appendix 7, table 1 details the systolic BP MRA against the predictors listed that include BMI 
as the build parameter.   N=201,  R2 = 33% 
 
Appendix 7, Table 1: MRA evaluating systolic BP with the predictors listed  
 
Predictor R SE coefficient 95% C.I p-value 
Constant +23 19.8 -16, +62 0.24 
log10BMI +30 12.4 +5.7, +54 0.02 
Activity(1) -1 2.2 -5.3, +3.3 0.64 
Male(1) +5 2.5 +0.1, +10 0.05 
Log10 TSH (mU/L) -0.5 5.8 -12, +11 0.94 
T3 (pmol/L) +11 2.1 +7, +15 <0.001 
TPO (+ve) -0.4 2.2 -4.7, +4 0.87 
Age (years) +0.5 0.08 +0.34, +0.66 <0.001 
FOXE1 (14) -7.8 2.2 -12, -3.5 <0.001 
 
Appendix 7, Tables 1 and 2 detail the regression coefficients (R), standard errors (SE), 95% confidence 
interval (C.I) and p-values for each predictor variable evaluated in the systolic BP MRA (table 1) or the 
diastolic BP MRA (table 2). The minus (-) or plus sign (+) indicate the direction of the association.  
 
MRA to evaluate associations with diastolic BP 
 
Appendix 7, table 2 details the diastolic BP MRA against the predictors listed.  
    N=201  R2 = 17% 
 
Appendix 7, Table 2: MRA evaluating diastolic BP against the predictors listed  
 
Predictor R SE coefficient 95% C.I p-value 
Constant +26.6 13.2 +0.7, +52 0.045 
log10BMI  +22 8.3 +5.7, +38 0.009 
Activity(1) -0.1 1.5 -3, +2.8 0.93 
Male(1) +5.7 1.7 +2.4, +9 0.001 
Log10TSH (mU/L) +4.1 3.9 -3.5, +11.7 0.3 
T3 (pmol/L) +2.7 1.4 -0.04, +1.4 0.06 
TPO (+ve) +1.2 1.5 -1.7, +4.1 0.43 
Age (years) +0.1 0.06 -0.02, +0.2 0.1 
FOXE1(14) -3.5 1.4 -6.2, -0.8 0.015 
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MRA to evaluate associations with percentage body fat 
 
Appendix 7, table 3 details the percentage body fat (%BF) MRA against the predictors listed.  
     N=205,  R2 = 28% 
Appendix 7, Table 3: MRA evaluating percentage body fat.  
 
Predictor R SE coefficient 95% C.I p-value 
Constant +27 6.5 +14, +40 <0.001 
Smoking(1) +1.8 1.2 -0.6, +4.2 0.09 
Alcohol(1) +0.06 2.1 -4, +4.1 0.92 
Activity(1) +4.9 1.1 +2.7, +7 <0.001 
Male(1) -7.9 1.3 -10.5, -5.4 <0.001 
Log10 TSH (mU/L) -2 3.3 -8.5, +4.5 0.5 
T3 (pmol/L) +1.9 1.2 -0.5, +4.3 0.1 
T4 (pmol/L) +0.5 0.4 -0.3, +1.3 0.3 
Appendix 7, Table 3 and table 4 detail the regression coefficients (R) for each predictor variable 
assessed in the MRA evaluating ‘%BF (table 3) or WHR (table 4)’. Its corresponding standard errors 
(SE), 95% confidence intervals (C.I) and p-values are provided. The minus (-) or plus signs (+) indicate 
the direction of the associations. 
 
MRA to evaluate associations with Waist to Hip Ratio 
 
Appendix 7, table 4 details the waist to hip ratio (WHR) MRA against the predictors listed.  
N =206, R2 = 37% 
Appendix 7, Table 4: MRA evaluating waist to hip ratio  
Predictor R SE coefficient 95% C.I p-value 
 
Constant +0.77 0.06 +0.65, +0.89 <0.001 
Smoking History (1) +0.03 0.01 +0.01, +0.05 0.004 
Alcohol (1) -0.01 0.02 -0.05, +0.03 0.55 
Activity (1) -0.05 0.01 -0.07, -0.03 <0.001 
Male (1) +0.1 0.01 +0.08, +0.12 <0.001 
Log10 TSH mU/L -0.01 0.03 -0.05, +0.07 0.67 
T3 pmol/L +0.007 0.01 -0.1, +0.03 0.52 
T4 pmol/L +0.003 0.004 -5x10-3,+0.01 0.5 
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MRA to evaluate associations with HOMA-IR 
Appendix 7, table 5 details the HOMA-IR MRA against the predictors listed. HOMA-IR is log 
transformed to normalise the data. 
    N = 195,  R2 = 35% 
Appendix 7, Table 5:  MRA evaluating HOMA-IR.  
Predictor R SE 
Coefficient 
95% C.I p-value 
Constant -2.2 0.36 -1.5,-2.9 <0.001 
WHR +2.4 0.34 +1.7, +3 <0.001 
Activity (1) -0.2 0.05 -0.3, -0.1 <0.001 
Male (1) -0.01 0.07 -0.15, +0.1 0.2 
Log10 TSH mU/L -0.1 0.15 -0.4, +0.2 0.4 
T3 pmol/L +0.14 0.05 +0.04, +0.2 0.007 
 
Appendix 7, Tables 5 and 6 detail the regression coefficients (R), standard errors (SE), 95% confidence 
intervals (C.I) and p-values for each predictor evaluated in the HOMA-IR (table 5) or LDL cholesterol 
(table 6) MRAs. The minus (-) or plus sign (+) indicate the direction of the association. 
 
MRA to evaluate associations with LDL Cholesterol 
 
Appendix 7, table 6 details the LDL cholesterol MRA against the predictors listed.  
As the following predictors did not associate with LDL cholesterol; alcohol, smoking and TPO 
status, TSHR-M and FOXE1 PTL (14) polymorphism status, they are not included in the MRA 
below:-  
 
The absence of associations with LDL cholesterol was unchanged with WHR substituted for 
BMI. 
    N = 202,  R2 = 8% 
Appendix 7, Table 6: Summarises the MRA evaluating LDL cholesterol 
 
Predictor R SE coefficient 95% C.I p-value 
Constant +0.8 1.4 -1.9, +3.5 0.6 
Log10BMI +1.1 0.8 -0.5, +2.7 0.2 
Activity(1) +0.2 0.15 -0.1, +0.5 0.1 
Male (1) -0.25 0.17 -0.08, +0.6 0.14 
Log10TSH +0.7 0.4 -0.08, +1.5 0.09 
T3 pmol/L +0.2 0.16 -0.1, +0.5 0.2 
T4 pmol/L -0.04 0.05 -0.06, +0.14 0.5 
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MRA to evaluate associations with HDL Cholesterol 
Appendix 7, table 7 details the HDL cholesterol MRA against the predictors listed. HDL is 
square-rooted and log transformed to normalise the data. 
This MRA was originally evaluated against predictors including the TFTs, TPO status and the 
genetic data. However, as these parameters did not associate with HDL (coefficients <0.2, p-
values >0.1) they are not included in the MRA below.   
    N=207,  R2 = 24% 
Appendix 7, Table 7: MRA evaluating HDL Cholesterol 
Predictor R SE coefficient 95% C.I p-value 
Constant +0.23 0.06 +0.11, +0.35 <0.001 
Log10BMI -0.11 0.04 -0.2, -0.03 0.008 
Activity(1) +0.03 0.007 +0.02, +0.04 0.001 
Smoking(1) -0.01 0.008 -0.03, +0.006 0.10 
Alcohol(1) 0.02 0.014 -0.007,+0.05 0.20 
Male(1) -0.05 0.008 -0.07, -0.03 <0.001 
 
Appendix 7, Table 7 provides the regression coefficients (R), standard errors (SE), 95% confidence 
interval (C.I) and p-values for each predictor in the MRA assessing HDL. The minus (-) or plus signs (+) 
indicate the direction of the association. 
 
MRA to evaluate associations with Total Cholesterol to HDL ratio 
Appendix 7, table 8 details the Total Cholesterol to HDL ratio MRA against the predictors 
listed. This MRA was originally assessed against thyroid parameters including TPO status and 
the thyroid genetic data determined.  However, as these showed no associations (R <0.03, p-
values>0.1) they are not included in the MRA below.  Similarly, alcohol and smoking status 
were assessed and showed, showed no associations and are not not included in this MRA.  
 
The TC: HDL ratio was log transformed prior to analysis to normalise the data.   
    N=206,  R2 = 16%     
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Appendix 7, Table 8:     MRA evaluating total cholesterol to HDL ratio  
Predictor R SE Coefficient 95% C.I p-value 
Constant -0.04 0.15 -0.3, +0.25 0.8 
Log10BMI +0.35 0.1 +0.15, +0.55 <0.001 
Activity(1) -0.03 0.02 -0.07, +0.01 0.13 
Male(1) +0.06 0.02 +0.02, +0.1 0.005 
T3 (pmol/L) +0.02 0.02 -0.02, +0.06 0.27 
Log10TSH (mU/L) 0.03 0.05 -0.07, +0.13 0.09 
 
Appendix 7, Table 8 provides data regarding the regression coefficients (R), standard errors (SE), 95% 
confidence interval (C.I) and p-values for each predictor variable evaluated within the MRA for total 
cholesterol to  HDL ratio. The minus (-) or plus sign (+) indicate the direction of the associations. 
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Appendix 8: Comparative data between thyrotrophin assays 
This displays the comparative analyses between the Siemens ADVIA Centeur immunoassay 
system and the Abbott Architect i2000SR for thyrotrophin (as a PDF document). These 
analyses were provided by the department of biochemistry and immunology, UHW. 
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